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Abstract
The Bm-3a and Bm-3b POU transcription factors are expressed in the developing nervous 
system where Bm-3a is associated with sensory neuronal differentiation and survival. It has 
been shown that Bm-3a directly interacts with the p53 protein and this interaction resulted in 
differential regulation of gene targets which affect cell fate i.e. death or differentiation. The 
p53 related protein, p73, is involved in neuronal development and is expressed as multiple 
alternatively spliced C-terminal isoforms (TAp73a-Q, and N-terminally deleted, dominant 
negative proteins (ANp73a-P) that show reciprocal function to the TA forms and p53.
In this study we show that the Bm-3a/Bm-3b proteins also physically interacted with the p73 
isoforms via the POU domain of Bm-3 and the region containing the OD domain of p73 and 
this interaction is modulated by the different C-terminals of the p73 isoforms. The effect of 
the Bm-3a/p73 interaction was tested on p53 target genes where co-expression of Bm-3a was 
shown to potentiate the transcriptional effect of TAp73 on the p2lcu>1/Wafl promoter whilst 
antagonizing TAp73/p53 mediated activation of the pro-apoptotic genes bax and noxa. 
Additionally Bm-3a uses a variety of different mechanisms to modulate the expression of 
different p53 target genes as well as playing a role in determining the selectivity of individual 
TAp73 members in controlling the expression of the bax promoter. In agreement with a 
functional effect, co-expression of Bm-3a and TAp73 increased cell cycle arrest and survival 
in the ND7 neuronal cell line, whereas co-expression of Bm-3a and ANp73 had no effect on 
cell cycle arrest but increased cell survival.
Similar to p53, p73 (TA and AN) co-localised to a subset of Bm-3a positive neural crest cells 
(NCC) fated for a sensory lineage. Some of these Bm-3a/p73 co-expressing cells suggested a 
differentiated cell type and co-localization of TAp73 but not ANp73 with the differentiation 
marker NF-160, suggested that TAp73, like p53 is associated with differentiation of Bm-3a 
positive NCC. Functional effects of Bm-3a-p73/p53 co-expression was analysed in NCC 
cultured from Bm-3a-/- embryos showed significantly increased apoptosis upon induction of 
p53/p73 compared with WT cultures, suggesting that Bm-3a is necessary to overcome the 
p73/p53 apoptotic pathway. Thus, interaction with Bm-3a in sensory neurones may be 
critical for modulating p73/p53 mediated gene expression and hence cell fate.
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CHAPTER 1
Introduction
1.1 Transcriptional regulation in eukaryotes
Multicellular organisms execute complex patterns of gene expression to produce and 
maintain numerous specialized cell types. In general the development and maintenance of 
functionally distinct cells is governed by the combination of transcription factors that it 
contains, which control its pattern of gene expression. This ensures that each cell produces 
the correct compliment of proteins.
The control of tightly regulated gene expression is achieved at different levels by a number 
of different processes. These include: chromatin remodeling, that is required to facilitate 
DNA access; gene transcription which involves the synthesis of mRNA from DNA; post- 
transcriptional regulation determining the stability of the mRNA transcript and regulation of 
splicing; translation which involves the synthesis of proteins from a mRNA template and 
post-translational modifications required for the production of functional proteins or as a 
mechanism to regulate protein function.
1.2 Pre-transcriptional control of gene expression
The DNA in the eukaryotic nucleus is compacted and organized into chromatin. The 
fundamental unit of chromatin, the nucleosome core particle, consists of 147 bp of super 
helical DNA wrapped in 1.75 turns around a histone octamer core composed of two copies of 
the four core histones, H2A, H2B, H3 and H4. The chromatin structure is repressive for gene 
transcription as the nucleosomes prevent transcription factors from binding to regulatory 
elements. Thus in the broadest terms, gene activation in eukaryotic cells takes place in two 
steps. The first is to penetrate the chromatin barrier; the second is to assemble the pre­
initiation complex consisting of RNA pol II and general transcription factors (GTF). 
Transcriptional activators function at both these steps. As well as enhancing transcription 
directly by stimulating PIC assembly (see later) transcriptional activators have also been 
shown to stimulate transcription through interaction with and recruitment of chromatin-
17
modifying complexes (Narlikar et al., 2002). These complexes can be divided into two 
classes. The first class includes the ATP dependent remodeling complexes which use energy 
to noncovently modify chromatin structure. These complexes function by using ATP 
hydrolysis to slide the DNA with respect to the histone octamer and thereby expose the DNA 
sequence (Merseman et al., 1992). The second class is composed of histone-modifying 
complexes which add or remove covalent groups from the amino termini of histones (histone 
tails) that protrude out of the nucleosome. These modifications include acetylation, 
methylation, phosphorylation, ubiquitination and ADP-ribosylation (reviewed by Margueron 
et al., 2005). The best characterized are the histone acetyltransferase complexes (HAT) and 
the histone deacetylase complexes (HDAC) (Vogelauer et al., 2000) in which 
hyperacetylation and hypoacetylation correlate with transcriptional activation and repression 
respectively.
Hence the chromatin structure regulates transcription and provides a highly flexible 
environment where spatially and temporal coordinated remodeling takes place between 
transcriptionally repressive and structurally condensed states and transcriptionally active 
structurally accessible states.
1.3 Eukaryotic transcription
Eukaryotic transcription is the synthesis of RNA from a DNA template by RNA polymerase 
(RNA pol). There are three classes of RNA pols: I, II and III, each catalyzing the 
transcription of genes encoding different classes of RNA. RNA pol I is located in the 
nucleolus and transcribes rRNA except 5S rRNA. RNA pol III functions outside the 
nucleolus and transcribes 5S rRNA, tRNA and a whole array of small stable RNAs. These 
latter RNAs include those involved in RNA splicing and 7S RNA of the signal recognition 
particle involved in the transport of proteins into the endoplasmic reticulum. RNA pol II is 
involved in the transcription of all protein-coding genes and hence functions in the 
production of mRNA. RNA pol II also transcribes snRNA genes that take part in RNA 
splicing. All three polymerases contain two large subunits and 12-15 smaller subunits, some 
of which are present in two or all three of the polymerases. The carboxyl terminus of the 
largest subunit in RNA pol II contains a stretch of seven amino acid repeat (consensus
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sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser known as the carboxyl terminus domain (CTD). 
During transcription, the serines and some tyrosines in the CTD are phosphorylated as the 
polymerase transcribes away from the promoter.
The basal transcription complex includes the RNA polymerase and other general 
transcription factors that are necessary for the accurate initation of transcription. Following 
the formation of the pre-initiation complex (PIC) containing these factors, the RNA pol II 
then initiates its function by directing 3’-hydroxlation of the RNA chain on the 
ribonucleotide triphosphate, leading to extension of the chain in a 5’—>3’ direction.
1.4 DNA sequences elements that regulate transcription
Transcription of eukaryotic genes is regulated by transcription factors that bind to cis-acting 
DNA response elements. Several types of cis-acting elements have been defined including 
promoters, enhancers, upstream promoter element (UPEs) and response elements.
Promoter sequences are usually located 5’ end to the coding sequence and analysis of many 
eukaryotic promoters have revealed short conserved sequences within the proximal promoter 
that are required for transcription initiation. Many genes, especially those encoding 
abundantly expressed proteins contain a TATA box element located 25-30 base pairs 5’ to 
the transcriptional start site and is recognized by the TBP (TATA binding protein). The 
TATA box functions to position the RNA pol II for transcription initiation. Instead of a 
TATA box, some house keeping and tissue specific genes contain an initiator (Inr) which is 
described in the general form Py2CAPy5 and is located between positions -3 and +5. Again, 
promoters containing an initiator element usually initiate transcription from a single 
downstream site.
Upstream promoter elements (UPEs) are recognized and bound by specific transcription 
factors which act to stimulate the activity of the basal promoter. These upstream sequences 
and the factors that bind them may be common and found in a wide variety of promoters or 
specific and particular for transcription in a restricted time or place. A variety of UPE 
common to promoters can contribute to promoter function and some examples of these 
elements are given in table 1.1. All promoters probably require one or more of these elements
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to function efficiently and these elements may be found in different combinations, copy 
numbers and locations in any given promoter. The simplicity of the elements recognized by 
upstream factors disguises a complexity of interactions. For instance the ubiquitous CAAT 
box can be recognized by several transcription factors including the CAAT box transcription 
factor (CTF) family and poly(C)-binding protein-1 (CPI).
Module Element Factor
TATA box TATA TBP
CAAT box GGCCAATCT CTF/NF1
GC box GGGCGG SP1
Octamer ATCGAAAT Octl/2
kB GGGACTTTCC NF-kB
ATF GTGACGT ATF
Table 1.1: Examples of some common sequence elements found in promoters
Upstream transcription factors bind to sequence elements that are common to mammalian RNA pol II 
promoters
Enhancers are DNA sequences that can activate high levels of transcription of a gene or 
linked genes from distal locations. Enhancers are found in regions that are hypersensitive to 
nucleases, and are usually located within a few kilo bases 5’ or 3’ of a gene. In some cases 
they lie much further upstream or downstream or can be found within an exon or intron of a 
gene. Like promoters, enhancers have a modular structure but tend to contain a greater 
concentration of transcription factor binding sites. Also similar to promoters, enhancers may 
contain DNA elements that bind either common or tissue specific activators. However, in 
contrast to promoters, enhancer function is independent of position and orientation.
Finally, DNA sequences that enhance activation of a promoter in response to exposure of 
different stimuli are termed response elements. These include the Heat Shock Element 
(HSE), Glucocorticoid Response Element (GRE), Estrogen Response Element (ERE) and 
Metal Response Element (MRE). These elements are bound by specific transcription factors 
induced by a particular stimulus. Furthermore, if these response elements are cloned into
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heterologous promoters, these genes become capable of being induced in response to the 
particular stimulus (reviewed by Latchman, 1997).
1.5 The process of transcription
Transcription factors are proteins that bind to cis-DNA acting elements and play a pivotal 
role in the regulation of gene expression. Eukaryotic transcription factors can be divided into 
two main groups, namely general transcription factors that form the PIC and gene specific 
transcription factors which act to either stimulate or repress the assembly of the PIC.
The general transcription factors (GTF) are sufficient for low levels of accurate transcription 
initiated by RNA pol II from core promoters, many of which contain the TATA box or Inr 
sequence (reviewed by Roeder, 1996). On a TATA box containing promoter, TFIID is the 
first general transcription factor to bind to the promoter. The best characterized subunit of 
TFIID, TBP (TATA box binding protein) binds the TATA box sequence specifically through 
minor groove contacts which bends the DNA considerably bringing the sequences upstream 
and downstream of the TATA element into closer apposition. As the TATA box is a fixed 
distance from the start site, its recognition by TBP is important for positioning the RNA 
polymerase. The complex is then greatly stabilized by TFIIA binding, which also acts to 
inhibit TBP bound negative co-factors that prevent TFIIB binding to the PIC. TFIIB binds 
adjacent to TBP and recruits the pre-formed RNA pol II-TFIIF complex by direct interaction 
with both TFIIF and RNA-pol II which has an unphosphorylated CTD at this stage. TFIIF is 
also involved in transcription elongation. TFIIE binds next followed by TFIIH which 
completes the assembly of the PIC. TFIIH has DNA helicase activity and separates the 
strands of the duplex template DNA, allowing RNA pol II to initiate transcription. TFIIH 
also phosphorylates the CTD of the largest subunit of RNA pol II which is thought to be 
important for releasing the polymerase from the initiation complex, as it initiates 
transcription (Roeder 1996).
1.6 Regulation of transcription
While general transcription factors are common to all RNA pol II transcribed genes,
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independent of cell type, gene specific transcription factors are responsible for activation or 
repression of specific genes. These ensure tightly controlled temporal and /or tissue specific 
expression. These transcription factors bound to upstream elements or enhancers influence 
the initiation of transcription by recruiting chromatin modifiers and/or members of the PIC.
Thus a transcription factor contacts the general transcription factors via its regulatory 
(activator or repressor) domain to either promote of inhibit assembly of the PIC. For 
activators this might involve recruitment of the general transcription factors to form the PIC. 
For example, assembly of TFIID into the complex is a rate limiting step and is stimulated by 
the presence of transcriptional activators that bind the TFIID complex by contacting TBP or 
specific TAF (TBP associated factor) subunits. One example is Spl which interacts with 
dTAFllO and facilitates PIC assembly. Other activation domains bind and recruit other 
general transcription factors to the PIC (Roeder et al,. 1996). Alternatively, activators may 
recruit factors that modulate chromatin structure to make the promoter and enhancer 
elements more accessible. For example CREB (cyclic AMP response element binding 
protein) recruits a co-activator such as CBP (Creb Binding Protein). As well as interacting 
with specific general transcription factors and thereby linking CREB to this complex and 
allowing gene activation, CBP also possess histone acetyltransferase activity which leads to 
chromatin remodeling through histone acetylation which allows the DNA to become more 
assessable. Conversely transcriptional repressors may act by preventing activators binding to 
their DNA binding sites either by competition or formation of non-DNA binding protein- 
protein complexes with activators. Inhibitors may also interact with the activator and block 
the activity of the activation domain, in a phenomenon known as quenching. Direct inhibition 
may also occur by transcriptional repressors binding to their DNA elements in promoters and 
making contacts with the general transcription factors that hinders the formation of the PIC 
(reviewed by Latchman, 1996). An example is the Eve (Drosophila even skipped) protein 
which functions by preventing the association of TFIID with the TATA box element.
Additionally, some transcription factors bind co-activators or co-repressors that in turn 
interact with the basal apparatus, highlighting the importance of protein-protein interactions 
in the control of transcription. These co-activators and co-repressors themselves do not bind 
DNA but their specificity is conferred by their ability to associate with DNA binding 
transcription factors. Like the transcription factors themselves, co-activators and co­
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repressors may be common regulatory proteins or cell type specific.
As higher eukaryotic promoters and enhancers contain multiple binding sites for 
transcriptional activators, this posed the question of how multiple activators co-operate with 
one another to activate transcription. The first model suggests that different activators act at 
distinct steps-thus one activator could stimulate PIC assembly while others could recruit an 
essential chromatin modifying activity or promote transcriptional elongation. An alternative 
model is that the multiple bound activators simultaneously interact with different PIC 
components, synergistically increasing PIC assembly and transcription. Recently Fishbum et 
al 2005 showed that a single DNA bound activator can interact with multiple components of 
the PIC. A combination of interactions would result in increased stabilization of the factors 
on the promoter, thus increasing transcription.
Thus, transcription factors function to regulate gene expression by binding to specific 
elements in promoters and act to control the assembly of the PIC and/or affect chromatin 
remodeling. Likewise the transcription factors bound to distinct enhancers also interact 
directly with the PIC, by forming a DNA loop between the enhancer and proximal promoter. 
It is generally believed that transcription takes place at loci enriched for RNA pol II and 
transcriptional machinery, known as transcription factories (Osborne et al., 2004). Expressed 
genes appear to migrate to these regions by looping out of their chromosome territories away 
from non-expressed genes. By this mechanism the active gene is bought in close proximity to 
its enhancer sequence (reviewed by West et al., 2005).
1.7 Specific Transcription factors
Although examples of regulation of eukaryotic gene expression at different levels have been 
discovered, transcription initiation is by far the most widespread mechanism to control gene 
expression in eukaryotes. The precise temporal and spatial regulation of transcription by 
RNA pol II is pivotal to the execution of precise and complex gene expression programmes 
in mammalian cells in response to growth, developmental and homeostatic signals. 
Coordinated gene expression is brought about by gene specific transcription factors. 
Transcription factors require the ability to bind DNA and then to influence transcription 
either positively or negatively. Many transcription factors are modular proteins
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consisting of defined functionally independent domains: one or more regulatory domains are 
connected to a sequence specific DNA binding domain through relatively flexible protein 
domains. This allows the flexibility required for the protein-protein interactions formed to 
regulate transcription.
The activity of specific transcription factors can be regulated in several ways. For example 
they may have restricted distribution being synthesized only in certain tissues or at a specific 
time which is typical of factors that regulate development. The MyoD family of closely 
related myogenic proteins (MyoD, Myf5, MRF4 and myogenin), represent a family of 
transcription factors only expressed in a specific cell type. MyoD is expressed only in 
skeletal muscle cells and induces muscle specific genes. Over-expression of MyoD in 
undifferentiated fibroblasts is sufficient to convert them into skeletal muscle cells 
(Edmondson and Olson,. 1993) indicating that MyoD activates transcription of all genes 
involved in muscle differentiation. The MyoD family is switched on early in myoblasts and 
some of these members activate their own expression as well as other family members in 
order to maintain their expression. Under suitable conditions these transcription factors then 
activate the expression of muscle-specific genes (see below).
Additionally transcription factors may be regulated by tissue specific co-factors. For example 
the octamer motif is recognized by the POU proteins of which the best characterized are Oct- 
1 and Oct-2. Oct-1 is ubiquitously expressed and correlates with activation of the histone 
H2B genes and expression of snRNA genes. In contrast Oct-2 is expressed in B lymphocytes 
and together with Oct-1 transactivates several lymphoid specific promoters (Wirth et al., 
1987). The reason why Oct-1 does not transactivate lymphoid specific promoters in other cell 
types is because both Oct-1 and Oct2 require the presence of the B-cell specific co-activator 
OCA-B. By interacting with both Oct-1 and Oct-2, OCA-B is recruited to a subset of octamer 
sites where it serves as a co-activator for transcription of specific genes. Interestingly Oct-2 
is also expressed in a subset of neuronal cells, but rather than activating expression of genes, 
the Oct-2 transcription factor was found to inhibit expression of many target neuronal genes 
(Lillycrop et al., 1991;Dawson et al., 1994). This was due to the expression of different Oct-2 
isoforms as a result of alternative splicing in different tissues. Thus in B-lymphocytes the 
predominant Oct-2.1 isoform has activator function. However in neuronal cells the Oct-2.4 
and Oct-2.5 isoforms are more abundant. These two isoforms lack the activation
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domain which results in the general repressive effects of these isoforms on gene transcription 
(Wirth et al., 1991;Lillycrop and Latchman., 1992).
Transcription factors may become active under certain conditions by protein modification. 
For example p53 is activated by DNA damage by a variety of protein modifications which 
functions to stabilize the protein and enhances its transcriptional activity. The AP-1 
transcription factor (a heterodimer between the subunits Jun and Fos) is converted to the 
active form by phosphorylation of the Jun subunit. Interaction between different transcription 
factors as dimers may also result in different effects so that a particular binding partner 
causes it to be inactive, whereas the synthesis of the active partner would displace the 
inactive partner to allow an active complex to form. Such a network of alternative pairing is 
seen with the HLH proteins. For instance MyoD, is expressed in myoblasts well before 
activation of its target genes. Its activity at this stage is tightly regulated by the production of 
inhibitory binding partners (such as twist, another HLH protein). Twist is down regulated 
preceding cell specific differentiation and is absent from the myotome, the compartment of 
the somite where skeletal muscle differentiation takes place. This allows MyoD to form 
active complexes allowing for expression of muscle specific genes (reviewed by Berkes and 
Tapscott, 2005). Transcription factors may also be regulated by sequestration upon 
interaction with inhibitory partners. For example NF-kB is sequestered in the cytoplasm by I- 
kB. Similarly E2F-1 is held in an inactive complex by pRb. Release of these inhibitory 
factors via phosphorylation of either I-kB or pRb allows the transcription factors to become 
active either by moving into the nucleus or by being free to activate transcription of target 
genes. A factor may also be activated or inactivated by binding a ligand. The steroid 
receptors are prime examples, in which ligand binding may cause the receptor to translocate 
to the nucleus thus allowing gene transcription to occur, as well as determining its ability to 
bind DNA.
Hence in a specific cell type or in response to a stimulus, specific transcription factors are 
synthesized or become active. The binding of these transcription factors to their response 
elements in different promoters thus produces highly orchestrated patterns of gene 
expression.
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1.8 Families of transcription factors
Most transcription factors have been grouped into families on the basis of conserved DNA 
binding domains (DBD). These include the zinc finger motif, the basic leucine zipper motif, 
beta-scaffold factors with minor groove contacts, the helix-loop-helix motif (HLH) and the 
related helix-tum-helix motif (HTH)
The zinc finger motif was originary identified in TFIIIA which is required for RNA pol III to 
transcribe 5S rRNA genes. It has since been identified in several other transcription factors 
(and presumed transcription factors). There are three classes of Zinc finger proteins. The first 
is termed C2H2 and consists of the repeating unit (Tyr/Phe)X Cys X2-4 Cys X3 (Phe/Tyr) X5 
Lue X2 His X3-4 His, where X is any amino acid. Each repeating unit binds one zinc ion 
though the two histidine and cysteine side chains. The binding of the zinc ion by the two 
cysteines and histidines folds the relatively short polypeptide sequence into a compact 
domain that inserts its a helix into the major groove of the DNA. The second class of the zinc 
finger motif termed C4 found in the steroid receptors consists of Cys X2 Cys XI3 Cys X2 
Cys XI4 Cys X5 Cys X9 Cys X2 Cys. The two groups of four cysteines each bind a zinc ion 
but unlike the C2H2 zinc finger proteins the C4 zinc finger proteins bind DNA as 
homodimers or heteodimers. The DNA binding domain in the yeast Gal4 protein exhibits the 
third type of zinc finger motif which is known as the C6 (class 3) which has the consensus 
sequence Cys X2 Cys X6 Cys X5-6 Cys X2 Cys X6 Cys. The six cysteines bind two zinc 
ions folding the region into a compact globular domain. This class of zinc finger proteins also 
binds DNA as a dimer.
Leucine zippers consist of a stretch of amino acids with a leucine residue at every seventh 
position. A leucine zipper in one polypeptide interacts with a zipper in another polypeptide to 
form a dimer. Adjacent to each zipper is a stretch of positively charged residues that is 
involved in DNA binding (Fig 1.1). The leucine zipper underlies the interactions between the 
proto-oncogene products Jun and Fos, which constitutes the heterodimeric transcription 
factor activating protein-1 (AP-1), a well known downstream target of the mitogenic 
activated protein kinase (MAP kinase) signaling pathway.
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Figure 1.1: A leucine zipper dimer bound to DNA
Two a-helical DNA binding domains (bottom) dimerize through their helical leucine zipper region (top) 
to form an inverted Y-shaped structure. Each a-helix binds to one half of a symmetric DNA structure 
in the major of DNA (Adapted from Alberts et al, 1994 Molecular biology of the cell-third edition).
The beta-scaffold factors with minor groove contacts, includes the STAT transcription 
factors and p53. The three-dimensional structure of the p53 DBD, complexed with DNA has 
been determined (Fig 1.2) (Cho et al., 1994) and binds to its DNA site as a tetramer. The core 
domain consists of a large p sheet-sandwich of two anti-parallel sheets of 4 and 5 strands, 
respectively. This acts as a scaffold supporting a loop-sheet-helix motif (LI), and two large 
loops (L2 and L3). L2 and L3 are stabilized by zinc coordination (via three cysteines and one 
histidine) and side-chain interactions. DNA is bound by LI and L3 in which the helix and 
loop of LI slot into the major groove and L3 binds in the minor groove. The L2 loop 
stabilizes L3 by packing against it. The function of p53 with particular focus on its 
homologue, p73 is discussed in later sections (1.26-1.39).
Figure 1.2: Structrue of the p53 DBD-DNA complex.
Ribbon model of the p53 DBD (light blue) with some of the most frequently mutated resdues indicated 
in yellow. The DNA is coloured dark blue and the zinc atom is represented as a red sphere (Adapted 
from Alberts et al, 1994 Molecular biology of the cell-third edition).
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The amphipathic helix-loop-helix (HLH) motif has been identified in some developmental 
regulators. Each amphipathic helix presents a face of hydrophobic residues on one side and 
charged residues on the other side. The length of the connecting loop varies from 12-23 
amino acids. The motif enables proteins to dimerize and a basic region near this motif 
contacts DNA (Fig 1.3a). bHLH heterodimers bind the sequence CANNTG known as the E- 
box and they function in the co-ordinated regulation of gene expression, cell lineage 
commitment, and cell differentiation in most mammalian tissues. An example o f a bHLH 
protein is Mashl which is involved in neuronal differentiation (Nakada et al., 2004)
The helix-tum-helix motif was originally identified as the DNA binding domain of phage 
repressors. One a-helix lies in the wide groove of DNA (a-helix -3 or the recognition helix), 
the other lies at an angle across the DNA (a-heilix -2) (Fig 1.3b). A related form of the motif 
is present in the homeodomain, a sequence first characterized in several proteins coded by 
genes concerned with developmental regulation in Drosophila. Homeodomain proteins are 
also found in mammalian cells and the 60 amino acid domain termed the homeobox is highly 
conserved.
Figure 1.3: Helix-loop-helix and helix-turn helix motifs
a) Helix loop helix dimer boud to DNA. The two monomers are held together in a four-helix bundle: 
each monomer contributes two a-helices connected by a flexible loop of protein (red) b) The helix- 
turn-helix motif is shown where each white circle denotes the central carbon of an amino acid. The 
carboxyl-terminal a-helix is called the recognition helix because it participates in sequence-specific 
recognition of DNA. This helix fits into the major groove of DNA (Adapted from Alberts et al, 1994 
Molecular biology of the cell-third edition).
Further characterization of transcription factors with homology in the homeodomain gave 
rise to a sub-classification of these proteins. One such class contained a unique POU domain 
in addition to the homeodomain, which include the Bm-3 family of transcription factors. The 
structure and binding properties of the POU domain factors is discussed next followed by a
a)
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detailed account of the Bm-3 proteins focusing on the Bm-3a transcription factor.
1.9 The POU domain family of transcription factors
The POU transcription factors were named after identifying high homology in a region 
common to the original proteins, namely the mammalian pituitary specific Pitl, the 
ubiquitously expressed Oct-1, the largely B-cell restricted Oct-2 and the nematode gene Unc- 
86 which were discovered simultaneously in 1988 (Sturm et al., 1988;Bodner et al., 
1988;Ingraham et al., 1988;Clerc et al., 1988;Finney et al., 1988). All members of this family 
have been demonstrated to play important roles in the development of specific cell types, 
particularly in the nervous system, where they were first identified as powerful transcription 
factors.
1.10 The structure of the POU domain
Subsequent comparison of the nucleotide and amino acid sequences of the founding members 
identified a unique bipartite DNA binding domain that is common to all these factors, termed 
the POU domain (named by using the first letter of the founding members, Pitl, Oct-1/2, and 
Unc-86). The POU domain comprises two highly conserved sub-domains referred to as the 
POU specific (POUs) and the POU homeodomain (POUhd) tethered by a more poorly 
conserved linker region (Herr et al., 1988). The N-terminal POUs domain is 70-80 amino 
acids long and is unique to this subclass of transcription factors whereas the C-terminal 60 
amino acid POUhd is homologous to homeodomains found in the homeobox transcription 
factors. These two sub-domains are linked by a less conserved linker region of 15-25 amino 
acids in length (Fig. 1.4). Despite the structural independence of the two sub-domains 
(Botfield et al., 1992), they are always found together and mutational analysis of the POU 
domain of Pitl and Oct-1 have shown that both subdomains are required for sequence 
specific high affinity DNA binding to their appropriate response elements (Sturm and Herr, 
1988;Ingraham et al., 1990;Verrijzer et al., 1990a;Aurora and Herr, 1992;Verrijzer et al.,
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Figure 1.4: Schematic representation of the secondary structure elements of the POU domain
The POU domain can be subdivided into the highly conserved POUs domain and the POUhd 
separated by a linker region that varies in length (14-25 amino acids). The POUs domain consists of 4  
a-helices (cylinders) while the POUHd consists of 3 a-helices. Conserved regions of basic amino acids 
are found in both the POUsand POUhd (indicated by black boxes). (Adapted from Wegner, 1993)
1992a). The 3D structure of the POU domain of the Oct-1 protein was the first to be 
determined and is representative of the general structure of the POU proteins. Initially, the 
solution structure of the Oct-1 POUs domain in isolation was determined by nuclear 
magnetic resonance spectroscopy (NMR) and was shown to consist o f four alpha helices 
connected by short loops surrounding a conserved hydrophobic core. The second and third 
helix was shown to form a structure similar to the helix-tum-helix (HTH) motif of the 
bacteriophage lambda and 434 repressors (Assa-Munt et al., 1993;Dekker et al., 1993;Klemm 
et al., 1994). It is the third helix that makes contact with bases in the octamer recognition site 
whilst helices 1 and 4 stabilise the HTH motif. Remarkably, the positions o f several residues 
important for DNA binding are maintained in both the POUs and bacteriophage HTH motif, 
illustrating evolutionary conservation of this structure due to its effectiveness at binding 
DNA (Assa-Munt et al., 1993;Dekker et al., 1993).
Resolution of the crystal structure of the Oct-1 POU domain bound to DNA revealed that the 
POUhd consists of 3 alpha helices that form a compact globular structure. Helix 2 and helix 3 
form the HTH motif with helix 3 making several contacts with the octamer binding site 
(Klemm et al., 1994). As in all other homeodomains, the single helix 1 stabilises the HTH 
motif. The poorly conserved linker region does not make specific contacts with the DNA 
binding site itself (Aurora et al., 1992;Botfield et al., 1992), but acts as a flexible arm to 
facilitate the co-operative binding and orientation of the two sub-domains to an octamer 
DNA motif with high affinity (Klemm et al., 1994).
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1.11 Sub classification of POU family of transcription factors
In contrast to the highly conserved POU domain, the regions outside the POU domain are 
highly divergent, and the growing numbers of POU domain transcription factors were 
grouped into 6 classes, POU I-VI (Table 1.2). Originally this division was based on sequence 
homology in the linker region and the POU domain, although it became apparent that 
additional features are conserved within these classes. For example, members of the class III 
POU domain genes are intronless and have various regions of homo- and poly-meric residues 
at their amino terminal (reviewed by McEvilly and Rosenfeld, 1997). In contrast, members of 
the class IV POU proteins contain a highly conserved region in the N terminal activation 
domain that is refered to as the POU-IV box, that is not found in any other POU containing 
proteins. Interestingly the POU IV box shares homology with the mammalian gene MYC-N, 
which is frequently amplified in neuroblastoma. The POU IV family includes the three 
mammalian Bm-3 proteins, Unc-86 of C.elegans and the D.melanogaster I-POU and tl-POU.
1.12 Characterization of the DNA response elements recognized by 
the POU domain
Consistent with the high degree of conservation in the POU domain, the POU proteins bind 
similar DNA recognition sites which are A/T rich. However there is a degree of divergence 
in the DNA binding sites that are recognised by closely related sub classes of POU protiens. 
For example the class I Pit-1 protein which controls transcription of pituitary-specific genes 
including the growth hormone and prolactin genes (Rosenfeld, 1991), efficiently binds the 
consensus sequence 5’ ATGNATAWW-‘3 (where N= any base and W= A/T). The class II 
proteins (e.g. Oct-1/2) prefer the octamer sequence ATGCAAAT, found in a variety of 
different promoters (Verrijzer et al., 1990;Aurora and Herr, 1992;Verrijzer et al., 1992). 
However, both Oct-1 and Oct-2 recognise cis-regulatory sites which bears little homology to 
the octamer motif such as the (OCTA-)TAATGARAT (where R= A/T) site that is critical for 
herpes simplex virus gene regulation (Baumriker et al., 1998;Verrijzer and van der Vliet,
1993). However these non octamer sites bind Oct-1/2 with reduced affinity (Baumruker et
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Class Factor Chromosome
location
expression Knock out phenotype
I Pit-1 Mouse 16 Pituitary Dwarfism
II Oct-1 Mouse 1 
Human 1
Ubiquitous Not reported
Oct-2 Mouse7 
Human 19
Nervous system, 
lymphoid cell, 
testis and kidney
Aberrant B-cell 
maturation
in Bm-1 Mouse 1 CNS, Kidney Not reported
Bm-2 Mouse 4 
Human 6
CNS Defects in
differentiation/migrati 
on of hypothalamic 
neurones
Bm-4 Mouse X CNS Defects in inner ear 
development
Tst-1 Mouse4 Nervous system, 
testis
Defective myelination
IV Bm-3a Mouse 14 
Human 13
Nervous system, 
reproductive 
system, heart and 
lungs
Lack of specific 
sensory Mid autonomic 
neurones, non-viable
Bm-3b Mouse 8 
Human 4
Nervous system, 
reproductive 
system and heart
Loss of retinal 
ganglian cells, blind
Bm-3c Mouse 18 
Human 5
Nervous system,
reproductive
system
Loss of inner ear cells, 
Deaf
V Oct3/4 Mouse 17 
Human 6
Testis, ovaries, 
germ cells, ES 
cells
All cells in the early 
embryo become 
trophoblasts
VI Bm-5 Mouse 15 
Human 12
Nervous system, 
skeletal muscle, 
heart, lung
Not reported
Table 1.2: The six classes of POU transcription factors
The chromosomal location of the different POU proteins in both mouse and humans and expression 
pattern is indicated. The phenotype of the knock out mouse models, where known, is also briefly 
discussed. (CNS-central nervous system, ES-embryonic stem cell). (Adapted from Andersen and 
Rosenfeld, 2001)
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al., 1988;Aurora et al., 1992;Verrijzer et al., 1992). The class III and IV POU proteins bind to 
and activate promoters with the consensus sequence CAT(N)nWAAT (where N=any base, 
W=A/T) whose class specificity is achieved by accommodating different nucleotide spacing 
between the bipartite core DNA binding motifs. For example, class III POU proteins bind 
this sequence where n=0, 2 and 3 whereas class IV proteins bind with high affinity only 
when the core motifs are spaced by 3 nucleotides (n=3) (Li et al., 1993).
1.13 Bipartite DNA binding by the POU proteins
Sequence specific, high affinity binding of the POU proteins requires both the POUs and 
POUhd sub-domains which both contain HTH motifs (Sturm et al., 1988;Ingraham et al., 
1990). However, isolation of either the POUs or POUhd of Oct-1 demonstrated that both 
domains can bind separately to sequence specific DNA but with low affinity. In vitro binding 
site selection and band shift assays, as well as ultraviolet cross linking assays have revealed 
that each sub-domain makes contact with a subset of residues contacted by the entire POU 
domain. Specifically it was shown that the POUs domain recognised the 5’-half of the 
octamer sequence (ATGC) whilst the POUhd domain target sequence corresponded to the 3’- 
half (AT rich region) of the POU domain octamer site (ATGC(A/T)AAT) (Verrijzer et al., 
1990b;Verrijzer et al., 1992a).
These results were confirmed by crystallography studies of the Oct-1 POU domain bound to 
its octamer sequence in the H2B promoter (Klemm et al., 1994). It was shown that the third 
helix of the POUs domain binds the ATGC region in the major groove of the DNA, while the 
third helix (termed recognition helix) of the POUhd was shown to bind the AAAT sub-site of 
the octamer sequence in the major groove of the DNA on the opposite side. Only part of the 
linker that joins the sub domains is visible and this segment is found to track along the minor 
groove, while the remaining residues of the linker are disordered, indicating unrestrained 
flexibility, (Fig 1.5a + b). The region of this third helix which makes contact with the AAAT 
sub-site contains the invariant RVWFCN residues which are present in all members of the 
POU proteins.
The contacts made by the POU domain of Oct-1 with specific bases on its DNA recognition
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Figure 1.5: Crystal structure of the Oct-1 protein bound on the H2B promoter and schematic 
representation of the contacts made by the POUs and POUHd domains upon binding to the 
DNA recognition site
a) View of the crystal structure of Oct-1 bound to its site on the H2B promoter looking into the major 
grove of the DNA double helix, showing the POUs and POUHd bound to their distinct sites on the 
DNA. The helices are labeled H1-4 and the N and C termini of the protein domains are indicated, b) 
View down the DNA axis of the Oct-1/H2B crystal structure, c) Schematic view of the DNA contacts 
made by the POU domain of Oct-1. Hydrogen bonds are shown by unbroken arrows while non-polar 
interactions are depicted by broken arrows. Interactions with the minor grove are indicated by 
turquoise arrows while all other arrows represent interactions with the major groove. The octamer 
binding site is highlighted in pink. (Adapted from Phillips, 2000)
sequence is illustrated in Fig 1.5c. The highly conserved Gln44, Thr45 and Arg49 in helix 3 
of the POUs domain makes hydrogen bonds with the ATGC subsite while there is one 
hydrophobic interaction between Leu50 and this subsite. These direct sequence-specific 
interactions are complemented by a large array of phosphate backbone contacts which are 
contributed by residues in all four of the POUs helices and some in the loops. The details of 
the POUhd interaction are very similar to those observed from other homeodomain/DNA 
complex structures. In addition, the first nine residues of the POUhd form an extended N- 
terminal arm which comprises part of the flexible linker peptide that fits into the minor 
groove of the DNA and the POUhd contains a set of basic amino acids at both the amino and 
carboxyl terminals and these regions have been shown to be critical for DNA binding (Li et 
al., 1993).
Interestingly, when bound to DNA the POUs and POUhd do not contact each other, so that 
their only connection is provided by the linker region which acts as a flexible arm allowing 
for different arrangements of the two sub-domains on the DNA. Thus this linker region 
provides for flexible DNA sequence recognition by the POU proteins.
1.14 The POU IV subclass of POU proteins
Following the identification of the founder POU domain proteins, He and colleagues (1989) 
isolated novel POU proteins one of which was Bm-3a (also referred to as Bm-3.0 or 
POU4F1) form rat brain using a reverse transcriptase/polymerase chain reaction (RT/PCR) 
approach with degenerate oligonucleotides corresponding to conserved regions of the POU 
domain (He et al., 1989). The same technique was employed by Lillycrop and colleagues 
(1992) but using cDNA obtained from the neuronal cell line, ND7 (Lillycrop et al., 1992) 
which is derived from a fusion of a mouse neuroblastoma cell line and sensory neurones 
derived from dorsal root ganglia (DRG). These studies resulting in the isolation of a novel 
Bm-3 protein with high homology to Bm-3a now referred to as Bm-3b (Bm-3.2 or 
POU4F2). Subsequent studies resulting in the isolation of a third member of this family, Bm- 
3c from a cDNA library prepared from DRG and spinal cord (Ninkina et al., 1993), showed 
that there are, in fact, 3 distinct Bm-3 proteins transcribed from separate genes (Theil et al.,
1994). Bm-3a, Bm-3b and Bm-3c are found on human chromosomes 13, 4 and 5
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respectively and the murine homologues are located on chromosomes 14, 8 and 18 
respectively (Collum et al., 1992;Xia et al., 1993;Xiang et al., 1993;Theil et al., 1994).
The Bm-3 factors, the nematode Unc-86 and the drosophila I-POU and tiPOU proteins are 
members of the POU-IV sub-family. Proteins in this family share a particularly high 
homology in the POU domain but additionally some members also share a highly conserved 
region in the N-terminal domain referred to as the POU-IV box (Theil et al., 1993;Gerrero et 
al., 1993). The POU-IV box, which is 40 amino acid long, shares homology with the N- 
terminal region of c-Myc, and in fact the human Bm-3a transcription factor was isolated 
from human placental DNA on the basis of hybridizing to DNA probes derived from the N- 
terminus of c-Myc (Collum et al., 1992).
Bm-3a has particularly high homology to Unc-86 which has been shown to be critical for 
determining specific neuronal cell types, especially sensory lineages in the nematode. It was 
therefore speculated that the Bm-3 transcription factors may have a similar role in neuronal 
development and as such most studies have focussed on their expression and function in the 
nervous system.
1.15 The different isoforms of Brn-3a and Brn-3b
Analysis of the genomic sequence encoding Bm-3a and Bm-3b revealed a relatively simple 
organization in which two exons are separated by an intron. Both Bm-3a and Bm-3b proteins 
are expressed as two distinct isoforms which differ in the N terminal region. The longer 
isoforms are encoded by exons 1 and 2 whereas the shorter proteins are encoded by exon 2 
(Theil et al., 1993;Gerrero et al., 1993;Xiang et al., 1993;Theil et al., 1994;Tumer et al.,
1994).
Analysis of the Bm-3a locus identified two transcriptional start sites located about 500 base 
pairs apart in the gene sequence, and alternative promoter usage generates two distinct 
mRNAs that differ at their 5’ end which is shown in Fig 1.6 (Theil et al., 1993;Theil et al.,
1994) The upstream promoter of Bm-3a gives rise to a pre-mRNA which is spliced to 
produce the long variant 46 KDa Bm-3a(l) containing an additional N terminal domain 
encoded by exon 1 which is not present in the cDNA of the short isoform. Similarly,
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transcription from the upstream promoter in the Brn-3b gene generates the 42 KDa Bm-3b(l) 
which also contains the additional N terminal domain (Xiang et al., 1993;Tumer et al., 1994). 
In contrast, transcription from the downstream promoter of both Bm-3a and Bm-3b generates 
the shorter isoforms of these proteins, 35 KDa Bm-3a(s) and 32 kDa Bm-3b(s) that lacks 
approximately 80 amino terminal residues and thus both the short forms lack the POU-IV 
box found in the long isoforms of Bm-3a and Bm-3b.
The functional significance of this region in the Bm-3b protein has yet to be determined but 
in the case of Bm-3a(l), the N-terminal domain containing the POU-IV box is required for 
Bm-3a to activate a subset of its target promoters, involved in neuronal survival (see section 
1.27.1). Thus the N-terminal domain in Bm-3a may represent an interface for interactions 
with other co-activators or co-repressors that may modify transcription on specific target 
genes.
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N-terminal activation domain
Figure 1.6: Schematic representation of the Brn-3a and Brn-3b transcription factors and their 
two isoforms.
The long isoform [Brn-3a(l) and Brn-3b(l)] of both transcription factors contain an extra N-terminal 
domain that contains a highly conserved region, the POU IV box. The highly conserved POU IV box 
is only found in the long isoforms of both proteins while the POU domain is found in both long and 
short isoforms of each protein. (Adapted from a PhD thesis Transcriptional regulation by Brn-3a POU 
domain containing transcription factors, Author Dr J. Dennis, 1999)
1.16 The developing nervous system
The Bm-3 factors are expressed in distinct but overlapping subsets o f neurones in the 
developing and adult nervous systems, further suggesting that they play key roles in the
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development of specific neuronal cell types in mammals. In fact Bm-3a has been shown to be 
necessary for the differentiation and survival of sensory neurones (sections 1.18 and 1.19). 
These processes will be discussed below before focusing on the expression and function of 
Bm-3a protein in the developing nervous system which together with its interaction with the 
p53 family of proteins may be important in modulating neuronal cell fate, and so forms the 
focus of this study.
The nervous system develops from the embryonic ectoderm (Fig 1.7) in which the the neural 
tube gives rise to the central nervous system whereas the neural crest cells gives rise to most 
of the neurones and supporting cells of the peripheral nervous system (PNS). Neuronal cells 
are produced from dividing progenitor cells which at the appropriate time exit the cell cycle 
and extend axons which innervate their target tissue. The target cell releases a limited amount 
of specific neurotrophic factor that are required by the neurones innervating that target in 
order to survive (section 1.16.2). Those neurones that compete successfully go on to 
differentiate into specific cell type whereas those neurones that do not compete successfully 
die by programme cell death.
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Figure 1.7: The three primary cell lineages
During gastulation, 3 major cell lineages are being established. These are the Ectoderm, Endoderm 
and Mesoderm. Following gastulation, various cell lineages are derived from these three primary cell 
types. For example the ectoderm gives rise to the central nervous system as well to the epidermis 
and its derivatives such as nails hair and teeth.
38
1.16.1 Neuronal development and differentiation
Neuronal development and differentiation can be divided into 4 phases; neural induction, 
patterning of the neural tube, lineage determination and differentiation of adult neuronal 
phenotypes. Each stage is controlled by several classes of transcription factors that display 
defined spatial and temporal expression during development.
The formation of the neural tube and crest cells involves the folding of the flat neural plate 
into the neural tube a process termed neurulation. During this process the dorsal midline of 
the neural tube forms from the edges of the neural plate that abut the epidermal ectoderm, 
and this is called the neural fold (Fig 1.8a-c). The interaction between the neural plate and 
epidermal ectoderm are required for the induction of the neural crest and other cell types of 
the neural tube. More specifically, the Bmp family of signalling molecules (specifically 
Bmp-4 and Bmp-7) expressed by the epidermal ectoderm have been shown to induce the 
production of neural crest cells from the neural plate tissue. Also expression of Noelin-1, a 
secreted glycoprotein present in the neural plate, is required for neural crest development 
(Bronner-Fraser, 2002). Once the neural crest cells have been induced, they must further 
undergo an epithelial to mesenchymal transition to allow for migration, a process called 
delamination. This process is also under the control of Bmps and includes changes of 
expression of cell adhesion molecules. Patterning of the neural tube takes place among 
dividing neuroepithelial cells and lineage determination also takes place in cells that are still 
dividing, while expression of many differentiation markers occurs in post-mitotic neurones.
The neural tube is divided into distinct anterior/posterior domains; the cephalic, trunk, vagal 
and sacral crest (Fig 1.8d). The cephalic neural crest migrate into the developing brain to 
generate bone, cartilage, connective tissue, smooth muscle cells and the cranial ganglia. In 
contrast, the first structures that the trunk neural crest encounter is the somites. (Somites are 
paired, segmented masses of mesodermal tissue that form along the length of the neural tube 
during the early stage of embryonic development. They will eventually give rise to the 
vertebral column and other tissues including muscle, bone, and the dermal layers of the skin). 
Trunk neural crest cells follow one of two distinct pathways of migration. The ventral 
pathway passes through the sclerotome, the region of the somite that forms the axial skeleton,
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Figure 1.8: Induction of the neural crest during neurulation and main regions of the neural 
crest
a-c) The neural plate (light blue) progressively folds to form the neural tube. The ventral midline of the 
neural plate attaches to the notochord (red). The neural folds (yellow) form at the interface between 
the neural plate and the epidermal ectoderm (dark blue) and the interaction between these two 
tissues is required for the induction of the neural crest. The neural folds progressively come together 
to form the dorsal aspect of the neural tube and the neural crest (yellow). Adapted from Graham, 
2003. d) The four main regions of the neural crest (adapted from Duband et al, 1995-Neural crest 
culture, A Practical Appraoch)
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but only through the anterior half. This gives rise to the dorsal root ganglia, the sympathetic 
ganglia, adrenal medulla and also makes contributions to the heart. The dorsolateral pathway 
passes between the epidermis and the somites and gives rise to the melanocytes. Finally cells 
from the vagal and sacral neural crest contribute cells to the network of enteric ganglia.
Clonal analysis of neural crest cells and in vivo cell lineage analysis using a variety of 
labelling techniques have demonstrated that even at the migratory stage the neural crest is 
made up of cells at different states of determination. For instance there are multipotent 
progenitor populations that can give rise to both sensory and sympathetic neurones as well as 
associated glia. Furthermore both in vivo and in vitro studies have demonstrated the presence 
of neural crest stem cells displaying both self-renewal and pluripotent behaviour. In contrast, 
monopotent cells generating only neurones or only glia cells for example when exposed to a 
range of environmental conditions, have been demonstrated (Frank and Sanes, 1991;Luo et 
al., 2003), suggesting there is also some element of autonomous commitment to particular 
fates.
Taken together the evidence implies that neural crest cells comprises both pluripotent and 
fate restricted progenitor cells, so that the fate of specific neural crest populations must be 
controlled though environmental factors during normal development. For example, the 
sympathetic ganglia settle in the vicinity of the dorsal aorta which secretes Bmp-4 and Bmp- 
7 both of which trigger the differentiation of sympathetic neurones, whereas the formation of 
the dorsal root ganglia depends on exposure to brain derived neurotrophic factor (BDNF). 
Such environmental factors would alter gene expression in the neural crest cells by switching 
on the expression of transcription factors that are important for controlling the fate of these 
cells.
Whilst most is known about the role and function of mammalian transcription factors that 
control pattern formation, recent studies are beginning to unravel the transcription factors 
involved in the process of lineage determination and differentiation of specific neuronal 
subtypes. In general, genes controlling pattern formation during development show 
segmental expression in the neuroepithelium and are generally expressed in diverse cell types 
within a region. For example the homeobox containing genes of the HOX family have a clear 
role in hindbrain segmentation. In contrast, transcription factors that play a role in lineage
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determination and differentiation of neurones are expressed in cells that share common 
features. Several classes of transcription factors have been shown to play a role in lineage 
determination and in terminal differentiation and these can be used to identify specific cell 
types in these populations such as sensory neurones or autonomic neurones. For instance, the 
basic helix-loop-helix (bHLH) factor Mash-1 is required for the development of specific 
olfactory and autonomic neural lineages. Mash-1 is expressed in dividing neural crest 
precursor cells destined for these neuronal lineages. As expected for a lineage determining 
factor it is switched on just before they exit the cell cycle (Greenwood et al., 2000).
In contrast the bHLH family of transcription factors, neurogenin-1 (Ngn-1) and neurogenin-2 
(Ngn-2) are required for early development of sensory neurones. Expression of Ngn-2 has 
been well documented in migrating neural crest cells. Studies using an inducible Cre 
recombinase-based fate mapping system to mark a subpopulation of NCC that expresses 
Ngn2 (Zirlinger et al., 2002), showed that Ngn2 expressing cells are 20 times more likely to 
generate sensory than autonomic neurones. Thus this data suggests that other determinants of 
sensory identity are required in addition to Ngns in order to commit cells to a sensory fate. 
The expression of Bm-3a is one such factor that shows specific expression in sensory 
neurones and is induced by Ngns. Thus Bm-3a is expressed at a later stage than Ngns but is 
found in precursors destined for a sensory lineage as well as differentiating sensory neurones 
(Greenwood et al., 1999).
Interestingly, Ngn2 expression was observed in both pre-migratory and migrating neural 
crest cells (Sommer et al., 1996;Zirlinger et al., 2002) suggesting that the sensory 
developmental bias acquired by this subset of cells occurs at a relatively early stage in their 
ontogeny, and supports findings that the neural crest is made up of both pluripotent and fate 
restricted neural crest cells. The expression and role of Bm-3a in sensory neurones is 
discussed in more detail in later sections.
1.16.2 Neuronal developmental cell death
Cellular apoptosis is crucial for the proper development of the nervous system as both 
progenitor cells and post-mitotic neurones are overproduced in the nervous system. Through 
a process of elimination, those cells that have made appropriate connections survive and
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differentiate into neurones whereas others undergo apoptosis. This process of elimination 
occurs at two distinct phases of neuronal development. The first phase takes place just prior 
to the onset of neurogenesis when neural stem cells and progenitor cells migrate and populate 
the brain and spinal cord. This phase serves to eliminate excess progenitor cells and 
immature neurones to ensure that the correct number of cells is generated in structures such 
as the cerebral cortex. The existence of this period of developmental cell death has only 
recently been appreciated and the underlying mechanisms that determine life versus death in 
these cells are not well understood (reviewed by Kuan et al., 2000;Roth and D’SA et al, 
2001).
The second period of developmental cell death in the nervous system takes place after newly 
differentiated post-mitotic neurones have migrated to their final destinations, extended axons 
and have attempted to establish appropriate target connections. This period of naturally 
occurring cell death is crucial to match neuronal numbers to the size of the target tissue and 
results in elimination of approximately half of the neurones in any given population. The 
mechanisms controlling this process are best understood in developing sympathetic neurones, 
which compete for limited amounts of target derived trophic factors such as nerve growth 
factor (NGF). Those neurones that compete successfully survive and go on to innervate their 
target tissue in an NGF dependent fashion, whereas those neurones that fail rapidly undergo 
apoptosis.
NGF promotes survival by binding to neuronal TrkA tyrosine kinase receptors on axon 
terminals and mediates a retrograde survival signal (Miller and Kaplan, 2001) the most 
important of which is the Ras-P13-kinase-Akt pathway (see section 1.35) (Kaplan and Miller,
2000). This pathway supports sympathetic neuronal survival by blocking apoptotic signals 
that initiate from a second neurotrophin receptor, the p75 neurotrophin receptor (p75NTR) 
(Kaplan and Miller, 2000). Evidence for the functional antagonism between these two 
neurotrophin receptors is derived from analysis of TrkA-/- and p75NTR-/- animals. Firstly, 
during the post natal period of naturally occurring death, virtually all sympathetic neurones 
die in the TrkA-/- animal (Smeyne et al., 1994) whilst naturally occurring sympathetic 
neurone death is greatly delayed in p75NTR-/- mice (Majdan et al., 2001). Secondly a 
proportion of the sympathetic neurone apoptosis seen in TrkA-/- animals is rescued by the 
concomitant loss of p75NTR (Majdan et al., 2001), indicating that sympathetic neurones
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are destined to die as a consequence of ongoing p75NTR mediated apoptotic signalling and 
survive only if they sequester sufficient NGF to robustly activate TrkA.
Whether or not neurotrophins trigger neuronal apoptosis or survival depends on which Trk 
receptors are expressed in the cell. For instance the p75NTR binds all neurotrophins, whereas 
TrkA preferentially binds NGF whereas TrkB binds BDNF, NT-3 and NT-4. Thus NGF has 
the potential to be pro-apoptotic for cells that do not express TrkA, whereas BDNF would be 
pro-apoptotic for those cells that do not express TrkB. Therefore, upon reaching the 
appropriate target, a neurone must sequester enough of the appropriate pro-survival factor 
which reflects its expression of Trk receptors. Therefore a sympathetic neurone arriving to its 
target destination would sequester NGF leading to robust TrkA activation, over-riding the 
p75NTR signal. However if the sympathetic neurone arrives late or to the wrong target, TrkA 
will be weakly activated whereas p75NTR can be robustly activated by non-TrkA-binding 
neurotrophins encountered at the target environment such as BDNF, leading to apoptosis.
Apoptosis is a highly conserved process to rid of unwanted cells either during development 
or in damaged cells to halt the propagation of damaged DNA. Two major apoptotic pathways 
are defined in cells, the intrinsic and extrinsic pathways (Fig 1.9). The intrinsic pathway is 
engaged when the cells are challenged by stress and it is primarily mediated by the 
mitochondria, in which the Bcl-2 family members play a key role regulating this pathway 
(Korsmeyer, 1999). The extrinsic pathway is mediated by the death receptor family of 
proteins which involves ligand binding, the recruitment of adaptor molecules and resultant 
activation of Caspase 8 and apoptosis (Korsmeyer, 1999). Apoptosis can also be induced via 
endoplasmic reticulum (ER) pathways. The ER pathway is triggered by unfolded proteins 
and other abnormal cytosolic signals. The p53 tumour suppressor plays a key role in all three 
of these apoptotic pathways (see later).
In the case of neuronal cells, apoptosis occurs due to an imbalance of pro-apoptotic signals 
over anti-apoptotic which are regulated by the levels of various neurotrophic factors. The 
central role of the JNK-p53-Bax apoptotic pathway in response to neurotrophic withdrawal 
or p75NTR activation is discussed in detail in section 1.35. The general mechanisms of p53 
mediated apoptosis in the nervous system are reviewed here and shown in Fig 1.9.
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Figure 1.9: Downstream targets of p53 mediated apoptosis
The role of p53 and p73 in neuronal developmental apoptosis is discussed in section 1.35. Purple 
targets represent genes regulated by the p53 transcription factor. Note that some of these targets are 
also regulated by p73 such as Bax, Noxa, Puma, p53AIP1 and Fas.
Apoptosis is regulated by the interaction of pro- and anti-apoptotic members o f the Bcl2 
family which function to either promote (Bax, Noxa, Puma, Bid and Bad) or prevent (Bcl-2, 
Bc1-xl) membrane permeability transition and the release of Cytochrome c (Yang et al., 
1997;Narita et al., 1998). There are approximately 15 members o f the Bcl-2 family which 
share one or more Bcl-2 homology domains (BH1-BH4) (Korsmeyer, 1999). The anti- 
apoptotic members o f the Bcl-2 family, all possess BH1 and BH2 domains with some also 
containing additional BH3 and BH4 domains. The pro-apoptotic members all contain the 
BH3 domain which is essential for their pro-apoptotic effect and can be subdivided based on 
the presence or absence o f other BH domains.
The pro-apoptotic Bax protein has been shown to interact with Bc1-xl and Bcl-2 to regulate 
mitochondrial Cytochrome c release. Thus heterodimerization o f Bax with either Bcl-2 or 
Bc1-xl  inhibits the pro-apoptotic functions of Bax. However activation o f Bax, results in the 
formation of Bax-Bax homodimers which function by disrupting the mitochondria membrane 
resulting in the loss o f Cytochrome c and apoptosis. The BH3 only proteins (eg Noxa and
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Puma) act upstream of Bax where they interact with the anti-apoptotic family members and 
inhibit their function.
The anti-apoptotic Bcl-2 and B c 1 -x l proteins are widely expressed in both the embryonic and 
adult nervous system and are required for the survival of specific populations of neurones in 
both the CNS and PNS. (Allsopp et al., 1993;Motoyama et al., 1995;Gonzalez-Garcia et al.,
1995). Furthermore, the Bcl-x gene can undergo alternative splicing to produce the anti- 
apoptotic form B c 1 -x l and the pro-apoptotic form Bcl-xs, of which B c 1 -x l is the predominant 
transcript found in the developing and adult nervous system (Gonzalez-Garcia et al., 1994). 
However, Bcl-2 KO mice showed only a subtle neuronal developmental phenotype affecting 
primarily the maintenance of specific neuronal subpopulations during postnatal life 
(Michaelidis et al., 1996). In contrast, disruption of the Bcl-x gene results in massive 
apoptosis of post-mitotic neurones throughout the developing nervous system but fails to 
affect apoptosis of neural precursor cells in the ventricular zone. As such these mice die 
during embryogenesis at E13.5 (Motoyama et al., 1995). Moreover Bcl-x -/- /Bcl-2 -/- double 
deficient mice shown even more loss of post-mitotic neurones (Shindler et al., 1998) 
suggesting that Bcl-2 may compliment B c 1 -x l in these subpopulations, as well as its main 
function in the survival of mature neurones.
Of the ten known pro-apoptotic Bcl-2 members, Bax has proven to be the most important in 
neuronal development. Indeed, Bax -/- animals show dramatically increased neuronal cell 
numbers as a result of lack of naturally occurring death of post-mitotic neurones. Moreover, 
Bax-/- neurones survive even in the absence of neurotrophic factors (Deckwerth et al., 
1996;White et al., 1998). Furthermore the generation of Bcl-xi/Bax double knock out mice 
demonstrate that loss of Bax rescues the increased apoptosis seen in the Bcl-xL-/- null mice 
(Shindler et al., 1997). Thus the relative levels of expression of Bax and Bcl-xL appear to 
determine neuronal susceptibility to apoptosis during naturally occurring cell death.
The action of the Bcl-2 family is frequently mediated via activation of caspases whose 
defined role in neuronal cell death has been well established. Caspases comprise a family of 
cysteine containing aspartate-specific proteases which contain three domains. These are the 
N-terminal domain, a large subunit and a small subunit. Caspases are present in the cell as 
proenzymes and activation of caspases involves proteolytic cleavage and the association of
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the large and small subunits to form an active heterodimer or tetramer (Thomberry and 
Lazebnik, 1998). Once activated caspases cleave other caspases further downstream, an event 
that leads to cell death. For example the cleavage of Caspase-3 by either caspase 8 (activated 
via the death receptor pathway) or Caspase-9 (activated via the mitochondria pathway) is 
irreversible and commits the cell to undergo cell death. The importance of caspases in 
neuronal cell death is shown by the phenotypes of mice in which the Caspase-3 or Caspase-9 
genes have been deleted (Kuida et al., 1996;Kuida et al., 1998).
Both Caspase-3 and Caspase-9 null mutants are embryonic lethal and in both cases show 
gross structural abnormalities in the nervous system, including indentations of the cerebrum 
and periventricular masses as a consequence of a failure of progenitor cells to undergo 
apoptosis (Kuida et al., 1996;Kuida et al., 1998). The similar neuronal phenotypes of these 
caspase knock out mice is also common to Apafl null animals (Cecconi et al., 1998) and a 
subset of p53-/- animals (see section 1.32) (Armstrong et al., 1995;Sah et al., 1995) 
suggesting that these different proteins may function in the same death pathway in neuronal 
cells. Indeed p53 acts upstream of Apafl and induces its expression (Kannan et al., 2001). 
The Apafl protein mediates apoptosis by activating Caspase-9 after mitochondrial damage. 
Thus, Apafl forms a complex with Cytochrome c and Caspase-9 via the caspase recruitment 
domain (CARD) motif that is present in Caspase-9 but not Caspase-3. The interaction of 
Apafl, Caspase-9 and Cytochrome c forms an active apoptosome, which results in the 
cleavage of Caspase-9 which in turn cleaves Caspase-3, leading to apoptosis (Fig 1.9).
Death receptor mediated activation of caspase-8 has also been shown to function in neuronal 
cells. In this case Caspase-8 mediated cleavage of pro-apoptotic Bid produces truncated Bid 
(tBid), which functions by aiding Bax insertion into the mitochondrial membrane resulting in 
membrane dysfunction and subsequent release of cytochrome c (Fig 1.9).
Therefore, the proper control of neuronal proliferation, differentiation and cell death is 
essential for the normal function of the nervous system. The role of the Bm-3 transcription 
factor in neuronal development is discussed in the following sections.
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1.17 Expression of Brn-3a and Brn-3b in the nervous system
Most of the studies on expression and function of Bm-3 proteins in the nervous system have 
been focused on the Bm-3a and Bm-3b transcription factors. Both Bm-3a and Bm-3b show 
extensive overlap in the CNS and PNS during development, but in the adult, Bm-3b 
expression is more restricted. Table 1.3 summarises the expression of these two genes in the 
developing and adult nervous system.
1.17.1 Bm-3a in neuronal cells
Bm-3a is the most widely expressed of the Bm-3 transcription factors in the nervous system. 
In the peripheral nervous system (PNS), Bm-3a is found in the dorsal root ganglia, trigeminal 
ganglia and spinal cord whereas in the central nervous system (CNS), Bm-3a is expressed in 
the hindbrain and midbrain. In the PNS, Bm-3a is first detected in the neuronal precursor 
cells, immediately before the cells exit the cell cycle, as well as in differentiated sensory 
neurones. However, in the CNS, Bm-3a expression is observed only in post-mitotic 
neurones. This suggests that Bm-3a is involved in specification/maintenance of a subset set 
of neurones in the PNS and in the terminal differentiation/maintenance of a subset of 
neurones in the CNS (Gerrero et al., 1993;Tumer et al., 1994;Fedtsova and Turner, 
1995;Xiang etal., 1995).
In the PNS, expression of Bm-3a is first detected at E9.0 in the migrating neural crest cells 
which are destined for a sensory lineage (Fedtsova et al., 1995;Greenwood et al., 1999). 
Precursors arising from the neural crest can give rise to both sensory and autonomic cells of 
the PNS, in which Bm-3a is expressed in cells destined for a sensory lineage but not in those 
of autonomic lineage (Greenwood et al., 1999). At E9.5, Bm-3a is also detected in the 
trigeminal ganglia (TG), dorsal root ganglia (DRG) and the spinal cord. In the spinal cord, 
Bm-3a is detected in the dorsal half and intermediate gray of the cord in post-mitotic cells 
(i.e. outside the ventricular zone) and by E l8, Bm-3a is predominantly detected in the deep 
dorsal hom (Ninkina et al., 1993;Fedtsova et al., 1995). Bm-3a continues to be expressed in 
the sensory ganglia throughout development when the cells have become post-mitotic and
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Brn-3a Brn-3b
E15.5 adult E15.5 adult
Localization
Brain Structures
Thalamus + + + + + - - Medial habenula 
Lateral habenula
Midbrain
-Interpeduncular n. 
-Mesencephalic n. 
-Red nucleus
+ +
+ +
+ +
+ / -
+ + +
+ +
+ + +
+ +
+ + +
+ + +
Superior colliculus 
Inferior colliculus 
Parabigeminal n. 
Periaquaductal 
gray
Hindbrain + + + + + / + + + + - Brain stem (motor 
Nucleus ambiguus 
Medulla 
Pons
Inferior olivary n.
Other neurones
Retina + + + + + + +
Sensory neurones 
-Trigeminal 
-Dorsal root ganglia
+ + +
+ + +
+ + +
+ + +
+ +
-H -
+
+
Spinal cord + + + + -H - + Bm-3a in dorsal 
gray
Bm-3b in 
intermediate gray
Table 1.3: Expression patterns of Bm-3a and Bm-3b in the developing and the adult nervous 
system.
Expression of Bm-3a and Bm-3b in the developing and adult nervous system. Strong expression +++, 
moderate expression ++, weak expression +, no detectable expression Nucleus is abbreviated to n. 
This table was reproduced from a PhD thesis, titled Regulation and Function of POU domain 
transcription factors Bm-3a and Bm-3b, Author Dr. Budhram-Mahadeo
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remains high in the TG and DRG postnatally (Turner et al., 1994;Fedtsova et al., 
1995;Greenwood et al., 1999).
As expression of Bm-3a in the periphery is restricted to the sensory ganglia, and is not 
detected in any other neural crest derivative, this suggests that Bm-3a is an early specific 
marker of migrating neural crest cells fated for a sensory lineage which contribute to the 
DRG and sensory cranial ganglia (the DRG is derived specifically from the neural crest, 
whereas the different sensory cranial ganglia receive contributions from the neural crest 
and/or neural placodes which are discrete patches of ectoderm on the head of the vertebrate 
embryo). The expression of Bm-3a in the sensory neuronal lineage arising from the 
mammalian neural crest has been investigated by Greenwood and colleagues (1999). In 
proliferating sensory precursor cells, BrdU +ve cells expressing Bm-3a were shown to divide 
for 2 days following migration from the neural tube, before differentiating into sensory 
neurones. This suggests that expression of Bm-3a in NCC might mark the point of 
commitment to the sensory lineage. This was supported by studies in which addition of 
BMP2, which induces autonomic neurogenesis did not prevent sensory neurogeneis in Bm- 
3a expressing NCC (Greenwood et al., 1999). Interestingly, further characterisation of the 
sensory neurones generated from such precursors exhibited a proprioceptive and/or 
mechanosensory but not a nociceptive phenotype under these culture conditions, which 
correspond to a sublineage of early differentiating precursors of Bm-3a-positive large 
diameter sensory neurones, identified in vivo (Frank et al., 1991).
Thus the early expression of Bm-3a in precursor cells destined for a sensory lineage suggests 
that Bm-3a is involved in the specification of these cells. This is analogous to the role of 
Unc-86, which is also expressed prior to the exit of cells from the cell cycle in the neuronal 
precursor cells in the nematode and plays a critical role in the determination of sensory 
neurones (Finney and Ruvkun, 1990).
In the central nervous system, Bm-3a is detected at high levels in the developing midbrain, 
hindbrain and the spinal cord and continues to be expressed in specific regions of the adult 
brain. Bm-3a is first detected in occasional cells near the midline of the rostral 
mesencephalic tectum at E8.5, prior to closure of the anterior neuropore (Fedtsova et al.,
1995). In contrast to the Bm-3a expressing cells in the PNS, these cells do not express PCNA
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and are thought to have exited the cell cycle. By E9.5 Bm-3a mRNA can clearly be detected 
in the mesencephalic neurones in the midbrain. Between E12.5 and E l5.5 Bm-3a expression 
is observed in the inferior olivary complex of the hindbrain, the outer layer of post-mitotic 
cells in the tectum of the midbrain, the developing red nucleus and the medial habenula 
(Turner et al., 1994). Around this time Bm-3a is also expressed in the inner most layer of 
cells in the retina (which give rise to the ganglion cell population) at the time when these 
cells start to differentiate and initiate axon growth, with retinal expression continuing 
postnatally (Gerrero et al., 1993;Tumer et al., 1994). Hence during CNS development, Bm- 
3a expression is restricted to post-mitotic neurones in specific regions of the brain.
In the adult brain, Bm-3a is detected in similar areas to that observed in the developing brain 
but in a more restricted manner. Thus, Bm-3a is detected in the medial habenula, superficial 
gray of the superior colliculus, red nucleus, mesencephalic nucleus of the TG, nucleus 
ambiguous, inferior olivary nucleus, retina and the peripheral sensory ganglia (Turner et al.,
1994). Moreover, even though present in lower levels, Bm-3a is also found in the adult heart, 
(S.Farooqui 2004) lungs, breast epithelium, ovary and testis (Budhram-Mahadeo et al., 
2001). Bm-3a mRNA is not detected in other tissues such as the liver, kidney, spleen and 
adrenal glands (Gerrero et al., 1993;Ninkina et al., 1993;Tumer et al., 1994;Fedtsova et al.,
1995).
1.17.1.1 Regulation of Brn-3a expression
As already mentioned the expression of Bm-3a is controlled by two distinct promoters (Frass 
et al., 2002). The first more distal upstream promoter is TATA-less and contains two bona 
fida mRNA start sites spanning over 500 base pairs 5’ of the ATG translation initiation and 
directs the expression of the long isoform of Bm-3a [Bm-3a(l)]. The second promoter, also 
TATA-less, spans the first intron of the Bm-3a gene and controls the expression of the 
shorter form of Bm-3a [Bm-3a(s)] specifically in neuronal cells but not in epithelial cells. 
Thus, alternative promoter usage allows these two isoforms to be differentially regulated in 
different cell types and during development.
Interestingly, two clusters of Bm-3 recognition sites have been identified within the Bm-3a 
locus, which are located approximately 10 and 5 kb from the start site of transcription. The
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distal and proximal sites contain 1 and 4 copies, respectively, of a sequence motif that 
conforms closely to the optimal Bm-3 recognition site. In transfection assays, the proximal 
cluster was more effective at transactivating Bm-3a expression compared with the distal 
region (Trieu et al., 1999). Thus, these regions are likely to mediate autoregulation providing 
a mechanism by which Bm-3a expression in maintained in differentiated neuronal cell types 
and in the adult nervous system. Furthermore, this autoregulation may provide the positive 
feedback mechanism that increases expression of Bm-3a to compensate for loss of one allele 
in Bm-3a -/+ animals which develop normally.
1.17.2 Brn-3b in neuronal cells
Bm-3b expression in both the developing and adult brain shows considerable overlap with 
Bm-3a, but also shows some distinct expression from Bm-3a which strongly suggests that 
unique roles for each gene exists in the development of specific neuronal phenotypes (see 
table 1.3).
Bm-3b expression is first detected in the mouse embryonic body at E l0.5 with expression in 
the head observed by El 1.5, which is later than that observed for the expression of Bm-3a 
which is first detected at E9.5 in similar structures (Turner et al., 1994).
In the hindbrain and midbrain, Bm-3b mRNA is detected by E l3.5 and the pattern of 
expression shows some similarity with Bm-3a. For example, both Bm-3a and Bm-3b are 
detected in the post-mitotic neuronal cell population of the inferior olivary complex by 
E l5.5. However, Bm-3b also demonstrates some sites of unique expression so that by El 7.5 
Bm-3b expression is detected in the medullary anterior external migratory stream, a group of 
cells that do not express Bm-3a. In the midbrain, both Bm-3a and Bm-3b are detected in the 
tectum of the mesencephalon. However, by El 7.5 Bm-3b but not Bm-3a is uniquely detected 
in the interpeduncular of the midbrain where its expression persists into adulthood (Turner et 
al., 1994). Analysis of Bm-3b protein expression in serial coronal sections from postnatal day 
1 (PI) mouse brain, showed that Bm-3b is expressed in the lateral margin of the cerebellum 
and in the midbrain. Specifically, Bm-3b expression was found in the superior colliculus 
(which integrates the sensorimotor inputs to control eye movement) and the adjacent
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periaquaductal gray of the midbrain (Xiang et al., 1993).
In the retina, Bm-3b mRNA is first detected in the innermost layer of ganglion precursor 
cells at El 1.5 and by E17.5, this expression is restricted to the post-mitotic layer (Turner et 
al., 1994). In the retina, Bm-3b expression precedes Bm-3a expression (Bm-3b is detected by 
El 1.5 whilst Bm-3a is not detected until two days later). The relative expression of both 
factors peak at birth but gradually decreases by P30 (Turner et al., 1994).
In contrast, to its expression in the retina, Bm-3b is first detected in the sensory ganglia, TG 
and DRG, at E l3.5, two days later than the onset of Bm-3a expression in these neurones. By 
E l5.5, Bm-3b is also detected in the cochlear and vestibular parts of the cranial nerve 
ganglion VIII and the ganglion of glossopharyngeal nerve IX. In the spinal cord, Bm-3b is 
widely expressed by E l2.5 but by E l5.5, its expression is restricted to the intermediate gray 
while Bm-3a mRNA is expressed throughout the dorsal gray region (Turner et al., 1994).
In the adult mouse and rat neuronal tissues, Bm-3b expression is restricted to specific regions 
of the brain and PNS. In the adult rat CNS, Bm-3b is detected in the optical, intermediate and 
deep gray areas of the superior colliculus, the dorsal column of the mesencephalic, pontine 
central gray, and the lateral interpeduncular nucleus. It is also expressed in the adult TG, 
DRG and retina (Turner et al., 1994). Bm-3b is also expressed in the adult heart and 
reproductive tract but not in the liver, spleen, kidney, lung and thymus (Turner et al., 
1994;Budhram-Mahadeo et al., 2001;S.Farooqui 2004).
1.17.2.1 Regulation of Bm-3b activity
The regulation of Bm-3b expression in different cell types has yet to be fully determined and 
the characterization of the Bm-3b promoter and identifying factors that regulate its activity 
are currently being investigated in our laboratory.
The co-expression of Bm-3a and Bm-3b in several sub-populations of neurones led to the 
idea that that they may regulate each others expression. Indeed, Bm-3b was shown to activate 
the proximal regulation sequence in the Bm-3a locus in transfection assays. This is 
interesting as it suggests that Bm-3b may activate the expression of Bm-3a in neuronal sub­
populations in which Bm-3b expression is switched on first such as in the retina and the
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inferior olivary. Such a regulatory mechanism may also explain the severity of the retinal 
defects in Bm-3b -/- animals (section 1.20) where the absence of Bm-3b would lead to the 
absence of Bm-3a which would otherwise compensate for the lack of Bm-3b in these 
animals.
Thus, expression studies in the developing nervous system have shown that both Bm-3a and 
Bm-3b are expressed in the CNS coinciding with the terminal phase of neuronal 
development in each area of their expression, suggesting a developmental role for each factor 
in the terminal differentiation and maintenance of specific neuronal phenotypes. The 
expression of Bm-3a in sensory neural crest precursors and differentiated sensory neurones is 
interesting as it suggests that expression of Bm-3a plays a significant role in committing 
these cells to a sensory neuronal fate as well as being required for their differentiation.
The generation of mice models in which the Bm-3a and Bm-3b gene has been deleted have 
proved very useful in elucidating the role of these proteins in neuronal development and 
confirmed the critical role that these factors play in determining the cell fate of specific 
neuronal cell types. The functions of Bm-3a and Bm-3b in neuronal cells are discussed in the 
following sections.
1.18 Role of Bm-3a in neuronal survival
The expression pattern of Bm-3a suggested that this transcription factor might play an 
important role in the development of sensory ganglia as well as a subset of neurones in the 
CNS in which this transcription factor is expressed. Indeed, analysis of Bm-3 a-/- embryos 
has revealed significant apoptosis in sensory neurones during late embryogenesis in the TG, 
DRG as well as in the red nuclei, and nucleus ambiguus of the hindbrain and the inferior 
olivary nucleus and medial habenula (Xiang et al., 1996;McEvilly et al., 1996;Huang et al., 
1999). Thus it appears that the neurones that would normally express Bm-3a are specified 
but they fail to survive at these sites in the Bm-3a -/- mice, indicating that Bm-3a is essential 
for their survival.
The phenotype of Bm-3a -/- animals show gross phenotypic abnormalities which include 
ineffective swallowing and uncoordinated limb and trunk movements resulting in the
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inability to right themselves. These animals also show intermittent abnormal movement and 
posture including rigid outstretched limbs and head. Consequently these animals die within 
24 hr of birth possibly as a result of the inability to suckle. Both the red nucleus and the 
inferior olivary nucleus are involved in co-ordination of movement and the striking loss of 
neurones in these locations in the Bm-3a -/- mouse would contribute to the abnormal 
locomotion and posture in these animals. Also the loss of motor neurones in the nucleus 
ambiguus, which innervate the oesophagus, might contribute to the abnormal peristaltic 
swallowing reflex. In the PNS there is a significant reduction in the biochemical markers that 
characterise sensory neurones, which can also contribute to the uncoordinated limb and trunk 
movement in these animals.
To better understand the changes underlying sensory neurogenesis in mice lacking Bm-3a, 
Eng and colleagues (2001) generated transgenic mice in which they cloned a Lac Z reporter 
into the Bm-3a locus. Crossing this strain with mice carrying a Bm-3a null allele generated 
Lac Z Bm-3a knock out embryos which facilitated the analysis of cells that would normally 
express Bm-3a and to further examine the abnormalities that accompany the loss of this 
transcription factor. These studies demonstrated that mice lacking Bm-3a have defects in 
sensory axon growth. Thus at El 1.5 the neurones in the TG and DRG condense as expected 
and grow towards their peripheral targets. However by E l3.5 the Bm-3a null mice 
demonstrate abnormal axon bundles and migration as well as premature branching in the TG. 
Furthermore, the TG neurones do not effectively innervate their peripheral targets and this is 
particularly obvious in the whisker follicles. By E l5.5 there is extensive apoptotic death 
resulting in loss of cells that would normally express Bm-3a (Eng et al., 2001) These results 
suggest that death in Bm-3a-/- mice results from the failure of sensory axons to correctly 
innervate their targets and access target derived factors. Hence Bm-3a appears to control 
survival and normal differentiation/path-finding of specific neurones.
The analysis of target gene expression in the TG of Bm-3a-/- embryos showed a decrease in 
the number of TrkA and TrkB expressing sensory neurones by E l3.5 whereas TrkC could 
not be detected in the TG of Bm-3a-/- embryos. However the timing of initiation of neuronal 
cell death Bm-3a-/- TG occurs at E l5.5. This suggests that Bm-3a, normally expressed at E9 
is critical for the activation of TrkA and TrkB genes or the growth promoting effects of Bm- 
3a is required to maintain TrkA and TrkB expression neurones during the period of
55
naturally occurring developmental cell death. Conversely the failure of TrkC expressing 
neurones to emerge in the TG suggests that Bm-3a is involved in their induction. However, 
despite the expression of Bm-3a in TG precursor cells, loss of Bm-3a does not result in a 
reduction in the number of these cells (Huang et al., 1999).
Although Bm-3a is critical for the regulation of expression for Trk receptors, these receptors 
do not appear to directly affect survival. For instance, the wave of apoptosis seen in the TG 
of Bm-3a -/- mice occurs at E15.5, two days after loss of TrkA and TrkB expression. 
Moreover, the generation of double KO Bm-3a/Bax mice resulted in surviving neurones but 
TrkA expression is eventually lost, suggesting that this receptor is necessary for neuronal 
differentiation rather than the apoptosis observed in the Bm-3a-/- neurones (section 1.19) 
(Ma et al., 2003). In addition, Bm-3a was shown to induce survival under conditions of 
neurotrophin deprivation both in vitro and in vivo (see below) (Smith et al., 2001;Ensor et al.,
2001) indicating that it is unlikely that the Bm-3a survival fimction is mediated just by up- 
regulating neurotrophic receptors (McEvilly et al., 1996). Interestingly, Bm-3a has been 
shown to control expression of both anti-apoptotic and pro-apoptotic factors which may 
represent the main mechanism by which Bm-3a controls survival of neurones in which it is 
expressed (see below). Additionally, recent studies have shown that Bm-3a can control 
neuronal cell fate by modifying gene transcription by interaction with other cellular proteins 
such as p53 (section 1.24) (Perez-Sanchez et al., 2002;Budhram-Mahadeo et al., 2002).
The requirement of Bm-3a in neuronal survival has also been shown using in vitro systems. 
Initial studies were carried out in the ND7 cell line which was derived by fusing neurones 
from non-dividing rat DRG with the Cl300 mouse neuroblastoma cell line (Woods et al., 
1990). One resultant clone could proliferate indefinitely in full growth medium behaving like 
the parental neuroblastoma cells. However these cells can be induced to differentiate upon 
serum withdrawal or addition of defined medium supplemented with growth factors and 
cyclic AMP analogues. Upon differentiation, these cells undergo cell cycle arrest and 
morphological changes such as neurite outgrowth accompanied by movement of secretory 
granule component and synaptic vesicle component to the apex of processes, mimicking the 
events associated with differentiation of sensory neurones. These findings make this cell line 
ideal to investigate the role of Bm-3a in neuronal survival and differentiation.
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Thus, in vitro studies have shown that the overexpression of Bm-3a in the ND7 neuronal cell 
line increases survival even upon removal of neurotrophic factors compared with controls 
(Smith et al., 1998a). This protective effect of high Bm-3a levels is also observed in cultured 
DRG and TG neurones upon NGF withdrawal (Smith et al., 1998b;Ensor et al., 2001). 
Similarly, increasing Bm-3a expression protects DRG cells following sciatic nerve lesion in 
vivo. Conversely, the reduction of Bm-3a expression using an anti-sense approach results in 
apoptosis in ND7, DRG and TG neurones even in the presence of neurotrophic factors 
(Smith et al., 2001;Ensor et al., 2001).
Subsequently, anti-apoptotic genes associated with survival in these cells were shown to be 
regulated by Bm-3a. Firstly Bm-3a was shown to strongly activate the Bcl-2 P2 promoter 
(which is the predominant promoter that drives Bcl-2 expression in neuronal cells) and to a 
lesser extend the Bcl-2 PI promoter in ND7 cells as well as in primary DRG cells. 
Furthermore, Bcl-2 expression was significantly elevated in ND7 cells over-expressing Bm- 
3a and in primary cultures of DRG and TG neurones transfected with Bm-3a compared with 
controls (Smith et al., 1998a;Smith et al., 1998b;Ensor et al., 2001). Similarly, a decrease in 
the levels of Bcl-2 expression is evident in cells transfected with Bm-3a anti-sense which 
reduced the expression of this transcription factor (Ensor et al., 2001). More recently, Bm-3a 
was shown to transactivate another anti-apoptotic gene, B c 1 -x l which shares high homology 
to Bcl-2. Interestingly the phenotype of the Bcl-xL null mice is similar to the Bm-3a knock­
out in terms of requirement for neuronal survival (Motoyama et al., 1995;Xiang et al., 
1996;McEvilly et al., 1996). Hence these findings support the hypothesis of these factors 
being in a similar pathway that is required for protection of neurones in vivo. Moreover, 
overexpression of Bm-3a in DRG and TG primary cultures results in clear elevation in the 
endogenous mRNA and protein levels of B c 1 -x l (Smith et al., 2001). Conversely, use of anti­
sense to decrease levels of Bm-3a show a concomitant decrease in B c 1 -x l levels. 
Furthermore, Bm-3a activates the B c 1 -x l promoter in primary sensory neurones and ND7 
cells (Smith et al., 2001). Additionally Bm-3a has been shown to inhibit expression of the 
pro-apoptotic Bcl-2 family member, Bax either directly, through a mild repression and 
indirectly through antagonism of p53 (see section 1.24) (Budram-Mahadeo et al., 2002).
Thus the direct up-regulation of Bcl-xi and down-regulation of box may be more relevant in 
protecting neurones during development and may explain why significant numbers of
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sensory neurones fail to survive the naturally occurring death period in Bm-3a-/- animals, as 
Bm-3a-/- mice and Bcl-xL-/- mice display similar loss of neurones in terms of time of death 
and in the population of neurones affected (Motoyama et al., 1995;Xiang et al., 
1996;McEvilly et al., 1996; White et al., 1998). In contrast, the Bm-3a up-regulation of Bcl-2 
may be more important in the survival of postnatal neurones.
1.19 Role of Brn-3a in neuronal differentiation
Both in vivo and in vitro studies have shown that in addition to the protective effects 
conferred by Bm-3a in neuronal cells, this transcription factor also plays a critical role in 
neuronal differentiation.
Bm-3a is expressed only in post-mitotic neurones in the CNS and identifies the first 
differentiated neurones to appear in the midbrain, hindbrain and spinal cord. Thus the onset 
of Bm-3a expression in the CNS suggests that it is not required for neurogenesis of the 
neuroepithelium but is involved in specification of mature neuronal phenotypes. In the PNS, 
Bm-3a expression is initiated in neural crest cells destined for a sensory lineage, just before 
neurones exit the cell cycle suggesting that Bm-3a is involved in commitment as well as 
differentiation in these cells that express it (Fedtsova et al., 1995;Greenwood et a., 1999). In 
particular, the aberrant axon guidance observed in TG of Bm-3a-/- animals at E l3.5 suggests 
a role for this factor in the development of functional axons, (Eng et al., 2001).
As already mentioned the TG ganglia in Bm-3a-/- animals fail to express TrkC and show a 
significant secondary loss of TrkA and TrkB expressing neurones by E l3.5. This suggests 
that Bm-3a might be important in regulating the expression of these Trk receptors. However, 
so far Bm-3a has only been shown to directly regulate TrkA (Huang et al., 1999), which may 
be involved in Bm-3a mediated differentiation rather than survival (Ma et al., 2003). Indeed, 
lack of TrkA/NGF signalling results in defective innervation of peripheral targets by sensory 
neurones (Patel et al., 2000). Moreover, the TG of Bm-3a-/- mice display aberrant axonal 
growth around the time that TrkA protein levels are minimally reduced (Huang., 1999;Eng et 
al., 2001). Thus it is possible that the abnormal axon defects in Bm-3a -/- mice are a result of 
altered expression of Trk receptors. To date, other regulatory targets through which Bm-3a
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might exert its effects on sensory axon formation are still to be identified.
The requirement for Bm-3a in neuronal differentiation and outgrowth of neuronal processes 
has also been demonstrated in vitro. Amplification of mRNA from ND7 cells using primers 
specific to Bm-3a, show very low levels are expressed in actively proliferating ND7 cells. 
However, Bm-3a mRNA levels are greatly increased when ND7 cells switch from the 
proliferating phenotype to a differentiated state with neurite outgrowth. This pattern of 
expression was also confirmed by changes in Bm-3a protein levels (Lillycrop et al., 
1992;Budhram-Mahadeo et al., 1995a). Therefore Bm-3a appears to be associated with 
neuronal differentiation in this cell model. A more detailed investigation in ND7 cells and 
cultured adult rat DRG neurones revealed that the ratio of the long and short forms of Bm-3a 
is regulated at the mRNA level in response to various differentiation-inducing stimuli. Upon 
differentiation it was demonstrated that the increase in Bm-3a mRNA was due to increasing 
levels of the short form of Bm-3a, whereas the mRNA encoding the long form was only 
marginally elevated (Liu et al., 1996).
In agreement with a role for Bm-3a in neuronal differentiation, over expressing Bm-3a in 
ND7 cells is sufficient to cause increased neurite outgrowth by up to 60% even when these 
cells are grown in conditions that would not normally promote neurite formation (i.e. when 
grown in full serum medium which promotes proliferation) (Smith et al., 1997b). 
Furthermore, over-expression of Bm-3a in ND7 cells resulted in enhanced neurofilament 
heavy (NF-H), neurofilament medium (NF-M) and neurofilament light chain (NF-L) 
expression at both the mRNA and protein level. Moreover, Bm-3a was shown to 
transactivate all three neurofilament genes in co-transfection assays (Smith et al., 1997c). 
Similarly, Bm-3a over-expressing ND7 cells exhibited a clear up-regulation of SNAP-25 
mRNA which is involved in vesicle exocytosis and axon outgrowth, and Bm-3a was shown 
to be a direct activator of the SNAP-25 gene (Lakin et al., 1995), Moreover, Bm-3a was 
shown to directly activate the neuronal intermediate filament, a-intemexin gene (Budhram- 
Mahadeo et al., 1995b). Finally, up-regulation of three other proteins involved in the 
synaptic vesicle cycle was exhibited in Bm-3a over-expressing ND7 cells. These were 
synapsin I, synaptophysin and synaptotagmin I which were found to be up-regulated at both 
the protein and mRNA level in Bm-3a over-expressing ND7 cells compared to controls 
(Smith et al., 1997b). Conversely reduction of Bm-3a levels using an anti-sense
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approach, results in failure of neurite outgrowth even when cells were grown in optimal 
differentiation conditions (Lakin et al., 1995).
Activation of the neurofilament genes and the a-intemexin gene provides the cytoskeletal 
framework for neurite elongation and for the radial growth of axons, and are essential for 
maintaining axon diameter and transport. The regulation of different neurofilament genes by 
one transcription factor is interesting in view of the fact that neurofilament are obligate 
heteropolymers and any change in the expression of individual subunits results in aberrant 
axon size and transport. Hence a common regulator of all three neurofilament genes would 
be critical for their correct functioning, making Bm-3a a master regulator for controlling the 
expression of these genes in Bm-3a expressing neurones.
Thus the induction of neurite outgrowth upon Bm-3a over-expression or following the rise in 
Bm-3a expression during ND7 cell differentiation is likely to be dependent on its ability to 
activate specific target genes whose protein products are required for neurite outgrowth.
1.20 Role of Brn-3b in neuronal development
Detailed analysis of Bm-3b-/- animals showed most significant changes in the eye, where 
there is loss of approximately 70% of their retinal ganglion cells between PI 7-20, resulting in 
these animals being blind (Erkman et al., 1996;Gan et al., 1996). The significance of the 
phenotype of the Bm-3b animals is demonstrated by its high expression in the retinal 
ganglion cells which precedes that of Bm-3a. Interestingly, retinal ganglion cells of Bm-3b-/- 
animals show disorganised neurites which fail to fasciciculate efficiently and thus undergo 
apoptosis (Gan et al., 1999;Erkman et al., 2000). Therefore Bm-3b is required for normal 
retinal ganglion cell differentiation. Even though Bm-3b is expressed in other regions of the 
CNS and PNS there were no apparent defects in these structures suggesting functional 
redundancy by the presence of other related proteins such as Bm-3a/Bm-3c.
In differentiating ND7 cells, Bm-3b shows reciprocal expression to that of Bm-3a. Thus 
proliferating ND7 cells grown in hill growth media express high levels of Bm-3b which 
dramatically decreases upon differentiation (Lillycrop et al., 1992;Budhram-Mahadeo et al., 
1995a). Interestingly, when grown in differentiation medium, ND7 cells that artificially
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over-express Bm-3b showed reduced length of neurites and reduced expression of SNAP-25, 
synaptophysin and synaptotagmin that are activated during Bm-3a-induced differentiation 
(Smith et al., 1997a). The association of Bm-3b with proliferation and Bm-3a with 
differentiation was further shown in cell lines derived from human neuroblastoma tumours 
(IMR-32, SK-N-SH and SK-N-MC). Additionally, Bm-3b over-expressing cells failed to 
respond to growth inhibitory stimulus such as retinoic acid (RA) which causes differentiation 
of wild type neuroblastoma cells (Irshad et al., 2004). Moreover, treatments that induces 
differentiation results in activation of a test promoter that is normally induced by Bm-3a and 
repressed by Bm-3b (Morris et al., 1994;Smith and Latchman, 1996). Indeed Bm-3b has 
been shown to directly antagonise Bm-3a activation of specific target genes (see section 
1.22).
Therefore, these findings indicate that the regulation of neuronal cell differentiation is 
controlled by the enhanced expression of the differentiation inducing factor, Bm-3a and a fall 
in the level of the proliferation associated factor, Bm-3b. As these factors are expressed in 
distinct but overlapping patterns in the developing and adult nervous system (Gerrero et al., 
1993;Tumer et al., 1994;Fedtsova et al., 1995) it is possible that they play a complex role in 
regulating neurite outgrowth during development. This is particularly evident for Bm-3b 
which exhibits different roles in different cell types, as it is associated with the survival and 
terminal differentiation of retinal ganglion cells whereas in ND7 and breast cancer cells it is 
associated with proliferation and frequently shows antagonistic effects to Bm-3a.
1.21 Expression and function of Brn-3a and Brn-3b in non-neuronal 
tissue
Even though Bm-3a and Bm-3b were originally detected in the developing and adult nervous 
system where they play a critical role in development of specific subsets of neurones, 
subsequent studies have demonstrated expression of both these transcription factors in non­
neuronal cells, specifically in tissues of the reproductive tract (Budhram-Mahadeo et al., 
2001) and certain cancers including cervical and breast cancer (Budhram-Mahadeo et al., 
1998;Budhram-Mahadeo et al., 1999b;Ndisang et al., 2000;Ndisang et al., 2001).
Using Immunocytochemistry, both Bm-3a and Bm-3b were shown to be expressed in the
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adult rat testis with the expression of each factor being observed at distinct stages of germ 
cell development. Thus, while Bm-3a is detected in the spermatogonia, Bm-3b is detected in 
post-meiotic spermatids. Interestingly the expression of Bm-3a(l) during germ cell 
development coincides with that of the BRCA-1 anti-oncogene, which Bm-3a has been 
shown to transactivate in co-transfection assays, while Bm-3b represses this promoter. Thus 
Bm-3a and Bm-3b may play distinct roles in the regulation of gene transcription during germ 
cell development as well as during neuronal development.
Bm-3a and Bm-3b have also been detected in breast epithelia cells but the expression of Bm- 
3b and not Bm-3a is increased in breast tumours compared with normal mammary tissue. 
Furthermore malignant tumour samples that show increased expression of Bm-3b also had 
reduced levels of BRCA-1 at both the mRNA and protein level. Interestingly, Bm-3b but not 
Bm-3a(l) was shown to strongly repress the BRCA-1 promoter in mammary tumour cells. As 
BRCA-1 halts cell proliferation in normal mammary cells then the negative regulation of its 
expression by Bm-3b supports a role for Bm-3b in controlling cellular proliferation of 
mammary cells (Budhram-Mahadeo et al., 1999b). Indeed, stably transfected MCF7 breast 
cancer cell lines that over-express Bm-3b, exhibited increased growth and proliferation rates 
compared to control cells containing empty vector, and also shown enhanced growth under 
anchorage independent conditions (Dennis et al., 2001). Similarly IMR-32 (neuroblastoma 
cell line) cells over-expressing Bm-3b also showed increased cellular growth and 
proliferation in monolayer as well as in an anchorage dependent manner compared with 
controls whereas stably reducing Bm-3b levels reduced the growth rate of these cells. Bm-3b 
also increased migration of these cells in migration assays compared to controls. 
Furthermore, mice injected with Bm-3b over-expressing clones showed rapid increase in 
tumour volume compared to controls (Irshad et al., 2004). Thus Bm-3b contributes to the 
proliferation of both neuroblastoma cells and breast cancer cells.
Further analysis of the role of Bm-3b in breast cancer progression, demonstrated that Bm-3b 
altered gene expression associated with growth and cell cycle progression. For instance Bm- 
3b could strongly activate CDK4 which is required for the G1 to S transition while it 
repressed the BRCA1 gene promoter (Samady et al., 2004). Plakogobin, which is involved in 
cell-cell adhesion, cytoskeleton organization and signal transduction, is repressed by Bm-3b 
which may explain the increased proliferation and migration of breast cells
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which show increased Bm-3b expression (Samady et al 2005). Furthermore Bm-3b was 
shown to activate the HSP-27 promoter whose protein product is associated with increased 
anchorage-independent growth, increased invasiveness, and is a poor prognosis marker (Lee 
et al., 2005).
Both Bm-3a and Bm-3b have been detected in cervical epithelia cells. However, while 
expression of Bm-3b is detected in both cancerous and non diseased cervical epithelium, 
Bm-3a expression is highly elevated up to 300-fold in high grade cervical intraepithelial 
neoplasia type 3 (CIN3) whereas the levels of Bm-3b do not change significantly in these 
cells (Ndisang et al., 2000). Interestingly Bm-3a was shown to activate the upstream 
regulatory region of the human papilloma viral genome (HPV) (Morris et al., 1994). As it is 
generally accepted that HPV (particularly types 16 and 18) infection contributes to the 
development of cervical neoplasia (Burghardt, 1984) it is possible that both HPV and 
elevated Bm-3a levels may contribute to the progression of cervical cell transformation.
Thus both Bm-3a and Bm-3b are expressed in neuronal and non-neuronal cells and regulate 
gene expression associated with survival, differentiation and proliferation. The important role 
of these transcription factors in determining cell fate is reflected in their altered expression 
being associated with certain cancers. Specifically Bm-3a is up-regulated in cervical cancer 
whereas Bm-3b is over-expressed in breast cancer as well as neuroblastoma.
1.22 Gene targets regulated by the Brn-3a and Brn-3b transcription 
factors
In general Bm-3a activates genes involved in neuronal differentiation, survival and cell cycle 
arrest. Studies undertaken in our lab have shown that Bm-3a activates two types of gene 
promoters, those that are activated by the C-terminal POU domain of the protein and those 
that require in addition, the N-terminal activation domain. Additional control of 
transcriptional regulation is provided by the Bm-3b transcription factor which has been 
shown to repress the basal activity of many promoters activated by Bm-3a and can also 
inhibit Bm-3a mediated activation of many neuronal promoters which are generally 
dependent on the Bm-3a POU domain for activation. Thus the opposite expression pattern of 
Bm-3a and Bm-3b in proliferating versus differentiated neuronal cells is interesting as it
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parallels their antagonistic effect on several different promoters. Table 1.4 gives a summary 
of the various gene targets regulated by Bm-3a and Bm-3b.
Many Bm-3a target genes that have been characterised are involved in the dynamic process 
of neuronal differentiation, including neuronal outgrowth, synaptogenesis, and early axonal 
cytoskeleton establishment. These include a-intemexin (Budhram-Mahadeo et al., 1995b), 
the neurofilament genes (Smith et al., 1997c) SNAP-25 (Lakin et al., 1995) and synapsin I 
(Morris et al., 1996). Bm-3a over expression in ND7 cells also up regulates synaptophysin 
and synaptotagmin I (Smith et al., 1997b), though a direct effect of Bm-3a on these 
promoters has not been investigated. Interestingly Bm-3b has been shown to repress Bm-3a 
target genes involved in neuronal differentiation including a-intemexin (Budhram-Mahadeo 
et al., 1995b), the neurofilament genes (Smith et al., 1997c) and SNAP-25 (Morris et al.,
1996), Interestingly, Bm-3b over-expressing ND7 cells also resulted in reduction of 
synaptophysin and synaptotagmin I at both the mRNA and protein levels (Smith et al., 
1997b) but a direct effect on promoter regulation has not been shown.
This antagonistic effect of Bm-3a and Bm-3b on promoters involved in neuronal 
differentiation may explain their opposite expression patterns during differentiation of ND7 
cells and in primary neuronal cells (Lillycrop et al., 1992;Liu et al., 1996). These target genes 
regulated by Bm-3a and Bm-3b may also help to understand why ND7 cells over-expressing 
Bm-3a showed increased neurite outgrowth even in the absence of a differentiation stimuli 
whereas ND7 cells over-expressing Bm-3b actually inhibits neurite outgrowth even in 
response to stimuli that normally induce differentiation (Smith et al., 1997a;Smith et al., 
1997b). However, Bm-3b was found to activate the promoter synapsin I gene in a manner 
similar to Bm-3a suggesting that Bm-3b can compensate for Bm-3a in terms of activation of 
some but not all target genes in neuronal cells (Morris et al., 1996).
Interestingly the induction of neurite outgrowth in ND7 cells could be achieved by over­
expressing the isolated POU domain of Bm-3a, indicating that this region of the protein is 
sufficient for this effect. Overexpression of the POU domain of Bm-3b did not alter neurite 
extension in these cells (Smith et al., 1997b). This effect of the isolated Bm-3a POU parallels 
the ability of this domain but not the Bm-3b POU domain to activate an artificial test
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Promoter Brn-3a Brn-3b Domain
Snap-25 + _* N-term
a-intemexin + .* POU
Synaptotagmin 1 + - POU
Synapsin 1 + + POU
NFH + _* POU
NFM + _* POU
NFL + _* POU
Bcl-2 + 0 N-term
Bcl-x + 0 Upstream promoter requires N-term, the downstream 
promoter requires sequences located between the POU 
and N-term domain
Bax - N.T POU and sequences located between the POU and N- 
term domain
p2j Wafl/Cipl + N.T POU
CDK4 N.T + N.T
Plakoglobin N.T - N.T
BRCA1 + - N.T
HSP-27 + + N.T
Vitellogenein 0 + POU
Table 1.4: Promoter regulation by Bm-3a and Bm-3b transcription factors
Activation of the promoter is indicated by +, repression is indicated by no effect is indicated by 0, 
effect not tested is indicated by N.T and * indicated that Bm-3b not only represses the promoter but 
also negates activation by Bm-3a. The domain involved in the Bm-3 mediated transcription on each 
promoter is also listed (Adapted from a PhD thesis Transcriptional regulation by Bm-3a POU domain 
containing transcription factors, Author Dr J. Dennis, 1999)
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promoter containing a synthetic binding site for the Bm-3 factors. In contrast the isolated 
Bm-3b POU domain repressed this promoter (Morris et al., 1994). Interestingly the 
differential effect exhibited on the artificial test promoter is associated with the single amino 
acid difference at position 22 in the first helix of the POUhd which is a valine residue in Bm- 
3a and an isoleucine residue in Bm-3b. Thus, substituting the valine at position 22 in Bm-3a 
with the isoleucine found in Bm-3b converted Bm-3a into a repressor of the promoters that 
are normally activated by wild type Bm-3a (Morris et al., 1997;Smith et al., 1997c), and 
inhibits neurite outgrowth (Smith et al., 1997b). Similarly, the mutant form of Bm-3b 
containing the valine residue converts it into an activator on promoters that are normally 
repressed by Bm-3b (Dawson et al., 1996;Morris et al., 1997;Smith et al., 1997c) and allows 
it to stimulate neurite outgrowth (Smith et al., 1997b).
Although the POU domain of the Bm-3 factors directs their binding to DNA, there is no 
difference in the DNA binding abilities of both the wild type and mutant forms of Bm-3a and 
Bm-3b (Budhram-Mahadeo et al., 1996). This is in agreement with the location of this 
residue at position 22 in the C-terminus of the first helix which does not make contacts with 
the DNA as shown by crystallographic analysis of the POU domain of the related Oct-1 
protein. In fact this residue is located on the surface of the POU domain at a position that 
could be involved in protein-protein interactions (Klemm et al., 1994).
Therefore it is possible that the different effects of Bm-3a and Bm-3b on the same promoters 
may be the result of interaction with different co-regulatory factors with transactivator or 
repressor function. Thus the presence of the valine at this position in Bm-3a or the mutant 
Bm-3b allows the protein to interact with and recruit a co-activator to the promoter, whilst 
the isoleucine at this position in Bm-3b or the mutant Bm-3a protein allows the recruitment 
of a co-repressor to the promoter of these neuronal target genes. Thus interaction of the POU 
domains proteins with other co-activators/repressors which similar to the POU proteins, may 
also be cell type specific or present at different developmental stages represents a further 
mechanism to regulate the activity of the POU proteins.
The Bm-3a and Bm-3b transcription factors have also been shown to regulate non-neuronal 
target genes. For example, CDK4 and HSP-27 gene promoters are transactivated by Bm-3b 
in breast cancer cells while BRCA1 and plakoglobin are repressed by Bm-3b, providing a
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mechanism by which Bm-3b promotes cellular proliferation and invasion in these cells. Bm- 
3a has also been shown to activate BRCA1 expression in the testis. Additionally the HSP-27 
gene can be transactivated by both Bm-3a and Bm-3b in neuronal and breast cancer cells. 
Thus Bm-3a and Bm-3b can act as either activators or repressors of gene transcription and 
this effect depend on the target and cell specificity.
1.22.1 Brn-3a has two distinct transactivation domains
As mentioned, Bm-3a activates two types of gene promoters, those which are dependent on 
the POU domain and those that require the N terminal activation domain, in addition to the 
POU domain for their activation. The latter promoters are activated only by the long form of 
Bm-3a [Bm-3a(l)], (Morris et al., 1994). Thus the relative expression of the Bm-3a isoforms 
also determines which genes will be expressed in specific cell types by alternative promoter 
usage generating the two different Bm-3a isoforms. Furthermore production of these two 
isoforms has been shown to be regulated in different neuronal cell types and in response to 
specific stimuli (Theil et al., 1993;Liu et al., 1996).
Further investigation revealed that the effects of Bm-3a on neuronal survival and 
differentiation require distinct domains of this transcription factor. Thus differentiation can 
be induced by overexpression of the isolated Bm-3a POU domain only (Smith et al., 1997b) 
and this domain is sufficient for the transcriptional activation of a number of genes involved 
in neuronal differentiation (Lakin et al., 1995;Smith et al., 1997b;Smith et al., 1997c) as 
described above. Hence this domain can act as an activation domain as well as a DNA 
binding domain.
In contrast, only Bm-3a(l) but not Bm-3a(s) or the isolated Bm-3a POU domain could 
protect ND7 cells against apoptosis as a result of serum withdrawal (Smith et al., 1998a). 
Thus, in the case of Bm-3a, the differential promoter usage to produce the two isoforms has 
consequences for cell survival, as the long form can promote both neurite outgrowth and 
enhanced cell survival while the short form promotes neurite outgrowth without increasing 
survival. The generation of mice lacking the N-terminal domain of Bm-3a or containing the 
valine to isoleucine mutation in the Bm-3a POU domain has further helped to investigate the 
functions of the distinct Bm-3a domains in vivo (Faulkes et al., 2004). While the
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homozygous valine to isoleucine (V-I) Bm-3a mutants were viable, the N-terminal deletion 
mice die shortly after birth, suggesting that the lethal phenotype that occurs in the complete 
Bm-3a knock out is due specifically to loss of function of the N-terminal domain. Thus, it 
was demonstrated that a similar loss of neurones seen in Bm-3a null mice was also observed 
in mice in which the N-terminal was lost but Bm-3a(s) continued to be expressed. In 
contrast, no neuronal loss was observed in the homozygous V-I mice. Hence in vivo as well 
as in vitro, the N-terminal domain is essential for the Bm-3a effect on neuronal survival.
More specifically, it was demonstrated that the POU domain of Bm-3a was insufficient for 
the activation by Bm-3a of genes encoding factors such as Bcl-2 and Bcl-xL which have a 
protective effect against cell death (Smith et al., 1998a;Smith et al., 1998b;Sugars et al.,
2001). Thus Bcl-2 activation was only observed by Bm-3a(l) but not Bm-3a(s) or the isolated 
Bm-3a POU domain in co-transfection experiments. Additionally this activation was not 
affected by altering the valine at position 22 in the POU domain of Bm-3a to isoleucine 
which prevents activation of promoters which are dependent on the POU domain of Bm-3a 
although it does not prevent DNA binding. Similarly, Bm-3b carrying the converse 
isoleucine to valine change was not able to activate this promoter although this change allows 
Bm-3b to activate POU domain dependent promoters. Thus these co-transfection 
experiments demonstrate that that activation of the Bcl-2 promoters is dependent upon the N- 
terminus of Bm-3a being present (Smith et al., 1998a). Furthermore transfecting in the 
isolated N-terminal domain together with Bm-3a(l) resulted in inhibition of Bcl-2 activation 
suggesting that addition of the N-terminal domain binds to and removes factors required for 
activation of this promoter while the POU domain is responsible for DNA binding. Therefore 
the N-terminal domain is required for transactivation, possibly by interacting with a neuronal 
specific co-activator that may either be bound at another site of the promoter or is recruited to 
the promoter by interaction with the N-terminus, thus allowing transactivation of this 
promoter (Smith et al., 1998a).
Transactivation of the B c 1 -x l gene promoter by Bm-3a was proven to be more complex. 
Like, Bcl-2, the B c 1 -x l gene has two distinct promoters, both of which are activated by Bm- 
3a (Smith et al., 1998b;Sugars et al., 2001). However, whilst activation of the Bcl-2 and the 
upstream B c 1 -x l promoter depends upon the presence of the N-terminal domain of Bm-3a 
(Smith et al., 1998b;Sugars et al., 2001), this is not the case for the downstream Bcl-xL
68
promoter in which further sequences located downstream of the N-terminal but upstream of 
the POU domain, as well as the POU domain, are required for activation of this promoter 
(Sugars et a l .,  2001). This is interesting as under some conditions, B c 1 -x l expression but not 
Bcl-2 expression can be induced by Bm-3a. This may be of particular significance in view of 
the key role played by B c 1 -x l in regulating the extent of naturally occurring cell death in the 
development of the nervous system.
Interestingly, another gene that requires the N-terminal of Bm-3a for its activation is the a- 
intemexin gene which encodes a type IV intermediate filament protein (Budhram-Mahadeo 
et al., 1995b). This is an interesting observation as expression of the neurofilament genes 
(dependent on the POU domain for activation) and a-intemexin show different expression 
patterns which may be a consequence of the different alternatively spliced Bm-3a isoforms 
which have shown to be regulated under different conditions (Liu et al., 1996). However, 
unlike both the Bcl-2 and B c 1 -x l genes that also require the N-terminal of Bm-3a for 
activation, Bm-3a activation of the a-intemexin gene can be repressed by Bm-3b (Budhram- 
Mahadeo et al., 1995b).
Thus, the generation of these novel mice (the N-terminal null and V-I mice) has confirmed in 
vivo, the results that were obtained from in vitro experiments. That is, the N-terminal domain 
is critical for neuronal survival and the POU domain, in particular the valine at position 22 is 
critical for neurite outgrowth. These studies indicate that not only the correct regulation of 
Bm-3a and Bm-3b but also the correct regulation of the Bm-3a isoforms is critical for the 
proper development and functioning of the nervous system.
1.23 Mechanism of Brn-3a regulation on its target promoter
Other than the requirement of domains outside the POU domain, promoters activated by Bm- 
3a also differ in the nature of the sequences required for their transcriptional activation. Some 
promoters contain distinct upstream binding sites for Bm-3a which is essential for their 
transcriptional activation by Bm-3a. Such promoters include those encoding SNAP-25 and 
Bcl-2 (Lakin et al., 1995;Smith et al., 1998b). In contrast, in a number of other promoters it is 
not possible to dissect away the Bm-3a response from the minimal promoter activity. 
Promoters of this type include those of the genes encoding B c 1 -x l,  p21Cipl/Wafl, the
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neurofilaments and a-intemexin (Budhram-Mahadeo et al., 1995b;Smith et al., 1997c;Sugars 
et al., 2001;Budram-Mahadeo et al., 2002). Thus in some cases Bm-3a induces transcription 
by binding to upstream sequences whereas in other cases Bm-3a participates in a minimal 
basal transcriptional complex required for gene transcription. Thus Bm-3a responsive 
promoters differ in both their requirement for the N terminus of Bm-3a and in the nature of 
the sequences required for their response.
1.24 Interactions of Brn-3a/Brn-3b with other proteins to regulate 
gene transcription
As a transcription factor, Bm-3a and Bm-3b must associate with other cellular proteins to 
modify transcription. These include specific co-activators and repressors, the basal 
transcription apparatus and other cellular proteins that can modulate transcription. Interaction 
with other transcription factors would effectively increase the range of target genes regulated 
by the Bm-3 proteins. Therefore studies were undertaken to identify interaction partners that 
associated with the Bm-3 proteins
Yeast 2 hybrid studies demonstrated association of Bm-3a with p53 and affinity 
chromatography showed direct physical interaction between Bm-3a and p53 which occurs 
via the POU domain of Bm-3a and the DNA binding domain of p53. This interaction resulted 
in differential regulation of both Bm-3a and p53 mediated gene targets. Indeed in co­
transfection experiments in the ND7 neuronal cell line, p53 reduced the Bm-3a mediated 
activation of the Bcl-2 and B c 1 -x l promoters compared with the activity observed in the 
presence of Bm-3a alone (Budhram-Mahadeo et al., 1999a;Sugars et al., 2001)
The effect of the Bm-3a/p53 interaction on apoptosis was further characterised by 
investigating the effect of Bm-3a on p53 specific target genes. Therefore the effect of Bm-3a 
on the box and p21Cipl/Wipromoter was investigated in transient co-transfection experiments 
carried out in our laboratory. Bm-3a was shown to weakly repress the box promoter but more 
importantly it also repressed the p53 mediated activation of the bax promoter to background 
levels. In addition, Bm-3a alone was able to up-regulate the p21Cipl/Waf] promoter by 2-fold 
compared to empty vector control, while upon co-transfection with p53 a strong activation of 
the promoter was obtained which was significantly greater than that observed with p53 alone.
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Functionally this was reflected in decreased expression of endogenous Bax protein and 
increased expression of endogenous p21Cipl/WafI protein in ND7 cells co-expressing Bm-3a 
and p53 compared with p53 alone (Budram-Mahadeo et al., 2002).
Thus from these results it follows that in cells co-expressing both these proteins, Bm-3a may 
increase neuronal survival by antagonising p53 mediated apoptosis and repressing p53- 
dependent activation of the box promoter whilst promoting cell cycle arrest that precedes 
differentiation, via its synergistic activation with p53 on the p21Cipl/Wqfl promoter. Indeed it 
was shown that ND7 cells over-expressing Bm-3a and p53 show enhanced growth arrest and 
reduced apoptosis compared to cells expressing p53 alone, confirming that, at least in ND7 
cells, the presence o f Bm-3a can increase cell cycle arrest and over-ride p53 mediated 
apoptosis (Budram-Mahadeo et al., 2002).
Thus it can be hypothesised that during neuronal development Bm-3a can also regulate cell 
fate by repressing p53 mediated activation o f pro-apoptotic genes and co-operating on the 
p 2 jdpWafi promoter t0 enhance cell survival and cell cycle arrest preceding differentiation. 
As Bm-3a increases the expression of neuronal proteins such as neurotrophic receptors 
(TrkA), neurofilament and a-intemexin this would enhance differentiation of surviving 
neurones into mature neurones (Fig 1.10).
Induction of pro-apoptotic g e n e s  
R ep ressio n  of anti-apoptotic 
g e n e s  AInduction
-Bcl-2/Bcl-xL
R epression
-Bax
apoptosi:
Cell survival
£>Up-regulation of Brn-3a neuronal target genes
p53Brn-3a
Cell cycle arrest/differentiation
Increased Decreased 
p21 Bax
(interm ediate filam ents (a-internexin), neurofilam ents. 
snap-25  ect)
Figure 1.10: Model for the role of Brn-3a in modulating p53 mediated cell fate
Expression of Brn-3a would result in activation of anti-apoptotic factors such as Bcl-2 and Bcl-xL while 
repressing the expression of Bax. In the presence of p53, Brn-3a represses p53 mediated activation 
of Bax but co-operates with p53 to increase p21 levels with consequent cell survival and cell cycle
71
arrest. Brn-3a can then stimulate the expression of genes involved in neuronal differentiation. In the 
absence of Brn-3a, p53 induction would result in high levels of Bax resulting in apoptosis. Thus in this 
neuronal cell model, Bm-3a may play an important role in determining the p53 pathway that is 
activated and thus the fate of these cells. (Adapted from Budram-Mahadeo et al., 2002)
Another factor that associates with Bm-3a and Bm-3b is the proliferation-associated estrogen 
receptor (ER) which transactivates estrogen responsive element (ERE) containing promoters. 
In breast cancer cells, Bm-3b/ER interaction results in greater induction of ERE containing 
promoters compared with Bm-3b alone. Conversely the Bm-3a/ER interaction results in a 
mild repression of ERE promoters, suggesting a negative role for Bm-3a in cellular 
proliferation in these cells compared to the enhanced proliferative effect of Bm-3b in breast 
cancer cells (Budhram-Mahadeo et al., 1998).
1.25 Mechanism of regulation of bax and p 2 iCip1/waf1 promoters
The ability of Bm-3a to differentially modulate expression of p53 target genes has also 
proven to be complex. For example, the box promoter contains a p53 response element, that 
is required for p53 activation of this promoter, and the p53 response element was found to be 
flanked by two consensus binding sites for Bm-3a. Both of these Bm-3a binding sites are 
required for its effects on this promoter as mutation of both these sites results in a failure of 
Bm-3a to repress transcription either alone or via association with p53. Furthermore, the 
isolated Bm-3a POU domain was not sufficient to repress the box promoter either directly or 
indirectly with p53, illustrating that sequences outside the POU domain are required to 
repress p53 induction of this promoter (Perez-Sanchez et al., 2002).
In contrast, on the p21Cipl/Wafl promoter, Bm-3a appeared to mediate its effect by recruitment 
to the basal transcriptional complex, as Bm-3a activation was lost concomitantly with loss of 
basal promoter activity. However, the synergistic effect of Bm-3a and p53 on this promoter 
requires the presence of the upstream p53 response elements (Perez-Sanchez et al., 2002). 
Furthermore, it was demonstrated that the isolated POU domain of Bm-3a was sufficient to 
activate both the full length and minimal p21CipI/Wc** promoter as well as synergize with p53 
on the full length p21Cipl/Wi^  promoter, which is in contrast to that shown on the bax 
promoter. Thus the p21CipI/WafI promoter is a target of Bm-3a whose activation is dependent 
on basal promoter sequences and the Bm-3a POU domain whilst repression of bax by Bm-3a
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depends on upstream Bm-3a binding sites as well as sequences outside the POU domain.
Therefore the ability of Bm-3a to modulate the expression of p53 target genes is complex 
and describes an alternative mechanism by which Bm-3a controls the fate of cells. The p53 
related protein, p73, has a clear role in the development of the nervous system and is 
expressed in both pro-apoptotic and anti-apoptotic forms. The work described in this thesis 
aims to characterize the interaction between Bm-3a and the p73 proteins and to analysis the 
functional role of this interaction in terms of their effects on neuronal cell fate. The p53 
family of proteins is discussed in the following sections.
1.26 The p53 tumour suppressor protein
First identified in 1979, p53 (chromosome 17p 13.1) was found to act as a tumour suppressor 
gene that was inactivated in more than 50% of all human cancers. The importance of the p53 
tumour suppressor activity stems from its ability to preserve genomic integrity by arresting 
cell cycle progression or activating apoptosis in response to a wide range of genotoxic and 
cellular stresses, including DNA damage, oncogene activation, ribonucleotide depletion, 
mitotic spindle damage and hypoxia (Ko and Prives, 1996).
The p53 protein is highly conserved throughout evolution (Soussi et al., 1996) and like other 
transcription factors, p53 is a modular protein containing structurally independent 
transactivation and DNA binding domains. The structure of the p53 protein is divided into 
four functional domains (Fig 1.11). The N-terminal acidic transactivation domain TAD 
(amino- acids 1-42) contacts specific components of the PIC, including the TBP and 
associated factors TAFII40 and TAFII60, which allows p53 to recruit the basal transcription 
factors required for transcriptional initiation. This region is also involved in the regulation of 
stability and activity of p53 via interactions with MDM2. Binding of MDM2 to p53 blocks 
the ability of p53 to transactivate its target genes as well as targeting the p53 protein to the 
ubiquitin-mediated proteolytic machinery (Haupt et al., 1997;Vousden, 2000). The region 
between the TAD and DBD contains a proline rich region containing several PXXP motifs. 
Deletion of this region results in loss of pro-apoptotic function in some experimental systems 
(Sakamuro et al., 1997).
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Figure 1.11: DNA damage induced post-modifications to human p53 and cellular proteins 
known to interact with and influence p53 function
The transactivation domain (TAD), proline rich region (PXXP), DNA binding (DBD), oligomerization 
(OD), and a C-terminal basic domain are represented. The positions of known phosphorylations, (S= 
serine, T= threonine) are shown in pink, acetylations (Ac, K= lysine) are shown in purple and 
sumoylation (Sumo, K= lysine) is shown in green. Proteins that interact with the p53 protein and 
modulate p53 transactivation of target genes are represented underneath the p53 domain they were 
found to interact. Regulatory proteins that are boxed have yet to have their interaction with p53 
mapped to specific domains. ASPP, apoptosis stimulating proteins of p53; CTF2, CCAAT binding 
transcription factor 2; MDM, mouse double minutes; WT1, Wilms tumour protein.
The sequence specific DNA binding domain (DBD) o f p53 is localised between amino acids 
113 and 292. It is a protease resistant and independently folded domain containing a zinc ion. 
This domain folds into a four stranded and five stranded antiparellel p sheet that in turn is a 
scaffold for two a-helical loops that interact directly with the DNA. The majority of missense 
mutations (>90%) seen in human cancers occur in the DNA binding domain, in which either 
the critical amino acids involved in contacting DNA are altered or residues that disrupt the 
whole conformation of the DBD are altered.
The C-terminus contains the OD domain (325-363) which is required for oligomerization of 
the p53 protein to form a tetramer that is efficient for transactivation (Pietenpol et al., 1994). 
The structure o f the OD domain reveals an a-sheet-tum-p-helix motif which forms a pair of 
dimers (Jeffrey et al., 1994). Adjacent to the OD domain is a basic region (amino acids 363- 
393). This region contains a DNA damage recognition domain which can bind to DNA ends 
and single stranded DNA. The C-terminal interacts with a number o f cellular proteins such as 
the TFIIH dual transcription/ DNA repair factor and other helicase proteins involved in DNA
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repair such as CSB (Wang et al., 1995). The p53 C-terminal region also contains NLS and 
NES that lie within the OD (Strommel et al., 1999).
Activation of the p53 protein in response to stresses is mediated and regulated by protein 
kinases, histone acetyl-transferases, ubiquitin and sumo ligases. Once activated the p53 
protein transactivates downstream targets involved in two major pathways: cell cycle arrest 
and apoptosis. These include p21Clpl/Wafl, 14-3-3, GADD45, MDM2, Bax, Puma, Noxa and 
Apafl. Additionally the activated p53 protein associates with other cellular proteins which 
selectively modulates p53 transcription of target genes, and thus influence p53 function. The 
cellular proteins that interact directly with p53 and selectively alter p53 gene transcription are 
shown in Fig 1.11 and are discussed in more detail in section 1.39.
1.27 Sequence specific binding by p53
The activities of the p53 tumour suppressor protein are mainly due to the ability of p53 to 
form homotetramers that bind to specific DNA sequences and transactivate a great number of 
downstream genes (Jeffrey et al., 1995). Promoter recognition by p53 is determined by the 
presence of p53-response elements (PREs) which share homology with the consensus 
sequence which consists of two identical repeats of the decamer sequence 5’- 
(PuPuPuC(A/T)(T/A)GPyPyPy)-3’ separated by 0-13 base pairs (El Deiry et al., 1992). 
However, comparison with functional PREs found in p53 regulated promoters shown that 
they can differ significantly from this optimised version, and generally consist of multiple 
decamers. Specifically, only one decamer stringently adheres to the consensus whereas the 
other decamer(s) deviate from the consensus to a varying extent and in some cases the p53 
responsiveness may be mediated by sequences other than the defined PRE (Contente et al.,
2002). The explanation for this sequence variation comes from findings that p53 interactions 
with DNA depend on both sequence specific elements and DNA structure. p53 interaction 
with linear binding sites was shown to be weak, while presentation of the same target site in a 
stem loop confirmation strongly promotes specific DNA binding of p53 (Gohler et al., 2002). 
Thus, the multidecameric composition provide the PREs to adopt different confirmations, 
allowing individual decamers that deviate from the consensus to be converted from poor 
binding sites to structurally favourable sites that strongly bind p53.
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1.28 Discovery of p53 homologues
The possible existence of p53 homologues was suggested by findings showing that regulation 
of p53 targets were observed independently of p53 (Weinberg et al., 1995). In 1997, Kaghad 
and colleagues (1997) discovered the p53 homologue referred to as p73 which shares high 
sequence homology with p53, particularly in the functional domains. The gene encoding p73 
is located on chromosome lp36, a region frequently deleted in neuroblastoma and other 
tumours. In 1998, Yang and colleagues (1998) discovered a further homologue with high 
homology to p53, p63 which is located on chromosome 3q27. Both the p73 and p63 proteins 
share high homology to p53 in their DNA binding domains and have subsequently been 
shown to transactivate a wide range of p53 regulated genes (reviewed by De-Laurenzi and 
Melino, 2000). Since this study deals primarily with p73, the discussion of the p53 family 
will mainly be focused on the p73 transcription factor.
1.29 Gene organization and protein structure of the p53 family
The human p53 gene is located on chromosome 17pl3 and is approximately 20kb and 
consists of 11 exons while p73 and p63 are both over 65kb with 14 and 15 exons respectively 
(reviewd by Marin and Kaelin, Jr. 2000). All three genes share a large first intron (10.7kb in 
p53 and 32kb in p73 and p63) and a non coding first exon which may influence translation. 
Interestingly, a 1 kb region in the intronic sequence found upstream of the ATG in the p73 
gene functions as a silencer, suggesting that regulatory sequences located in this region may 
contribute to the tight regulation of p73 expression (Fontemaggi et al., 2001). Essentially, the 
human p53 gene has a single promoter which encodes a single protein of 393 amino acids. 
However accumulating data has reported the existence of shorter forms of p53 that arise from 
various mechanisms such as alternative splicing, autodegradation, proteolytic cleavage and 
use of an in-frame ATG located at codon 40. However the shorter isoforms of p53 appear to 
be expressed at very low levels and in specific cell types suggesting they play very narrow 
and limited roles (Courtois et al., 2004). In contrast, both the p73 and p63 genes consistently 
produce multiple mRNA transcripts resulting from C-terminal splicing giving rise to six 
different p73 isoforms (a, p, y, 6, e, Q (Kaghad et al., 1997;De Laurenzi et al., 1998;Zaika et 
al., 1999;De Laurenzi et al., 1999;Moll et al., 2001) and three isoforms of p63 (a, p, y) (Yang
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et al., 1998). These p73 and p63 proteins are referred to as TAp73 and TAp63 respectively. 
In addition, truncated isoforms of p63 and p73 that lack the N terminal transactivation 
domain (ANp73 and ANp63) have been described in both mice and humans (Yang and 
McKeon, 2000;Yang et al., 2000;Ishimoto et al., 2002). These isoforms are generated by an 
alternative promoter spanning exon 3 and exist as several isoforms that contain the different 
carboxyl-terminal domains seen in the TA isoforms. Furthermore, other p73 splice variants 
that lack exon2 (A2p73) or exon3 (A3p73) and hence the transactivation domain have been 
described in cancer cell lines (Fillippovich et al. 2001). The TA promoter (PI) and AN 
promoter (P2) of the p73 gene are 30-40 kb apart and are differentially regulated. For 
example E2F-1 sites are present in the TA promoter but not in the AN promoter (Irwin et al.,
2000), while p53 sites have been characterised in the AN promoter but not in the TA 
promoter (Grob et al., 2001;Kartasheva et al., 2002;Vossio et al., 2002).
The p73 and p63 proteins share high sequence homology to p53 in the regions corresponding 
to the acidic N-terminal activation domain (TAD), the central DNA binding domain (DBD) 
and the C-terminal oligomerization domain (OD). Comparison of the similarity in structure 
of the different domains of the p53 proteins and major isoforms encoded by p73 is shown in 
Fig 1.12. The p73 N-terminal TAD domain which is missing in the AN forms, is the least 
conserved of the three domains among the family (30% identity between p73 and p53). This 
domain of all three proteins is acidic in nature and for both TAp73 and p53 the TAD 
facilitates interaction with the MDM2 protein, which plays a critical role in regulating the 
stability of the p53/p73 (Vousden, 2000).
Although the DNA binding domains of p53 and p73 show 63% homology, the 3-dimensional 
structure of the two regions are almost identical (reviewed by Melino et al., 2002). 
Interestingly, the residues of p53 that directly contact DNA, including those most frequently 
mutated in cancers, are conserved in the DNA binding domain of p63 and p73 (Kaghad et al.,
1997), suggesting that they could activate the same target genes, and indeed, both p73 and 
p63 have been shown to bind to p53 response elements and transactivate p53 target genes 
(Kaghad et al., 1997;Jost et al., 1997;De Laurenzi et al., 1998;Yang et al., 1998;Ueda et al., 
1999;Lee and La Thangue., 1999;Zheng et al., 1999)
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Figure 1.12: Comparative protein structures and functional organization of the p53 family 
members.
a) The transactivation domain (TAD), proline rich region (PXXP), DNA binding (DBD), oligomerization 
(OD), sterile a motif (SAM) and post SAM basic domains are represented, b) Genomic organization of 
the p73 gene. The proximal promoter (P1) yields TAp73a, (3, y. 6, £. 5 isoforms while the distal 
promoter (P2), spanning intron 3, gives rise to the ANp73a, (3 isoforms. (Adapted from Benard et al., 
2003;Maisse et al., 2003).
Similar to p53, the p73 OD domain consists o f an a-sheet-tum-p-helix motif that forms 
tetramers (Davidson et al ., 1999). Using the yeast two hybrid system, it was demonstrated 
that the p73 isoforms interacted with each other with various affinities. For example p73a 
showed a low tendency to form homotypic interactions whereas p73p displayed strong 
homotypic interactions and binds weakly to p73a (Kaghad et al., 1997;De Laurenzi et al.,
1998). In contrast, p73y demonstrated strong interaction with p73a, p73p, p738 and itself 
whereas the p738 isoform homodimerizes efficiently and binds p73a and p73y but its 
interaction with p73p is much weaker (De Laurenzi et al., 1998). The different p73 isoforms 
were also shown to interact in the cell by immunoprecipitation experiments (Ueda et al.,
2001). The high conservation of the OD domain (38% homology) between p53 and p73 
suggest that members of this family form heterotetramers as well as homotetramers. Using 
the yeast two hybrid system, it was shown that both p73a and p73p could very weakly 
interact with p53 (Kaghad et al., 1997;De Laurenzi et al., 1998;) whereas p73y and p738
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showed no interaction with p53, suggesting that p53 prefers to form homotetramers rather 
than heterotetramers with the p73 proteins (De Laurenzi et al., 1998). This is supported by 
the findings that wild type p53 failed to co-immunoprecipitation with p73 (Di Como et al., 
1999;Marin et al., 2000;Gaiddon et al., 2001;Ishimoto et al., 2002).
Also similar to p53, p73 contains two proline rich regions which contain PXXP motifs. These 
regions are located between the TAD and DBD and the DBD and OD. The occurance of 
PXXP motfs suggests that the p53 family can bind proteins with an SH3 (src homology 3) 
domain. Additionally, the extended C-terminals of the p63 and p73 proteins may perform 
specific functions, and only the a isoforms of both p63 and p73 contain a sterile alpha motif 
domain (SAM) which is implicated in protein-protein interactions. Using NMR spectroscopy 
the structure of the p73 SAM domain reveals a five helix bundle that resembles the SAM 
domain present in the Eph receptor tyrosine kinases (Chi et al., 1999). The majority of SAM 
domain-containing proteins are involved in the regulation of development but unlike other 
SAM domains, those present in p73 and p63 do not mediate homo- or hetero-dimerization 
(Chi et al., 1999). So far the p73 SAM domain shows differential binding to different 
artificial lipids, though the functional significance of this has yet to be investigated (Barrera 
et al., 2002;Barrera et al., 2003).
1.30 Transcriptional regulation by the TA isoforms
TAp73 has been shown to transactivate p53 responsive genes and when overproduced can 
induce cell cycle arrest or apoptosis (Kaghad et al., 1997;Jost et al., 1997;Osada et al., 
1998;Yang et al., 1998). For example, TAp73a can transactivate several p53 responsive 
genes implicated in cell cycle arrest, DNA repair and apoptosis such as p21Cipl/Wafl, 
GADD45, mdm2, Bax, Puma, Noxa, 14-3-3, p53AIP and cyclin G (Kaghad et al., 1997;Jost 
et al., 1997;De Laurenzi et al., 1998;Dicomo et al., 1998;Yang et al., 1998;Lee et al., 
1999;Takada et al., 1999;Melino et al., 2003). However the transcriptional activity differs 
between the splice variants of TAp73. For instance, the isoforms containing the shorter C 
terminus e.g. p73y and p73e are poor transcriptional activators (De Laurenzi et al. 1998). The 
p73{3 isoform is generally a more potent transcriptional activator than p73a. This is thought 
to be due to the suppressive effects of the p73a specific C-terminal as deletion of this region
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results in increased transactivation of some gene targets (Ueda et al., 2001). Interestingly, in 
co-transfection assays both p73a and p73e (which share the C-terminal 110 amino acids, 
527-636) were shown to inhibit p73p transactivation of its target promoters possibly resulting 
from a direct interaction via the OD domain (Ueda et al., 2001).
It is important to note that these effects were demonstrated using systems for over-expressing 
of the TA isoforms. Nevertheless, differences in potency of these proteins to induce 
activation of p53 target genes may exist in the cell and this would impact on the cell’s 
decision to induce cell cycle arrest or apoptosis. Furthermore, the relative abundance of the 
different p53 family members including the TAp73 and TAp63 isoforms in the cell and the 
resulting functional/non-functional tetrameric complexes formed between these proteins 
might play an important role in regulating p73 and p63 functions, depending on the cell type.
More recently, several p73 specific target genes have also been identified. For example using 
cDNA subtraction assays, aquaporin-3 (AQP3) was found to be a p73 regulated gene target, 
although p53 was also shown to activate this gene, though to a lesser extent (Zheng and 
Chen, 2001). AQP3 is a glycerol/water transporter and may mediate the activity of p73 in 
maintaining the cerebral spinal fluid dynamics which is dyregulated in p73-/- animals (Yang 
et al., 2000). The characterisation of the human adenosine deaminase (ADA) gene, which 
encodes an enzyme involved in nucleotide metabolism, revealed a putative p53 response 
element located in the first intron. The ADA gene was demonstrated to be a p73 target gene, 
coupling dNTP imbalance and cell cycle arrest. Under physiological conditions, the ADA 
gene did not appear to be a p53 target, demonstrating that p73 and p53 proteins play different 
roles in growth and development by activating different sets of genes (Tullo et al., 2003). 
Studies using cDNA microarray analysis, also identified the Interleukin 4 receptor a (IL- 
4Ra) to be a p73 target and this gene was demonstrated to be up-regulated by p73 in several 
cancer cell lines and in response to cisplatin treatment in a p73 dependent manner, 
demonstrating that IL-4Ra can mediate p73 dependent cell death (Sasaki et al., 2003). The 
p53 protein was shown not to activate this promoter and the length of the spacer sequences 
between the decamer motifs were shown to be important for specific binding of the p73 
transcription factor (Sasaki et al., 2003). Interestingly, abnormal regulation of IL-4R 
signalling is associated with allergic, autoimmune diseases and parasitic infections. As the 
p73-/- animals display chronic infections and inflammation (Yang et al., 2000), the finding
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that p73 is a direct transcriptional activator of IL-4Ra may explain, in part, some of this 
phenotype observed in the p73-/- animals.
1.31 The AN isoforms
The amino terminal truncated isoforms ANp73 and ANp63 are naturally occurring members 
identified for the p53 family and are thought to act in a dominant inhibitory manner on the 
TA isoforms and p53 (Yang et al., 1998;Liefer et al., 2000;Pozniak et al., 2000;Yang et al., 
2000; Grob et al., 2001;Ishimoto et al., 2002). Both ANp73 and ANp63 isoforms lack the TA 
domain and do not induce growth arrest or apoptosis. Instead, the AN isoforms exert a 
dominant negative effect on p53 and their corresponding TA isoforms by blocking their 
transactivation activity on promoters such as Bax, p21Clpl/Waflor MDM2. (Yang et al., 
1998;Grob et al., 2001;Ishimoto et al., 2002;Kartasheva et al., 2002;Stiewe et al., 2002a;) 
Both the ANp73 and ANp63 isoforms have been shown to interact with their corresponding 
TA isoforms and their inhibitory function is exerted by the formation of transactivation 
deficient hetero-duplexes with their corresponding TA isoforms, as well as by direct 
competition for DNA binding sites, as the AN proteins retain the core DNA binding domain 
(Yang et al., 1998;Grob et al., 2001;Stiewe et al., 2002a;Ishimoto et al., 2002). In contrast, 
wild type p53 does not associate with p73 in mammalian cells as shown by co- 
immunoprecipitation assays (Di Como et al., 1999;Marin et al., 2000;Gaiddon et al., 
2001;Ishimoto et al., 2002). Thus, in the case of p53, this inhibitory effect is mediated by the 
AN isoforms by direct competition for promoter binding sites (Yang et al., 1998;Grob et al., 
2001;Stiewe et al., 2002a Kartasheva et al., 2002). Therefore the TA and AN isoforms show 
pro- and anti-apoptotic properties respectively. Interestingly, ANp73 is the most abundant 
isoform in the nervous system, and their functionally antagonistic actions towards 
p53/TAp73 are known to be of key importance in neuronal survival.
Moreover, expression of ANp73 is increased at the mRNA level by p53 and TAp73 acting on 
this promoter, by binding to two p53 REs located in the P2 promoter (Grob et al., 
2001;Kartasheva et al., 2002;Vossio et al., 2002). Therefore both p53 and TAp73 induce 
ANp73, which inhibits their effects, forming a negative regulatory loop (Grob et al., 
2001;Kartasheva et al., 2002;Vossio et al., 2002;Nakagawa et al., 2002). Thus, the ANp73
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mediated negative feedback loop that regulates activity of TAp73 and p53 on the ANp73 
promoter provides a novel autoregulatory system that serves to modulate cell survival and 
death. This has been shown specifically in malignant cells and in developing neurones, where 
the relative ratio of ANp73 to p53/TAp73 is important in determining the apoptotic response 
to different types of stresses such as DNA damage and growth factor withdrawal respectively 
(Pozniak et al., 2000;Zaika et al., 2002).
1.32 The p53 family knock out mouse models
Results of studies supporting the proposal that different p53 family members have distinct 
biological roles come from analysis of knock out mice in which the genes encoding for p53, 
or p73 have been specifically deleted. Anaylsis of these mice lacking each protein provides a 
powerful model to reveal the developmental alterations but non-cancerous phenotypes of the 
p73 -/- animals.
1.32.1 p53 knock-out
The p53-/- animals lack an overt developmental phenotype but are highly tumour prone at an 
early age, (Donehower et al., 1992). Although loss of the p53 gene results in normal 
development, a subset of p53-/- animals developed mid-brain exencephaly resulting from the 
overproduction of neural tissue and failure of neural tube closure as well as craniofacial 
abnormalities (Armstrong et al., 1995;Sah et al., 1995). Until the discovery of p73 and p63, 
this partial penetrance of the p53-/- phenotype was difficult to explain. It is possible that p73 
and p63, both of which are expressed in the embryonic nervous system can compensate for 
the lack of p53 resulting in normal neuronal development in the p53-/- mouse. The role of 
p53 and p73 in neuronal developmental is discussed in section 1.35.
1.32.2 p73 knock out
The p73 deficient mice which are functionally deficient for all of the known p73 isoforms, 
display varying degrees of hydrocephalus, (the basis of which appears to be associated with 
excessive cerebral spinal fluid production by cells of the choroid plexus), show defects in
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hippocampal formation, primarily due to a loss of a discrete set of neurones that act to guide 
the organisation of the hippocampus and show enlarged ventricles and decreased cortical 
tissue. There is also an enhancement of developmental death in sympathetic neurones which 
may be attributed to loss of ANp73 which has been shown to be essential for survival of these 
neurones (discussed in section 1.35). p73 null mice also display abnormal social behaviour 
due to abnormalities in the development of the olfactory bulb which is involved in 
pheromone detection, as well as loss of pheromone receptor expression. In addition to these 
severe neurological defects, p73 null mice suffer from chronic infections and inflammation 
showing that p73 is required for the normal fluid dynamics of both the cerebrospinal fluid 
and the respiratory mucosa (Yang et al., 2000).
The striking difference in function of the p53 family is at first surprising as they share -60% 
of amino acid identity in the DNA binding domain and as expected transactivates many of 
the same target genes with the TA members of the family able to induce cell cycle arrest and 
apoptosis. However, more specific gene targets must exist for each family member, based on 
their unique developmental functions. Such data will be forthcoming with advances in 
techniques such as microarray technologies that would help to elucidate the different roles of 
specific sub-families such as p73 and p63. However, since both p73 and p63 are expressed as 
a wide array of spliced variants then these variants may also play a role in controlling the 
specific activities of these proteins in particular cells. Furthermore both p73 and p63 are 
expressed as dominant negative isoforms. The complex interaction within the p53 family that 
result in activation or inhibition of individual family members will impact strongly on the 
ability of these members to modulate cell fate. Furthermore the interaction of the p53 family 
with other cellular proteins that act to inhibit, activate, stabilise or specifically direct p53 
family members to activate subsets of p53 target genes, will also strongly influence each 
members biological outputs in controlling the diverse cellular activities such as proliferation, 
differentiation and regulated cell death
1.33 Role of the p53 family in apoptosis
The p53 protein is activated in response to a variety of cellular stresses such as DNA 
damage, hypoxia, nucleotide depletion and oncogene activation (Prives and Hall, 1999) and
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the nature of the damage is communicated to the p53 protein via post-translational 
modifications. A number of such modifications that alter its function have been identified 
and include phosphorylation of multiple N terminal residues (Ser6, 9, 15, 20, 33, 37, 46 and 
Thrl8, 81) and C-terminal residues (Ser315, 392) as well as acetylation (Lys320, 373 and 
382) and sumoylation (Lys386) (Appella and Anderson, 2001;Harris and Levine, 2005). 
Furthermore, the combinations of different modifications may well be specific to the type of 
stress acting on the cell. For example, y-radiation activates the ATM kinase and the CHK-2 
kinase, both of which phosphorylate the p53 protein while UV-radiation activates ATR, 
CHK-1 and casein kinase which results in the modification of different amino acid residues 
on the p53 protein (Chehab et al., 1999;Hirao et al., 2000). These alterations appear to 
change the p53 protein in two ways. Firstly they may act to stabilize the p53 protein by 
interfering with MDM2 binding, therefore, preventing the targeted degradation of p53. This 
can increase the half life of the p53 protein from 6-20 min to hours and results in a 3-10 fold 
increased concentration of the p53 protein in the cell in response to stress. Secondly, these 
post-translational modifications act to enhance p53 transcriptional activity.
Once activated, the p53 protein transactivates a network of genes whose products are 
involved in the initiation of either cell cycle arrest or apoptosis, which represent two major 
pathways induced by p53. For instance transactivation of the p2iCipl/Wafl gene promoter by 
this protein is a major player in p53 mediated cell cycle G-l arrest (El-Deiry et al., 1993). 
p21Cipl/Wa11 inhibits the cyclin D-CDK4/6 and cyclin E-CDK2 complexes resulting in 
accumulation of the unphosphorylated form of pRB. In this state, pRB binds E2F-1 and thus 
prevents the activation of the transcription of genes that are required for cell cycle 
progression from G1 to S phase in the cell cycle (Sherr, 1998). Other p53 targets involved in 
controlling the cell cycle include GADD45, cyclin G and 14-3-3. p53 also activates 
transcription of genes involved in auto-regulation of p53 function, such as MDM2 and 
ANp73.
A large number of p53 regulated genes have been shown to control p53 mediated apoptosis 
via both the intrinsic and extrinsic pathways. The first evidence suggesting that the 
mitochondria might be involved in p53-dependent apoptosis was demonstrated by the ability 
of Bcl-2 to protect cells from p53 mediated apoptosis (Gottlieb et al., 1994). Indeed p53 was 
shown to activate the pro-apoptotic Bax protein (Miyashita and Reed, 1995) and the
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BH3 only proteins Noxa (Oda et al., 2000) and Puma (Yu et al., 2001) whereas the anti- 
apoptotic genes Bcl-2 and B c 1 -x l are repressed by p53 (Vousden and Lu, 2002). 
Cytochrome c interacts with another p53 transcriptional target Apaf-1 which activates 
Caspase-9 which in turn activates Caspase-3 resulting in apoptosis (Kannan et al., 2001). In 
addition, p53 regulates a series of other genes that initiate the extrinsic apoptotic pathway 
(Fas, DR4 and DR5 death receptors) leading to Caspase-8 activation and Caspase-3 cleavage, 
resulting in apoptosis (Sheikh et al., 1998). It has been recently shown that p53 can trigger 
apoptosis via transcription independent mechanism by interacting with the mitochondria. In 
this report, translocation of p53 to the mitochondria was observed in response to DNA 
damage and this translocation triggered apoptosis that occurred prior to p53 gene activation. 
It was shown that p53 could activate BAK and permeabilizes the mitochondrial membranes 
by physically interacting with the anti-apoptotic Bcl-2 proteins (Erster et al., 2004;Erster and 
Moll, 2005).
Recent studies, utilising mouse embryo fibroblasts deficient for one or a combination of p53 
family members, showed interplay among the p53 family members where p53 is completely 
inactive on promoters of apoptotic genes such as Noxa, PERP and Bax if p63 and p73 are 
absent (Flores et al., 2002). However, although p73 and p63 are capable of weak heterotypic 
interactions, wild type p53 was showed not to interact with p73 or p63 (Davison et al., 1999), 
suggesting that the interplay of these protiens on apoptotic promoters is likely to be complex. 
A number of different stress signals and upstream regulators that activate the p53 pathway 
have been described (reviewed by Appella and Anderson, 2001). The stress signals that 
activate p73 and regulates it function are discussed in this section.
p73 has been shown to accumulate in response to specific forms of DNA damage resulting 
from specific stresses such as y-radiation, cisplatin and taxol. This protein was also identified 
as a target of the non receptor tyrosine kinase c-Abl, which provided evidence that a p73 
repair pathway for DNA damage exists that is p53 independent. Gong and colleagues (1999) 
showed that the half life of p73 is prolonged by cisplatin treatment and demonstrated that 
MEF cells deficient in mismatch repair proteins or c-Abl are unable to up-regulate p73 and 
hence are more resistant to cisplatin treatment (Gong et al. 1999). Furthermore Yuan and 
colleagues (1999) demonstrated that y-radiation promotes c-Abl induced tyrosine 
phosphorylation on residue Tyr99 of p73, which results in the potentiation of the pro-
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apoptotic activity of p73 and increased stability (Yuan et al. 1999). These post-translational 
modifications of p73 occur via physical interaction between the SH3 domain of c-Abl with 
the PXXP motif present at the C-terminus of p73 (Yuan et al., 1999;Agami et al., 1999). As 
c-Abl is itself phosphorylated by the ATM gene product this suggests that ATM is involved 
in the pathway leading to c-Abl dependent activation of p73 in response to DNA damage 
(Shaul, 2000). Furthermore, over-expression of c-Abl also induces p38 dependent 
phosphorylation on threonine residues adjacent to prolines in the p73 protein (which was 
detected by the use of specific antibodies against phosphorylated threonine adjacent to a 
proline). Although the precise threonines were not identified, it is anticipated that p38 would 
phosphorylate threonine residues in the proline rich regions found in p73 (Fig 1.12) 
(Sanchez-Prieto et al., 2002). Both these phosphorylation pathways enhance the stability and 
transcriptional activity of p73.
In addition to DNA damage induced phosphorylation of p73, which increases its stability, 
p73 is also regulated by acetylation in response to DNA damage. It has been demonstrated 
that p300 interacts with the N terminal region of p73 and this interaction enhances its pro- 
apoptotic activity (Zeng et al., 2000). p300 acetylation of p73 on three conserved lysines 321, 
327 and 331 occurs in a c-Abl dependent manner, and this increases p73 transcriptional 
activity on pro-apoptotic targets such as p53AIPl and potentiated p73-mediated apoptosis. 
Conversely, non-acetylated p73 protein is transcriptionally inactive on pro-apoptotic genes 
but can still transactivate cell cycle related genes such as p2lClpl/wafl (Costanzo et al., 2002) 
demonstrating how cellular co-activators can couple activation of p73 to either cell cycle 
arrest or apoptosis.
Both p53 and p73 can also be activated by oncogenes such as E2F-1, c-myc and El A (Sherr, 
1998;Zaika et al., 2001). Here, the inappropriate signalling for entry into the cell cycle is 
detected by the p53 checkpoint resulting in apoptosis, and is thus an example of the tumour 
suppressor function of the p53 protein. A key player in this pathway is E2F-1 whose 
dysregulation by mitogenic oncogenes is believed to trigger p53 dependent apoptosis and 
also p53 independent apoptosis that was shown to occur via p73 (Irwin et al., 2000;Lowe and 
Sherr, 2003). In the first instance, deregulated expression of oncogenes causes E2F-1 
mediated induction of pl9ARF which inhibits MDM2, thus protecting p53 from MDM2- 
mediated degradation (Bates et al., 1998). p73 activation by oncongenes was
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demonstrated by the findings that the disruption of p73 function inhibits oncogene induced 
apoptosis in p53 null human tumour cells (Zaika et al., 2001). Furthermore, p73 also mediate 
E2F-1 induced apoptosis in SAOS2 cells and p53-/- MEFs (Irwin et al., 2000) and thus was 
shown to mediate E2F-1 apoptosis that is p53 independent. Moreover E2F-1 was shown to 
directly increase p73 expression by binding to the E2F-1 sites within the TAp73 promoter 
(Irwin et al., 2000). In addition, unlike p53, activation of p73 by E2F-1 is required for 
apoptosis after T-cell receptor activation (Lissy et al. 2000). Consistent with this finding, 
E2F-1 null mice have increased numbers of T-cells and splenomegaly (Field et al., 1996) 
suggesting that p73 also plays a role in tumour surveillance pathways of lymphoid cells.
Thus, several differences are apparent in the post-translational modifications that occur on 
the p53 family in response to DNA damage and whether or not they are phosphorylated by 
the same kinases remains to be established. Firstly, p73 is activated by only a subset of DNA 
damaging agents and unlike p53, the p73 response to stress is mediated by tyrosine 
phosphorylation which is not observed with p53 (Yuan et al., 1999;Agami et al., 1999). This 
suggests that p73 recruits proteins with SH3 domains, and hence can mediate apoptosis via 
distinct pathways from those engaged by p53 upon DNA damage. Secondly E2F-1 induced 
apoptosis occurs following regulation of the level of p73 mRNA accumulation whereas E2F- 
1 induced apoptosis associated with p53, occurs indirectly by altering p53 stabilisation.
1.33.1 Mechanism of p73 mediated apoptosis
Several recent papers have addressed the mechanisms by which p73 triggers cell death. 
Melino and colleagues (2004) demonstrated that p73 induces the mitochondria death 
pathway via the up-regulation of Bax and Puma. Puma is a BH3 only protein that mediates 
the mitochondrial translocation of Bax and changes the conformation of the Bax protein into 
its active state (Melino et al., 2004). Using Tet-On Saos-2 inducible cell lines, it was 
demonstrated that while p73 overexpression induced the box promoter, the kinetics of 
apoptosis did not correlate with increased Bax protein levels (Bax levels were induced only 
after 72-96 hrs whereas cell death occurred 48 hrs after p73 induction). Instead, p73 mediated 
up regulation of Puma and Puma-dependent mitochondrial translocation of Bax is kinetically 
compatible with the induction of cell death as this process takes less than 48 hours (Puma
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protein was induced after 12 hours of p73 induction and Puma mediated Bax movement from 
the cytosol to the mitochondria membrane took place within 24 hrs of transfection of Puma 
in to cells stably transfected with Bax-GFP). Thus, at least in this experimental system, p73 
mediated transactivation of PUMA and the subsequent PUMA mediated mitochondrial 
translocation of Bax is highly efficient for cell death. Furthermore, ANp73 inhibited TAp73 
mediated apoptosis and importantly, ANp73 inhibited TAp73 mediated PUMA up regulation 
and in turn blocked Bax translocation to the mitochondria and subsequent Cytochrome c 
release (Melino et al., 2004).
The p73 protein has also been shown to induce apoptosis via the activation of death receptors 
(Terrasson et al., 2005). Firstly it was shown that p73 expression was sufficient to trigger 
apoptosis through death receptors, such as the tumour necrosis factor receptor (TNFR)- 
related proteins, Fas. Moreover this sensitisation to pro-apoptotic ligands of the Fas receptor 
such as the TNF-related apoptosis inducing ligand (TRAIL) or 7C11, (an agonistic anti Fas 
antibody) depended on caspase activation. Furthermore, p73 transcriptional activity is 
required for this effect and sensitisation of cisplatin treated cells to death receptor apoptosis 
is due to p73 dependent transactivation of Fas and subsequent increased protein expression at 
the cell surface. In accordance with this, infection with human cytomegalovirus (HCMV) 
which is known to increase the levels of the AN isoform in infected cells, inhibits p73 
dependent Fas mediated apoptosis and transfection with small interfering RNA against the 
AN isoform, restored sensitivity to 7C11 in HCMV infected cells (Terrasson et al., 2005).
The p73 protein has also been demonstrated to induce apoptosis via the endoplasmic 
reticulum (ER). Specifically it was shown that p73 but not ANp73 caused changes in the 
morphology of the ER including calnexin clumping, reduction of intracellular free calcium 
and induction of Gadd 153, all of which are associated with ER stress. Furthermore p73 and 
p53 but not ANp73 could up-regulate Scotin, a small transmembrane protein (23kDa) that 
localizes within the ER and triggers apoptosis from the ER as a consequence of ER stress 
(Terrinoni et al., 2004). Therefore both p73 and p53 can transactivate Scotin and induce cell 
death via the ER which is an important sensor of abnormal cytosolic signals such as 
accumulation of unfolded proteins, calcium depletion, inhibition of glycosylation and viral 
and hypoxic stress.
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1.34 Role of p53 family members in cancer
The p53 tumour suppressor gene is the most frequent target for genetic alterations in human 
cancers (Hollstein et al. 1997). Most mutations occur within the highly conserved DBD of 
the protein leading to loss of wild type activity (Levine 1997). In addition, patients with germ 
line mutations in p53 develop the Li-Fraumeni hereditary syndrome which predisposes 
affected individuals to the development of multiple types of cancers including sarcomas, 
brain tumours and breast cancer. The data supporting the role of p73 in cancer is presented 
below.
p73 maps to chromosome lp36.33 which is frequently deleted in a variety of human cancers 
including neuroblastoma, melanoma, breast and colon cancer (Kaghad et al., 1997;Irwin and 
Kaelin, Jr., 2001). However, extensive studies of p73 status in a variety of primary tumours, 
including those with lp deletions, revealed that p73 mutations are exceedingly rare. The 
analysis of p73 as a tumour suppressor was further complicated by the finding that p73 
mRNA and protein levels tended to rise in tumour tissue compared with surrounding normal 
tissue, suggesting that p73 plays a role in tumourigenesis. To date, p73 over-expression has 
been found in tumours of the breast, lung, esophagus, stomach, colon, ovary, liver, CML, 
AML ependymoma and neuroblastoma (Zaika et al., 1999;Levrero et al., 2000;Moll et al., 
2001;Stiewe and Putzer, 2002).
Of note, many early studies measured global p73 levels and the recent use of isoform specific 
RT-PCR has shown that in many cases, it is the ANp73 isoform that is specifically up- 
regulated in primary tumours such as breast carcinoma, gynaecological cancers, 
hepatocellular carcinoma and neuroblastoma (Zaika et al., 2002;Douc-Rasy et al., 2002). 
Furthermore, novel truncated isoforms of TAp73 lacking exon 2 or 3 (A2p73, A3p73) have 
also been shown to be expressed in neuroblastoma, hepatocellular, breast and ovarian cancers 
but not the originating normal tissue (Ng et al., 2000;OrNions et al., 2001;Fillippovich et al., 
2001;Stiewe et al., 2004). Moreover increased levels of ANp73 were found to be an 
independent prognostic marker for reduced survival in neuroblastoma patients (Casciano et 
al., 2002) and the ANp73 isoforms have been shown to exhibit oncogenic properties as a 
result of its ability to inhibit p53/TAp73 mediated transactivation, apoptosis and growth
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suppressing functions (Stiewe et al., 2002b;Petrenko et al., 2003).
Interactions between TAp73 and mutant p53 (but not wild type p53) have also been shown to 
occur in cancer cells and this interaction resulted in inhibition of the apoptotic function of 
p73 (Di Como et al., 1999;Strano et al., 2000;Gaiddon et al., 2001). This interaction with p73 
was shown to be mediated by the DBD of mutant p53 (Strano et al., 2000;Gaiddon et al.,
2001) and the DBD and OD of p73 (Strano et al., 2000). Interestingly, cancer cells that 
express p53 mutants that do not bind to p73 and therefore do not inhibit the functions of p73 
have increased sensitivity to anticancer drug induced apoptosis whereas, those cancers that 
have p53 mutants that efficiently inhibit p73 function show the most resistance (Bergamaschi 
et al., 2003). Therefore the inactivation of p73 by mutated p53 may provide a selective 
advantage in promoting tumourigenesis.
1.35 The p53 family and developmental cell death and 
differentiation in the nervous system
The up-regulation of p53 in the adult nervous system as a result from traumatic insults 
ranging from ischemia and excitoxicity to oxidative stress in multiple neuronal populations 
has been extensively investigated (Li et al., 1994;Sakhi et al., 1994;Wood and Youle, 
1995;Morrison et al., 1996). It is thought that DNA damage may be the major common 
feature integrating the different stress signalling pathways and initiating p53 mediated 
apoptosis.
However, emerging evidence also indicate that the p53 family play a critical role in both 
phases of apoptosis occurring during neuronal developmental, which has been widely 
investigated. The first phase serves to eliminate those progenitors that do not differentiate 
appropriately and ensures that the correct number of cells is generated in structures of the 
nervous system, while the second phase of developmental cell death serves to match neuronal 
number to the size of the target tissue. Recent evidence has also highlighted a role for p53 as 
well as p73 in neuronal differentiation which is discussed in the next section. The role of the 
p53 family in developmental apoptosis in the nervous system is discussed in this section.
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1.35.1 The role of p53 in determining fate of neural progenitor cells
Initial analysis of animals with a targeted deletion of the p53 gene provided strong support 
for the hypothesis that p53 was a key tumour suppressor protein because p53-/- mice 
exhibited a high rate of spontaneous tumour formation (Donehower et al., 1992). However, 
upon further examination, it was shown that a large number of female p53-/- embryos died in 
utero as a result of mid-brain exencephaly, a neural tube malformation resulting from the 
overproduction of neural tissue and failure of neural tube closure (Armstrong et al., 1995;Sah 
et al., 1995). Interestingly, this phenotype is shared in animals with targeted deletions in 
genes encoding for other members that act in the intrinsic mitochondrial death pathway 
including the pro-apoptotic proteins Apaf-1, caspase-9 and caspase-3. In all these cases, 
exencephaly resulted from a deficiency of apoptosis in progenitor cell in the neuroepithelium 
of the developing neural tube, thus indicating the importance of the intrinsic apoptotic 
pathway for controlling neural progenitor cell fate during neuronal development. Apaf-1-/- 
animals also exhibited craniofacial abnormalities similar to that observed in the p53-/- 
animals. However the partial penetrance of the p53-/- phenotype was difficult to explain until 
the discovery of p73 and p63 proteins, both of which are expressed in the embryonic nervous 
system and can potentially compensate for the lack of p53 resulting in normal neuronal 
development in the p53-/- mouse.
Additional support of a role for p53 in neuronal developmental cell death comes from 
analysis of mice with a targeted deletion of the pRb tumour suppressor gene. These mice 
suffer massive apoptosis in the embryonic nervous system (Jacks et al., 1992). Interestingly, 
the concomitant deletion of p53 rescued this apoptotic phenotype (Macleod et al., 1996), 
suggesting that p53 plays a critical role in eliminating neural progenitors and post-mitotic 
neurones that do not differentiate appropriately.
1.35.2 An essential role for p53 and p73 during naturally occurring neuronal 
cell death
The first evidence that p53 might play a role in naturally occurring developmental cell death 
of post-mitotic neurones came from studies of the peripheral sympathetic neurones of the 
superior cervical ganglion (SCG). During this second wave of apoptosis, approximately 40%
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of sympathetic neurones in the SCG are eliminated. This process starts in late embryogenesis 
in rodents and occurs primarily during the first two weeks after birth. The survival of any 
given neurone during this period is determined by its ability to compete for limiting amounts 
of target-derived NGF. Those neurones that do not receive appropriate trophic support 
undergo apoptosis due to an imbalance of pro-apoptotic signals over anti-apoptotic signals.
A number of studies indicate that p53 and p73 play a role in regulating the survival of 
sympathetic neurones during this developmental period. Firstly, it was shown that 
overexpression of p53 was sufficient to cause the death of sympathetic neurones in the 
presence of NGF which normally protects these cells from apoptosis (Slack et al., 1996). 
Secondly, p53-/- sympathetic neurones showed enhanced survival in culture in the absence of 
NGF, (Vogel and Parada, 1998). Thirdly, p53 levels increased when sympathetic neurones 
undergo apoptosis in response to either NGF withdrawal or activation of p75NTR and this 
apoptosis could be inhibited if the increase in p53 levels was prevented by concomitant 
expression of the adenoviral E1B55K protein which inhibits p53 function (Aloyz et al.,
1998). Finally, analysis of p53-/- SCG revealed that the rate of apoptosis and loss of 
neurones was decreased but not eliminated in vivo during the first two postnatal weeks 
compared to wild type. This also suggests that other factors are involved in the apoptosis of 
SCG during this developmental cell death. Furthermore the decrease in apoptosis was similar 
in p53 +/- and p53-/- animals which suggests that developmental compensation occurs in the 
p53-/- background e.g. by the presence of p73 (Aloyz et al., 1998). Collectively, these 
findings strongly supports the idea that p53 plays a pro-apoptotic role in developing 
sympathetic neurones that is activated following NGF withdrawal or p75NTR activation.
The apoptotic pathways that are activated following NGF withdrawal in peripheral neurones 
has been well characterised and involves at least two apoptotic pathways which may 
converge on p53 (Fig 1.13a). One is the JNK-p53-Bax pathway that is also activated by 
p75NTR (Deckwerth et al., 1996;Aloyz et al., 1998;Kaplan et al., 2000). MEKK and JNK 
function upstream of p53 in p75NTR mediated apoptosis but cdc42/Racl, Askl, MKK, JNK, 
c-jun and p53 have all been shown to act in a signalling pathway regulating NGF 
withdrawal-induced apoptosis. The second pathway shown to be important for apoptosis after 
NGF withdrawal involves the activation of the cell cycle regulatory molecules CDK4/6
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Figure 1.13: The role of p53 and p73 in neuronal developmental cell death
Naturally occurring cell death is regulated by the balance of signals deriving from the NGF/TrkA pro­
survival receptor and the pro-apoptotic p75 neurotrophin receptor (p75NTR). a) Withdrawal of the 
survival ligand triggers two apoptotic cascades, the JNK pathway that is also triggered by p75NTR 
activation and the cell cycle deregulation pathway that is independent of p75NTR activation. Both of 
these pathways are essential for neuronal apoptosis. p53 plays an essential pro-apoptotic role in this 
process while ANp73 plays an anti-apoptotic role by antagonising p53 function (see text for details), 
b) TrkA mediates neuronal survival during naturally occurring death by blocking p75NTR-mediated 
apoptotic signals. TrkA overrides the p75 TR-JNK-p53 apoptotic pathway via RAS activation. The 
RAS-PI3K-AKT survival pathway is the major pathway used by TrkA to suppress apoptosis. The Ras 
activated MEK/MAPK pathway also contributes to survival but to a lesser extent.
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which activate pRb by phosphorylation. This results in the release of E2F-1 and subsequently 
causes sympathetic neurone apoptosis that is p53 dependent (Park et al., 1997). As 
inappropriate cell signalling has shown to result in E2F-1 mediated activation of p!9ARF 
which activates p53 (by inhibiting MDM2 function) in non neuronal cells, then it follows that 
this cell cycle pathway may also converge onto p53, in the embryonic nervous system. 
Therefore, this suggests that p53 plays a pivotal role in integrating these stimuli and thus 
activating apoptosis in neurones only when these upstream signals reach a certain critical 
threshold. This cell cycle pathway may also represent a p75NTR independent pathway that is 
responsible for the delayed apoptosis of p75NTR -/- sympathetic neurones.
Activation of the TrkA receptor by binding of NGF, can silence the JNK-p53-Bax cell death 
pathway via the RAS signalling pathway (shown in Fig 1.13b) which has been shown to be 
sufficient to suppress p53 mediated apoptosis in sympathetic neurones (Mazzoni et al., 
1999). Ras activates several downstream effector proteins including Raf and 
phosphatidylinosition 3-kinase (PI3-K). Raf binds to and activates the MAP kinase kinase 
(MEK) signalling cascade that cumulates in the activation of ERK1/2, which can act in direct 
opposition to JNK (Xia et al., 1995;Mazzoni et al., 1999) and has been shown to protect 
against p53 mediated apoptosis in sympathetic neurones. PI3-K activates the 
serine/threonine kinase Akt and is the major pathway by which Ras mediates its anti- 
apoptotic effects. (Mazzoni et al., 1999). How Akt mediates survival in response to TrkA 
activation is not well understood, but may do so via both direct and indirect pathways. For 
instance it is thought to inactivate Bad thus releasing Bcl-xL to antagonise Bax and/or by the 
down regulation of Puma, a mediator of the p53 family apoptotic response (Datta et al., 
1997;Vousden et al., 2002). Furthermore Akt has been shown to phosphorylate and promote 
translocation of MDM2 to the nucleus, thus facilitating the degradation of p53 (Mayo and 
Donner, 2001;Vousden et al., 2002).
The pro-apoptotic Bax protein, a downstream transcriptional target of p53, has a defined role 
in neuronal apoptosis. Importantly, Bax, has been shown to be essential for apoptotic death 
of most peripheral neurones (Deckwerth et al., 1996;White et al., 1998;Aloyz et al., 1998) 
and for p53 dependent apoptosis of cortical and cerebellar granule (Xiang et al., 1998;Cregan 
et al., 1999). After commitment of neuronal cells to undergo apoptosis the balance of pro- 
apoptotic and anti-apoptotic factors is shifted and the hypothesis that p53 transcription of
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Bax contributes considerably to this shift towards cell death, is supported by several findings. 
These include experiments showing that exogenous p53 is unable to mediate apoptosis of 
Bax -/- cortical neurones and Bax -/- cerebellar granule neurones (Xiang et al., 1998;Cregan 
et al., 1999). Moreover, Bax -/- sympathetic neurones do not under apoptosis in response to 
NGF withdrawal (Deckwerth et al., 1996) and the generation of Bax/Bcl-xL double deficient 
embryos reduced the excessive apoptosis seen in the developing nervous system of B c1-xl  - /-  
animals (Shindler et al., 1997).
Interestingly, the increased numbers of cells in the Bax-/- embryo and decreased number of 
cells in the B c1-xl embryo were the result of elimination/survival of post-mitotic neurones 
but deletion of Bax or B c1-xl  did not affect the apoptosis of progenitor cells (Motoyama et 
al., 1995;White et al., 1998;Kuan et al., 2000). In contrast, deletion of Caspase-3 gene 
effectively eliminates death of progenitor cells, resulting in marked hyperplasia of the 
embryonic nervous system (Kuida et al., 1996). Thus, Caspase-3 and presumably p53, 
caspase 9 and Apaf-1, which show similar phenotype to Caspase-3-/- animals, are regulators 
of progenitor cell proliferation as well as being involved in post-mitotic apoptosis with the 
latter requiring both Bax and B c1-x l /B c1-2 function.
Analysis of p73 expression in the developing brain and sympathetic ganglia showed that the 
ANp73 isoform predominates, yielding protein levels that were 20-fold greater than those of 
the TAp73 isoform (Pozniak et al., 2000;Yang et al., 2000). Pozniak et al (2000) reported 
that levels of ANp73 are highest in sympathetic neurones maintained in NGF but decrease 
significantly upon NGF withdrawal. After NGF withdrawal these neurones undergo p53 
mediated apoptosis (Aloyz et al., 1998), a process that is repressed when ANp73 is 
exogenously expressed in these sympathetic neurones. Moreover, in p73 -/- animals there is a 
40% loss of sympathetic neurone number in the SGCs, suggesting that ANp73 plays an 
essential anti-apoptotic role in vivo. Further evidence supporting ANp73 as a determinant of 
survival in developing neurones by blocking p53-dependent apoptosis comes from genetic 
studies showing that deletion of even one allele of p53 is sufficient to partially rescue the 
enhanced sympathetic neurone death seen in p73-/- animals (Lee et al., 2004). These studies 
demonstrate that wild type p53 and ANp73 proteins act in a functionally antagonistic manner 
during naturally occurring death. Specifically ANp73 blocked the up-regulation of two direct 
p53 targets, P21cip/Wafl and Apaf-1 as well as inhibiting cleavage of caspase-3 (Lee et al.,
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2004). In addition, ANp73 was also shown to prevent neuronal apoptosis in cortical neurones 
(Pozniak et al., 2002) suggesting that the pro-survival role for ANp73 may well generalize to 
other populations of neurones. It can therefore be postulated that the balance between p53 
and the TA and AN forms of p73 modulate the levels of apoptosis in neurones during 
development. Additionally other interacting factors such as Bm-3a may be important in 
modulating the functions of these proteins in determining neuronal cell fate.
The findings that loss of p53 in p73 -/- animals resulted in only partial rescue of apoptosis, 
indicates that ANp73 must mediate neuronal survival via other targets as well. In this regard, 
Lee et al (2004) shown that exogenous expression of ANp73 in sympathetic neurones 
prevented the release of mitochondrial Cytochrome c, inhibited JNK activation and 
suppressed the induction of BimEL, a pro-apoptotic Bcl-2 family member, after NGF 
withdrawal.
The role of ANp73 in neuronal survival is not limited to developing neurones as p73-/- 
animals exhibit continued neuronal loss throughout life (Pozniak et al., 2002;Lee et al., 
2004). Therefore ANp73 is an essential survival protein in both the PNS and CNS as well as 
having a role in the long term maintenance of at least some populations of adult neurones. In 
agreement with this, ANp73 has been demonstrated to be required as a survival factor in the 
response of some adult neurones to certain stresses such as DNA damage and trauma. The 
survival of neurones during embryogenesis is dependent on making appropriate connections 
but after this event the mature neurones become resistant to apoptotic stimuli, so that they 
survive the remainder of the animal’s life time and this is thought to require ANp73. Walsh et 
al (2004) showed that adult p73+/- DRG neurones were more vulnerable to apoptotic stimuli 
then were their p73+/+ counterparts and that invulnerability was restored to the p73 +/- 
neurones by increasing expression of ANp73.
In context of these findings the significant neurological abnormalities seen in p73 -/- mice can 
be explained by either the absence or decrease of neurones. Therefore it can be speculated 
that the neurological abnormalities in the p73-/- mouse is due to the loss of the anti-apoptotic 
form of p73. As the AN forms are generated from the same gene as the TA forms of p73 by 
alternative promoter usage, this provides a mechanism for rapidly altering the ratios of the 
pro-apoptotic versus anti-apoptotic isoforms of p73 in the nervous system. This would allow
96
p73 to compensate for the absence of p53 in the nervous system and may explain the partial 
penetrance of the neural phenotype in the p53-/- embryos.
1.36 Role of p53 in differentiation
The role of p53 in neuronal differentiation during development has only become a recent 
field of investigation. A transient increase in the expression of p53 mRNA and protein was 
demonstrated in rat hippocampal neurones and in PC 12 neuronal cells during differentiation 
and in these studies p53 expression was mainly nuclear. However, in mature differentiated 
neurones, p53 levels decreased and the protein was mainly found in the cytoplasm. 
Exogenous expression of a dominant negative mutant of p53 in PC 12 cells reduced the 
percentage of differentiating neurones demonstrating that p53 is directly involved in the 
differentiation of these cells (Eizenberg et al. 1996). p53 expression has also been associated 
with differentiation of Oligodendrocyte precursor cells (OPC) so that transfection of 
dominant negative forms of p53 into purified OPCs inhibited both thyroid hormone (TH) or 
retinoic acid (RA) induced OPC differentiation but not platelet derived growth factor (PDGF) 
withdrawal induced differentiation (Billon et al., 2004). Furthermore there is a decrease in 
Oligodendrocyte number and an increase in the number of OPCs in the P7 optic nerve of p53 
-/- mice compared with wild types, suggesting that p53 plays a role in differentiation of 
OPCs (Billon etal., 2004).
A role for p53 in kidney development and differentiation has also recently been suggested. 
The expression of p53 in the developing kidney was shown to coincide spatiotemporally with 
terminal differentiation, so that p53 stabilisation and enhanced DNA binding are 
accompanied by p53 phosphorylation and acetylation. Moreover p53 was able to 
transactivate promoters of several genes associated with differentiation in the kidney 
including the bradykinin B2-receptor (B2R), AQP-2, and angiotensin type 1. (Saifudeen et 
al., 2002). Furthermore analysis of p53-/- animals exhibited aberrant terminal differentiation 
of nephrons (Saifudeen et al., 2002).
These results therefore demonstrate that p53 plays an important role in the differentiation of 
specific cell types, including neurones, during development as well as inducing apoptosis in
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these cells during development and in response to stresses.
1.37 Role of p73 in differentiation
In agreement with the neuronal defects found in the p73 knock out mice, in vitro studies 
demonstrated that TAp73 expression increased during retinoic acid induced differentiation of 
neuroblastoma cells and TAp73 overexpression alone was capable of inducing both 
morphological (neurite outgrowth) and biochemical markers (NCAM expression) of 
neuroblastoma differentiation. Moreover, transfection of dominant negative p73 in 
neuroblastoma cells abrogates the transactivation of NCAM promoter induced by retinoids, a 
well known trigger of neuronal differentiation in these cells. (De Laurenzi et al., 2000). 
Moreover, it has recently been demonstrated that over-expressing p73 explanted purified 
Oligodendrocyte precursor cells (OPCs) increases the spontaneous differentiation of OPCs in 
the absence of a differentiation stimulus, but also enhanced the differentiation of these cells 
induced by TH or RA- treatment or withdrawal of PDGF. Furthermore expression of the 
ANp73 transgene in OPCs inhibits all forms of OPC differentiation, possibly by blocking 
TAp73 function (Billon et al., 2004).
Additionally the TA73 and ANp73 isoforms have also been shown to be developmentally 
regulated during kidney organogenesis. Thus, TAp73 is predominantly expressed in the 
differentiation domain of the renal cortex whereas ANp73 isoforms are induced early in 
development and are preferentially expressed in proliferating nephron precursors. 
Furthermore p73 was shown to activate two renal function genes AQP-2 and B2R promoters 
independently of p53, while ANp73 repressed the B2R promoter. Therefore the spatial switch 
from ANp73 to TAp73 may be an important factor in cell fate determination during terminal 
nephron differentiation (Saifudeen et al., 2005).
Additionally, up-regulation of p73 expression has also been shown to increase during C2C12 
muscle cell line differentiation (Fontemaggi et al., 2001;Li et al., 2005) and during myeloid 
cell line differentiation (Tschan et al., 2000).
Thus, as well as the response to DNA damage, p73 has also been shown to be up regulated 
during neuronal, muscle, kidney and hematopoietic muscle differentiation (Tschan et al.,
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2000;De, V et al., 2000;Fontemaggi et al., 2001). In order to investigate the possible 
mechanisms of p73 modulation during differentiation, Fontemaggie and colleagues 
demonstrated that the transcriptional repressor ZEB binds to the first intron of the p73 gene 
and silences the p73 promoter. Furthermore ZEB binding is greater in proliferating cells than 
in differentiating cells thus providing a possible mechanism by which p73 levels increase in 
differentiating cells. This is supported by findings that overexpression of dominant negative 
ZEB restores p73 mRNA in proliferating C2C12 myoblasts and P19 neuronal cells 
(Fontemaggi et al., 2001).
These results demonstrate that as with p53, p73 is also associated with differentiation of 
specific cell types as well as inducing apoptosis in these cells depending on cell type and 
conditions. However p73 shows greater molecular complexity compared to p53 as it is 
expressed as multiple spliced N- terminal and C-terminal isoforms that show differential 
expression during development, indicating they have different biological properties.
1.38 Regulation of stability and function of the p53 family
The levels of p53 and p73 significantly increase in the cell in response to stress signals such 
as DNA damage, mainly through stabilisation of the protein and subsequent increase in half 
life. Both p53 and p73 activation leads to the transactivation of a subset of genes that results 
in either cell cycle arrest or induction of apoptosis depending on the nature of the stress 
signal, cell type, the combination of p53/p73 modifications and proteins associated with 
p53/p73. The activity of the p53 family of proteins is tightly regulated and this is achieved by 
regulation of protein degradation, post-translational modifications and cellular localisation 
which is discussed in this section. Furthermore the activation of p53/p73 and its network of 
genes, sets in motion a process of autoregulatory feedback mechanisms that either permits 
the completion or the reversal of the p53/p73 programmed response to stress (Harris and 
Levine, 2005)
The MDM2 protein is a crucial regulator of p53 stability, as it is able to bind to the p53 
transactivation domain and inhibit its transcriptional activity while stimulating its 
ubiquitination and subsequent nuclear export (Haupt et al., 1997). Furthermore, p53 induces 
the expression of MDM2 which in turn controls p53 activity and stability giving rise
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to an auto-regulatory feedback loop (Kubbutat et al., 1997). Studies using p53 and/or MDM2 
animals in which expression has been lost showed that the early embryonic death observed in 
the MDM2 -/- embryos is rescued by further deleting the p53 gene. These findings 
demonstrate that the MDM2/p53 interaction is crucial for proper development (Jones et al., 
1995). According to the current model, ubiquitination of p53 by MDM2 uncovers a nuclear 
export signal for p53, which is inactive when p53 is in a tetramer, thus permitting nuclear 
export of p53 and degradation by the proteasome (Geyer et al., 2000;Stommel and Wahl, 
2004).
Like p53, p73 levels in the cell are also dependent on the balance between protein synthesis 
and degradation. The p73 protein also participates in an auto-regulatory feed back loop with 
MDM2. However, binding of MDM2 to the p73 transactivation domain inhibits p73 
mediated transcription and apoptosis but does not target p73 for degradation (Zeng et al., 
1999). In fact MDM2 binding promoted p73 stability (Ongkeko et al., 1999). Both 53 and 
p73 bind the p300 co-activator which is necessary for their transactivation function. Since 
MDM2 and p73 both bind to the N-terminal domain of the p300 co-activator, it is likely that 
MDM binding inhibits the function of p73 by competing with it for p300 (Zeng et al., 
1999;Zeng et al., 2000). In contrast, MDM2 binding to p53 does not disrupt the p53-p300 
complex. Furthermore, the presence of p300 in the p53/MDM2 complex was shown to 
actually stimulate degradation and that p300 also ubiquitinated p53 (Zeng et al., 
1999;Grossman et al., 2003). Additionally, binding of MDM2 to p53 and p73 resulted in 
completely different subcellular redistributions of these proteins. In contrast to the nuclear 
export of p53 mediated by MDM2, the p73/MDM2 complex accumulates as nuclear 
aggregates (Gu et al., 2001). Thus, although the p53/p73-MDM2 negative feedback is 
preserved, the mechanism of MDM2 regulation of these two proteins is distinct.
Although MDM2 does not target p73 for proteasome dependent degradation, it does appear 
that p73 stability is dependent on the proteasome as well as on protein modifications 
(phosphorylation, acetylation). Specifically, it was shown that the steady state levels of p73 
increases in the presence of the proteasome inhibitor, LLnL, demonstrating that p73 is 
degradated by an ubiquitin-dependent proteasome pathway (Lee et al., 1999). Recently it was 
demonstrated that Itch, a human E3 ligase binds to the PXXP motif found in p73a, p73p and 
ANp73a and targets these proteins for degradation (Rossi et al., 2005).
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Furthermore Itch is down regulated in response to DNA damage and it was therefore 
anticipated that both TAp73 and ANp73 protein levels would rise. However it was shown 
that only the TAp73a protein level rises whilst ANp73 was rapidly degraded upon DNA 
damage regardless of the down regulation of Itch (Maisse et al., 2004;Rossi et al., 2005) 
therefore implying a second pathway that would specifically target ANp73a degradation in 
response to DNA damage. As a consequence of ANp73 degradation, both TAp73 and p53 
can exert their apoptotic function. The mechanism of this selective degradation of ANp73 
with respect to TAp73 in response to DNA damage remains to be determined. Additionally, 
it has been shown that p73a but not p73(3 can be modified by SUMO-1 (small ubiquitin like 
molecule) on Lys627 which potentiates p73a’s proteolytic degradation (Minty et al., 2000). 
Conversely, sumoylation of p53 activates its transcriptional activity (Gostissa et al., 1999). 
Also the transcriptional activity of p73 has been shown to be required for its rapid 
degradation, indicating that direct transcriptional targets of p73 might have the ability to 
induce its proteolytic degradation (Wu et al., 2004).
p53 is a nuclear phosphoprotein that is phosphorylated by several protein kinases in response 
to DNA damage and the phosphorylation of specific residues of the p53 protein can lead to 
increased stabilisation as well as increased activity (Prives et al., 1999). In particular, the 
phosphorylation of the N-terminus residues Seri 5, Ser20, Ser37 and Thrl8 has been shown 
to reduce the interaction of p53 with MDM2 thereby preventing its degradation (Prives et al., 
1999). There is also evidence showing that phosphorylation in the C-terminal region of the 
protein also stabilises p53 (Buschmann et al., 2001) while inhibition of p53 deacetylation 
which is required for MDM2 mediated degradation increased the half life of p53 (Ito et al.,
2002). In contrast, p53 transcription is activated by both C-terminus phosphorylation and 
p300 mediated acetylation of the p53 C-terminal domain (Lill et al., 1997).
Similar to p53, genotoxic stress prolongs the half life of p73 and enhances its pro-apoptotic 
activity but in a c-Abl dependent manner (Yuan et al., 1999;Agami et al., 1999;Gong et al.,
1999). In response to DNA damage the p73 protein was found to be stabilised by the 
phosphorylation of Tyr99 by c-Abl and phosphorylation of threonine residues by p38 kinase 
(Sanchez-Prieto et al., 2002). The transcriptional function of p73 is also regulated by p300 
acetylation (Costanzo et al., 2002). As well as activation observed upon p73, phosphorylation 
can also inhibit function. This was shown by the findings that p73 phosphorylation on
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Thr-86 by CDK complexes in a cell dependent manner causes a significant inhibition of p73 
transcriptional ability (Gaiddon et al., 2003).
As with all transcription factors, nuclear localisation of the p53 family members is crucial for 
their transcriptional activity. Thus the MDM2 protein plays an important role in this respect. 
Cellular proteins that act to retain p53 or p73 in the cytoplasm can also result in inhibition of 
p53 mediated transcription and apoptosis. Indeed, tumour types with cytoplasmic 
confinement of p53 are less responsive to genotoxic stress and this is therefore an 
unfavourable prognostic factor. The p53 protein has been shown to be retained in the 
cytoplasm via interactions with cytoskeletal filaments, and cytoplasmic proteins such as Parc 
and mot2 (reviewed by O’Brate, 2003). Recently, the amphiphysin IIb-1 protein was shown 
to mediate cytoplasmic retention of p73 thus inhibiting p73 function (Kim et al., 2001). 
Amphiphysin IIb-1 is a member of a super family that play a role in clathrin-mediated 
endocytosis, particularly of synaptic vesicles,
1.39 Regulation of the transcriptional effects of p53 family 
members by other cellular proteins
As with p53, it is still not clear what regulates the ability of p73 to activate specific classes of 
genes e.g. cell cycle genes or apoptotic genes selectivity. However the pattern of post- 
translational modifications as well as other cellular proteins that interact with the p53 family 
are thought to play an important role in this decision (reviewed by Melino et al., 2003, and 
Coutts and La Thangue, 2005). As already stated p300 acetylates p73 upon DNA damage and 
directs p73 to apoptotic targets (Costanzo et al., 2002). PCAF is also a co-activator of p73 
and acetylates the p73 C-terminal, although the significance of this acetylation is not yet 
known (Zhao et al., 2003). The co-activator p300 also acetylates p53 at K373 and K382 and 
this modification enhances p53 transcriptional activity (Gu et al., 1997;Gu and Roeder, 
1997), and like p73, p300 acetylation of p53 may increase p53 activity on apoptotic targets. 
Interestingly, PCAF has also been shown to acetylate p53 on K320 which enhances sequence 
specific DNA binding (Sakaguchi et al., 1998).
A cofactor for p300, junction-mediating and regulatory protein (JMY) has been shown to 
enhance p53 mediated expression of genes such as Bax whilst not significantly influencing
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the induction of p21Cipl/Wafl (Shikama et al., 1999). Moreover, STAT-1 acts as a co-activator 
for p53 to induce the expression of Bax, Noxa and Fas (Townsend et al., 2004). The ASPP 
family members (apoptosis stimulating proteins of p53) bind to all the p53 family of proteins 
via the highly conserved DNA binding domain and both ASPP1 and ASPP2 specifically 
stimulate the transactivation function of p53, p73 and p63 on the Bax, PIG3 and Puma 
promoters but not the mdm2 and p21Cipl/Wafl promoters. Correspondingly, the ASPP proteins 
enhances the apoptotic function of all three p53 family members (Samuels-Lev et al., 
2001;Bergamaschi et al., 2004). The Wilms tumour 1 (WT1) proteins, which is lost in 15% 
of wilms tumours, also binds to p53, p73 and p63. However, WT1 was demonstrated to 
inhibit p73 and p53 mediated transcription of the Bax and mdm2 promoters and reduce 
p53/p73-induced apoptosis. Additionally, p73 and p53 were also shown to inhibit WT1 
transactivation of a reporter containing three copies of the WT1 DNA binding sequence 
(Schamhorst et al., 2000). Furthermore binding of WT1 to p53 stabilized the p53 protein 
whilst WT1 did not stabilize p73, highlighting yet again that different pathways regulate the 
stabilization of p53 and p73. The Bm-3a transcription factor has been demonstrated to 
interact with p53 and differentially regulate p53 target genes resulting in protection from 
apoptosis and increased cell cycle arrest. Conversely p53 was shown to differentially regulate 
Bm-3a target genes (Budhram-Mahadeo et al., 1999a;Sugars et al., 2001;Budram-Mahadeo 
et al., 2002;Perez-Sanchez et al., 2002).
The importance of the C-terminal region unique to p73a (but not present in other C-terminal 
isoforms) in protein-protein interactions has also been widely reported. For example, the 
receptor for activated C kinase 1, (RACK1) was shown to interact with the unique region of 
p73a and decreased p73a mediated expression of target genes and its effects on apoptosis 
whilst having no effect on p73p or p53 (Ozaki et al., 2003). Similarly, the YES associated 
protein (YAP) was shown to interact with the PPPPY motif present in p73a and p73p but not 
in the other p73 isoforms and this interaction enhanced p73 mediated transcription of 
apoptotic targets but not the p21Cip/WafI promoter. It was further demonstrated that YAP 
requires PML to co-activate p73 and enhance p73 mediated apoptosis in response to DNA 
damage by potentiating p73 acetylation by p300 (Strano et al., 2001;Strano et al., 2005)
Therefore the cellular proteins that interact with the p53 family members and influence their 
biological outputs by selectivity activating a subset of p53/p73 target genes play a crucial
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role in dictating whether cells undergo apoptosis or growth arrest in response to p53/p73 
activation.
This study sets out to investigate the possible functional interaction between Bm-3a and p73 
in the modulation of cell fate in specific cells. The ability of cellular proteins to interact with 
and influence the biological output of the p53 family members is important as these 
regulatory proteins allow for either universal regulation of the p53 family or differential 
regulation that is cell type specific or dependent on interaction with specific p53 family 
members. For instance, these regulatory proteins may be widely expressed and function as 
universal regulators of the p53 family (e.g. the ASPP proteins which regulate the pro- 
apoptotic activity of all p53 family members). Alternatively these regulatory proteins may act 
specifically on a particular p53 sub-family or even on a certain member or restricted 
members of a sub-family (e.g. RACK1 specifically interacts with p73a and reduces p73a 
mediated apoptosis). Finally these regulatory molecules may be cell type specific, thus 
regulating p53 family function spatially (e.g. the ability of Bm-3a to modulate p53 mediated 
cell fate in sensory neuronal cells). Therefore the possibility of a functional interaction 
between Bm-3a and p73 is important as it is postulated to regulate p73 mediated cell fate in 
specific cell types.
1.40 Aims
It has been demonstrated that Bm-3a interacts with the p53 protein via direct protein-protein 
interaction, between the POU domain of Bm-3a and the DBD of p53. This interaction 
resulted in differential effects on target gene expression resulting in modulation of p53 
mediated cell fate in neuronal cells (Budram-Mahadeo et al., 2002). Because of the high 
degree of homology between the p53 and p73 DBD, this observation raised the question of a 
functional interaction between Bm-3a and the p73 proteins, both of which have clear roles in 
the developing nervous system. The Bm-3a/p73 interaction was assessed as follows:
1. To investigate the interaction between Bm-3a and the different p73 isoforms and 
effects of these associations in regulating genes such as box and p21CIP1/Wc^  in 
determining cell fate.
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To investigate the effects of Bm-3a on p53/p73 mediated stimulation of the pro- 
apoptotic noxa gene
To analyse the expression of Bm-3a with p53/p73 proteins in primary cultures of 
NCC and investigate the effects of this interaction in determining cell fate.
CHAPTER 2 
MATERIALS AND METHODS
2.1 materials
2.1.1 Suppliers
Analytical grade laboratory chemicals were obtained from Boehringer Maheim (Lewes, East 
Sussex, UK), Merck (Poole, Dorset, UK) or Sigma chemical company Ltd (Poole, Dorset, 
UK). Disposable plasticware was supplied by Greiner (Stonehouse, Gloucester, UK) or 
Sterilin (Stone, Stafforshire, UK). Additional laboratory materials were obtained from the 
suppliers mentioned below, unless otherwise stated.
Amersham (Little Chalfont, Bucks, UK)
Glutathione Sepharose 4B, DNase 1,Rainbow™ protein weight marker, dNTPs, 
Hybond™-C membranes, ECL western blotting detection reagents and analysis system.
BD pharMingen
Annexin V-PE, Annexin Buffer, 7ADD 
Bio-Rad (Hemel Hempstead, Herts,UK)
Ammonium persulphate, N,N’-methylene-bis-acrylamide, N’N’N’N’-tetramethylethylene- 
diamine (TEMED), GS-250 molecular Imager-densitometer and phosphor imager, 
SmartSpec 3000 spectrophotometer
Dako (High Wycome, Bucks, UK)
All peroxidase conjugated secondary antibodies
Difdo Laboratories (Basingstoke, Hants, UK)
Bacto-agar, Bacto-tryptone, Yeast extract
Gelman Life Sciences (Ann Arbor, Michigan USA)
Disposable 0.2 and 0.45 pm sterile filters
Gibco-BRL life technologies Ltd (Renfrewshire, Scotland, UK)
lkb DNA ladder, all tissue culture culture solutions, media and supplements
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Gibco, Invitrogen Corporation (Paisley, Scotland, UK)
Geneticin G-418 Sulphate, PBS tablets
Insight biotechnology
IPTG
Molecular probes
Alexa Fluor 488 goat anti-mouse igG (FITC), Alexa Fluor 468 goat anti- rabbit igG (Rh) 
New England biolabs
2-log ladder, prestained protein marker broadrange
Nunc (Roskilde, Denmark)
All tissue culture plasticware
Pierce Biotechnology (Rockford, IL,USA)
BCA protein assay kit
Pharmacia
Turner TD-20e luminometer
Promega Corporation (Madison, Wisconsin, USA)
All restriction and modifying enzymes and buffers, Dual-Luciferase® reporter Assay 
System, TNT Rabbit Reticulocyte Lysate System, lOObp ladder, 1 kb ladder
Qiagen (Crawley, West Sussex, UK)
Mini and Maxi-prep plasmid kits, gel extraction kit, Syber Green kit.
Roche (Mannhein, Germany)
Fugene reagent, proteinase K
Sigma
RibonucleaseA, bFGF, NT-3, antibiotic/antimycotic
Whatman International Ltd (Maidstone, Kent, UK)
3MM chromatography paper
2.1.2 Standard buffers and solutions
The standard buffers and solutions used throughout are given below (all concentrations are
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represented at IX).
1% (w/v) Bacto®-tryptone
1% (w/v)NaCl
0.5% Bacto®-yeast extract
LB media was immediately autovclaved after preparation at 120°C for 
20 minutes T 10IB/SQUARE INCH (psi)
96% (v/v) chloroform 
4% (v/v) isoamyl alcohol
Liquefied phenol equilibrated twice with excess 0.1 M Tris- HCL pH 
8.0
10 mM Tris-HCL pH 8.0 
1 mM EDTA pH 8.0
400 mM Tris base 
200 mM Soduim acetate 
20 mM EDTA pH 8.0
90 mM Tris-HCL pH 8.0 
90 mM Boric acid 
1 mM EDTA pH 8.0
2.1.3 Bacterial strains used
Strain genotype Source
DH5-o E.Coli recAl, endAl gyrA96 thi-1 hsdR17 supE44 
relAl lac (F’proAB laclq Z M l5 tn 10 (tet)r)
Stratagene, Cambridge UK
BL21 (DE3) pLysS E.Coli B F- ompT hsdS(rB-mB-) dcm+ Tetr gal 
A(DE3) endA Hte (pLysS Camr)
Stratagene, Cambridge UK
The BL21(DE3) gold derived expression strains are ultracompetent cells which lack the Lon 
and Ompt proteases which can degrade recombinant proteins. They can be used in 
combination with plasmids containing the bacteriophage T7 promoter to control expression 
of the protein of interest (e.g. pET vectors). The T7 promoter is recognised by the T7 
polymerase. To express the gene of interest the BL21(DE3) strain contains the T7 
polymerase gene under the control of the lac/UV5 promoter which is induced by isopropyl-1- 
thio-p-D-galactopyranoside (IPTG). The BL21(DE3)pLysS gold strain carries an
Luria Bertani 
(LB) media
Chloroform / 
isoamylalcohol
Tris equilibrated 
phenol
TE
Tris-Acetate 
Buffer (TAE)
Tris Borate Buffer 
(TBE)
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additional plasmid carrying the T7 lysozyme gene derivative to provide tight control of 
protein expression of toxic proteins. Additionally, the expression of the GST fusion protein 
can be driven by the host RNA polymerase using a vector utilizing the tac promoter (e.g. 
pGEX vectors) which is induced by IPTG.
2.1.4 List of Plasmids used
Plasmid: pLTR
Description: Eukaryotic expression vector in which the MoMuLV promoter drives
the expression of the target gene cloned into it.
Resistance: Ampicillin
Source/Reference: Dr.T.Moroy, Phillips University, Marburg, Germany
Genes cloned: pLTR Bm-3a long
Description: Eukaryotic expression vector in which the MoMuLV promoter
expressing the long form of Bm-3a. The cDNA of Bm-3a(l) was 
cloned into the Sall/Nrul site of the pLTR vector.
Plasmid: pGEX 2T
Description: Prokaryotic expression vector in which the tac promoter drives
expression of a GST fusion protein. Appropriate cDNA is cloned 
downstream of GST domain to express protein of interest with a GST 
tag at the N-terminal for affinity chromatography purification.
Resistance: Ampicillin
Source/Reference: Amersham Bioscience, Bucks UK
Genes cloned: pGEX-Bm-3a(l) and pGEX-Bm-3b(s)
Description cDNA for either Bm-3a(l) and Bm-3b(s) were cloned into pGEX-2TK
to produce the GST-Bm-3a(l) and GST-Bm-3b(s) proteins.
Source/Reference: (Budhram-Mahadeo et al., 1998)
Plasmid pDEST15
Description:
Resistance: 
Source/Reference 
Genes cloned
Description
Source/Reference
Plasmid
Description:
Resistance:
Source/Reference:
Genes cloned:
Prokaryotic expression vector in which the T7 promoter drives 
expression of a GST fusion protein. Appropriate cDNA is cloned 
downstream of a GST sequence, resulting in expression of a GST- 
fiision protein that can be used for affinity chromatography 
purification.
Ampicillin
Invitrogen
pDEST 15-Bm-3b(l), pDEST15-Bm-3a(s), pDEST 15-Bm-3aPOU 
pDEST15-Bm-3b (POU)
cDNA of either Bm-3b(l) or Bm-3a(s) was cloned into pDEST 15 
using gateway technology to produce the GST-Bm-3b(l) and GST- 
Bm-3a(s) proteins.
pDEST 15-Bm-3a-POU and pDEST15-Bm-3b-POU were cloned 
using gateway technology and the primers 3aPOUfoward (5’- 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGGATCCCTG 
GCGTCCATCTGCGAC-3’), 3aPOUreverse (5’- 
GGGGACCACTTTGTACAAGAAAGCTGGGTTGTCGACTCAGT 
AAGTGGCAGAGAATTTC-3’)
3bPOUfoward (5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGGATCCGAC 
GTGGATGCAGACCCG-3’), 3bPOUfoward (5’- 
GGGGACCATTTGTACAAGAAAGCTGGGTTGTCGACCTAAAT 
GCCGGCAGAGTATTTC-3’)
Dr. D .Falkes ICH, Dr Duncan Gascoyne, ICH (Gascoyne et al., 2004)
pGEX 4T-1
Prokaryotic expression vector in which the tac promoter drives 
expression of a GST fusion protein. pGEX 4T-1 is derived form 
pGEX-2T and contains a thrombin recognition site. Appropriate cDNA 
is cloned downstream of GST domain to express protein of interest 
with a GST tag at the N-terminal for affinity chromatography 
purification.
Ampicillin
Amersham bioscience, Bucks UK 
pGEX-Bm-3aN
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Description:
Source/Reference:
Plasmid:
Description:
Resistance: 
Source/Reference: 
Genes cloned: 
Description:
Source/Reference:
Genes cloned: 
Description:
Source/Reference:
Plasmid:
Description:
Resistance:
Source/Reference:
Genes cloned:
GST-Bm-3aN was subcloned in to the pGEX4T-l vector form the 
yeast vector pBD-3aN.
(Gascoyne et al., 2004)
pcDNA3.1
Eukaryotic expression vector in which the CMV enhancer drives the 
in vivo expression of the target gene cloned into it and the T7 
bacteriophage promoter for in vitro expression.
Ampicillin
Invitrogen
pcDNA-p53, pcDNA-TAp73a, pcDNA-TAp73p and pcDNA-ANp73a
Human p53, p73a, p73p and ANp73a was cloned into the Nhel and 
Notl restriction sites in the pcDNA vector.
Dr Vincent De Laurenzi university Tor Vergata, Rome (De Laurenzi 
et al., 1998)
p73 deletions
The deletion constructs p73aN56, p73aN315, p73aN423, p73C505, 
p73aC424 and p73pOD were subcloned from pcDNA-p73a and 
pcDNA-p73p using PCR based cloning.
(Takagi et al., 2001)
pcDNA3.1-HA
Eukaryotic expression vector in which the CMV enhancer drives the 
in vivo expression of the target gene cloned into it downstream of the 
HA sequence and the T7 bacteriophage promoter for in vitro 
expression.
Ampicillin
Invitrogen
pcDNA-TAp73a, p, y ,6 and ANp73a
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Description:
Source/Reference:
Plasmid:
Description:
Resistance: 
Source/Reference: 
Genes cloned: 
Description:
Source/Reference: 
Genes cloned: 
Description:
Source/Reference:
Plasmid:
Description:
Resistance:
Source/Reference:
Genes cloned:
Human cDNA encoding TAp73a, p, y and 5 and ANp73a was cloned 
into the Nhel and Notl restriction sites in frame with a HA tag.
Dr Vincent De Laurenzi university Tor Vergata, Rome (De Laurenzi 
et al., 1998)
pGL3-Luciferase
Provides a quantitative analysis of factors that may potentially 
regulate mammalian gene expression. It has a coding region for firefly 
luciferase, which allows detection of transcriptional activity in 
transfected eukaryotic cells.
Ampicillin
Promega, Wisconsin USA 
Human bax promoter
A 370 bp EcoRl-sacl fragment of the human bax promoter was 
cloned into the PGL3 vector upstream of the luciferase sequence.
(Myashita et al., 1995)
Human p2lCIP1/Wafl promoter
A 2326 HindIU fragment of the human p21 promoter was cloned into 
the pGL3 vector upstream of the luciferase sequence.
(EL-Deiry et a., 1993)
Picagene
Provides a quantitative analysis of factors that may potentially 
regulate mammalian gene expression. It has a coding region for firefly 
luciferase, which allows detection of transcriptional activity in 
transfected eukaryotic cells.
Ampicillin
Wako, Osaka, Japan
Mouse Noxa promoter and Ap53-Noxa promoter
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Description: A 329bp Sac II fragment containing the noxa promoter was inserted
into the picagene reporter plasmid Ap53-Noxa was constructed with a 
286bp Xho I  to Sac II fragment which lacked the p53 binding site.
Source/Reference: (Oda et al., 2000)
Plasmid: pRL-TK
Description: Renilla lucerase repoter, under the HSV-thymidine kinase promoter.
pRL-TKcontains cDNA encoding renilla luciferase, acts as a control 
vector for transactivation efficiency.
Resistance: Ampicillin
Source/Reference: Promega, Wisconsin USA
2.1.5 List of antibodies used in westerns and immunostaining
Actin
Bax (clone 6A7)
Bm-3a mAb
Immunogen: human Actin carboxy terminus
Specificity: polyclonal
Dilutions: Western blot 1:2000
Secondary: 1:3000 HRP-conjugated anti-goat Ig
Source: Santa Cruz
Immunogen: amino acids 12-24
Specificity: monoclonal
Dilutions: Western blot 1:500
Secondary: 1:3000 HRP-conjugated anti-mouse
Source: BD PharMingen
Immunogen: mouse amino acids 186-224 
Specificity: monoclonal
Dilutions: Western blot 1:1500, Immunostaining 1:50
Secondary: 1:3000 HRP-conjugated anti-mouse Ig, 1:2000 Alexa Fluor 
488 anti-mouse (FITC)
Source: Chemicon International (MAB 1585)
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Bm-3a pAb
Cleaved Caspase 
3 (Asp-175 ab)
HA (805)
Neurofilament-
160
(clone NN18)
p21cn>i/wafi
p53 (ab26) mAb
Immunogen: synthetic polypeptide amino acids 51-67 
Specificity: polyclonal 
Dilutions: Immunostaining 1:100
Secondary: 1:2000 Alexa Fluor 468 anti-Rabbit (Rhodamine) 
Source: Chemicon International (AB5945)
Immunogen: large fragment of activated Caspase-3 (17-19kda) 
resulting from cleavage of adjacent Asp 175)
Specificity: polyclonal
Dilutions: Immunostaining 1:100
Secondary: 1:2000 Alexa Fluor 468 anti-Rabbit (Rhodamine) 
Source: Cell Signalling Technology™
Immunogen: YPYDVPDYA (influenza HA epitope)
Specificity: polyclonal
Dilutions: Western blot 1:3000
Secondary: 1:2500 HRP-conjugated anti-rabbit Ig
Source: Santa Cruz
Immunogen: Purified neurofilament polypeptides
Specificity: monoclonal
Dilutions: Immunostaining 1:100
Secondary: 1:2000 Alexa Fluor 488 anti-mouse (FITC)
Source: Sigma
Immunogen: purified mouse p21 protein
Specificity: monoclonal
Dilutions: Western blot 1:500
Secondary: 1:3000 HRP-conjugated anti-mouse Ig
Source: BD PharMingen
Immunogen: mouse amino acids 14-289
Specificity: monoclonal
Dilutions: Western blot 1:1000
Secondary: 1:3000 HRP-conjugated anti-mouse Ig
Source: Abeam
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p53 (ab-7) pAb Immunogen: recombinant human p53 protein
Specificity: polyclonal
Dilutions: Western blot 1:1000, Immunostaining 1:100
Secondary: 1:3000 HRP-conjugated anti-mouse Ig, 1:2000 Alexa Fluor 
468 anti-Rabbit (Rhodamine)
Source: Abeam
p73-Total Immunogen: C-terminus common to all isoforms of p73
Specificity: polyclonal 
Dilutions: Immunostaining 1:100
Secondary: 1:2000 Alexa Fluor 468 anti-Rabbit (Rhodamine)
Source: Emre Sayan, (University of Leicester).
p73-SAM Immunogen: extreme C-terminal only recognising the a isoforms of
TAp73 and ANp73
Specificity: polyclonal
Dilutions: Western blot 1:3000, immunostaining 1:100
Secondary: 1:3000 HRP-conjugated anti-mouse Ig, 1:2000 Alexa Fluor 
468 anti-Rabbit (Rhodamine)
Source: Emre Sayan, (University of Leicester).
p73-AN Immunogen: first 16 amino acids of ANp73 that is not found in TAp73
Specificity: polyclonal
Dilutions: Western blot 1:3000, Immunostaining 1:100, Co- 
immunoprecipitation 1 pi.
Secondary: 1:3000 HRP-conjugated anti-mouse Ig, 1:2000 Alexa Fluor 
468 anti-Rabbit (Rhodamine)
Source: Emre Sayan, (University of Leicester).
2.1.6 List of oligonucleotides used
All oligonucleotides were manufactured by Thermo Electron Corporation. Primers for Real­
time PCR were generated using the primer 3 programme. The p53 response element in the 
pair of oligonucleotides used for the EMSA assay is highlighted in bold in the sense strand. 
The primers used in the ChIP assay amplify a 152bp region of the noxa promoter that 
encompasses the p53 response element.
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Real-time PCR
mGAPDH-f 5-TTC ACC ACC ATG GAG AAG GC-3'
mGAPDH-r 5’-GGC ATG GAC TGT GGT CAT GA-3’
mBm-3atotal-f 5’-TCA CGC TCT CGC ACA ACA AC -  3'
mBm-3atotal-r 5’-TCC GGC TTG TTC ATT TTC TCA- 3*
mp53-f 5’-ACC TCA CTG CAT GGA CGA TCT - 3’
mp53-r 5’-GAC ACT CGG AGG GCT TCA CTT -  3'
mANp73-f 5 -CGA GCC TAC CAT GCT TTA CG-3'
mANp73-r 5'-GGA GAC ATG GTG TCG AAG GT-3'
mTAp73-f 5-AGC CAG ACA GCA CCT ACT TTG AC-3'
mTAp73-r 5'-GCC TTG CAG GTG GAA GAC AT-3'
EMSA
p53-Noxa-f 5 -AGG CTT GCC CCG GCA AGT TG-3'
p53-Noxa-r 5'-CAA CTT GCC GGG GCA AGC CT-3'
ChlP assay
NoxaChip-f 5'-CTC GAG ACC TGC TCC ACT TC-3'
NoxaChip-r 5'-CGC TGG AAT CCT CTC TGT TC -3’
Genotyping
Bm-3a ko-1 5-GGC GCG CAG CGT GAG AAA ATG AA-3
Bm-3a ko2-2 5-GTC TCA CAC CCT CCT CAG TAA GT-3
Bm-3a neo-1 5'-TGA TGC CGC CGT GTT CCG GCT GT - 3'
Bm-3a neo-2 5'-TCG CCG CCA AGC TCT TCA GCA AT - 3’
p53-K01 5-ACA CAC CTG TAG CTC CAG CAC - 3'
p53-K02 5-ACGGTC TCA CGA CCT CCG TC - 3'
OPT-21 5-GTG TTC CGG CTG TCA GCG CA - 3'
2.1.7 List of cell lines used
ND7 cell line: This cell line was derived by fusing non-dividing rat dorsal root ganglion cells 
with the Cl300 mouse neuroblastoma cell line. These cells can be maintained in a
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proliferate state and when differentiated exhibit the morphology and biochemical markers of 
sensory neurones.
Culture medium: lx LI5 with 10% fetal calf serum, 0.3% D-glucose, 0.37% sodium 
bicarbonate and 0.2mN L-glutamine. Freezing medium: Fetal calf serum + 10% DMSO.
SAOS-2 cell line: Human osteogenic sarcoma established from the primary osteogenic 
sarcoma of an 11-year-old Caucasian female 1973 (American Type Culture Collection 
(ATCC) HTB 85)
Culture medium: lx DMSO with 10% fetal calf serum. Freezing medium: Culture medium + 
10% DMSO.
IMR-32 cell line: Human neuroblastoma cells derived from an abdominal mass removed 
from a 13-month old Caucasian male. The cell line was submitted to the ATCC in the 36th 
passage
Culture medium: lx DMSO with 10% fetal calf serum, and 1% non-essential amino acids. 
Freezing medium: Culture medium + 10% DMSO.
2.1.8 Primary cell line-Neural crest cells (NCC)
NCC cultures were prepared from neural tube explants removed from E9.5 embryos obtained 
after timed mating between the CD1 mice strain, Bm-3a heterozygotes or p53 heterozygotes 
(see section 2.7.4 for detailed method of neural crest dissection and culture).
Culture medium: lx DMSO with 10% fetal calf serum, basic fibroblast growth factor (bFGF: 
50 ng/ml), neurotrophin-3 (NT-3: 40 ng/ml) and antibiotic/antimycotic (Sigma: 10,000 U 
penicillin 10 mg streptomycin, 25 pg amphotericin per millilitre).
2.2 Manipulations in E.coli
2.2.1 Propagation of bacterial strains
Bacteria were grown in either liquid LB media or on plates prepared from LB media
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containing 2% Bacto-agar. Liquid cultures were grown overnight at 37° C in an orbital shaker 
at 200 rpm. Bacterial plates were incubated overnight at 37° C in a standard incubator. Both 
media contained antibody selection as appropriate. Ampicillin, chloramphenicol and 
Kanamycin were used as a final concentration of 100 pg/ml, 30 pg/ml and 50 pg/ml 
respectively.
2.2.2 Long term storage of bacteria
Bacteria were grown overnight as mentioned above with the appropriate antibiotic. The 
bacteria were distributed in 500 pi aliquots into 1.5 ml autoclaved vials plus 30% (v/v) sterile 
glycerol. The glycerol cell stocks were slowly cooled to -70 and stored at this temperature 
until ready to use. The stored strain was revived by streaking onto LB plates containing 
appropriate antibiotics for a single colony.
2.2.3 Preparation of competent cells
Competent DH5a cells were prepared in transforming buffer (TFB) and stored in frozen 
storage buffer (FSB). LB plates were streaked from a frozen stock of DH5a cells and 
incubated at 37° C overnight. A single fresh bacterial colony was used to inoculate 10 mis of 
LB and grown overnight. In the morning 100 pi of the starter culture was used to inoculate 
100 mis of LB and the culture was grown until cell density reached OD600 of 0.4-0.8. The 
culture was then poured into chilled 50 ml falcon tubes and chilled on ice for 5 minutes. The 
culture was then pelleted in a centrifuge at 3000 rpm for 5 minutes at 4° C, and the 
supernatant was discarded and the tubes inverted for 1 minute to get rid of any residual LB. 
The cells were then quickly resuspended in 20 ml of TFB (lOmM MES pH5.8, lOOmM 
RbCb, 10 mM CaCl2 and 50 mM MnCk) by swirling or gently vortexing. The cells were 
then incubated on ice for 5 minutes and then pelleted at 3000 rpm for 5 minute at 4° C. The 
supernatant was discarded and the cell pellet was resuspended in 1ml of FSB (10 mM pipes 
pH6.5, 75 mM CaCl2 , 10 mM RbCl2 and 15% (v/v) glycerol) and mixed by swirling or 
gently vortexing and incubated on ice for 15 minutes. The cells were then stored at -70° C in 
100 pi aliquots.
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2.2.4 Transformation of Bacteria
Competent cells were transformed using the heat shock protocol. Competent DH5a and 
Competent BL21 (DE3) cells were placed at room temperature and then transferred to ice 
just as the cells started to thaw. 50 ng of plasmid was added to 50 pi of competent DH5a or 
100 pi BL21 (DE3) cells and incubated on ice for 30 minutes. The samples were heat 
shocked at 42° C for 90 seconds followed by incubation on ice for 10 minutes. 1ml of LB 
was then added and the cells incubated in an orbital shaker at 37° C, 200 rpm for 1 hour. The 
cells were then pelleted, resuspended in 200 pi of LB and plated onto LB agar plates 
containing the appropriate antibiotic selection. The plates were incubated at 37° C overnight. 
The plates were then stored at 4° C.
2.3 Nucleic acid isolation
2.3.1 Small scale preparation of plasmid DNA from bacteria cells
Single bacterial colonies were inoculated into 5 ml of LB supplemented with the antibiotic 
and grown overnight at 37° C in and orbital shaker (200 rpm). Plasmid DNA was extracted 
using QIAprep Spin Miniprep DNA purification system (Qiagen) according to the 
manufacturer’s instructions, average yield being approximately 15 pg plasmid DNA from 1.5 
ml of overnight culture.
2.3.2 Large scale preparation of plasmid DNA from bacteria cells
A starter culture was set up during the day in 10 mis of LB containing the appropriate 
antibiotic. The starter culture was then used to inoculate 200mls of LB + antibiotic which 
was incubated at 37° C overnight. The culture was then pelleted and plasmid DNA was 
extracted using the Qiagen Maxi-Prep kit according to the manufacturer’s instructions. The 
concentration of the eluted DNA was measured using a spectrophotometer and subjected to 
analytical digests and agarose gel electrophoresis before use in either transient transfections 
or GST affinity pull down chromatography. The average yield of DNA obtained by this 
method was approximately 500 pg of plasmid DNA.
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2.3.3 Genomic DNA isolation from mouse tissue
Approximately 5-10 mm of tail tip from breeding mice or the tail and hind limbs from 
embryos were removed for genotyping analysis. The mouse tissue was placed in 1.5 ml 
centrifuge tube containing 700 pi of tail tip buffer (50 mM Tris Ph 8.0, 100 mM EDTA pH 
8.0,100 mM NaCl and 1% SDS). 35 pi of 10 mg/ml proteinase K (Roche) was added and the 
tubes were incubated at 55° C overnight with occasional agitation. Protein was extracted by 
mixing with an equal volume of phenol, centrifuging to separate phases and removal of the 
aqueous phase to a fresh tube. A second phenol extraction was performed followed by a 
chloroform:iso-amyl alcohol extraction. The DNA was precipitated by adding an equal 
volume of isopropanol to the final aqueous phase. The DNA was then pelleted by 
centrifugation, washed in 70% ethanol, dried and resuspended in TE and stored at 4° C until 
the samples were analysed by PCR
2.3.4 Spectrophotometric determination of nucleic acids
Nucleic acid concentrations were determined by measuring the UV absorbance of diluted 
samples at 260 nm using the SmartSpec 3000 spectrophotometer (Bio-Rad). Concentrations 
were calculated on the basis that 1 absorbance unit at 260 nm corresponds to approximately 
50 pg/ml for double stranded DNA and 40 pg/ml for RNA. Absorbance at 280 nm was also 
measured and the ratio between absorbances at 260 nm and 280 nm were used to provide an 
estimate of the purity of the nucleic acid sample.
2.3.5 Restriction enzyme digestion
DNA analysis was carried out by restriction digests. These digests were carried out in 20pl 
reactions with 1 pg of DNA. Restriction enzyme(s) (5 units) were added and the buffer 
recommended by the manufacturer was used at IX concentration (Promega). Digests were 
incubated at the appropriate temperature for 2 hours. The digested DNA was electrophoresed 
on an agarose gel of appropriate percentage. An undigested sample was run in parallel, as a 
reference for the enzyme cut samples.
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2.3.5 Agarose gel electrophoresis
Depending on the expected sizes of the DNA fragments, appropriate percentage gels in 1 X 
TAE were cast. For example 1% gel was cast for fragments larger than lkb, 1.5% for general 
purpose and 2% to resolve DNA fragments less than lkb. Ethidium bromide was added to a 
final concentration of 0.5 pg/ml. Approximately 0.1 volume of 10X loading buffer (IX TAE, 
50% v/v glycerol, 0.025% bromophenol blue) was added to the DNA samples prior to 
loading. For size reference, the 1 kb ladder (Gibco) or 100 bp ladder (Promega) was used. 
Electrophoresis of the DNA was carried out at 20-90 V for 0.5-2 hours allowing for good 
resolution of bands. Finally the bands were visualized on a long wave UV transilluminator 
and photographed using the Syngene doc system.
2.4 polymerase Chain reaction (PCR)
Standard PCR was used to amplify the region of the noxa promoter containing the p53 
response element in the ChIP assays (section 2.9) and for genotyping Bm-3a and p53 
animals. All PCRs were carried out on an Eppendorf Mastercycler.
2.4.1 Genotyping knock out animals
The Bm-3a-KO 1/2 and Neo-1/2 primers were used to check the genotypes of Bm-3a mice to 
ensure mating of Bm-3a heterozygous males and females (DNA was isolated from tail tips). 
The Bm-3a-/-, Bm-3a+/- and Bm-3a+/+ embryos obtained from these matings were used to 
prepare neural crest cultures and were also genotyped (DNA was isolated from the hind 
limbs and tail). As the size of the products differed and the conditions of the reaction are the 
same, it was possible to perform both amplification reactions in the same tube. Together with 
the template (50 ng of genomic DNA isolated from mouse tails/embryos) each PCR 
contained 1 unit of Taq polymerase (Promega) in a final concentration of 25 pi [1 X Mg-free 
buffer, 2.5 mM MgCk, 1 mM dNTP mix, 100 ng of each primer(Bm-3a-KO 1/2 and Neo 
1/2)]. The cycling parameter is shown below:
Step Temperature Time Process
1 95° C 5 minutes Denaturation
2 95° C 45 seconds Denaturation
3 64° C 45 seconds Annealing
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4 72° C 45 seconds Extension
Repeat steps 29 times
5 72° C 5 minutes Final extension
6 4° C Until removed
The products were then visualized on a 2% agarose gel. Expected banding pattern: Bm-3a 
KO = 600bp (neo), Bm-3a WT = 300bp (Bm-3a) and Bm-3a Het = 600bp + 300bp (neo and 
Bm-3a products)
The p53-KO 1/2 and OPT-21 primers were used to check the genotypes of p53 mice and 
their progeny to ensure mating of p53 heterozygous males and females to provide p53-/-, 
p53+/- and p53+/+ embryos from which neural crest cultures were prepared. As the size of 
the products differed and the conditions of the reaction are the same, it was possible to 
perform both amplification reactions in the same tube. Together with the template (50 ng of 
genomic DNA isolated from mouse tail/embryos) each PCR contained 1 unit of Taq 
polymerase (Promega) in a final concentration of 25 pi (1 X Mg-free buffer, 2 mM MgCb, 
0.2 mM dNTP mix, 1 pM of p53-KO-l, 0.5 pM of p53-KO-2 and 0.5 pM of OPT-21). The 
cycling parameter is shown below:
Step Temperature Process
1 95° C for 15 minutes Denaturation
2 94° C for 45 seconds Denaturation
3 60° C for 1 minute Annealing
4 72° C for 1 minute Extension
Repeat steps 29 times
5 72° C for 5 minutes Final extension
6 4° C Until remover
The products were then visualized on a 2% agarose gel. Expected banding pattern: p53 KO = 
730bp (OPT), p53 WT = 520bp (p53) and p53-HET = 730bp + 520bp (p53 and OPT 
products)
2.5 RNA methods
2.5.1 Isolation of total RNA
Neural crest cells (NCC) were cultured as described in section 2.7.4 and three separate 
cultures were harvested at each time point for total RNA (time point: 3, 5, 7, 8, 9 and 12 days
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in culture).Total RNA was also extracted from mouse embryo brain. The NCC cultures or 
mouse embryo tissue was pipetted repetitively in 1ml TRIzol (Gibco) to lyse. If the tissue did 
not completely homogenize a gauge needle was used so that no pieces of tissue remained. 
The homogenate was then left to incubate at room temperature for 5 minutes. 200 pi of 
chloroform was then added and the mixture was shaken vigorously for 15 seconds, followed 
by 3 min incubation at room temperature before centrifugation at 12000 rpm for 15 minutes 
at 4° C. The clear upper aqueous phase was removed to a fresh tube and 500 pi of 
isopropanol was added. The tube was inverted several times to ensure mixing and left at 
room temperature for 10 minutes to allow of precipitation of RNA. The tube was then 
centrifuged at 12000 rpm for 10 minutes at 4° C to spin down the RNA which forms a gel­
like pellet. The supernatant was carefully removed and the RNA pellet was washed in 70% 
ethanol and air dried for 5 minutes. The RNA was then dissolved in 15-30 pi Rnase-free tfeO 
by passing the solution through a pipette tip several times and incubating for 10 minutes at 55 
°C.
Prior to cDNA synthesis the RNA was DNase 1 (Amersham) treated to remove genomic 
contamination. The reaction contained 10 pi of RNA, 1.5 pi of DNase 1, 10 pi of 10 X 
DNase-1 buffer in a 100 pi reaction made up with DEPC-treated water. The reaction mixture 
was incubated at 37° C for 30 minutes followed by 10 minutes at 65° C to stop the reaction. 
100 pi of DEPC-treated water was added to the reaction mixture so that the total volume was 
200 pi, before extraction with 200 pi of phenol saturated with DEPC-water. This was then 
mixed and centrifuged at 12000 rpm for 10 minutes at 4° C and the aqueous layer was 
removed to a fresh tube. A further extraction was performed with an equal volume of 
phenol/chloroform (at a 1:1 ratio) followed by chloroform extraction and the aqueous phase 
was removed to a new tube. The RNA was the precipitated with 2 X volume of ethanol and 
0.1 volume of 3M sodium acetate for 2 hours at -20° C and then pelleted by centrifugation at 
12000 rpm for 10 minutes at 4° C. After being washed in 70% ethanol the RNA pellet was 
then air dried and resuspended in 15-30 pi Rnase-free H2O
The DNase 1 treated RNA was then either run on a 1% agarose gel for 15 minutes at 240 V to 
assess the quality of RNA and relative quantities (can easily visualise 0.5 pg of RNA) or 
concentration was determined using a spectrophotometer if RNA concentration was low.
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2.5.2 cDNA synthesis
1-5 pg of total RNA isolated from mouse tissue or approximately 0.1 pg of total RNA 
isolated from NCC cultures was reversed transcribed into first strand complimentary DNA 
(cDNA) using SUPERSCRIPT™ II enzyme (Gibco) following the manufacturers 
instructions. In order to amplify total cDNA, 250 ng of random hexamer primers (Roche) 
were added to the RNA (total volume 11 pi) which was then incubated for 10 minutes at 70° 
C and was then placed on ice to allow to cool before being spun down for 10 seconds to 
collect the mixture. During this time the following master mix was made:
Component per reaction
5 X first stand buffer 4 pi
0.1MDTT 2 pi
lOmMdNTPs 1 pi
RNAse inhibitor 1 pi
8 pi of the master mix was added to the RNA and random hexamers followed by incubation 
at 25° C for 2 minutes. 1 pi (200 units) of SUPERSCRIPT II was then added and the mixture 
was incubated at 25° C for 10 minutes before incubation at 42° C for 90 minutes. The 
reaction was then terminated by incubation at 70° C for 10 minutes. The cDNA was then 
stored at -20° C. This protocol results in a final volume of 20 pi. A similar protocol was also 
carried out to produce a final volume of 50 pi by scaling up the reaction. In parallel, cDNA 
synthesis was also carried out without the SUPERSCRIPT II enzyme and used in subsequent 
RT-PCR reactions to check the presence of genomic contamination.
2.5.3 Real time quantitative RT-PCR
Real-time quantitative RT-PCR was carried out to quantify the amount of Bm-3a, p53, 
TAp73 and ANp73 mRNA in neural crest cells kept in culture for 3-12 days. All reactions 
were carried out on the DNA Engine Opticon (MJ Research) using primers designed with 
primer express or primer 3. The TA and ANp73 primers were designed by targeting regions 
that are specific to either protein. For TAp73 both forward and reverse primers were targeted 
to sequences within the TAD which is found in the TA isoforms only. For ANp73 the 
forward primer is specific to the N-terminus only found in ANp73 whereas the reverse primer 
is in a sequence common to both TAp73 and ANp73. Real time PCR was carried out utilizing
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the Sybr Green technology (QuantiTect /Sybr green- Qiagen) in which the Sybr green 
fluorescent dye binds to all double stranded DNA molecules and once bound emits a 
fluorescent signal that can be detected and measured (excitation at 494 nm and emission at 
521 nm).
Initially conditions were optimized for each set of primers using cDNA prepared from RNA 
extracted from mouse embryo brain, as the RNA isolated from NCC cultures were 
considered too precious for these set up reactions. In general, together with 2 pi of the cDNA 
template, each PCR contained 1 X QuantiTect /Sybr green PCR Master Mix, 0.3 pM of 
forward primer and 0.3 pM of reverse primer in a final volume of 20 pi. The reactions were 
set up in a thin walled microcentrifuge tubes and subjected to the following basic cycling 
parameters. The annealing temperature, extra conditions and produce size for each primer set 
are stated (sequences of the primers used are listed in section 2.1.6).
Step Temperature Process
1 95° C for 15 minutes Activation of HotStarTaq 
DNA polymerase
2 95° C for 30 seconds Denaturation
3 58, 59, 60 or 61° C for 30 seconds Annealing
4 72° C for 30 seconds Extension
5 Plate read fluorescence data collection
6 Repeat 44 times Cycle number
7 55-95 0 C, 0.3 ° C, hold 0.00001 Melting curve
Primers Annealing temperature Product size
GAPDH 58° C
For GAPDH reaction, add extra 
step 80°C for 10 seconds before 
plate read to melt primer dimers
250bp
Bm-3a 59° C lOObp
p53 61 ° C 81bp
TAp73 60 ° C lOObp
ANp73 60 °C 195bp
A melt curve is performed at the end of each reaction in order to verify the specificity and 
identity of the RT-PCR products. The specificity of the RT-PCR products is also assessed by 
agarose gel electrophoresis. After primer optimization, a set of standards curves were 
generated using the PCR products of each primer set. Accordingly, the PCR product 
amplified by each primer set was run out on an agarose gel and the band was excised from
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the gel and the DNA purified into 50 pi of double distilled water by use of the QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturers instructions. An aliquot of the 
purified DNA aplicon was then run on an agarose gel next to the Log2 marker (New England 
Biolabs) to quantify the concentration of each aplicon. A set of standards for each amplicon 
was then prepared (up to 7 serial dilutions, 1000 fg/pl, 500 fg/pl, 100 fg/pl, 1 fg/pl, 0.1 fg/pl, 
0.001 fg/pl and 0.0000lfg/pl to ensure that the unknown amount of target in samples fall 
within this range), which were used to generate the standard curves in every experiment. The 
Ct (the cycle at which the aplicon plot crosses the threshold - i.e. the point at which there is a 
first detectable increase in fluorescence) of the standards is plotted against the log of the 
template amount resulting in a straight line. The unknown amounts amplified in the samples 
are then calculated by comparing the Cj values of the samples to the Cj values of the 
standard curve.
To check for variation in RNA between NCC samples, amplification of the invariant 
glyceralderhyde-3-phoshate dehydrogenase (GAPDH) was carried out with the Sybr green 
detection system. The data is produced as a sigmoid amplification plot in which the number 
of cycles is plotted against fluorescence. The Ct values were determined by using the 
Opticon software and the standard curve was then used to measure the target expression 
levels. Once the appropriate amount of cDNA required to equalise for the control mRNA was 
determined, the Bm-3a, p53, TAp73 and ANp73 gene targets were amplified under 
conditions optimised for each set of primers. The control GAPDH was then re-amplified with 
the same volume of cDNA used to amplify Bm-3a, p53, TAp73 and ANp73. All values for 
Bm-3a, p53, TAp73 and ANp73 expression were normalised relative to GAPDH levels.
RT-PCR reactions were also carried out with each primer sets on cDNA samples prepared in 
the absence of reverse transcriptase (minus RT controls) to determine if there is any genomic 
contamination. A no template control was also included in all experiments to control for 
contamination.
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2.6 Protein methods
2.6.1 Extraction of protein from cultured cells
For analysis of endogenous Bax and p2lClpl/Wafl expression, protein was extracted from ND7 
or SAOS-2 cells transfected with the appropriate DNA plasmids in 10 cm plates. Briefly 
ND7 cells were transfected with 2 pg of Vector, p53, TAp73a, TAp73p or ANp73a in the 
presence of either 2 pg of Bm-3a or empty vector in 10 cm plates using Fugene reagent 
(Roche) (for transfection method see section 2.7.5). After 48 hours the cells were washed in 1 
X cold PBS and harvested in 500 pi of standard sample buffer (5% P-mercaptoethanol, 50 
mM Tris-HCL pH 8.0, 6% (v/v) glycerol, 2% (w/v) SDS and 0.005% (w/v) bromophenol 
blue). The samples were kept on ice as much as possible during extraction. The samples were 
then heated to 95° C for 3 minutes, placed back on ice and either loaded immediately onto a 
SDS-polyacrylamide gel or stored at -20° C. Protein extraction methods for 
immunoprecipitation, EMSAs and ChIP assays are described separately.
2.6.2 SDS-polyacrylamide gel electrophoresis
Standard SDS-polyacrylamide gels were prepared with the composition for the stacking and 
resolving gels as described by Sambrook and colleagues. Protein samples were heated to 
95°C for 5 minutes. Approximately 100 pg (total protein) was loaded per lane. Coloured 
molecular weight protein standards (rainbow marker, Amersham) or broad range prestained 
protein marker (New England Biolabs) was loaded 3 pi per lane for a small gel, or 7 pi for a 
large gel. Gels were run at 150 volts for small gels and 200 volts for large gels in 1 X running 
buffer (25mM Tris, 250mM glycine and 0.15 (w/v) SDS). The gels were run until the protein 
of interest was sufficiently resolved as determined by the migration of the coloured marker.
2.6.3 Equalization of protein loading
In order to establish integrity of protein as well as for variation in total protein concentration, 
SDS-PAGE mini-gels were run to separate the protein samples. The gel was then placed in 
coomassie stain solution (2% (w/v) coomassie brilliant blue R250, 50% (w/v) methanol, 10% 
(v/v) glacial acetic acid) for 30 minutes at room temperature with continual shaking. Any
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unbound stain was then removed by repeated replacements of destain (10% (w/v) glacial 
acetic acid, 30% (v/v) methanol). Any variation in different samples was observed by the 
intensity of the protein bands in each sample and densitometry was utilized to obtain values 
for various band intensities. The amount of protein was also calculated by addition of 1 pi of 
extract to 1 ml of diluted Bradford assay reagent (Biorad) following the manufacturers 
instructions. Measured absorbance at 595 nm using a spectrophotometer indicated the 
amount of protein present when compared to a prepared standard.
2.6.4 Transfer of proteins to nitrocellulose membranes (western blotting)
Proteins separated on SDS-PAGE gels were transferred to Hybond C membranes using a 
wet-transfer method based on that of Sambrook and colleagues (1989). Briefly the SDS-page 
gel and nitrocellulose membrane were pre-soaked in transfer buffer (192 mM glycine, 25 
mM Tris and 20% (v/v) methanol), sandwiched between sheets of pre-soaked Whatman 
3MM paper, and a Trans-Blot Cell (BioRad) assembled according to manufacturers 
instructions. Transfer was carried out overnight at 30 volts and 4° C.
2.6.5 Immunodetection of proteins on Western blots
Following transfer, the membranes were incubated in blocking buffer (lx PBS containing 4% 
(w/v) skimmed milk powder and 0.1% Tween-20) for 1 hour at room temperature with 
constant shaking. The membrane was then incubated with primary antibody diluted in 
blocking buffer for 1-2 hours at room temperature with constant shaking or overnight at 4° C 
with constant shaking. The unbound antibody was removed by washing the membrane 3 X 
for 10 minutes in blocking buffer at room temperature with constant shaking. The membrane 
was then incubated in the appropriate anti-IgG horseradish peroxidase (HRP) conjugated 
secondary antibody diluted in blocking buffer for 1 hour at room temperature with constant 
shaking. A further 5 X 10 minute washes of the membrane was carried out in lx PBS 
containing 4% (w/v) skimmed milk powder and 0.5% Tween-20) at room temperature with 
constant shaking to remove unbound antibody. The bound HRP was then detected using an 
enhanced chemiluminescence system (ECL) according to the manufacturer’s instructions. 
The membrane was then exposed to X-ray film to detect the resultant light emissions. The
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exposure times were between 1 second and 15 minutes, depending on the strength of the 
signal.
2.6.6 Expression of labelled proteins by in vitro translation
35S-labelled proteins were expressed by in vitro translation using the T7 TNT-coupled 
transcription-translation system following the conditions as described by the manufacturer 
(Promega). The reaction mixture (final volume 50 pi) was assembled on ice in a 0.5 ml 
microcentrifuge tube and incubated at 30° C for 90 minutes. 5 pi of the mixture was then run 
out on a SDS-PAGE gel and analysed by autoradiography.
2.6.7 Preparation of GST fusion proteins
10 mis of LB containing 100 pg/ml ampicillin and 30 pg/ml chloramphenicol was inoculated 
with a single colony of BL21 (DE3) pLysS cells containing a recombinant pGEX 2TK or 
pDEST plasmid and grown overnight at 37°C in an orbital shaker at 200 rpm. The culture 
was then diluted 1:100 with fresh LB containing 100 pg/ml ampicillin and grown for 2-3 
hours until the OD600 reached 0.4. The cells were then induced with 0.3 mM IPTG and 
incubated for 4-5 hours at 37° C, 200 rpm. The culture was then transferred into 50 ml falcon 
tubes and the cells were then pelleted by centrifugation and each pellet was resuspended in 1 
ml of PBS wash buffer (lx PBS containing 1 M DTT, 0.5 M EDTA, 0.1% igepal and lx 
Protease inhibitor solution). The cell suspension was lysed by 3 cycles of freeze/thawing at - 
70° C /37° C , and the cell debris was then pelleted at 10,000 rpm for 10 minutes at 4° C. The 
supernatant was recovered and the GST fusion protein purified using glutathione sepharose 
beads
2.6.8 Affinity purification of GST fusion proteins using Glutathione sepharose 
4B
2 ml of the above supernatant was incubated on a rotating wheel with 150 pi of glutathione 
sepharose 4B (Sigma) 50% slurry at room temperature for 1 hour. The beads were then 
pelleted at 3000 rpm for 5 minutes at 4° C and the supernatant was discarded carefully before 
the beads were washed 3x in PBS wash buffer (lx PBS containing 1 M DTT, 0.5 M EDTA,
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0.1% igepal and lx Protease inhibitor solution) and stored in PBS wash buffer +15%  
glycerol at -20. The glutathione sepharose containing the purified fusion protein was then run 
on a SDS/12.5% polyacrylamide gel to check for size and to visually estimate equal protein 
concentration for the samples for each pull down experiment.
2.6.9 Glutathione-S-transferase affinity pull-down chromatography
The GST/Bm-3 proteins or GST alone bound to glutathione sepharose beads were 
resuspended in NENT buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris pH 8.0, 1% igepal 
and 0.5% milk powder) and incubated with rotation at room temperature for 30 minutes. The 
beads were then pelleted at 2000 rpm for 3 minutes and resuspended in 20% milk powder in 
NENT buffer and incubated with rotation for 15 minutes at room temperature. The beads 
were then washed in 1 ml of NENT buffer and then once in transcription wash buffer (20 
mM HEPES, 60 mM NaCl, 1 mM DDT, 6 mM MgCl, 8.2% glycerol, 0.1 mM EDTA). 5 pi 
of the in vitro translated proteins were then incubated with the sepharose beads in 100 pi of 
transcription buffer for 1 hour at room temperature with rotation. The beads were washed 5 X 
in NENT buffer and the proteins were solubilised in standard sample buffer, heated to 95° C 
for 5 minutes and resolved on a SDS-10% polyacrylamide gel. The gel was then dried and 
exposed to radiographic film. The amounts of protein retained following the interaction 
studies were assessed by comparing the intensity of the bands resulting after the protocol 
with that resulting when equivalent amounts of proteins (input) were run on a similar gel.
2.6.10 Co-immunoprecipitation
Protein extracts were made from cell lines transfected with the appropriate expression 
vectors. Adherent cells were washed in ice cold PBS and were then scraped into 800pl of ice 
cold PBS for 10 cm plates. The cells were pelleted and lysed by putting through a 1 ml 
syringe, 25 gauge needle in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40 and 
protein inhibitor at a concentration of 1 X) and left on ice for 20 minutes. 70 pi of protein 
extract was pre-cleared with 25 pi of protein A/G sepharose on a rotating wheel for 30 
minutes at 4° C. The sepharose was then pelleted at 2000 rpm for 5 minutes and the 
supernatant was collected into a new 1.5 ml microcentrifuge and incubated with the
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appropriate antibody overnight at 4° C with rotation. Immunocomplexes were collected by 
incubation with 30 pi of protein A/G sepharose for 1 hour at 4° C with rotation. The beads 
were centrifuged at 2000 rpm for 5 minutes and the supernatant was discarded and the beads 
were washed 5 X in HMKEN buffer (10 mM HEPES ph 7.2, 142 mM KC1, 5 mM MgCk 2 
mM EGTA, 0.2% Igepal and protein inhibitor at a concentration of IX). The beads were then 
resuspended in 15 pi of standard sample buffer, heated to 95° C for 5 minutes and analysed 
with SDS/PAGE and Western Immunodetection.
2.6.11 Immunofluorescence
Immunostaining of NCC were carried out to detect expression of different proteins. After 7 
days of culture, NCC cultures were gently washed 3 X in 1 X TBS (50 mM Tis HCL pH 7.5 
and 150 mM NaCl) and fixed in 4% paraformaldehyde (PFA) for 15 minutes. Cells were 
washed 3 X in 1 X TBS followed by incubation in 1 X TBST (TBS + 0.1% triton X-100) for 
5 minutes to permeablise the cells. The cells were then blocked in 1 X TBS containing 10% 
goat serum for 20 minutes followed by incubation with first primary antibody in 1 X TBST + 
1% serum. If double immunostaining was to be carried out, the other primary antibody was 
added after 3 X washes in TBS, and incubation was as described above. After incubation 
with primary antibodies, the cells were washed 3 X in 1 X TBS and the appropriate Alexa 
Fluor secondary antibodies (Molecular Probes) were added to the cells diluted in 1 X TBST 
+ 1% serum for 30 minutes. The cells were then washed 5 X in 1 X TBS and mounted in 
fluorescent mounting medium (Dako). Images were obtained using the Zeiss Axioscop 2 
fluorescent microscope fitted with an Axiophoto camera and analyzed with Axiovision 
software.
2.7 Cell culture
2.7.1 Culture conditions
For long term storage all cell lines were stored in liquid nitrogen at -180°C. During culture 
the cells were maintained at 37° C in a 5% CO2 incubator. All manipulations of cells were 
carried out under aseptic techniques.
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2.7.2 Freezing and recovery of cell stocks
Cell stocks for storage were prepared by resuspending the cell pellet from one 175 cm3 flask 
in 1.5ml of 10% (v/v) dimethysulphoxide (DMSO), 90% foetal calf serum (FCS). The 
temperature of the vials was slowly decreased to -70° C before being immersed in liquid 
nitrogen. For growth from frozen stocks, cells were recovered by rapidly thawing the 
contents of one vial and transferring the cell suspension in to a 25 cm3 flask containing 8ml 
of pre-warmed growth media. The medium was changed or the cells passaged the following 
day.
2.7.3 Routine cell passage
Cells were grown in the appropriate growth medium until the flasks were -80% confluent. 
They were passaged as follows. The monolayer of ND7 cells were washed with Hanks 
Balanced Salt Solution (HBSS) free of calcium and magnesium ions. Fresh medium was 
added to the cells and the cells were detached by tapping the side of the flask. Fresh flasks 
were seeded at a ratio of 1:10. SAOS-2 cells were washed with Hanks Balanced Salt Solution 
(HBSS) free of calcium and magnesium ions. Trypsin/versene (1:10) were added to the flask 
for 30 seconds before being removed and the flask was left for 2 minutes to allow for the 
cells to detach. Fresh medium was added to the flask and the cells were seeded at a ratio of 
1:3 into a new flask containing fresh medium.
2.7.4 NCC cultures
2.7.4.1 Preparation of coverslips
NCC cultures were grown on 13 mm diameter coverslips that were acid washed and baked, 
before being coated with poly-l-lysine (Sigma) and fibronectin (Sigma). Briefly, 13 mm 
coverslips were placed in a glass container and rinsed in concentrated nitric acid for 30 
minutes at room temperature with constant shaking followed by a rinsing for 3 X 10 minute 
in distilled water. The coverslips were then rinsed for 30 minutes in methanol at room 
temperature with constant shaking. The methanol was removed and the coverslips were air 
dried. The coverslips were then baked in a sealed glass container in an oven at 150° C for 4
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hours. Coating of coverslips took place in a sterile fume hood and was carried out on the 
morning of dissection. The acid/baked coverslips were placed into 24 well plates and 150 pi 
of 0.5 mg/ml of poly-l-lysine (Sigma) was added on top of each coverslip and left to incubate 
for 20 minutes. The poly-l-lysine was then removed and the coverslips were air dried for 20 
minutes before adding 150 pi of 40 pg/ml fibronectin (Sigma) to each coverslip and allowed 
to incubate for 20 minutes. The fribronectin was then removed and the coverslips were air 
dried for 20 minutes, at which point they are ready to use.
2.7.4.2 Dissection of neural crest
NCC cultures were prepared from E9.5 embryos obtained after timed mating, with midday 
on the day of finding the copulation plug considered as E0.5. Dissections were carried out in 
a fume hood with the aid of a microscope. The pregnant mouse was first sacrificed and the 
embryo sack was removed to a dish containing HBSS. Primary neural crest explants were 
prepared from embryos by removing the portion of neural tube corresponding to the trunk 
level (somites 7-18). After separation of fetal membranes, the explants were enzymatically 
treated with 0.5 mg/ml collagenase in HBSS for 5 minutes, to further aid separation of the 
neural tube from the ectoderm and somites. After enzyme treatment, 1 ml of DMEM was 
added to stop the enzyme reaction. Further dissection was carried out to remove excess 
tissue, which was made easier following enzyme treatment. The neural tube explant was then 
transferred onto poly-l-lysine and fribronectin coated coverslips in a droplet of DMEM 
supplemented with 10% fetal calf serum (FCS). Explants were maintained in culture in a 
humidified incubator with 5% CO2 at 37° C. The neural tube explant was removed and 
discarded the following day and the NCC cultures were maintained for the required period, in 
0.5 ml growth medium consisting of DMEM with 10% FCS, 50 ng/ml of basic fibroblast 
growth factor (bFGF,R and D systems) 40 ng/ml of neurotrophin-3 (NT-3, PeproTech EC 
Ltd) and antibiotic/antimycotic (Sigma; 10,000 U penicillin, 10 mg streptomycin, 25 pg 
amphotericin per millilitre). The medium was replaced every 2-3 days. At the appropriate 
times cells were either harvested for extraction of total RNA (section 2.5.1) or fixed in 4% 
PFA and processed for immunostaining (section 2.6.11).
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2.7.4.3 Analysis of apoptosis in NCC from Brn-3a-/- mutants
Timed mating of Bm-3a heterozygous males and females were used to provide Bm-3a-/- 
mutants as well as littermates [wild type (WT+/+) and heterozygous (-/+)] which were used 
as controls. Neural crest cultures were prepared from embryos as described, whereas DNA 
was extracted from the hind legs and tail of the embryo for genotyping experiments which 
were carried out as described in section 2.4.1. After 7 days, matched Bm-3a-/- NCC cultures 
and wild-type (+/+) and heterozygous (-/+) controls were treated with 20 pM cisplatin for 6 
hours to induce apoptosis. Cells were then fixed and immunostained for activated caspase-3 
(detected with FITC-conjugated secondary Ab). To quantify the apoptotic cells in NCC 
cultures derived from WT, KO or Het embryos, counts were made of cells that were positive 
for activated Caspase-3 in at least six KO embryos and matching WT and HET controls.
2.7.4.4 Analysis of p73 expression in NCC from p53-/- mutants
Timed mating of p53 heterozygous males and females were used to provide p53-/- mutants as 
well as littermates [wild type (WT+/+) and heterozygous (-/+)] which were used as controls. 
Neural crest cultures were prepared from embryos as described whereas DNA was extracted 
from the hind legs and tail of the embryo for genotyping experiments which were carried out 
as described in section 2.4.1. After 7 days, matched p53 -/- NCC cultures and wild-type (+/+) 
and heterozygous (-/+) controls were fixed and immunostained for p73 (detected with 
rhodamine-conjugated secondary Ab) and Bm-3a expression (detected with FITC-conjugated 
secondary Ab).
2.7.5 Transient transfection
ND7 were transfected using the calcium phosphate method or Fugene (Roche). Note that 
most of the transfections in ND7 cells were carried out with Fugene.
Calcium phosphate method - One day before transfection cells were plated out at 5x10s in 
10cm plates. The next morning the medium was replaced with 5 mis of pre-warmed DMEM 
plus 10% FCS and was incubated for 2 hours. The DNA plasmids, reporter plasmid and TK 
renila plasmid (at 1/10 the concentration of reporter) and HS DNA were combined to a final
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concentration of 30 fig per transfection in a sterile microcentrifuge tube. 31 pi of 2 M CaCfe 
was added to each plasmid DNA solution and the final volume was brought up to 250 pi with 
sterile dd-HhO. The DNA mix was then added to 250 pi of 2 X HBS (1.64% (w/v) NaCl, 
1.19% (w/v) HEPES, 0.04% (w/v) Na2HPC>4 adjusted to pH 7.12) dropwise whilst vortexing. 
The precipitate was allowed to form for 30 minutes at room temperature before a final vortex 
and addition of the 500pl of the precipitate to the cells. The cells were then returned to the 
incubator for 5 hours. After 5 hours the cells were washed in pre-warmed HBSS hanks buffer 
and replaced in pre-warmed growth medium and incubated for 48 hours.
Fugene- ND7 cells were plated out at lxl05 in 6 well plates the day before transfection. The 
next morning the growth medium was replaced with fresh pre-warmed DMEM plus 10% 
FCS. 3 pg of total DNA was then diluted in 100 pi of DMEM without FCS. 6 pi of Fugene 
was added and gently mixed before being left to incubate for 30 minutes at room temperature 
to allow the DNA-fugene complex to form. The DNA-fugene complex was then added to the 
cells drop wise and the cells were incubated for 5 hours. After this period the cells are 
washed with HBSS buffer and replaced with 2 mis of full growth medium and incubated for 
48 hours. Transfections were also carried out in 10 cm plates when extracting protein for co- 
immunoprecipitation experiments or detecting expression of endogenous protein. 
Transfections were carried out as before except ND7 were plated out one day before 
transfection at 5x10s in 10cm plates. DNA:Fugene ratio was 4 pg :9 pi.
Lipofectimine (Invitrogen) was used to transfect SAOS-2 cells plated out at 0.5x105 in 6 well 
plates the day before transfection. The next morning the growth medium was replaced with 
fresh pre-warmed DMEM without FCS. Briefly 3 pg of total DNA was diluted in 100 pi of 
DMEM without FCS. 6 pi of Lipofectimine was diluted in 100 pi of DMEM without FCS 
and left to incubate for 5 minutes before being combined with the diluted DNA. The 
combined diluted DNA and diluted Lipofectimine were incubated for 20 minutes at room 
temperature to allow the DNA-liposome complex to form. The DNA-liposome complex was 
then added to the cells drop wise and the cells were incubated for 5 hours. After this period 
the cells are washed with HBSS buffer and replaced with 2 mis of growth medium and 
incubated for 48 hours.
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2.7.6 Luciferase assays
After 48 hours, transfected cells were washed in ice cold PBS and lysed in 1 x passive lysis 
buffer (Promega), 100 pi were used for 6 wells, 500 pi for 10 cm plates. The plates were 
incubated on a shaker for 15 minutes and the lysate were transferred to 1.5ml micro 
centrifuge tubes and centrifuged at 13 000 rpm for 1 minute to pellet cell debris and 
supernatant was collected into a fresh eppendorfs. 30 pi from each lysate was used to 
measure firefly and Renilla luciferase activities. Both luciferase assays were quantified using 
a commercially available kit (Promega) and a TD-20e Luminometer. Values for firefly 
luciferase were divided by their corresponding Renilla luciferase values to obtain relative 
luciferase units (RLU).
2.7.7 FACS analysis
2.7.7.1 Propidium Iodide (PI) staining for cell cycle analysis
ND7 cells were transfected with the appropriate DNA plasmids together with 100 ng of GFP- 
spectrin expression vector to mark transfected cells. Cells were then cultured for 30 hours, 
scraped into the media, pelleted and washed in PBS. The pellet was resuspended in 100 pi 
PBS and 1ml of ice cold ethanol was added to the samples dropwise whilst vortexing and 
stored at -20 until the day of analysis. At that time cells were pelleted and resuspended in 300 
pi of staining solution (50 pl/ml of PI (Roche), 100 pl/ml RNaseA in PI lysis buffer (250 mg 
sodium citrate and 0.1% triton xlOO) and incubated for 15 minutes at 37° C prior to analysis 
for DNA content. Flow cytometric analysis for GFP and PI fluorescence was performed 
using a 4-colour Epics XL flow cyclemeter (Beckman) equipped with an argon laser. For 
each analysis at least 30,000 events were collected to permit cell cycle analysis of both GFP 
(+) and GFP(-) cell populations. A 525 nm long pass filter was used to collect GFP emission 
and 675 nm long pass filter was used to detect PI. Data analysis was preformed using Expo32 
software (Beckman, High Wycombe) in the first instance. The cell cycle of the GFP/PI 
stained cells was further analysed by the Multicycle software (Phoenix Flow Systems, San 
Diego) which is more accurate as it mathematically models cell cycle data by deconstructing 
linear histograms obtained by the Expo32 software into normal distribution. The set up
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conditions to collect the cell cycle data was carried out by Jo Buddie (UCL, London)
2.7.7.2 Annexin V-PE staining for determination of apoptosis
ND7 cells were transfected with the appropriate DNA plasmids together with 100 ng of GFP- 
spectrin expression vector to mark transfected cells. Cells were then cultured for 48 hours, 
scraped into the media, pelleted and washed in PBS. The pellet was resuspended in 100 pi of 
1 X Annexin buffer (BD Pharmingen;10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 
mM CaC^), 3 pi of Annexin V-PE (BD Pharmingen) and 5 pi of 7-Amino-actinomycin (7- 
AAD) (BD Pharmingen). The solution was incubated for 15 minutes in the dark at room 
temperature. 300 pi of annexin buffer was then added to each sample and the cells were 
immediately analysed using a 4-colour Epics XL flow cyclemeter (Beckman) equipped with 
an argon laser. For each analysis at least 30,000 events were collected to permit cell cycle 
analysis of both GFP (+) and GFP(-) cell populations. A 525 nm long pass filter was used to 
collect GFP emission and a 675 nm and 650 nm long pass filter was used to detect annexin 
V-PE and 7-AAD respectively. The set up conditions to collect the cell cycle data was 
carried out by Jo Buddie (UCL, London). Annexin V-PE negative and 7-AAD negative 
identified live cells, Annexin V-PE positive and 7-AAD negative identified early apoptotic 
cells and annexin V-PE positive and 7-AAD positive identified necrotic cells. Finally 
annexin V-PE negative, 7-AAD positive represented nuclear debris.
2.8 Electrophoretic Mobility Shift Assay (EMSA)
EMSA is a technique used to study protein-DNA interactions to determine if a particular 
protein binds to a specific DNA regulatory sequence. This assay is performed by incubating 
cellular extracts or in vitro translated protein with a Radiolabelled oligonucleotide that 
contains the putative binding site. The complex is then analyzed on a non-denaturing PAGE 
gel. Proteins that are bound to the labeled oligonucleotide will be visible by autoradiography. 
To detect for specificity, addition of an antibody that recognizes the protein in the DNA 
complex will result in a supershifted band.
137
2.8.1 Nuclei extract from cells
Nuclear protein was extracted from IMR-32 cells over-expressing Bm-3a and expressing 
wild type p53. IMR-32 cells were scraped from 10 cm plates in ice cold PBS. After 
centrifugation the cell pellet was resuspended in cold buffer A (10 mM HEPES pH7.9, 1.5 
mM MgCl2 , 10 mM KCL, 0.5 mM DTT, 0.2 mM PMSF) and cells were allowed to swell on 
ice for 10 minutes before vortexing and centrifugation at 700 rpm for 5 minutes at 4° C to 
pellet nuclei. Nuclei were resuspended in cold buffer C (20 mM HEPES pH 7.9, 25% 
glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF), 
lysed for 10 minutes on ice and centrifuged at 13,000 rpm for 10 minutes at 4° C to pellet 
nuclear debris. Protein concentration of the extract was determined by Bradford assay. 5 pg 
of the extract was used in the bandshift reactions.
2.8.2 Labeling of the oligonucleotide probe
Single stranded oligonucleotides corresponding to the Noxa promoter containing the p53 
response element (section 2.1.6) were reconstituted in dd-H20 at 160 pmoles. Equimolar 
amounts of complementary oligonucleotides were annealed by adding commercially 
available buffer C (Promega), heating to 90° C for 3 minutes and leaving at room 
temperature for 1 hour to allow annealing to take place. The double stranded oligonucleotide 
was diluted to the working concentration of 16 pmoles. End labelling of the double stranded 
probe was carried out using T4 kinase (Promega) which labels the 5’-OH ends. Typically 16 
pmoles of the double stranded probe was incubated with 20 pCi [32P] -^yATP, 1 X T4 buffer 
(70 mM Tris-Hcl (pH 7.6), 10 mM MgCl2, 5 mM DTT) and 1 pi (10 units) of T4 
polynucleotide kinase and incubated at 37° C for 30 minutes. The 50 pi reaction was 
increased to 100 pi by addition of dd-H20  and excess unlabelled nucleotides removed by 
passing the sample through a micro-spin™ G-25 column (Amersham). The labelling 
efficiency was measured using a Geiger counter, comparing the elute reading value to the 
radioactivity left in the column. The final volume should be approximately 100 pi containing 
160 ftnoles of the labelled probe. The labelled probe was stored at -20.
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2.8.3 Gel retardation assay
Analysis of protein binding to the labeled oligonucleotide corresponding to the noxa 
promoter containing the p53 binding site was preformed using a modified method described 
by Gasgoyne and colleagues 2003. 5 pg (~ 1 pi) of IMR-32 cellular extract was added to 10 
pi of 2 X EMSA buffer (20 mM HEPES pH 7.9, 5 mM MgCl2, 50 mM KC1, 0.1 mM EDTA, 
15 % glycerol, 1 mM DTT and 5 ng/pl Poly(dl-dC)-Amersham). For competition 
experiments, 16 pmoles or 32 pmoles of cold oligonucleotide was added to the appropriate 
tubes resulting in 50 or 100 fold molar excess of specific competitor. 32 pmoles (100 X 
excess) of unlabelled oligonucleotide corresponding to the estrogen receptor element (ERE) 
was used as a non-specific competitor. An oligonucleotide known to bind the Bm-3a protein 
was used to test whether this protein was in the complex and whether binding to its site could 
compete with binding to the probe. 1 pi of p53 PAb (Oncogene), actin PAb (Santa Cruz 
Biotechnology) or Bm-3a Mab (Chemicon) were also used to test whether the p53 protein 
bound to the p53 element in the noxa promoter and whether Bm-3a was in this complex. In 
all cases dd-H20  was added to give a final volume of 18 pi for each reaction mixture before 
adding 2 pi of the labelled probe (320 fmoles) per tube. The reaction mixture was then 
incubated on ice for 1 hour. Protein-DNA complexes were separated from free probe by 
electrophoresis carried out on a pre-run 7 % non-denaturing polyacrylamide gel run in 0.5 % 
TBE, at 220 volts for 2 hours at 4° C. Gels were carefully removed from the running 
apparatus by the removal of one glass plate and attaching 2 sheets of 3MM paper to the gel 
and carefully peeling off, and covering with cling film. The gels were dried at 80° C for 1 
hour and exposed to X-ray film overnight at 80° C.
2.9 Chromatin Immunoprecipitation (ChIP) assay
This assay was performed to test whether Bm-3a could be immunoprecipitated when bound 
to p53 on the wild type noxa promoter but not on the noxa promoter in which the p53 site has 
been deleted in intact cells. ND7 cells were co-transfected in 10 cm plates with the wild type 
or mutant promoter together with p53 and Bm-3a. One set of transfections were repeated 4 
times so that 4 X 10 cm plates were harvested into one tube. 48 hours after transfection cross 
linking was performed by adding 270 pi of 37% formaldehyde in 10 ml of medium to the 10 
cm plates and incubating the cells for 15 minutes at 37° C wrapped in parafilm. Cells
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were then washed 2 X in ice cold PBS before scraping the cells into 1ml of PBS which was 
transferred into a 50 ml falcon (4 X 10 cm plates were harvested per 50 ml falcon tube). The 
cells were centrifuged at 700 rpm for 5 minutes and the supernatant was removed. Each cell 
pellet was lysed in 400 pi of lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris HCL pH 8.0 
and 1 X protease inhibitor) and incubated on ice for 10 minutes. The lysates were then 
sonicated for 3 X 10 seconds at 7 micron to shear the DNA into 500 to 1 kb fragments. The 
supernatant was transferred to 1.5 microcentrifuge tubes and centrifuged at 13,000 for 10 
minutes at 4° C and the supernatant was removed into a fresh cold Eppendorf. 40 pi of the 
supernatant was removed and added to 160 pi of IP dilution buffer (0.01% SDS, 1% Triton 
X-100, 2 mM ETDA, 150 mM NaCl, 20 mM Tris HCL pH 8.0 and 1 X protease inhibitor). 
This is used as the input sample for subsequent PCR analysis. The remaining 360 pi lysate 
was then divided into two eppendorfs and 720 pi of IP dilution buffer was added to each 180 
pi of lysate. 5 pg of secondary anti-mouse IgG was added to one tube while 5 pg of Bm-3a 
MAb (Chemicon) was added to the other tube, and the lysates were incubated over night at 
4° C with rotation. Incubation with 20 pi of protein G-Sepharose bead for 1 hour at 4° C 
allowed immobilization of the protein-antibody complex. The beads were pelleted at 1000 
rpm for 1 minute and washed in buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM ETDA, 10 
mM Tris HCL pH 8.0, 150 mM NaCl), pelleted as above, and followed by a wash in 1 ml of 
buffer 2 (0.1% SDS, 1% Triton X-100,2 mM ETDA, 10 mM Tris HCL pH 8.0,0.5 M NaCl). 
followed by a final wash in buffer 3 (2.5 M LiCl, 1% Igepal, 200 mg Deoxycholic acid, 1 
mM ETDA, 2 mM Tris HCL pH 8.0) and centrifugation at 1000 rpm for 1 minute to pellet 
the beads. The supernatant was discarded and the beads were then vortexed briefly in 250 pi 
of freshly prepared elution buffer (1% SDS in 0.1 M NaCOs), and incubated for 15 minutes 
at room temperature with rotation. The beads were then pelleted and the supernatant was 
transferred to a fresh tube. A further 250 pi of elution buffer was added to the beads and 
incubated for 15 minutes with rotation. The beads were centrifuged and the 250 pi elute was 
combined with the first elute. 20 pi of 5 M NaCl was added to each elute and the samples, 
together with the input were incubated at 65° C for 4 hours to reverse cross link between the 
DNA and protein. 10 pi of 0.5 M EDTA + 20 pi of 1 M Tris pH 6.8 and 20 pi of 1 mg/ml 
proteinase K was added to the sample elutes and 20 pi of 1 mg/ml proteinase K was added to 
the input samples followed by incubation at 45° C for 1 hour to digest away the protein. The 
volume of the input was made up to 500 pi with dd-H20 to match the volume of the
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sample elutes. All samples were extracted with 250 pi phenol/250 pi chloroform followed by 
extraction with 500 pi of chloroform to remove any remaining traces of protein. To visualise 
pellet of DNA upon precipitation, 20 pg of glycogen was added to each sample before 
addition of 1 ml of ice cold ethanol and incubation at -20 for 1 hour. The samples were then 
centrifuged at 13,000 for 10 minutes at 4 ° C. The supernatant was removed and the pellet 
was air dried. The input samples were resuspended in 75 pi of TE and the test samples were 
resuspended in 30 pi of TE. 0.5 pi and 1.5 pi of the input and test sample DNA were used for 
the PCR reactions respectively.
The 152 bp product of the noxa promoter containing the p53 site was amplified with 
NoxaChip-f and NoxaChip-r primers shown in section 2.1.6. Together with the template each 
PCR contained 1 unit of Taq polymerase (Promega) in a final concentration of 25 pi (1 X 
Mg-free buffer, 2.5 mM MgCh, 1 mM dNTP mix, 100 ng of each primer) and subjected to 
the following cycling parameter: After 1 cycle at 94° C for 3 minutes, the samples underwent 
25 cycles of denaturation at 94° C for 30 seconds, annealing at 60° C for 30 seconds and 
amplification at 72° C for 30 seconds followed by 1 cycle of 72° C for 5 minutes. The PCR 
products were resolved on a 2.5% agarose gel.
2.10 Statistical analysis
Data points were compared using the Students T-test analysis and the level of significance of 
the test is given as a p-value in the text. Statistical help was provided by Dr.V.Budhram- 
Mahadeo.
141
CHAPTER 3
The Brn-3a transcription factor physically interacts with 
the different p73 isoforms and differentially regulates p73 
mediated transcription to determine cell fate.
3.1 Introduction
The Bm-3a transcription factor is required for the survival and differentiation of sensory 
neurones during development. In particular, Bm-3a knock out mice demonstrate significant 
loss of specific sensory neurones during development, and these mutants die soon after birth 
(McEvilly et al., 1996). Interestingly, cells that would normally express Bm-3a are specified 
but failed to survive because of a wave of apoptosis in later development. This suggests that 
the progenitor cells are present, but once they are committed to their developmental fate, 
Bm-3a is necessary for survival and differentiation.
Bm-3a can directly transactivate genes associated with neuronal survival such as Bcl-2 and 
B c1-xl and neuronal differentiation such as Trk receptors, the neurofilament proteins, a -  
intemexin and Snap-25 (Budhram-Mahadeo et al., 1995b;Smith et al., 1997b;Smith et al., 
1998;Huang et al., 1999;Sugars et al., 2001) as well as regulating gene expression associated 
with cell fate, indirectly via the interaction with p53 (Budhram-Mahadeo et al., 1999;Sugars 
et al., 2001;Perez-Sanchez et al., 2002;Budram-Mahadeo et al., 2002). The ability of Bm-3a 
to alter p53 mediated cell fate is interesting as it is the first protein shown to decrease 
apoptosis but increase cell cycle arrest function of the p53 protein.
p73 is a recently discovered member of the p53 family which can induce cell cycle arrest and 
apoptosis in cells irrespective of their p53 status (Kaghad et al., 1997;Jost et al., 1997;De, V 
et al., 2000). Despite the structural and functional similarities between p53 and p73, p73 
knock out mice do not develop spontaneous tumours but show defects in neuronal 
development (Yang et al., 2000). The striking difference in function between p73 and p53 is 
underscored by the fact that p73 shows much greater molecular complexity than p53 as it is 
expressed as multiple alternatively spliced C-terminal and N-terminal isoforms (TAp73a-^ 
and ANp73a-P) (Kaghad et al., 1997;De, V et al., 1998a;Ueda et al., 1999) (Please refer to
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introduction sections 1.29, 1.30 and 1.31). Although the physiological functions of these 
different p73 isoforms are still unknown, they have different transcriptional and biological 
properties (Kaghad et al., 1997;Jost et al., 1997;Zhu et al., 1998;De, V et al., 1998b;Ueda et 
al., 1999). Furthermore, the ANp73 isoforms which lack the N-terminal transactivation 
domain are dominant negative proteins that show reciprocal function to the TA isoforms and 
p53 (Pozniak et al., 2000).
The ability of Bm-3a to modulate the activity of p53 on promoters associated with cell fate 
may be an important mechanism by which this transcription factor can help to determine 
survival and differentiation of neuronal cells that co-express both these proteins. The 
importance of p73 in neuronal development as shown by the phenotype of the p73 null mice, 
raised the possibility of a functional interaction between the Bm-3a and p73 proteins in 
specific cells that result in the modulation of cell fate. Thus the interaction and functional 
effects of this interaction between Bm-3a and the p73 proteins were investigated.
3.2 Brn-3a and Bm-3b specifically binds to the different p73 
isoforms
In order to determine if Bm-3a and Bm-3b proteins interact physically with the p73 proteins, 
in vitro interaction experiments (“GST pull-down” chromatography) were performed. Initial 
studies were carried out using the p73a and p73p isoforms. Fusion proteins were prepared for 
Bm-3a(l), Bm-3a(s), Bm-3b(l) and Bm-3b(s) using constructs in which the cDNA encoding 
each protein was cloned into the pGEX or pDEST15 vector downstream of a GST sequence. 
GST alone was also prepared and used as a negative control for all the interaction studies. 
The fusion proteins were expressed as described in materials and methods, immobilised on 
sepharose beads and incubated with in vitro translated (IVT) 35S-labeled p73a and p73p 
proteins. In vitro translated p53 was used as a positive control. Following washes to remove 
unbound proteins, the bound complexes were then resolved on a 10% SDS polyacrylamide 
gel (see methods). Radiolabelled p73 proteins retained by the Bm-3-GST proteins were 
detected after the gel was vacuum dried and exposed to film. The amounts of protein retained 
following the interaction studies were assessed by comparing the intensity of the bands with 
10% input on the same gel using scanning densitometry. The results show the relative
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affinity of binding of the Bm-3 family of proteins and the p53 family of proteins
As shown in Fig 3.1, IVT p73a and p73(3 proteins readily interacted with Bm-3a(l) (Fig 3.1a) 
and Bm-3a(s) (Fig 3.1b). Similarly these proteins also readily interacted with the Bm-3b 
proteins, Bm-3b(l) (Fig 3.1c) and Bm-3b(s) (Fig 3.Id). No interaction was observed between 
IVT p73a and p73p proteins with GST alone confirming that the interaction with the Bm-3 
proteins was specific and significant. p53 was included in these experiments as a positive 
control and as expected this protein did interact with both Bm-3a and Bm-3b. In contrast the 
labelled luciferase control protein failed to interact with any of the Bm-3-GST fusion 
proteins or with GST alone, once again confirming the specificity of the interaction. Each of 
the “pull-down” experiments were repeated in three independent experiments and the 
scanned results are represented in graphical form in Fig 3.1 e. These results show that while 
the Bm-3 proteins interacted with the p73 proteins, the strength of the interaction differed 
between the Bm-3 proteins and the different p73 proteins. The longer isoforms of Bm-3a and 
Bm-3b interacted with higher relative affinity with all of the p73 isoforms when compared 
with the shorter isoforms of Bm-3a and Bm-3b (for example, Bm-3a(l) and Bm-3b(l) 
retained 23% and 31% of p73p respectively, while Bm-3a(s) and Bm-3b(s) retained only 9% 
and 3% of p73p respectively). Further analysis also showed that the p73 proteins appear to 
interact with Bm-3a and Bm-3b more strongly than p53, with p73p consistently showing 
stronger association with the Bm-3 proteins. This suggests that p73p binds the Bm-3 proteins 
with the greatest affinity. The difference between the p73a and p73p isoforms lies in the C- 
terminal sequence. The p73p isoform arises from the alternative splicing of exon 13 in the 
mRNA which results in a shorter protein. Apart from the last 5 amino acids which are 
unique to p73p, the rest of the protein is identical to the corresponding regions in p73a. This 
suggests that the longer C-terminal sequence specific to p73a may reduce p73 binding to the 
Bm-3 proteins (please see later).
As p53 and p73 proteins can bind to DNA, it was necessary to identify if contaminating 
nucleic acid in these assays might mediate interaction with the Bm-3 proteins. In order to 
assess this, the interaction studies were repeated in the absence or presence of ethidium 
bromide (EtBr). The EtBr was added in excess to the samples to sequester contaminating 
nucleic acid. Importantly the interaction between Bm-3 and p53/p73 was maintained in the
144
a)
1/10 input Brn-3a(l) -GST GST only
coo
s G0L •*-> O caCO CO CO C CO CO COIO I". h- o IO h-a a Q. o a. a. Q.
m m
co
o
cotoa
a ca
CO CO1"-a a
1 2 3 10 11 12
b)
1/10 input Brn-3a(s)-GST GST only
coo
COinQ.
o ca H<«-> O ca is o ca
CO CO c CO CO CO c CO CO CON. i". o IO o IO N- r>-a a o CL a a o Q. a. a
1 2 3 9 10 11 12
Figure 3.1: Affinity chromatography “pull-down” assay used to test for interaction of in vitro 
translated 35S-labeled p53, p73a and p73p with Bm3a(l)-GST, Brn3a(s)-GST and GST alone.
a) lanes 1-4 shows 1/10 of the input protein used in the “pull-down” assays, lanes 5-8 shows proteins 
retained following incubation with Brn3a(l)/GST fusion proteins. While the IVT control protein, 
luciferase was not retained in a complex with Brn-3a(l), the positive control p53 as well as p73a and 
p73p proteins were associated with Brn-3a(l). This effect is specific to Brn-3a proteins as the GST 
moiety on its own failed to bind to p53, p73a or p73p (lanes 9-12) b) Similar to Brn-3a(l), Brn-3a(s) 
could also interact specifically with p53 (lane 6) and p73a and p73p (lanes 7,8) but not the negative 
control (lane 5).
145
C)
Brn-3b(l)-GST 1/10 input GST only
coo
a c a *-> O c a
CO CO CO c CO CO CO
IO K. o IO K. 1^
Q. a a o Q. a a
coo
d ca
CO CO CO
10 h -a  a. cl
9 10 11 12
d )
Brn-3b(s)-GST 1/10 input GST only
co
o
o ca is e ca i .*■> o ca
CO CO co c CO CO CO c CO CO CO
IO h - o IO h - h - o t o h- h-a a a o Q. a a. o a Q. CL
1 2 3 10 11 12
Figure 3.1 continued: Affinity chromatography “pull-down” assay used to test for interaction 
of in vitro translated 35S-labeled p53, p73a and p73p with Brn3b(l)-GST, Brn3b(s)-GST and GST 
alone.
c) lanes 5-8 shows 1/10 of the input protein used in the “pull-down” assays, lanes 1-4 shows proteins 
retained following incubation with Brn3b(l)/GST fusion proteins. While the IVT control protein, 
luciferase was not retained in a complex with Brn-3b(l), the positive control p53 as well as p73a and 
p73|3 proteins were associated with Brn-3b(l). This effect is specific to Brn-3b proteins as the GST 
moiety on its own failed to bind to p53, p73a or p73p (lanes 9-12) b) Similar to Brn-3b(l), Brn-3b(s) 
could also interact specifically with p53 (lane 2) and p73a and p73p (lanes 3,4) but not the negative 
control (lane 1).
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Figure 3.1 continued: e) Interaction of Brn-3a and p73 proteins as measured by percentage of 
labeled in vitro translated p53, p73a and p73p retained by Brn3-GST proteins. Densitometer scans of 
“pull-down” assays expressed as a percentage of the input of 35S labeled IVT p53 and p73 proteins 
retained by Brn-3a(l), Brn-3b(l), Brn-3a(s) and Brn-3b(s) in the same experiment. Data is the average 
of 3 independent experiments with standard error shown, f) GST pull-down assays demonstrating 
interaction of p53, p73a and p73p with Brn-3a(l) in the absence/presence of EtBr. Assays were 
preformed as before but in the absence (-) or presence (+) of 50 pg ethidium bromide per sample. 
Interactions were observed in the presence of ethidium bromide although interaction of p53, p73a and 
p73p with Brn-3a(l) were reduced in the presence of ethidium bromide.
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presence of EtBr but at slightly reduced levels (Fig 3.If), indicating that binding of these 
proteins to Bm-3a may be strengthened by nucleic acid.
3.3 ANp73 which lacks the N-terminal TA domain also interacts 
with Brn-3
In addition to the alternatively spliced C-terminal isomeric forms of p73 that contain the TA 
domain, the p73 gene can also be transcribed from a second downstream promoter, spanning 
exon 3, producing the ANp73 isoforms that lack the transactivation domain and starts with an 
alternative exon (exon 3') (Yang et al., 2000;Ishimoto et al., 2002) (please refer to sections 
1.29 and 1.31). To assess whether ANp73a could also interact with Bm-3a to the same extent 
as the TA isoforms already tested (p73a and p73p), similar pull-down assays were performed 
using Bm-3a(l)-GST and Bm-3a(s)-GST fusion proteins with IVT ANp73a. IVT p73a and 
p73p were included as positive controls. As shown in Fig 3.2 ANp73a readily interacts with 
the Bm-3a proteins, with 10-20% of protein being retained in this assay. Therefore, it appears 
that ANp73a also interacts with the long and short forms of Bm-3a in a manner similar to 
that seen with the TA isoforms. Additionally, interaction of ANp73a with Bm-3a confirms 
that the interaction is not mediated via the TA domain of p73.
3.4 p73 interacts with the POU domain of Bm-3a
In order to determine the domain(s) of Bm-3a that are required for interaction with p73, 
similar experiments were carried out using constructs containing the Bm-3a POU domain 
only and the N- terminal activation domain only illustrated in Fig 3.3c. The interactions were 
compared with Bm-3(1)-GST and Bm-3a(s)-GST proteins. As expected, full length Bm-3a 
associates more strongly with the p73 isoforms (p73a, p73p and ANp73a) than Bm-3a(s) 
(Fig3.3a and Fig3.3b) and p73p is retained the most by full length Bm-3a. All the p73 
isoforms bound very weakly to the N-terminus of Bm-3a suggesting that this region on its 
own is not sufficient for the strong interaction with p73. In contrast, the isolated POU domain 
interacted with all the p73 isoforms with similar affinity to that observed with Bm-3a(l). This 
suggests that the interaction between Bm-3a and p73 is primarily via the Bm-3a POU
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Figure 3.2: Affinity chromatography “pull-down” assays showing ANp73a isoform interacts 
with the Brn3a-GST proteins with similar affinity to TAp73.
a) lanes 10-12 shows 1/10 of the input protein used in the “pull-down” assays, lanes 1-2, 4-5, 7-8 
shows p73a, p73(3 and ANp73a proteins retained by Brn3a(l)/GST and Brn3a(s)/GST fusion proteins. 
This effect is specific to Brn-3a proteins as the GST moiety on its own failed to bind to p73a, p73|3 or 
ANp73a (lanes 3, 6, 9). In vitro translation of ANp73a shows a double band due to use of two 
different ATGs. b) Densitometer scans of “pull-down” assays expressed as a percentage of the input 
of 35S labelled IVT p73 proteins retained by Brn-3a(l), and Brn-3a(s) in the same experiment. Data is 
the average of 3 independent experiments with standard error shown.
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Figure 3.3: The isolated Brn-3a POU domain but not the isolated N-terminal domain is 
sufficient for interaction with the p73 proteins.
a) Lanes 16-18 shows 1/10 of the input protein used in the “pull-down” assays, lanes 1-4, 6-9 and 11- 
14 shows p73a, p73p and ANp73a proteins respectively retained following incubation with the 
indicated Brn-3a-GST fusion proteins. The Brn-3a isolated POU domain interacts with the p73 
proteins with similar affinity to Brn-3a(l) (compare lanes 1 and 3, for p73a, lanes 6 and 8 for p73p and 
lanes 11 and 13 for interaction with ANp73a). The isolated N-terminal domain binds weakly to p73a 
(lane 4), p73p (lane 9) and ANp73a (lane 14). This effect is specific to Brn-3a proteins as the GST 
moiety on its own failed to bind to p73a, p73(3 or ANp73a (lanes 5,10,15) b) Densitometer scans of 
“pull-down” assays expressed as a percentage of the input of 35S labeled IVT p73 proteins retained 
by Brn-3a(l), Brn-3a(s), and the isolated Brn-3a POU and N- terminal GST fusion proteins. Data is 
the average of 3 independent experiments with standard error shown, c) GST fusion proteins 
containing Brn-3a domains were purified from Escherichia.coli using glutathione beads. Domains are 
indicated l-IV, homologous N-terminal activation domain is shaded, C-terminal activation domain are 
shown striped.
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domain but the N-terminal domain must contribute as Bm-3a(l) is better than Bm-3a(s) in 
retaining the p73 proteins.
3.5 The p73 oligomerization domain (OD) is critical for the Brn- 
3/p73 interaction and this interaction is modulated by the p73 
extended C-terminal
To precisely define the region(s) of the p73 protein that are required for the interaction with 
the Bm-3 proteins, GST pull-down assays were carried out using in vitro translated proteins 
(shown in Fig 3.4d), transcribed from constructs in which specific regions of p73a were 
deleted and cloned into the pCDNA vector (constructs kindly provided by K. Shimotohno, 
Institute of Viral Research, Kyoto University). The deletion constructs either have N- 
terminal or C-terminal deletions of p73a. The p73N56 construct lacks the first 56 amino 
acids resulting in a protein that lacks the entire N terminal transactivation domain. The 
p73N315 polypeptide lacks the first 315 amino acids resulting in a protein lacking the TA 
and DBD domains. p73N423 lacks the sequences encoding the first 423 amino acid sequence 
resulting in a C-terminal protein that lacks the TA, DBD and the OD domain. The C-terminal 
deletion constructs, p73C505 and p73C424, lacking either the last 132 or 213 amino acid 
sequences respectively, result in proteins lacking the extreme C-terminal region but both 
retaining the OD domain. In contrast p73pdelOD is a derivative of p73p in which the 
sequences for the OD domain was deleted resulting in a protein that lacks the OD domain 
only.
In vitro translated S-labeled truncated p73 proteins with appropriate deletions were 
incubated with either Bm-3a(l) or the Bm-3a isolated POU domain linked to GST using the 
methods described. The isolated Bm-3a POU domain was included as it has been previously 
shown to be sufficient to interact with the p73 proteins. As shown in Fig 3.4a and Fig 3.4b 
and graphically represented in Fig 3.4c, full length p73a interacts with Bm-3(1) and the Bm- 
3a POU domain with the same affinity as seen previously. The deletion protein lacking the 
amino terminal transactivation domain p73N56 also binds Bm-3a(l) and the isolated POU 
domain to a similar extent shown with full length p73a. This deletion protein is similar to the 
truncated isoform ANp73a which has been previously shown to bind to both Bm-3a(l) and
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Fig 3.4c
interaction of Brn-3a(l)/POU with p73 deletion proteins
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Figure 3.4: The p73 region containing the oligomerization domain (OD) is critical for the Brn- 
3a/p73 interaction.
a) Affinity chromatography “pull-down” assays showing interaction between in vitro translated p73 
deletion proteins with Brn3a(l)-GST proteins and GST alone. Lanes 9-16 shows 1/10 of the input 
protein used in the “pull-down” assays, lanes 1-8 shows proteins retained following incubation with 
Brn-3a(l)/GST fusion proteins. While the luciferase control protein was not retained in a complex with 
Brn-3a(l) (lane 1), the positive control p73a (lane 2) and to varying extents the deletion proteins (lanes 
3-8) were associated with Brn-3a(l). Deletion proteins p73N423 and p73|3del OD both of which lack 
the OD domain fail to bind significantly to Brn-3a(l) whist the deletion proteins p73C505 and p73C424 
show increased binding to Brn-3a(l) compared to p73a. This effect is specific to Brn-3a proteins as 
the GST moiety on its own failed to bind to p73a or the deletion proteins, (lanes 17-24) b) Similar to 
Bm-3a(l), Brm-3a isolated POU domain could also interact specifically with p73a (lane 2) and to 
varying extends the deletion proteins (lanes 3-8) but not the negative control (lane 1). Again, the 
deletion proteins p73N423 and p73pdel OD both of which lack the OD domain fail to bind significantly 
to the isolated Brn-3a POU domain whilst the deletion proteins p73C505 and p73C424 show 
increased binding to the Brn-3a POU domain compared to p73a. c) Graphical representation of 
densitometer scans of “pull-down” assays expressed as a percentage of the input of 5S labeled IVT 
p73 proteins retained by Brn-3a(l) and the Brn-3a isolated POU domain. Data is the average of 3 
independent experiments with standard error shown, d) A schematic representation of the p73 
deletion constructs of p73a and p used to map the region required for interaction with the Brn-3 
proteins. The indicated TAD, DBD and OD refer to the transactivation domain, DNA-binding domain 
and oligomerization domains respectively. The numbers above the boxes denotes the amino acid 
positions in the wild-type p73a and p corresponding to the terminal ends of the p73a and p 
derivatives.
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the isolated POU domain.
Interaction of the polypeptide, p73N315 (which lacks the DBD) with Bm-3a(l) appears to be 
similar to that of p73a, whilst interaction of p73N315 and the isolated Bm-3a POU domain is 
compromised compared to that observed with full length p73a. This suggests that full length 
Bm-3a, in its natural conformation can continue to interact with the p73N315 truncated 
protein. However the isolated POU domain requires binding to the DBD (as seen with p53). 
These results imply that full length Bm-3a might make some additional contacts with the p73 
protein lacking the DNA binding domain compared with the isolated POU domain. This may 
be accomplished by a) binding of full length Bm-3a might affect the conformation of the p73 
protein in order to increase affinity for p73 binding or b) that other domains in Bm-3a might 
make contact with the p73 protein lacking the DBD to retain binding.
Interestingly, the p73N423 C-terminal. protein fails to bind significantly to either Bm-3a(l) or 
the isolated POU domain. The only difference between p73N423 which fails to bind Bm-3a 
and p73N315 which still binds to Bm-3a, is that p73N423 lacks the OD domain. Furthermore 
the p73p protein that lacks the OD domain only, (p73pdelOD) also fails to interact with Bm- 
3a(l) or the isolated POU domain. Since it was previously shown that p73p can interact very 
strongly with Bm-3a(l) and the isolated POU domain, these results suggest that the region 
containing the OD domain is critical for the p73/Bm-3a interaction. Since p73 polypeptides 
lacking the OD domain can no longer form tetramers, it can be argued that Bm-3a can either 
directly contact points within the OD domain or is incapable of binding to monomers of p73.
The deletion proteins p73C505 and p73C424, both of which contain the OD domain but lack 
132 or 213 amino acids respectively from the C-terminal, continue to bind to the Bm-3a(l) 
and the isolated POU domain, but with greater affinity than wild-type p73a. The binding 
affinity of these two deletion constructs to Bm-3a is similar to that found with p73p, which 
lacks the 216 amino acid C-terminal region encoded by codons 421-636 found in p73a due to 
splicing out of exon 13 in the p73p mRNA. This further suggests that sequences within the 
C-terminal region specific to p73a may act to reduce its association with both Bm-3a(l) and 
the isolated POU domain.
Similarly the p73 deletion proteins showed a similar binding pattern with Bm-3a(s) as they
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did with Bm-3a(l) (data not shown) in which p73N56 and p73N315 bound Bm-3a(s) with 
similar affinity to p73a. The truncated proteins p73N423 and p73pdelOD failed to bind Bm- 
3a(s) whilst the p73 C-terminal deleted polypeptides p73C505 and p73C424 interacted with 
Bm-3a(a) with stronger affinity than p73a. In addition Bm-3a(s) interacted with the p73 
polypeptides with weaker affinity compared to the interaction of these polypeptides with 
Bm-3a(l)
These results demonstrate that Bm-3a interacts with p73 and this interaction is mediated 
mainly via the POU domain of Bm-3a and the OD domain of p73. The DBD of p73 also 
contributes by contacting the POU domain of Bm-3a, in a manner similar to that seen with 
p53. Furthermore, this interaction is modulated by the C-terminal region of p73. This is 
interesting, as it is possible that Bm-3a may differentially regulate the functions of the 
different C-terminal isomeric forms of p73, as a direct effect of different affinities of 
interaction provided by the variation in the p73 C-terminal region.
3.5.1 Interaction of Brn-3b with the p73 truncated proteins
Since Bm-3b was also shown to interact with the p73 proteins, a similar study was carried 
out to look at which regions of p73 are required to interact with Bm-3b. Using the methods 
described above, Bm-3b(l) and the isolated Bm-3b POU domain linked to GST were 
incubated with the 35S labeled p73 deletion proteins (Fig 3.5a and Fig 3.5b and graphically 
represented in Fig 3.5c). As expected p73a and p73N56 bound strongly to both Bm-3b(l) and 
the isolated Bm-3b POU domain, suggesting that p73 interaction with Bm-3b is also 
mediated via the Bm-3b POU domain. As was the case with Bm-3a, the p73N315 
polypeptide, appears to interact with Bm-3b(l) to a similar extent to that observed with p73a, 
whilst interaction of p73N315 and the isolated Bm-3b POU domain is compromised 
compared to that observed with full length p73a. Again, this suggests that the full length Bm- 
3b protein in its natural conformation can continue to bind p73N315 (which lacks the DBD) 
but the isolated Bm-3b POU domain further requires the DBD for strong interaction. Thus, as 
with Bm-3a, the correct folding of full length Bm-3b is required for strong interaction with 
p73 lacking the DBD or other domains in Bm-3a might make contact with the p73 protein 
lacking the DBD to retain binding.
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Fig 3.5c
Interaction of Brn-3b(l) and Brn-3b POU domain 
with p73 deletion proteins
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Figure 3.5: The p73 region containing the oligomerization domain (OD) is critical for the Brn- 
3b/p73 interaction.
a) Affinity chromatography “pull-down” assays showing interaction between in vitro translated p73 
deletion proteins with Brn-3b(l)-GST proteins and GST alone. Lanes 17-24 shows 1/10 of the input 
protein used in the “pull-down” assays, lanes 1-8 shows proteins retained following incubation with 
Brn-3b(l)/GST fusion proteins. While the luciferase control protein was not retained in a complex with 
Brn-3b(l) (lane 1), the positive control p73a (lane 2) and to varying extents the deletion proteins (lanes 
3-8) were associated with Brn-3b(s). Deletion proteins p73N423 and p73(3del OD both of which lack 
the OD domain fail to bind significantly to Brn-3b(l) whilst the deletion proteins p73C505 and p73C424 
show increased binding to Brn-3b(l) compared to p73a. This effect is specific to Brn-3b proteins as 
the GST moiety on its own failed to bind to p73a or the deletion proteins (lanes 9-16) b) Similar to 
Brn-3b(l), the isolated POU domain from Brn-3b proteins could also interact specifically with p73a 
(lane 2) and to varying extends the deletion proteins (lanes 3-8) but not the negative control (lane 1). 
Again, the deletion proteins p73N423 and p73(3delOD both of which lack the OD domain fail to bind 
significantly to the isolated Brn-3b POU domain whilst the deletion proteins p73C505 and p73C424 
show increased binding to the Brn-3b POU domain compared to p73a. c) Graphical representation of 
densitometer scans of “pull-down” assays expressed as a percentage of the input of 35S labeled IVT 
p73 proteins retained by Brn-3b(l) and the isolated Brn-3b POU domain. Data is the average of 3 
independent experiments with standard error shown.
M Li
□ Brn-3b(l)
■ Brn-3b POU
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As seen with Bm-3a, the p73N423 polypeptide that lacks the amino terminus and the OD 
domain and p73pdelOD which just lacks the OD domain failed to bind significantly to Bm- 
3b(l) or the isolated Bm-3b POU domain. This suggests that Bm-3b also interacts with the 
p73 OD domain. In addition, the polypeptides p73C505 and p73C424 which lack the C- 
terminal of p73a also show increased binding to Bm-3b(l) and the Bm-3b isolated POU 
domain compared to that obtained with full length p73a, suggesting that as with Bm-3a, 
sequences within the p73a specific C-terminal region may inhibit association with the Bm- 
3b protein. As was the case with the Bm-3a/p73 interaction, it is possible that the different 
interactions between Bm-3b and the C-terminal isomers of p73 may be a determinant of 
precise biological outputs.
Similarly the p73 deletion proteins showed a similar binding pattern with Bm-3b(s) as they 
did with Bm-3b(l) (data not shown) in which p73N56 and p73N315 bound Bm-3b(s) with 
similar affinity to p73a. The truncated proteins p73N423 and p73pdelOD failed to bind Bm- 
3b(s) whilst the p73 C-terminal deleted polypeptides p73C505 and p73C424 interacted with 
Bm-3b(s) with stronger affinity than p73a. In addition Bm-3b(s) interacted with the p73 
polypeptides with much weaker affinity compared to Bm-3b(l)
Therefore both isoforms of Bm-3a and Bm-3b interact with p73 via the Bm-3 POU domain 
and the OD of p73 which is critical for this interaction. Additionally, the DBD of p73 also 
makes contributions to this association via the POU domain. This interaction is further 
modulated by the p73 extended C-terminal region.
3.6 Brn-3a interacts with p73 in vivo
In order to examine whether these interactions occur in vivo, in the context of intact cells, co- 
immunoprecipitation experiments were carried out in ND7 cells transfected with Bm-3a and 
p73a.
These experiments were carried out with the ANp73a isoform as this protein is more stable 
than TAp73a when transfected into ND7 cells. Also the p73-SAM Ab (which recognizes 
TAp73a and ANp73a only) does not appear to be as good as the p73-AN Ab (recognises the 
ANp73 isoform only) for co-immunoprecipitation experiments (these antibodies were a kind
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gift from Emre Sayan, University of Leicester). Importantly, since the Bm-3a/p73 interaction 
is not dependent on the p73 N- terminal but on the common OD domain, it was desirable to 
use the p73-AN Ab to assess in vivo interactions between p73 and Bm-3a
Therefore, ANp73a-containing protein complexes were immunoprecipitated from ND7 cells 
transfected with Bm-3a and ANp73a and analyzed for the presence of Bm-3a by immunoblot 
analysis. The transfected ND7 cells were also immunoprecipitated with actin pAb antibody 
control or rabbit IgG. In these experiments, Bm-3a protein was detected in 
immunoprecipitates pulled down with p73-AN pAb antibody but not in immunoprecipitates 
pulled down with actin pAb antibody or rabbit IgG (Fig 3.6), confirming that p73 interacts 
with Bm-3a in vivo.
Brn-3a ^
p73 -
IB probed with Brn-3a Ab
IB probed with p73-AN Ab
Figure 3.6: Brn-3a and ANp73a interact in vivo
ND7 cells were transfected with Brn-3a and ANp73a and cultured for 48 h. Cell lysates were 
prepared, and immunoprecipitated with rabbit IgG, anti-Actin antibody or anti-p73 antibody. 10% of 
the lysate was retained for input sample. After SDS-PAGE expression and efficient purification of 
ANp73a was confirmed by immunoblot with p73-AN antibody with detects the ANp73 isoform, and 
presence of Brn-3a in the immunocomplexes were identified by immunoblot for Brn-3a. No Brn-3a 
was observed in the immunoprecipitate with Rabbit IgG. Similarly no Brn-3a was observed when 
immunoprecipitation was carried out with actin protein which does not interact with Brn-3a, but is 
present in immunoprecipitates pulled down with p73 antibody.
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3.7 Brn-3a co-operates with TAp73a and TAp73p on activating the
p 2 1 CIP1/Waf1 p r o m o t e r  in  t h e  N D 7  c e i | M ne
Bm-3a can induce neuronal differentiation and is associated with growth arrest and increased 
activity of the promoter that drives expression of the cyclin-dependent kinase inhibitor 
p21clpI/WafI gene (Perez-Sanchez et al., 2002;Budram-Mahadeo et al., 2002). p53 exerts its 
protective effects by inducing cell cycle arrest (with possible DNA repair) or apoptosis which 
is largely caused by differential transcriptional effects on target genes that control cell cycle 
(e.g. p21clpl/WafJ) or apoptosis (e.g. bax, puma, apaf-l,fas). It has been previously shown that 
Bm-3a interacts with and enhances p53 mediated activation of the p21CIP1/Wcfl promoter, 
suggesting that Bm-3a is a determinant in the decision of p53 mediated cell cycle arrest 
rather than apoptosis (Perez-Sanchez et al., 2002;Budram-Mahadeo et al., 2002). Similar to 
p53, p73 can also activate the p21CIP1/WafI promoter and induce cell cycle arrest when 
exogenously expressed (Kaghad et al., 1997;Levrero et al., 2000). To examine if a similar 
functional effect is observed upon interaction of Bm-3a with p73, transient co-transfections 
were carried out using the reporter construct containing the promoter that drives the 
expression of p21CIP1/Wafl cloned upstream of a luciferase reporter gene.
Characterization of Bm-3a as a transcription factor has been mostly investigated in neuronal 
cells with many studies carried out in the neuronal derived ND7 cell line. This cell line was 
derived from rat dorsal root ganglion neurons immortalized by fusion with C l300 mouse 
neuroblastoma cells (Woods et al., 1990). When ND7 cells are induced to differentiate (by 
serum withdrawal or by addition of defined medium supplemented with growth factors or 
cyclic AMP analogues) they undergo morphological changes and express biochemical 
markers mimicking the events associated with differentiation of sensory neurones (Suburo et 
al., 1992). Bm-3a mRNA and protein levels are low in actively proliferating ND7 cells, but 
upon differentiation, Bm-3a levels are significantly elevated (Lillycrop et al., 1992;Budhram- 
Mahadeo et al., 1995a). In contrast expression of Bm-3b is higher in proliferating ND7 cells, 
whereas Bm-3b levels are dramatically decreased upon differentiation of these cells 
(Lillycrop et al., 1992;Budhram-Mahadeo et al., 1995a). Thus ND7 cells are ideal to 
investigate the role of Bm-3a and Bm-3b in neuronal survival and differentiation.
To test whether Bm-3a could modulate p73 mediated activation of the p21clpl/Wafl,
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increasing concentrations of expression vectors encoding either p73a or p73p (2-20 fig) were 
co-transfected with the p21CIP1/WafI reporter plasmid (5 fig) in ND7 cells either in the 
presence of 5 pg of Bm-3a expression vector or the LTR empty vector control. These 
transfections were carried out in 10 cm plates using the calcium phosphate method (see 
methods). Transfection of p53 either alone or with Bm-3a was included as positive controls 
as earlier studies have shown that Bm-3a could enhance p53 mediated activation of the 
p21CIPI/Wafl promoter. The transfections resulted in the changes of expression of Bm-3a, p53 
and the p73 proteins in the transfected cells as shown by western blot (Fig 3.7d). 
Unfortunately the p73-Full Ab which detects all p73 isoforms did not work well in western 
blots. Therefore, to assess for transfected p73 expression, the p73-SAM Ab was used which 
detects the a isoforms of both TAp73 and ANp73. Thus expression of introduced p73(3 could 
not be confirmed in these experiments. However, since transfection of p73a and ANp73a 
were shown to be efficiently expressed and the p73p construct were cloned in the same 
expression vector, this suggests that high levels of p73p would also be expressed in cells 
transfected with the p73p expression vector (and this was confirmed by the observed effects 
on target gene expression).
As expected, increasing concentrations of either p73a or p73p results in increased activation 
of the p21CIP1/Wafl promoter, with p73p being the stronger activator on this promoter (Fig 3.7a 
and Fig 3.7b). For instance, p73a could activate thep21CIP1/Wafl promoter up to 30 fold, p73p 
activated this promoter up to 60 fold. However, 20 pg of p73a resulted in reduced activation 
of the p21CIPI/Waf1 promoter suggesting a squelching effect, in which such high concentrations 
of this protein lead to depletion of essential co-activators, thus resulting in transcriptional 
repression.
Whilst Bm-3a on its own can mildly activate the p21CIP1/Wafl promoter as previously seen, co­
expression of Bm-3a and p73 resulted in increased activation of the p21CIP1/Wafl promoter 
compared to that observed with either Bm-3a or p73 alone at their specified concentrations. 
For example, whereas 2 pg of p73a alone resulted in 10 fold activation, co-expression of 
Bm-3a with 2 pg of p73a resulted in 25 fold activation of the p21CIP1/Wafl promoter (p<0.05). 
In particular the effect was marked at 20pg of p73a which resulted in 22 fold activation of 
the p21CIP1/Wqfl whilst addition of Bm-3a resulted in 44 fold activation (p<0.005),
161
3 )  Effect of Brn-3a and p73a on p21 promoter activity b )  Effect of Brn-3a and p73p on p21 promoter activity in
ND7 cells ND7 cells
6000 9000 
8000 
5  e 7000
% C 6000
S 8 5000 
|  2  4000 
o S 3000 
2000 
~  ~  1000
>*
I  O 5000
"  |  4000 ® °
0 s  3000
1  g  2000 
>
se 1000
Q p53 or p73 
■ with Brn-3a
C)
vector Bm- p53 p73a p73a p73a p73a p73a 
3a 1pg 2pg 5pg 10pg 20pg
Effect of Brn-3a and ANp73a on p21 promoter activity 
in ND7 cells
vector Bm- p53 p73(3 p73p p73P p73|3 p73p 
3a 1pg 2pg 5pg 10pg 20pg
1 s
■ i2 wo o 
E t3
i>
3 0 0
2 5 0
200
1 5 0
100
5 0
0
vector Brn-3a ANp73 ANp73 ANp73
□  ANp73a 
■  With Bm-3a
5 0 n g  1 0 0 n g  2 0 0 n g
d)
B rn-3a
p53
p 7 3 a
A N p73a
A ctin
Figure 3.7: Brn-3a enhances p73a and p73p activation of the p2 lclp1/Waf1 promoter in ND7 cells.
Brn-3a alone activated the p 2 iclp1/Waf1 promoter while p73a or p733 alone strongly activated this 
promoter compared with vector only. Co-transfection of Brn-3a with a) p73a or b) p73p significantly 
enhances p73a/p73B mediated activation of the p2 iclp1/Waf1 promoter. ND7 cells were transfected with 
5 pg of the p21CP1 af1 promoter luciferase reporter construct with increasing amounts of p73a or (3 (1- 
20pg) in the presence of 5 pg of either Brn-3a expression vector or empty vector using the calcium 
phosphate transfection method, c) ANp73 has no effect on p21 promoter activity compared to vector 
alone. Co-transfection of Brn-3a with ANp73 resulted in loss of Brn-3a mediated transactivation of the 
p 2 iclp1/Wafi promoter compared with Brn-3a alone. ND7 cells were transfected with 1 pg of p2 iCIP1/Waf1 
promoter luciferase reporter construct with increasing amounts of ANp73 (50-200ng) in the presence 
of 1 pg of either Brn-3a expression vector or empty vector using Fugene. All luciferase values were 
equalized to the activity of a co-transfected renilla expression vector and expressed as a percentage 
of the empty control vector. The results represent the mean and standard error of three independent 
experiments, d) Brn-3a and/or p53, p73a, p73p, ANp73a expression in transiently transfected ND7 
cells were analyzed by Western blot after whole cell lysis.
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highlighting the importance of this co-factor in stimulating increased expression of this 
promoter. Similarly, whereas 2 pg of p73p alone resulted in 12 fold activation of the
promoter; co-expression of Bm-3a with 2 pg of p73(3 resulted in 26 fold 
activation of the p21CIP,/Wafl promoter (p<0.005). However, whereas 20 pg of p73p resulted 
in a 60 fold activation of the p21CIP1/Wafl promoter, co-expression of Bm-3a with 20 pg of 
p73p did not further enhance p2lCIPI/Wqfl promoter activity. This is probably because p73p at 
this concentration of 20 pg, there is maximal stimulation of this promoter so that co­
expression of Bm-3a can not further enhance expression above the level observed with 20 pg 
of p73p alone. The observation that Bm-3a can still co-operate with p73a and significantly 
enhance p73a mediated activation of the p21CIP1/Wqfl promoter when 20 pg of p73a is 
transfected is most likely due to the lower activation of p73a alone on this promoter which 
can still be enhanced upon co-expression of Bm-3a.
Hence, as with p53, Bm-3a can co-operate with the TAp73 isoforms, p73a and p73p to 
stimulate the activity of the p21CIP1/WafI promoter.
The effect of ANp73a with or without Bm-3a was also tested on the p21clpl/Wa^  promoter. 
Increasing concentrations of expression vectors encoding ANp73a (50-200 ng) were co­
transfected with the p21CIP1/Wqfl reporter plasmid (1 pg) in ND7 cells either in the presence of 
1 pg of empty vector or Bm-3a, in 6 well plates using Fugene (Roche) method of transfection 
(see methods). This set of transfections and subsequent transfections were carried out with 
the Fugene reagent as it is more efficient than the calcium phosphate method resulting in an 
80% transfection rate rather than 30-40% transfection rate achieved with the calcium 
phosphate method. Thus lower concentrations of plasmid DNA were used and transfections 
were carried out in 6 well plates when using the Fugene reagent.
Fig 3.7d shows the expression of ANp73a and Bm-3a in transfected cells. As shown in Fig 
3.7c ANp73a failed to activate the p21CIP1/Wafl promoter, which is expected as ANp73a does 
not contain the N-terminal TA domain required for transactivation. Again Bm-3a was shown 
to activate the p21CIP1/Wqfl promoter by 2.5 fold which is consistent with published data. 
Furthermore, co-expression of Bm-3a and ANp73a appeared to reduce Bm-3a activation of 
the p21CIP1/Wqfl promoter when compared to Bm-3a alone (p>0.005). Thus while Bm-3a co­
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operates with the TA isoforms p73a and p73(3 to increase p21CIP1/Wqfl activation, ANp73a 
acts to decrease Bm-3a mediated activation of this promoter in reporter assays.
3.8 Brn-3a co-operates with TAp73a and TAp73f3 on activating the 
p2jCiPi/wafi promoter in the SAOS-2 cell line
In order to determine if the co-operative effect of Bm-3a and TAp73 on the p21clpl/Wqfl is 
dependent on other neuronal factors, or endogenous p53, the above transfections were 
repeated in the SAOS-2 cell line which is derived from an osteogenic sarcoma harboring a 
homozygous deletion of the p53 gene. Additionally this cell line does not express detectable 
endogenous p73 protein (Kaghad et al., 1997) or Bm-3a (personal communication with C 
Perez-Sanchez and Fig 3.8b), hence providing a suitable model to look at target gene 
expression of the p53 family and the functional effect of this expression. In similar co­
transfection studies described before, the p21CIP1/Wafl luciferase reporter construct was co­
transfected into SAOS-2 cells with increasing amounts of Bm-3a with or without p73a or 
p73p (Bm-3a:p73 ratios were 1:1, 2:1, 3:1 and 4:1) using Lipofectimine (Invitrogen). As this 
cell line has no Bm-3a expression, a titration was carried out to ascertain how much Bm-3a 
was required to affect the promoter activity in the absence or presence of the p73 proteins. 
Again p53 was included as a positive control. Fig 3.8b shows the expression of the Bm-3a 
and p53/p73 proteins in the transiently transfected SAOS-2 cells. As expected, both p53 and 
the p73 proteins strongly activated the p21CIP1/Wa^  promoter, whilst Bm-3a alone could also 
induce the p21CIPI/Wa^  promoter, being more effective at higher concentrations (Fig 3.8a). As 
was the case in the ND7 cells, co-transfection of Bm-3a with either p53 or the p73 proteins 
resulted in significant enhancement of p21clpl/Wa^  promoter activity compared with either 
p53 or p73 alone (Fig 3.8a). It is noteworthy that the maximal activation of the p21 promoter 
upon co-expression of Bm-3a and p73 was when the ratio between Bm-3a and p73a was 1:1 
or 2:1 and a ratio of 3:1 between Bm-3a and p73p.
Hence Bm-3a can enhance p53/p73 mediated activation of the p21CIP1/Wq** promoter in both 
non neuronal (SAOS-2) and neuronal (ND7) cell lines suggesting that the effect of Bm-3a on 
p53/p73 mediated transcription of the p21CIP1/Wafl promoter does not depend on other 
neuronal specific co-factors. Also the co-operative effects of Bm-3a and TAp73 on the
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a) Effect of Brn-3a and p73a/p73p on p21 promoter activity in
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Figure 3.8: Brn-3a enhances p73a and p73p activation of the p 2 i clp1/Waf1 promoter in SAOS2 
cells
Brn-3a alone activated the p 2 lclp1/Waf1 promoter while p53, p73a or p73p alone strongly activated this 
promoter compared with vector only. Co-transfection of Brn-3a with a) p73a or p73(3 significantly 
enhances p73a/p73p mediated activation of the p 2 iclp1/Waf1 promoter. SAOS-2 cells were transfected 
with increasing amounts of Brn-3a (1:1, 1:2, 1:3, 1:4 ratio with p73) with 1.5pg of p 2 iclp1/Waf1 vector in 
the presence or absence of 1.5pg of p73a or p73p. All luciferase values were equalised on the basis 
of the activity observed upon co transfection with a control renilla expression vector and expressed as 
a percentage of the empty control vector. The results represent the mean and standard error of three 
independent experiments, b) Brn-3a and/or p53, p73a expression in transiently transfected SAOS2 
cells were analysed by Western blot after whole cell lysis
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p21CIPI/WafI promoter is observed in both a p53 wild type cell line (ND7) and a p53 null cell 
line (SOAS-2 cells) suggesting that p73 activation of the promoter and co-operative effects 
of Bm-3a and TAp73 on the p21CJPI/Wafl promoter is independent of p53 expression.
3.9 Brn-3a represses TAp73a and TAp73p mediated activation of 
the pro-apoptotic Bax promoter in the ND7 cell line
Bm-3a also promotes sensory neuronal survival by activating transcription of the anti- 
apoptotic Bcl-2 and B c1-xl  proteins and inhibiting the basal transcription of the pro-apoptotic 
bax promoter (Smith et al., 1998;Smith et al., 2001;Ensor et al., 2001;Budram-Mahadeo et 
al., 2002). The p53 family of proteins induce apoptosis by transactivating pro-apoptotic gene 
targets such as box. Moreover it has been shown that Bm-3a interacts with wild-type p53 and 
antagonizes p53 mediated activation of the box promoter, thus contributing to the survival of 
sensory neurones conferred by Bm-3a (Budram-Mahadeo et al., 2002).
Thus, in order to test the effect of Bm-3a on the p73 mediated activation of the box promoter, 
co-transfection experiments were carried out similar to those undertaken with the p2JCIP1/w‘ 
promoter in the ND7 neuronal cell line. The box reporter gene was co-transfected with 
increasing concentrations of expression vectors encoding either p73a or p73p (50-200 ng) in 
the presence of either 1 pg of Bm-3a expression vector or empty vector control, using 
Fugene. As before p53 alone or together with Bm-3a was included as a positive control
Western blots carried out using protein extracts prepared from transfected cells show that the 
changes observed on the activity of the box promoter is due to the changes in expression of 
Bm-3a, p53 and the p73 proteins in the transfected ND7 cells (see section 3.7, Fig 3.7d). As 
expected, p73a and p73p could strongly activate the box promoter (Fig 3.9a and 3.9b) 
compared with empty vector control. Interestingly, both p73 isoforms appeared to activate 
the bax promoter more strongly than p53, but in contrast to the p21CIP1/Wqfl promoter, where 
p73p was the stronger activator, the p73a isoform was better at transactivating the bax 
promoter. Thus whilst p73a could transactivate the bax promoter up to 115 fold, p73p 
induced this promoter by 58 fold. Bm-3a on its own resulted in slight repression of the bax 
promoter as previously shown while co-expression of Bm-3a with either p73a or p73p
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d) Effect of Brn-3a and p73a on bax promoter activity in
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Figure 3.9: Brn-3a represses p73a and p73p mediated activation of the bax promoter in ND7 
cells.
Brn-3a alone slightly repressed bax promoter activity while p73a or p73p alone strongly activated this 
promoter compared with vector only. Co-transfection of Brn-3a with a) p73a or b) p73p significantly 
repressed p73a or p73p mediated activation of the bax promoter, c) ANp73a alone failed to activate 
the bax promoter and co-transfection of Brn-3a with ANp73a failed to significantly alter bax activity. 
All luciferase values were equalized on the basis of the activity observed upon co transfection with a 
control renilla expression vector and expressed as a percentage of the empty control vector. The 
results represent the mean and standard error of three independent experiments. ND7 cells were 
transfected with increasing amounts of p73a, p73p or ANp73a (50-200ng) with 1pg of bax promoter in 
the presence or absence of 1pg of Brn-3a using Fugene reagent.
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resulted in strong repression of the transactivation observed with either p73a or p73|3 alone 
respectively on this promoter. For example, whereas 50 ng of p73a alone resulted in 93 fold 
activation of the bax promoter, co-expression of Bm-3a with 50 ng of p73a resulted in a 
75.8% decrease in p73a mediated activation of this promoter (p<0.005). Similarly, co­
expression of Bm-3a with 100 ng or 200ng of p73a resulted in a 65.3% (p<0.005) and 43.6% 
(p<0.05) decreased activation of the bax promoter compared to the activation observed with 
100 ng or 200 ng of p73a alone, respectively. As with p73a, co-expression of Bm-3a with 50 
ng, 100 ng or 200 ng of p73p resulted in a 63% (p<0.05), 40.7% (p<0.05) and 37.2% 
reduction in bax promoter activity compared with the transactivation observed with 50 ng, 
100 ng and 200 ng of p73p alone respectively. Moreover, the Bm-3a mediated repression on 
p73-mediated activation of the bax promoter is reduced as the concentration of p73 is 
increased.
The effect of ANp73a with or without co-expression of Bm-3a was also tested on the bax 
promoter. As expected, ANp73a failed to activate the bax promoter (Fig 3.9c) compared to 
the activation observed with p73a or p73p. Furthermore co-expression of Bm-3a did not 
significantly alter bax promoter activation compared with ANp73a alone.
Hence Bm-3a can strongly inhibit the stimulatory effect of the TAp73 isoforms p73a and 
p73p on the bax promoter, and co-operate with TAp73a and TAp73p on the p21CIP1/Wqfl 
promoter in a manner previously shown with p53. In contrast ANp73a fails to activate either 
of these promoters, though it does appear to reduce Bm-3a mediated activation of the 
p21CIP1/Wqfl promoter.
3.10 Brn-3a represses TAp73a and TAp73p mediated activation of 
the pro-apoptotic bax promoter in the SAOS-2 cell line
Recent findings have demonstrated that the p53 family members require each other to 
function as transcription factors on apoptotic gene targets (Flores et al. 2002). Therefore the 
above transfections were repeated in the SAOS-2 cell line. As before SAOS-2 cells were co­
transfected with the box reporter gene and increasing amounts of Bm-3a with or without 
p73a or p73f3 using Lipofectimine. Fig 3.8b shows the expression of the Bm-3a and p53/p73
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proteins in the transiently transfected SAOS-2 cells
As expected, p53, p73a and p73p strongly activated the bax promoter, with the p73 isoforms 
being the stronger activators of the bax promoter (Fig 3.10.) For example, whereas p73a 
activated the bax promoter by 76 fold, p73|3 activated the bax promoter by 55 fold. 
Increasing concentrations of Bm-3a on its own resulted in slight repression of the bax 
promoter as previously shown in ND7 transfections. Moreover the addition of increasing 
concentrations of Bm-3a with p53 or p73 resulted in repression of the p53 or p73 mediated 
activation of the bax promoter similar to that seen with the ND7 cell line. Hence co­
expression of Bm-3a with either p53, p73a or p73p at a 1:1 ratio resulted in 72.2%, 54.1% 
and 45.2% decreased activation of the bax promoter compared with p53, p73a or p73p alone 
respectively (p<0.05). Maximal repression is seen when the Bm-3a/p53 or Bm-3a/p73 ratio 
is 1:1 where maximum saturation is reached as increasing the levels of Bm-3a to p53 or the 
p73 isoforms does not reduce the bax promoter activity further.
Hence Bm-3a represses both TAp73a and TAp73p mediated activation of the bax promoter 
in both ND7 and SAOS-2 lines, suggesting that other neuronal factors and the expression of 
p53 is not required for this effect.
3.11 Brn-3a reduces the levels of endogenous Bax while increasing 
the levels of p21 protein when co-transfected with p73.
It has been previously shown that the co-operative effects of Bm-3a on p53 mediated 
activation of the p21CIP1/Wafl promoter as well as the Bm-3a antagonism on p53 mediated 
activation of the bax promoter is reflected in increased endogenous p2lcn>1/Wafl protein levels 
and reduced expression of endogenous Bax protein in ND7 cells transfected with both Bm-3a 
and p53 compared with levels in cells transfected with either Bm-3a or p53 alone (Budram- 
Mahadeo et al., 2002). It was therefore investigated whether the ability of Bm-3a to co­
operate with p73 on the p21CIP1/Wq^  promoter or repress p73-mediated activation of the bax 
promoter could be reflected in changes of p2lCIP1/Wafl and Bax protein expression. Since 
TAp73 is a strong transactivator of the p21clpI/WafI and bax promoters and the effects of Bm- 
3a on these targets were so significant, changes in p2icn>1/WafI and Bax expression was
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Figure 3.10: Brn-3a represses p73a and p73p mediated activation of the bax promoter in 
SAOS2 cells
Brn-3a alone slightly repressed bax promoter activity while p53, p73a or p73(3 alone strongly 
activated this promoter compared with vector only. Co-transfection of Brn-3a with p53, p73a or p73(3 
significantly repressed p53/p73a/p73p mediated activation of the bax promoter. All luciferase values 
were equalized on the basis of the activity observed upon co-transfection with a control renilla 
expression vector and expressed as a percentage of the empty LTR control vector. The results 
represent the mean and standard error of three independent experiments. SAOS-2 cells were 
transfected with increasing amounts of Brn-3a (in a 1:1, 1:2, 1:3 and 1:4 ratio with p73) in the 
presence or absence of 1.5pg of p73a or p73p
170
assessed by western blot analysis. Therefore, ND7 cells were transfected with p73a, p73p or 
ANp73a alone or in combination with Bm-3a in 10cm plates. p53 alone or together with Bm- 
3a was included as a positive control. The lysates obtained from the transfected cells were 
then used to carry out western blot analysis for endogenous p2lCIP1/Wafl and Bax proteins in 
the different transfected cells. Quantification of p2lcn>1/Wafl and Bax levels were carried out 
by densitometry and values were equalized for actin. Fold changes were obtained by 
comparing the levels of p2lCIP1/Wafl and Bax protein in cells transfected with p53 or the 
appropriate p73 constructs alone (value set as 1) to that obtained upon co-expression of p53 
or the appropriate p73 constructs with Bm-3a.
As shown in Fig 3.1 la, p2lcn>1/Wafl levels were significantly elevated in cells expressing p53, 
p73a, p73(3 but not ANp73a compared with the control (p<0.05). This reflects the strong 
activation of the bax promoter by p53, p73a and p73p in transfection experiments, whilst 
ANp73a fails to activate this promoter. Moreover, quantification of p2lCIP1/Wafl protein 
obtained from 3 independent experiments shown that, as predicated from the co-operative 
effect of Bm-3a and p73a or p73p on this promoter, there were significantly higher levels of 
the p2lcn>1/Wafl protein expressed in cells co-transfected with Bm-3a and p73a compared 
with p73a alone (1.7 fold increase, p<0.05) and with Bm-3a and p73p compared with p73p 
only expressing cells (2.9 fold increase, p<0.05) (Fig 31 lc). Thus, whereas Bm-3a alone only 
mildly activated the p2lCIPI/Wafl promoter, co-expression of Bm-3a with p73a or p73p can 
enhance the activity of the p21CIP1/Wa^  promoter and this is reproduced at the protein level. 
p53 was also included, and in accordance with published data, increased levels of p2lcn>1/Wafl 
protein is observed when Bm-3a is co-transfected with p53 compared to p53 expressing cells 
only (2.4 fold increase, p<0.05) (Budram-Mahadeo et al., 2002). In contrast the levels of 
p21cn>i/wafi protein in cells transfected with ANp73a alone compared to cells co-transfected 
with Bm-3a and ANp73a did not differ significantly.
Thus Bm-3a co-operates with both p73a and p73p on the p21CIP1/Wafl promoter and this 
results in significantly enhanced p2lcn>1/Wafl protein levels in cells that co-express these 
proteins. In contrast, co-expression of Bm-3a and ANp73a had no effect on p2icn>1/Wafl 
levels compared with ANp73a alone.
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Figure 3.11: Brn-3a represses TAp73 mediated expression of endogenous Bax protein and 
increases TAp73 mediated expression of endogenous p2 iclp1/Waf1 protein
Representative western blot showing a) Levels of p2 ic,P1/Waf1 and b) Bax protein in ND7 cells 
transfected with vector alone, p53, p73a, p73p or ANp73a with or without Brn-3a. The levels of Brn- 
3a and of the control actin protein are shown in each transfected cell population for comparison, c) 
Fold increase of p21 and d) Decrease of Bax protein levels upon co-expression of Brn-3a compared 
with p53, p73a, p73p or ANp73a alone. Quantification of p21 and Bax levels were carried out by 
densitometry and values were equalized for actin. Fold changes were obtained by comparing the 
levels of protein in cells transfected with p53 and appropriate p73 constructs alone to that obtained 
upon co-expression of Brn-3a with p53 or the appropriate p73 constructs. Values are expressed as a 
proportion of cells transfected with p53 and the appropriate p73 constructs alone which were taken as 
1. Data is from 3 independent experiments.
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As expected, Bax levels were significantly elevated in cells expressing p53 p73a or p73P 
compared with control transfected with empty vector only (p<0.05) (Fig 3.11b), reflecting 
their ability to strongly transactivate this promote in transfection assays. However, 
quantification of Bax protein obtained from 3 independent experiments shown that the 
induction of Bax expression by p73a or p73p is significantly reduced upon co-expression of 
Bm-3a compared with p73a or p73p alone (32% and 46% decrease in Bax levels 
respectively, p<0.05), (Fig 3.1 Id) which supports the antagonistic effects of Bm-3a on p73a 
and p73p mediated activation of the box promoter. In addition, significantly lower levels of 
Bax protein is observed when Bm-3a is co-transfected with p53, compared to p53 expressing 
cells only (46% decrease in Bax levels, p<0.05) which is consistent with published data 
(Budram-Mahadeo et al., 2002). As expected, the levels of Bax protein in cells transfected 
with ANp73a, which fails to activate this promoter in ND7 cells, remained similar to that 
observed in the control cells. Furthermore, co-expression of Bm-3a with ANp73a did not 
significantly alter the levels of Bax expression compared with ANp73a alone.
Thus Bm-3a antagonizes TAp73a and TAp73p mediated activation of the box promoter 
which results in significantly reduced Bax protein in cells that co-express these proteins. In 
contrast, co-expression of Bm-3a and ANp73a had no effect on Bax protein levels.
3.12 Brn-3a differentially regulates p73 mediated cell cycle arrest 
and apoptosis
3.12.1 Brn-3a co-operates with TAp73a and TAp73p to induce cell cycle arrest
It has been previously demonstrated that in the ND7 cell line, co-expression of Bm-3a and 
p53 is accompanied by increased survival and a higher proportion of cells in the G0/G1 
phase of the cell cycle, compared to cells transfected with either factor alone (Budram- 
Mahadeo et al., 2002). The co-operative effect of Bm-3a and p73a or p73p on the p21CIP1/Wa^  
promoter and increased p2lcn>1/Wafl protein in cells co-transfected with both factors compared 
with either alone, also suggest that induced cell growth arrest associated with differentiation 
may be enhanced when Bm-3a is co-expressed with the p73a or p73p isoforms. 
Additionally, the ability of Bm-3a to inhibit p73a or p73p mediated activation of the box 
gene and decrease in endogenous Bax protein levels when both factors are
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expressed suggests that Bm-3a might antagonize the pro-apoptotic effect of p73a or p73p in 
neuronal cells. Thus the effect of Bm-3a on p73 mediated cell cycle arrest and apoptosis was 
investigated, in the ND7 cell line.
Flow cytometry and fluorescence-activated cell sorting (FACS) analysis was carried out on 
ND7 cells transfected with either Bm-3a or the p73 isoforms (p73a, p73p and ANp73a) 
alone, as well as co-expressing Bm-3a with either p73a or p73p or ANp73a. p53 was 
included as a positive control, whereas the empty vector was used as a control to compare the 
effects of Bm-3a and /or p73. p73pdelOD which fails to interact with Bm-3a and is expected 
not to be functional due to its inability to form tetramers was included as a negative control. 
GFP-spectrin expression vector was included in all experiments to mark transfected cells. 
From previous titration experiments the maximal activation of the p21CIP1/Wa^  promoter is 
achieved when ND7 cells are transfected with the p73/Bm-3a ratio of 1:10 so this ratio was 
used in these studies. Transfected cells were maintained in culture for 30 hours, fixed in 
ethanol and stored at -20 till day of analysis. Cells were then stained with propidium iodide 
(PI) which binds to dsDNA and can therefore assess the DNA content in cells. PI staining is 
monitored in the FL2 channel, and the ability of the cytometer to exclude doublets 
(distinguishing between 2 cells in G1 passing through the beam together from a single G2 
cell) allows for the estimation of the percentage of cells in Gl, S phase and G2M using 
software analysis.
As well as using PI staining for cell cycle analysis of the total cell population, the cell cycle 
of GFP positive cells only can also be analysed, which is useful when assessing the cell 
cycle of transfected cells only (as marked by the expression of transfected GFP). The GFP 
plasmid makes up a small fraction of the total DNA transfected in the cells so that cells 
transfected with GFP are likely to express other transfected plasmids.
The total cell population as well as just the GFP positive cell population were analysed for 
DNA content to obtain their cell cycle profile by using Expo32 software in the first instance. 
The cell cycle of the GFP positive cells stained with PI was further analysed by the 
Multicycle software (Phoenix Flow Systems, San Diego) which is a more accurate analysis 
as it mathematically models cell cycle data by deconstructing linear histograms obtained by 
the Expo32 software into a normal distribution. Even though values from the Multicycle
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software were used in the analysis showed herein, they were similar to the cell cycle data 
obtained from the Expo32 software. Fig 3.12a demonstrates a typical cell cycle profile of 
GFP positive cells transfected with vector only using the Expo32 analytical software, 
compared with the same data analysed by the Multicycle software that gives a more accurate 
measurement of the percentage of cells in each stage of the cell cycle. Fig 3.12b shows a 
typical cell cycle profile obtained in a set o f experiments when analysed by the Multicycle 
software.
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Figure 3.12a: Comparison of the two different software’s used for cell cycle analysis in these 
experiments
At least 30,000 events were collected using a Beckman epicsXL flow cytometer equipped with a 
488nm argon laser and 525nm band filter to collect GFP emission and 675nm band filter for PI 
detection. When set up to exclude cell doublets, the percentage of cells in G1, S phase and G2M can 
be estimated using i)Expo32 software or by using a programme such as ii) Multicycle which will 
mathematically deconvolute the DNA histogram thus giving a more accurate measurement of the 
cells in each phase.
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Figure 3.12b: Brn-3a increases TAp73 mediated cell cycle arrest
Cell cycle analysis of GFP positive ND7 cells transfected with Brn-3a (b), p53 alone (c) or together 
with Brn-3a (d) p73a alone (e) or together with Brn-3a (f) or p73(3 alone (g) or together with Brn-3a 
(h) ANp73a alone (i) or together with Brn-3a (j), compared with empty control vector (a). At least 
30,000 events were collected using a Beckman epicsXL flow cytometer equipped with a 488nm argon 
laser and 525nm band filter to collect GFP emission and 675nm band filter for PI detection. Data 
analyzed by Multicycle software
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Fig 3.12ci shows a graphical representation of the percentage of cells in G0/G1 obtained 
from at least three independent experiments derived from data generated by the Multicycle 
software. Bm-3a alone resulted in an increase in G0/G1 arrest compared to control as 
expected from results of previous studies (control = 35% of cells in G0/G1, Bm-3a -  40% of 
cells in G0/G1, p<0.005). As expected p53 alone increased cell cycle arrest compared with 
control and co-expression of Bm-3a enhanced p53 cell cycle arrest as shown previously 
(Budram-Mahadeo et al., 2002).
Also as expected, a high proportion of cells transfected with p73a or p73p alone are in the 
G0/G1 phase of the cell cycle compared with control (p<0.0005). Cells transfected with p73a 
alone resulted in 45% of cells in G0/G1 whilst co-expression of Bm-3a with p73a resulted in 
a significant increase in the proportion of cells in G0/G1 phase (52%) compared with p73a 
alone (p<0.005). Similarly, p73p alone resulted in 45% of cells in G0/G1 whilst co­
expression of Bm-3a with p73p resulted in a significant increase in the proportion of cells in 
G0/G1 phase (55%) compared with p73p alone (p<0.0005). Thus the increase in cell cycle 
arrest appears to be more pronounced upon co-expression of Bm-3a with p73p, compared 
with p73p alone. Also the G0/G1:S phase ratio was highest in cells co-expressing Bm- 
3a/p53, Bm-3a/p73a and Bm-3a/p73p indicating that fewer cells are transiting the G0/G1 
boundary into S phase compared with either protein alone or vector control (Fig 3.12cii). 
Hence, as observed with Bm-3a and p53, Bm-3a also increases both p73a and p73p mediated 
cell cycle arrest.
In contrast transfection with ANp73a did not significantly alter the proportion of cells in 
G0/G1 compared with cells transfected with empty vector. Furthermore co-expression of 
Bm-3a with ANp73a did not significantly alter the proportion of cells in G0/G1 compared 
with Bm-3a alone, demonstrating that ANp73a fails to induce cell cycle arrest and does not 
significantly affect the ability of Bm-3a to induce cell cycle arrest. As expected transfection 
of p73pdelOD did not alter the proportion of cells in G0/G1 compared with the empty vector 
control and co-expression of Bm-3a with p73pdelOD did not increase cell cycle arrest above 
that seen with Bm-3a alone. Thus Bm-3a can co-operate with p53 and the TA isoforms p73a 
and p73p but not with ANp73a in inducing cell cycle arrest in ND7 cells. This would suggest 
that the ability of Bm-3a to enhance cell cycle arrest would depend on which p73 isoform
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Figure 3.12c: Brn-3a increase p73a and p73p mediated G1 arrest
i) Percentage of cells in G0/G1 transfected with Brn-3a, p53, p73a, p73|3 or ANp73a alone or together 
with Brn-3a compared to empty vector. Brn-3a increases p73a and p73p mediated cell cycle arrest 
compared to p73a or p73p alone (* p<0.005, ** p<0.0005). The results represent the mean and 
standard error of at least three independent experiments.ND7 cells were co-transfected with 100ng of 
the p53/p73 isoforms or 1pg of Brn-3a alone or together with 100ng of GFP-spectrin to facilitate the 
sorting of transfected cells from untransfected cells. Cells were harvested after 30 hours, fixed in 
ethanol and stained with PI. The DNA content was then measured by FACS as previously described.
ii) Percentage of ND7 cells in the different phases (G0/G1, S or G2/M). The G0/G1:S phage ratio 
represents the change in proportion of cells progressing through the cell cycle. The higher the 
number indicates that fewer cells are transiting the G0/G1 boundary into S phase. These values 
represent the mean of 3 independent experiments.
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predominates in the cell (i.e. TA versus AN).
3.12.2 Brn-3a antagonizes TAp73a and TAp73p mediated apoptosis and co­
operates with ANp73 to increase celi survival
The ability of Bm-3a to inhibit TAp73a or TAp73p mediated activation of the box gene and 
decrease in endogenous Bax protein levels when both factors are expressed suggests that 
Bm-3a might antagonize the pro-apoptotic effect of p73a or p73p in neuronal cells. Thus the 
effect of Bm-3a on p73 mediated apoptosis was investigated, in the ND7 cell line.
To assess whether Bm-3a can over-ride p73 mediated apoptosis, in a manner similar to that 
seen with p53, the percentage of cells undergoing apoptosis was assessed in cells transfected 
with the p73 expression vectors, with or without Bm-3a. As before, ND7 cells were 
transfected with Bm-3a or the p73 isoforms (p73a, p73p and ANp73a) alone as well as Bm- 
3a with either p73a or p73p or ANp73a (p73/Bm-3a ratio 1:10). p53 was included as a 
positive control and empty vector was used as a negative control. GFP-spectrin expression 
vector was again included in all experiments to mark transfected cells. Annexin V labelling 
was used to assess for cells undergoing early apoptosis, which recognizes modified 
phosphatidylserine on the surface of apoptotic cells. After 30 hours following transfection, 
cells were harvested in lx PBS and stained with Annexin V-PE and the percentage of early 
apoptotic cells was measured by FACS analysis on the GFP positive population.
Fig 3.13a shows the number of surviving cells (annexin V negative) from a representative 
experiment. Increased protection is obtained following transfection of Bm-3a alone 
compared with controls (Bm-3a= 65% survival, control= 46% survival p<0.0005) which is in 
accordance with previous studies. Transfection of ANp73a also shows slight protection 
compared to control while transfection of p53, p73a or p73p alone resulted in an increase in 
apoptosis compared with control which was significant for p73a and p73p (40.1% and 
34.4% survival respectively p<0.05). The findings that transfection of p53 or p73 failed to 
induce significantly more death is perhaps due to the high level of cell death already 
observed in the vector control as a result of the transfection. This procedure stresses the cells 
and might induce endogenous p53/p73 protein and hence cell death in the absence of Bm-3a.
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Effect of Brn-3a and p73 on cell survival in ND7 cells
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Figure 3.13: Brn-3a protects cells from p73a or p73|3 mediated apoptosis and co-operates with 
ANp73a to increase survival
Percentage of surviving ND7 cells transfected with Brn-3a and/or p53, p73a, p73p, ANp73a 
expression vectors measured by lack of annexin V-PE staining in GFP positive cells. ND7 cells were 
co-transfected with 100ng of the p53/p73 isoforms or 1pg of Brn-3a alone or together with 100ng of 
GFP-spectrin to facilitate the sorting of transfected cells from untransfected cells. Cells were 
harvested in 1x PBS after 30 hours and labeled with Annexin V-PE according to manufacturers 
protocol and then measured by flow cytometry and FACS analysis.
Thus it is difficult to induce increased cell death much over the basal level seen in the control 
transfected with vector only. However, upon co-transfection o f Bm-3a with p53, there is a 2 
fold increase in survival compared with p53 alone (p<0.05). Furthermore the increased 
survival observed upon Bm-3a and p53 co-expression was also above the levels observed 
with Bm-3a alone (p<0.05), demonstrating that Bm-3a overrides the p53 mediated apoptotic 
pathway, but also co-operates with p53 to enhance survival. Co-transfection of Brn-3a with 
either p73a or p73p resulted in a 1.5 fold and 1.3 fold increase respectively compared with 
p73a or p73p alone (p<0.05), but the survival observed was less than that obtained with Bm- 
3a alone. This result may be due to the increased apoptosis of these cells conferred by p73a 
or p73p compared to p53, resulting in Bm-3a only being able to rescue a smaller fraction of 
these cells. However, it is clear that Bm-3a reduces p73a and p73p pro-apoptotic effects in a 
significant percentage of these cells. In contrast, co-transfection o f Bm-3a with ANp73a 
resulted in a 2 fold increased survival compared with ANp73a alone (p<0.05). Furthermore 
this increase in survival is above the levels observed with Bm-3a alone (p<0.05). Thus Bm- 
3a co-operates with ANp73a to further increase cell survival.
Thus while Bm-3a confers some protection over p73a and p73p induced cell death, Bm-3a is 
more effective at inhibiting the pro-apoptotic effect of p53 and synergizing with ANp73a to
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protect cells from apoptosis.
3.13 Specific regions in the p73 C-terminus is required for Brn-3a to 
repress p73 mediated activation of the bax promoter but not for 
Brn-3a to enhance the p73 mediated activation of the p21 promoter
In this study it has been shown that Bm-3a can enhance p73 mediated activation of the 
p 2 j CIpi/wafi promoter while repressing p73 mediated activation of the box promoter in a 
similar manner to p53. However there is a marked increase in complexity of p73 compared to 
p53, largely owing to their extended C-terminal sequence, in which p73 has up to 6  
alternatively spliced C-terminal isomeric forms, which may be a determinant of unique 
biological functions. Furthermore, these C-terminal isomers can also be transcribed from the 
second downstream promoter to produce the N-terminally truncated isoforms (AN) that lack 
the TA domain (DeLaurenzi and Melino, 2000). It was therefore necessary to establish 
whether the extended C-terminal region found in p73a and the N-terminal domains of p73 
could alter the ability of Bm-3a to enhance p73-mediated activation of the p21CIP1/Wafl 
promoter or repress p73-mediated activation on the bax promoter. To investigate this, the 
transcriptional proficiency of the truncated p73 polypeptides (used previously for the 
interaction studies, see section 3.5) on these promoters was tested in the absence or presence 
of Bm-3a.
Therefore similar co-transfection experiments were carried out as described previously in the 
ND7 neuronal cell line. 1 pg of the bax reporter gene was co-transfected with 100 ng of 
expression vector encoding the appropriate p73 deletion protein in the presence of either 1 pg 
of Bm-3a expression vector or empty vector. The wild type p73a and p73p with or without 
Bm-3a were included as positive controls. As shown in Fig 3.14a, wild type p73a and p73|3 
transactivated the promoter and this was inhibited by Bm-3a. In contrast, p73N56 or 
p73N315, both of which lack the TA domain, failed to activate the bax promoter. Similarly 
co-transfection of p73N423 (which is incapable of forming tetramers, and lacks the TA 
domain) and p73|3delOD, (which fails to oligomerize) also failed to activate the bax promoter 
activity. Furthermore, co-transfection of Bm-3a with either of these polypeptides did not 
result in significant changes in the activity of the bax promoter, compared to either of the p73
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Figure 3.14: Deletion of the p73a C-terminal inhibits the ability of Brn-3a to repress p73 
mediated activation the bax promoter but not for Brn-3a to enhance p73 mediated activation of 
the p2i clp1/Waf1 promoter
a) Brn-3a alone slightly repressed bax promoter activity while p73a, p73(3, p73aC505 and p73aC424 
alone strongly activated this promoter compared with vector only. Constructs that lack the N-terminal 
activation domain (p73aN56, N315, N423) or constructs that lack the OD domain (p73|3delOD) failed 
to activate the bax promoter. Co-transfection of Brn-3a with p73a or p73p significantly repressed 
p73a or p73(3 mediated activation of the bax promoter as seen previously. In contrast, Co-transfection 
of Brn-3a with either of the p73a C-terminal deleted proteins, p73aC505 or p73aC424 failed to 
repress bax promoter activity, b) Constructs that lack the N-terminal activation domain (p73aN56, 
N315, N423) or constructs that lack the OD domain (p73(3delOD) failed to activate the p21 promoter, 
whilst p73a, p73(3 and both the C-terminal deleted proteins alone strongly activated this promoter 
compared with vector only. Co-transfection of Brn-3a with p73a, p73(3, p73aC505 or p73aC424 
significantly increased p73 mediated p21 activation showing that loss of the extended C-terminal 
does not affect the ability of Brn-3a to increase p73 activation of the p21 promoter. All luciferase 
values were equalized on the basis of the activity observed upon co transfection with a control renilla 
expression vector and expressed as a percentage of the empty control vector. The results represent 
the mean and standard error of three independent experiments. ND7 cells were transfected with 
either 1 pg of bax or p2 i clp1/Waf1 promoter with 100ng of expression vector encoding either p73a, 
p73(3 or the appropriate p73 deletion protein in the presence of either 1 pg of Brn-3a expression 
vector or empty vector using Fugene reagent.
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polypeptides alone. Hence these results further confirm that the TA domain is essential for 
gene activation and also show that the OD is required for activation presumably because the 
active form of p73 is a tetramer (Davison et al., 1999).
However, co-transfection of the C-terminal deleted polypeptides, p73C505 and p73C424, 
both of which contain the TA domain and OD domain but lacks 132 and 213 amino acids at 
the C-terminus respectively, resulted in strong activation of the bax promoter. The p73C505 
polypeptide is a stronger activator than p73p but less than p73a which has been consistently 
shown to be the strongest activator of the bax promoter in the ND7 cell line. P73C424 
lacking the C-terminal 213 amino acid was able to transactivate the bax promoter, though 
less efficiently. Interestingly, co-transfection of Bm-3a with either p73C505 or p73C424 
failed to repress bax promoter activity, in contrast to the significant repression of Bm-3a on 
p73a or p73p mediated activation of the bax promoter as shown previously. As Bm-3a and 
the p73C505/p73C424 polypeptides have been shown to interact (see Fig 3.4), the lack of 
repression observed by addition of Bm-3a must be due to the missing C-terminal 132 or 213 
amino acids not found in the p73C505 and p73424 polypeptides respectively.
Hence specific region(s) of the C-terminal sequence of p73 is essential for Bm-3a to repress 
p73 mediated activation of the bax promoter. However as repression by Bm-3a is not lost on 
p73p mediated bax activation, this would suggest that the sequence encoded by exon 13 
which is lost by splicing in the p73p mRNA is not important for Bm-3a to repress p73 
mediated activation of the bax promoter.
Since Bm-3a differentially regulates p73 mediated effects on the p21CIPI/WafI promoter with 
co-operation instead of repression, it was tested whether this effect was also dependent on the 
C-terminus region of p73. In experiments similar to those described above, the transcriptional 
proficiency of the different truncated p73 proteins on the p21CIP1/WafI promoter and the Bm- 
3a effect on this activation was investigated. As before, ND7 cells were co-transfected with 1 
pg of the p21CIP1/Wafl reporter gene with 1 0 0  ng of expression vector encoding the different 
p73 deletion proteins in the presence of either 1 pg of Bm-3a expression vector or empty 
vector. p73a and p73p, with or without Bm-3a were included as positive controls. As 
expected, co-transfection of p73N56, p73N315, p73N423 and p73pdelOD which lack the TA 
domain or OD domain or both, were unable to transactivate the p21CIPI/Wa^  promoter
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(Fig3.14b). Furthermore, co-transfection of Bm-3a with any of these p73 polypeptides 
resulted in no significant changes in the activity of the p21CIP1/Wa^  promoter, compared to 
either of the p73 polypeptides alone or Bm-3a alone which as shown previously can activate 
the p21CIP1/Wqf1 promoter. In contrast, co-transfection of the C-terminal deleted polypeptides, 
p73C505 and p73C424, resulted in strong activation of the p21CIP1/Wa^  promoter, with 
p73C424 activating the p21clpl/WaJ1 promoter the least, whilst p73C505 activation was 
comparable to that obtained with p73a and p73|3. Co-transfection of Bm-3a with either 
p73C505 or p73C424 resulted in a significant increase in p21CIP1/Wafl promoter activity, 
compared to p73C505 or p73C424 alone. Therefore, loss of 131 amino acids in p73C505 or 
213 amino acids in p73C424 of the p73a C-terminus does not affect the ability of Bm-3a to 
significantly enhance p73 mediated p21CIP1/Wc^  promoter activity.
Thus, the requirement of the p73 C-terminal for Bm-3a mediated effects on p73 transcription 
is specific to the bax promoter as the Bm-3a/p73 co-operation on the p21CIPl/WafI promoter is 
not lost upon deletion of the p73 C-terminal. These results suggest that the mechanisms by 
which Bm-3a regulates the p73 proteins on the bax and p21CIPI/Wqfl promoters are distinct. 
This parallels the findings of the distinct mechanism used by Bm-3a to regulate p53 mediated 
transcription on these promoters. Hence, whereas Bm-3a binding sites are required for it to 
repress p53 mediated transcription on the bax promoter (Budram-Mahadeo et al., 2002), Bm- 
3a mediated enhancement of p53 transcription on the p21CIP1/Wa^  promoter, was achieved by 
recruitment to the basal transcriptional complex (Perez-Sanchez et al., 2002).
3.13.1 Brn-3a differentially regulates the transcriptional effect of the different 
TAp73 isoforms on the bax promoter but not on the p 2 lclp1/Waf1 promoter
The findings that Bm-3a could repress p73a (636 aa) and p73(3 (resulting from splicing of 
exon 13) mediated activation of the box promoter but this repression was lost upon deletion 
of 132 or 213 amino acids from the p73a C-terminal, suggested that Bm-3a could 
differentially regulate the transcriptional effect of the different p73 C-terminal isoforms on 
box promoter activity. Therefore the effects of the truncated naturally occurring p73y and 
p736 mediated activation of the box promoter was investigated in the absence and presence 
of Bm-3a. Both p73y and p738 isoforms possess much shorter C-terminals than either p73a 
or p73(3. The splicing of exon 11 in p73y results in a frame shift from the original
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reading frame leading to a translation of 76 amino acids that is different from the sequence in 
p73a. The splicing of exons 11, 12 and 13 in p73S results in a p73 isoform that is 403 amino 
acids long and bears the most striking resemblance to p53, as it completely lacks the COOH 
terminus extension that are found in the other forms of p73. As already mentioned p73p is 
produced by splicing of exon 13 and is identical to the corresponding regions of p73a with an 
additional 5 residues at the end which is specific to p73p.
As before, the bax reporter gene was co-transfected with 100 ng of expression vectors 
encoding either p73y or p735 in the presence of either 1 pg of Bm-3a expression vector or 
empty vector. As both p73y and p738 proteins are HA tagged then HA tagged p73a and p73p 
were included as positive controls (all HA-tagged constructs were a kind gift from Professor 
Jerry Melino). Western blot analysis shows that each of the transfected p73 isoforms are 
expressed in the ND7 cells (Fig 3.15c).
As shown in Fig 3.15a, p73a is the strongest activator of the bax promoter resulting in a 92 
fold induction, whilst p73p activates this promoter 47 fold which is consistent with previous 
results demonstrating that addition of the HA tag does not effect p73 transcriptional activity 
on this promoter. As seen previously, co-expression of Bm-3a represses both p73a or p73p 
mediated activation of the bax promoter, further showing that the HA tag does not affect the 
repressive effects of Bm-3a on p73 mediated bax activation. Moreover, these results also 
show that both p73y and p738 can activate the bax promoter to a similar extent as p73p. 
However, co- transfection of Bm-3a with either p73y or p738 failed to repress either the p73y 
or p738 mediated activation of the bax promoter.
To confirm that these differences were not due to lack of interaction between the shorter 
isoforms of p73 and Bm-3a, GST pull down assays were performed as before using Bm- 
3a(l)-GST fusion proteins with IVT p73y, p738 and p73a as a control. As shown in Fig 
3.15d both p73y and p738 readily interact with Bm-3a(l) and appear to interact more strongly 
than p73a, being retained 22.5% and 33.2% respectively by Bm-3a(l), compared with 11.3% 
of p73a. Therefore similar to p73p, it appears that the p73 isoforms with shorter C-terminals 
interact more strongly with Bm-3a (Bm-3a(l) retained 23.7% of p73p- see section 3.2). 
Together, these results further provide evidence that the p73 C-terminal influences the ability
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Figure 3.15: Brn-3a interacts with the shorter isoforms of p73, p73y and p736 but fails to 
inhibit p73y or p736 mediated activation of the bax promoter but continues to co-operate with 
these isoforms on the p 2 iclp1/Waf1 promoter.
a) Brn-3a alone slightly repressed bax promoter activity while p73a, p73|3, p73y and p735 alone 
strongly activated this promoter compared with vector only. Co-transfection of Brn-3a with p73a or 
p73(3 significantly repressed p73a or p73|3 mediated activation of the bax promoter as seen 
previously. In contrast, Co-transfection of Brn-3a with either p73y or p735 failed to repress bax 
promoter activity, b) The p73 C-terminal isoforms p73a, p73p, p73y and p735 alone strongly 
activated the p21 promoter compared with vector only. Co-transfection of Brn-3a with either C- 
terminal isoform significantly enhanced p73 mediated p21 activation demonstrating that Brn-3a 
enhancement of p73 mediated p 2 iclp1/Waf promoter activation is independent of the p73 C-terminal 
sequence. All luciferase values were equalized on the basis of the activity observed upon co­
transfection with a control renilla expression vector and expressed as a percentage of the empty 
control vector. The results represent the mean and standard error of three independent experiments. 
ND7 cells were transfected with 1 pg of the p 2 iCIP1/Waf1 promoter with 100ng of expression vector 
encoding the appropriate p73 isoform in the presence of either 1 pg of Brn-3a expression or vector 
empty vector using Fugene reagent, c) Western blot analysis of the transfected ND7 lysates confirms 
expression of the transfected p73 proteins
186
d)
Brn-3a(l) -GST 1/10 input GST only
c
oO
> lO
i-■*->pi o > K> i s o
CO CO CO c CO CO CO c CO
h - r - o h ' r - r - o
Q . CL Q . O CL Q . CL a CL
>  »o
CO JO 
Q . CL
Interaction of Brn-3a(l) with the p73 C-terminal 
isoforms, p73y and 5
40 
35 
§ 3 0  
Z  25 
S 20a>
I  15
gs 10
5 _____  _____  _____
0 1----------------  T---------- ----------------------------T----------
p73a p73y p736
Figure 3.15 continued: d) GST pull down assay demonstrating interaction between Brn-3a(l) and the 
shorter isoforms of p73. Lanes 5-8 shows 1/10 of the input protein used in the “pull-down” assays, 
lanes 1-4 shows proteins retained following incubation with Brn-3a(l)/GST fusion proteins. While the 
luciferase control protein was not retained in a complex with Brn-3a(l), the positive control p73a as 
well as p73y and p735 were associated with Brn-3a(l). This effect is specific to Brn-3a(l) proteins as 
the GST moiety on its own failed to bind to p73a, p73y or p735 (lanes 9-12). The percentage 
interaction is also represented graphically. These results strengthens the importance of the 
requirement of specific C-terminal sequence not included in the C-terminal sequence of either p73y or 
p736 but is present in the C-terminus of both p73a and p73(3, in the ability of Brn-3a to repress p73 
mediated bax activation.
*
187
of Bm-3a to modulate p73 mediated activation of the bax promoter.
Hence the failure of Bm-3a to inhibit p73 mediated activation of the bax promoter by the 
shorter isoforms of p73 strengthens the requirement of specific C-terminal sequence not 
found in the C-terminal sequence of either p73y or p73S but present in the C-terminus of both 
p73a and p73p, for Bm-3a to repress p73 mediated bax activation. Interestingly as both p73y 
and p738 lack the sequences encoded by exon 11 and 12 whilst p73a and p73{3 isoforms 
retain these exons and original reading frame, this would suggest that the sequence encoded 
by exon 11 and/or 12 may be required for the repressive effects of Bm-3a on p73 mediated 
bax transactivation.
The non requirement of the C-terminal sequence in the ability of Bm-3a to enhance p73 
mediated p21CIPI/Wa^  promoter activity suggests that Bm-3a would enhance p73 mediated 
activation of the p21CIP1/WafI promoter by all p73 C-terminal isoforms. Therefore, to 
determine the effect of Bm-3a on the transcriptional activity of the shorter p73 isoforms, 
p73y and p738 on p21clpI/Wa^  promoter activity, transfections were carried out as before. The 
p 2 i CIpi/wafi rep0 rter gene was co-transfected with 1 0 0  ng of expression vectors encoding 
either p73y or p738 in the presence of either 1 pg of Bm-3a expression vector or empty 
vector. As before, p73a and p73p with and without Bm-3a were included as positive 
controls. The results shown in fig 3.15b, demonstrate that p73y and p738 activate the 
p 2 i CIpi/wafl promoter a similar extend as p73p which is slightly higher than that observed 
with p73a. Co-transfection of Bm-3a with either p73y or p738 resulted in co-operation on 
p 2 i CIpi/wafl promoter activity, as seen with p73a and p73p isoforms. Therefore, unlike the 
bax promoter, the enhancement of p73 mediated p21CIPI/Wafl promoter activation by Bm-3a is 
independent of the p73 C-terminal sequence.
3.13.2 Brn-3a may repress p73 mediated activation of the bax promoter by 
preventing the binding of a co-activator to the p73 C-terminal region
It is possible that the dependence of Bm-3a on the C-terminus of p73 to repress p73 mediated 
activation of the box promoter occurs because of either 1) the interaction of Bm-3a with p73 
on the box promoter may prevent p73 from interacting with cellular protein(s) that have co­
activator function and interact with the C terminus of p73 or 2) the interaction of Bm-3a with
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p73 on the bax promoter may facilitate the binding of a second repressor co-factor to the p73 
C-terminus, and this is required for Bm-3a to repress p73 mediated activation of the bax 
promoter or 3) post transcriptional modifications of the p73 C-terminus is required for Bm- 
3a to repress p73 mediated activation of the bax promoter.
In order to address 1 and 2, further transfections were carried out in ND7 cells to determine 
whether cellular proteins binding to the p73 C-terminus might affect p73 transactivation of 
the bax promoter and alter Bm-3a mediated repression. This was achieved by introducing the 
p73N423 construct (that encodes the p73a C-terminal domain but lacks the TA, DBD and the 
OD domain) with specified p73 constructs and/or Bm-3a. Therefore, ND7 cells were co­
transfected with 1 pg of bax reporter plasmid with 100 ng of constructs encoding either p73a 
or the C-terminal deleted polypeptides p73C505 or p73C424 with increasing concentrations 
of p73N423 (100 ng or 500 ng) in the absence or presence of 1 pg of the Bm-3a construct or 
empty vector.
As shown in Fig 3.16a, co-expression of the C-terminal polypeptide p73N423 (100 ng) with 
p73a, represses p73a mediated activation of the bax promoter by 50% which is similar to the 
repression observed when Bm-3a is co-expressed with p73a. Furthermore increasing the 
concentration of co-expressed p73N424 with p73a further repressed bax activity, and in fact 
makes TAp73a behave like p73C505 on this promoter (Fig 3.16b). This suggests that the 
excess C-terminal domain is competing for the binding of a cellular protein that might act as 
a co-activator which is required for maximal activation of the bax promoter by p73a. In 
addition, co-expression of Bm-3a with p73a in the presence of the C-terminal polypeptide, 
does not further repress bax promoter activity, suggesting that Bm-3a represses p73 
activation on this promoter in a similar manner achieved by addition of excess C-terminal 
protein, by interfering with a functional interaction between the p73 C-terminal and a cellular 
co-activator.
Interestingly, co-expression of the C-terminal polypeptide p73N423 with the C-terminal 
deleted protein p73C505 significantly increased p73C505 mediated activation of the bax 
promoter in a dose dependent manner so that addition of 100 ng of p73N423 leads to a 31 
fold increase in activity whereas addition of 500 ng of p73N423 leads to an 38 fold increased
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Figure 3.16: Brn-3a mediates its repressive effects on p73 mediated bax activation by 
preventing the binding of a co-activator to the p73 C-terminal.
Bm-3a alone slightly repressed bax promoter activity while p73a, p73aC505 and p73aC424 alone 
strongly activated this promoter compared with vector only, a) Co-expression of the C-terminal 
polypeptide p73aN423 with p73a, at the concentrations stated, represses p73a mediated activation of 
the bax promoter to a similar extend to that observed when Brn-3a is co-expressed with p73a. This 
suggests that Brn-3a represses p73 activation on this promoter in a similar manner achieved by 
addition of excess C-terminal protein, b) Co-expression of the C-terminal protein p73aN423 with the 
C-terminal deleted protein p73C505 significantly increased p73C505 mediated activation of the bax 
promoter. This suggests that addition of the C-terminal polypeptide is interacting with and recruiting a 
co-activator back to the p73C505 complex on the bax promoter. Co-expression of Brn-3a with 
p73aC505 fails to repress bax activity as seen previously. However, co-expression of Brn-3a with 
p73C505 and the C-terminal polypeptide restores the Brn-3a ability to significantly repress the 
p73aC505 mediated activation of the bax promoter. These results support the idea that Brn-3a 
mediates its repressive effects on p73 mediated activation by preventing the binding of a co-activator 
to the p73 C-terminal. Co-expression of the C-terminal protein p73aN423 with the C-terminal deleted 
protein p73aC424, also increases p73aC424 mediated activation of the bax promoter in a dose 
dependent manner. However co-expression of Brn-3a with p73aC424 and the C-terminal polypeptide 
p73aN424 failed to alter the activation of the bax promoter suggesting that this protein does not bind 
to the co-activator. All luciferase values were equalized on the basis of the activity observed upon co­
transfection with a control renilla expression vector and expressed as a percentage of the empty 
control vector. The results represent the mean and standard error of three independent experiments. 
ND7 cells were transfected with 1 pg of bax with 100ng of expression vector encoding the appropriate 
p73 isoform in the presence of either 1 pg of Brn-3a expression vector or empty vector. 100ng or 
500ng of p73aN423 or empty vector was also transfected where indicated, using Fugene reagent.
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activity on the bax promoter compared to the 19 fold induction of the bax promoter observed 
with p73C505 alone (p<0.005) (Fig3.16b). This enhanced activity observed suggests that 
addition of the C-terminal polypeptide might allow recruitment of a co-activator back to the 
p73aC505 complex on the bax promoter, thus increasing promoter activity. Additionally, co­
expression of Bm-3a with p73C505 and the C-terminal polypeptide restores the Bm-3a 
ability to significantly repress the p73C505 mediated activation of the bax promoter 
(p<0.005), supporting the idea that Bm-3a mediates its repressive effects on p73 mediated 
activation by preventing the binding of a co-activator to a region in the p73 C-terminal 
domain. This is further supported by the observation that co-expression of Bm-3a with 
p73C505 alone does not repress bax promoter activity as seen previously (section 3.13, Fig 
3.14a). This may be because the p73 co-activator that binds to the p73 C-terminus can not be 
recruited by the p73aC505 polypeptide to the bax promoter, therefore resulting in the 
inability of Bm-3a to further repress bax activity when co-expressed.
Although co-expression of the C-terminal protein p73N423 with the C-terminal deleted 
protein p73C424, increased p73C424 mediated activation of the bax promoter in a dose 
dependent manner, this effect was less significant than p73C505. Additionally, co-expression 
of Bm-3a with p73C424 and the C-terminal polypeptide p73N424 fails to repress the 
activation of the bax promoter (Fig 3.16b). This suggests that the region of the p73 protein 
required for binding to a cellular co-activator and thus allowing bax transactivation is 
between 423-505 amino acids, which is retained in p73C505 but lost in p73C424.
Collectively, these results suggest that the p73 C-terminal region (from 400 to 494 amino 
acids) encoded by exons 11 and 12 found in p73a and p73p but not in p73y and p738 is 
required for Bm-3a to repress p73 mediated activation of the bax promoter. Moreover, the 
results above suggest that the p73 C-terminal is responsible for binding of a co-activator 
which is required for maximal activation of the bax promoter by p73, and that this co­
activator interacts with the region spanning 424-505 amino acids of the p73a C-terminus. 
Thus, when the Bm-3a/p73 interaction occurs, the presence of Bm-3a on the bax promoter 
may interfere or prevent the binding of this co-activator to the p73 C-terminal, resulting in 
repression of bax promoter activity by disrupting gene expression. Thus the region of the p73 
C-terminus that is required for binding of a possible co-activator and repression by Bm-3a 
can be further refined to 424-494 amino acids that are encoded by exons 11 and 12
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and is thus only found in the p73a and p73p isoforms. Hence, the array of p73 transcripts 
expressed in the cell and which isoforms are dominant will determine the extent to which 
Bm-3a can repress p73 mediated bax activation and thus modulate p73 mediated cell death.
As the Bm-3a/p73 co-operation on the p21CIP1/Wafl promoter was shown to be independent of 
the p73 C-terminal region, it would therefore be anticipated that adding back the C-terminal 
peptide in transfections would not effect Bm-3a stimulation of p73 mediated activation of the 
p21CIPI/WaP promoter. Hence to test this, transfections were carried out in ND7 cells in which 
1 pg of the p21CIP1/Wajl reporter plasmid was co-transfected with 1 0 0  ng of constructs 
encoding either p73a or the C-terminal deleted polypeptides p73C505 or p73C424 with 
increasing concentrations (100 ng or 500 ng) of the p73N423 construct (that encodes the 
p73a C-terminal domain but lacks the TA, DBD and the OD domain). These were carried out 
in the absence or presence of 1 pg of the Bm-3a construct or empty vector.
The results show that co-expression of the C-terminal polypeptide p73N423 at the two 
different concentrations stated with p73a (Fig 3.17a), p73C505 and p73C424 (Fig 3.17b) did 
not significantly alterp21CIPlfWa^  activity compared with p73a, p73C505 and p73C424 alone. 
Moreover, the addition of the C-terminal peptide did not effect the Bm-3a mediated 
enhancement of either p73a, p73C505 or p73C424 mediated activation of the p21 promoter, 
confirming that the extended p73 C-terminal domain does not significantly alter the ability of 
Bm-3a to enhance p73 mediated activation of the p21CIPI/Wa^  promoter.
These results demonstrate that the p73 C-terminal domain is required for Bm-3a to inhibit 
p73 mediated activation of the bax promoter, but is not required for Bm-3a to enhance p73 
mediated activation of the p21CIPI/WafI promoter. This suggests the existence of different 
regulatory mechanisms used by Bm-3a to modulate the transactivation function of the p73 
family members on the two different promoters tested in this study. Thus, while Bm-3a is 
able to co-operate with all the different C-terminal p73 isoforms tested (p73a, p73p, p73y 
and p738) to enhance p73-mediated activation of the p21CIP1/Wa^  promoter, Bm-3a can only 
repress p73a and p73p mediated activation of the bax promoter whilst having no effect on 
p73y and p738 mediated activation of this promoter. Hence Bm-3a may play an important 
role in determining the selectivity of individual p73 members in controlling the expression of
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Figure 3.17: The extended p73 C-terminal sequence is not required for Brn-3a to enhance p73 
mediated activation of the p2 lclp1/Waf1 promoter.
Co-expression of the C-terminal polypeptide p73aN423 at the two different concentrations stated with 
a) p73a or the C-terminal deleted proteins b) p73aC505 and p73aC424 did not significantly alter 
p 2 lc'pi/Wafi activity compared with p73a, p73aC505 and p73aC424 alone. Additionally, co­
transfection of the C-terminal peptide did not effect the Brn-3a mediated enhancement of either p73a, 
p73aC505 or p73aC424 mediated activation of the p 2 iCIR1/Waf1 promoter, again confirming that the 
extended p73 C-terminal is not a factor in the ability of Brn-3a to enhance p73 mediated activation of 
the p21cl 1/Waf1 promoter. All luciferase values were equalized on the basis of the activity observed 
upon co- transfection with a control renilla expression vector and expressed as a percentage of the 
empty control vector. The results represent the mean and standard error of three independent 
experiments. ND7 cells were transfected with 1 pg of p2 iclp1/Waf1 with 100ng of expression vector 
encoding the appropriate p73 isoform in the presence of either 1 pg of Brn-3a expression vector or 
empty vector. 100ng or 500ng of p73aN423 or empty vector was also transfected where indicated, 
using Fugene reagent.
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their target genes.
Discussion
Since Bm-3a was shown to interact with p53 and these two factors were found to modulate 
the effects of each other on their target gene expression (Sugars et al., 2001;Perez-Sanchez et 
al., 2002;Budram-Mahadeo et al., 2002), part of this study set out to examine the physical 
interaction and the functional effect of the association between the Bm-3a and the p73 
proteins. Critically the interaction of Bm-3a and p53 resulted in the enhancement of p53 
mediated transcription of p21CIP1/Wafl gene associated with cell cycle arrest and antagonism of 
p53 mediated bax activation. p53 plays an essential role in regulating apoptosis in the 
nervous system in response to injury or stress (for review see Hughes et al 1997), as well as 
in developmental cell death as regulated by the TrkA and p75 neurotrophin receptors (Aloyz 
et al., 1998) and has also been shown to be up-regulated and activated in some neurones as 
they migrate to their target field and differentiate (Eizenberg et al., 1996). Thus it was 
anticipated that neuronal cells that co-express Bm-3a and p53 are more likely to survive and 
undergo cell cycle arrest that precedes differentiation. In the absence of Bm-3a, p53 would 
induce high levels of Bax resulting in an increase in cell death (Budram-Mahadeo et al., 
2002). Hence Bm-3a may be an important determinant in p53 mediated cell fate.
Employing the use of “GST pull-down” chromatography this study has shown that the TA 
isoforms of p73, p73a and p73p also specifically interact with both isoforms of Bm-3a and 
Bm-3b. In addition the ANp73 isoform that lacks the N-terminal TA domain, has also been 
shown to interact with Bm-3a. Co-immunoprecipitation studies also confirm that Bm-3a and 
ANp73 interact in vivo. Studies to map the domains of Bm-3a and Bm-3b required for 
association with the p73 proteins showed that the isolated POU domain of the Bm-3 proteins 
is sufficient for interaction with the p73 proteins, whilst the isolated N-terminal domain of 
Bm-3a shows relatively weak association with the p73 proteins. Additionally, the longer 
isoforms Bm-3a(l) and Bm-3b(l) interacted with higher affinity with the p73 proteins than 
the shorter Bm-3a(s) and Bm-3b(s) isoforms with Bm3b(s) interacting with the least affinity 
with the p73 proteins. The stronger interaction of the p73 proteins with the longer forms of 
Bm-3a and Bm-3b proteins could be due to sequences in the N terminal region found in the
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longer isoforms that may enhance binding to the p73 proteins. However, since the Bm-3a N- 
terminal alone did not interact strongly with p73 it is likely that the N-terminal contributes to 
binding of the p73 proteins by altering the conformation of the longer Bm-3 isoforms.
This differential interaction that was observed between the long and short forms of Bm-3a 
with the p73 proteins, are supported by the functional differences between the long and short 
forms of the Bm-3a transcription factors. For instance Bm-3a(l) has been shown to be 
required not only for neuronal differentiation but is also essential for neuronal survival, 
whilst Bm-3a(s) promotes neuronal differentiation without enhancing cell survival (refer to 
section 1.22.1). As TAp73 has been shown to be involved in neuronal differentiation and 
apoptosis, then a possible functional interaction between TAp73 and Bm-3a(l) proteins may 
have consequences for the survival as well as the differentiation of neuronal cells that express 
both these proteins in the developing nervous system.
Similar studies to map the region of the p73 protein required for this interaction was 
undertaken using p73 deletion proteins and confirmed that the region of p73 containing the 
OD domain is critical for this interaction, although the DBD does contribute to the 
interaction, which was particularly evident with the interaction studies carried out with the 
isolated POU domain which required the DBD of p73 for efficient binding. In this respect the 
Bm-3a/p73 interaction is similar to the Bm-3a/p53 interaction which is mediated via the 
POU domain of Bm-3a and the DBD of p53. However, the Bm-3a/p73 interaction also 
requires the OD of p73 suggesting that Bm-3a only binds to tetrameric p73 or Bm-3a 
contacts specific regions in the OD of p73.
Interestingly, the p73a C-terminal deletion mutants showed increased binding to both Bm-3a 
and Bm-3b compared to wild type p73a. Additionally, the shorter p73p isoform which lacks 
codons 421-636 found in p73a appears to associate with higher affinity with the Bm-3a and 
Bm-3b proteins compared to p73a. This may be a consequence of the structural differences 
in the C-terminus of p73a and p73p which appears to affect interaction with the Bm-3a/Bm- 
3b proteins, with the extended C-terminus specific to p73a possibly interfering with 
association with the Bm-3a/Bm-3b proteins. This is further supported by the findings that 
p73y and p738, both of which have shorter C-terminals also binds Bm-3a with higher affinity 
than p73a. Interestingly, the differential binding of various isoforms of p73 and Bm-3a/Bm-
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3b that is conferred by the p73 C-terminus may be a determinant of precise biological 
outputs. Thus it appears that Bm-3a interacts with p73 via the POU domain of the Bm-3 
proteins and the OD domain of p73 with contributions from the DBD of p73. This interaction 
is further modulated by the C-terminal of the p73 proteins.
The effects of Bm-3a on p73 mediated activation of the p21CIP1/WafI and bax promoters were 
tested in the ND7 neuronal cell line. As seen previously with p53, Bm-3a antagonized p73a 
and p73|3 mediated activation of the bax promoter in reporter assays and this is reflected in a 
decrease of endogenous Bax protein upon co-expression of Bm-3a with p73a or p73p 
compared with levels seen with p73a or p730 respectively. Similarly, Bm-3a co-operates 
with p73a or p73p on the p21CIPI/Wa^  promoter in reporter assays and this is reflected in 
increased endogenous p2 lCIP1/Wafl protein levels in cells co-expressing Bm-3a with p73a or 
p73p compared with either p73a or p73p expressing cells only. Additionally, Bm-3a co­
operation on the p21CIPI/Waf1 promoter and repression of p73 mediated activation of the bax 
promoter was reproduced in the osteogenic SAOS-2 cell line demonstrating that the Bm-3a 
modulation of p73 mediated activation observed was not neuronal specific or dependent on 
the endogenous expression of p53.
Thus Bm-3a antagonizes TAp73a and TAp73p mediated activation of the bax promoter 
whilst co-operating on the p21CIPl/Wa^  promoter, in a manner similar to that seen with p53.
In contrast, ANp73a alone failed to activate either of the p21CIP1/Wafl or bax promoters in the 
ND7 cell line. Furthermore, co-expression of Bm-3a with ANp73a did not significantly alter 
the activity of the bax promoter compared with ANp73a alone and this is represented in the 
lack of change of Bax protein levels upon co-expression of Bm-3a and ANp73a compared 
with ANp73a alone or control vector. However, co-expression of Bm-3a with ANp73a 
resulted in repression of Bm-3a mediated activation of the p21CIPI/Wafl promoter in reporter 
assays but this is not reflected in changes of p2 lcn>1/Wafl protein levels in cells co-expressing 
Bm-3a and ANp73a compared to Bm-3a only expressing cells. However, the fold changes 
are probably too small to be detected at the protein level, thus such small changes would be 
better investigated by RT-PCR to look at the changes in p2 l cn>1/Wafl mRNA level expression.
Importantly, the interaction of Bm-3a and the different p73 isoforms had distinct effects on
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regulation of cell cycle arrest and cell survival in the neuronal cell line ND7. Thus, co- 
expression of Bm-3a with p73a or p73p resulted in enhanced cell cycle arrest compared with 
p73a or p73p alone. Furthermore, the increase in percentage of cells arrested in G0/G1 phase 
of the cell cycle observed appeared to be more pronounced upon co-expression of Bm-3a 
with p73(3 than with p73a. This suggests that the extent to which Bm-3a can enhance TAp73 
mediated induced cell cycle arrest in cells co-expressing these proteins depends largely on 
which TAp73 C-terminal isomers are present in the cell. As expected ANp73a did not 
increase cell cycle arrest compared with control vector, and co-expression of Bm-3a with 
ANp73a did not increase cell cycle arrest above that seen with Bm-3a alone. Thus Bm-3a 
can co-operate with p73a and p73p but not with ANp73a in inducing cell cycle arrest.
The strong repression of p73 mediated bax activation conferred by Bm-3a suggest that less 
apoptotic cells will be observed in cells co-expressing Bm-3a and p73 than cells transfected 
with p73 alone, and this was indeed the case. However even though co-expressing of Bm-3a 
with p73a or p73p increased cell survival compared to p73a or p73p alone, the level of 
protection was less that that seen with Bm-3a alone. This is in contrast to the effect of Bm-3a 
on p53 induced cell death in which co-expression of Bm-3a with p53 resulted in increased 
survival that was higher than that observed with Bm-3a alone. Intriguingly co-expression of 
Bm-3a and ANp73a also resulted in increased survival above the levels observed with either 
Bm-3a or ANp73a alone. Thus the anti-apoptotic effects of Bm-3a co-operate with ANp73a 
to further increase cell survival as well as overriding the pro-apoptotic effects of p53 and to a 
lesser extend the pro-apoptotic effects of p73a and p73p.
The ANp73 isoforms are highly potent survival proteins, inhibiting death of cultured 
sympathetic and cortical neurones treated with a variety of stimuli including NGF withdrawal 
and DNA damage (Pozniak et al., 2000;Pozniak et al., 2002). One of the ways ANp73a 
mediates these effects is by acting as a naturally occurring dominant inhibitory antagonist of 
p53 and TAp73. More recently ANp73a has also been shown to mediate survival in neurones 
via p53 independent mechanisms by inhibiting multiple points in the mitochondrial apoptotic 
pathway and inhibiting JNK activation after NGF withdrawal (Lee et al., 2004). Even though 
the molecular mechanism by which the Bm-3a/ANp73a interaction co-operates to increase 
cell survival remains to be characterized, it can be hypothesized that they may act co­
operatively on other anti-apoptotic targets such as the Bcl-2 and B c1-x l , both of which
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are known targets of Bm-3a, or on as yet unknown targets of ANp73a.
Thus while Bm-3a co-operates with the TAp73 isoforms in enhancing cycle arrest when co­
expressed, Bm-3a modulates both TAp73 and ANp73 mediated cell fate leading to increased 
cell survival when co-expressed.
As demonstrated with the data generated so far, Bm-3a can physically interact in vitro with 
the different isoforms of p73 and has been shown to interact with ANp73 in intact cells. 
Furthermore Bm-3a can modulate p73 transcriptional activity and functional effects on cell 
cycle and apoptosis in a similar manner shown previously with p53. As the p73 proteins are 
expressed as multiple alternatively spliced C-terminal isoforms and as N-terminally truncated 
isoforms, it was interesting to see if Bm-3a could differentially modulate the individual p73 
members in controlling the transactivation of the p21CIPl/WafI and box promoters. It has 
already been shown that the ANp73 does not activate either of these promoters, but does co­
operate with Bm-3a in increasing cell survival of ND7 cells. Therefore the different p73 
deletion proteins lacking either the N or C terminal sequences were tested for transactivation 
of either the p21CIPl/Wa^  or box promoters and the effect of Bm-3a on this transactivation was 
tested.
As expected none of the p73 deleted proteins which lacked the N-terminal transactivation 
domain could activate transcription from either the p21CIPI/Wqfl or box promoters, though the 
two C-terminal deleted polypeptides p73C505 and p73C424 could transactivate both 
promoters. Interestingly, the deletion of either 131 or 213 amino acids from the extreme C- 
terminus of p73, (in p73C505 and p73C424 respectively) prevented Bm-3a from repressing 
p73 mediated box activation, demonstrating that regions in the C-terminal domain of p73 are 
essential for Bm-3a to repress p73 transactivation of this promoter. Upon further analysis, 
this study demonstrated that specific regions in the p73 C-terminus found in p73a and p73p 
but not in p73y and p738 are required for Bm-3a to repress p73 mediated activation of the 
box promoter. The C-terminal regions of p73a, p73p, p73y and p735 are shown below (Fig 
3.18). The fact that both p73y and p735 lack the sequences encoded by exon 11 and 12 (due 
to the alternative reading frame of p73y and splicing out of these exons in the mRNA of 
p738) whilst p73a and p73p isoforms retain these exons and original reading frame, this 
would suggest that sequences encoded by exon 1 1  and/or 1 2  may be required for the
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repressive effects of Bm-3a on p73 mediated box transactivation. Exon 11 and 12 encodes 
the region 400-494 that is between the OD (345-390) and SAM (526-549) domain of p73a 
and is shared by p73p. Interestingly this region contains the PPPPY (residues 482-488, 
underlined in Fig 3.18) motif that has been shown to interact with other cellular proteins (see 
later). It is possible that co-factors bound to this region of p73a or p73p are affected when 
Bm-3a binds to these proteins on the box promoter.
10 11
381 I I
p 7 3 a  VPQPLVDSYR QQQQLLQRPS HLQPPSYGPV LSFHHKVBGG HHKLPSVNQL VGQPPPHSSA ATFNLGPVGP
p 7 3 p  VPQPLVDSYR QQQQLLQRPS HLQPPSYGPV LSPHEKVHGG MHKLPSVNQL VGQPPPHSSA ATFNLGPVGP
p 7 3 y  VPQPLVDSYR QQQQLLQRPS RDAQQPWPRS ASQRRDSQQP QRPVHGLGVP LHSATPLPRR PQPRQFFNRI
p 7 3 6  VPQPLVDSYR QQQQLLQRPS TOP
12
451 I
p 7 3 a  GHLNIHGHAV PAHGBHSSSH SAQSMVSGSH CTPPPPYHM) PSLVSFLTGL GCPHCIBYFT SQGLQSIYHL
p 73p  GHLNKHGHKV PANGEHSSSH SAQSHVSGSH CTPPPPYHSD PSLVRTBGP
p 7 3 y  GVSKIHRVFH LPRVTBHLPP AEPDH
13
521 I
p 7 3 a  QNLTISDLGA LKIPEQYRHT IWRGLQDLKQ GHDYSTAQQL LRSSHAATIS IGGSGELQRQ RVHEAUHFRV
591
p 7 3 a  RHTITIPNRG GPGGGFDEHft. DFGFDLRDCK ARHQP3KEEF TEAEIH
Figure 3.18 Amino acid alignment of the C-terminal region of the four splice variants
The human amino acid sequences of the C-terminal regions of the p73 spice variants are shown. The 
corresponding exons are shown above the p73a amino acid sequence.
The idea of a co-factor bound to these proteins was strengthened by results of co-transfection 
studies in which the isolated C-terminal polypeptide (p73N423) repressed p73a mediated box 
activation by 50-60%. This suggested that transfecting in excess isolated p73 C-terminal 
polypeptide is competing for the binding of cellular proteins with co-activator function which 
is required for maximal activation of the box promoter by p73. In contrast, co-expression of 
the C-terminal protein p73N423 with the C-terminal deleted protein p73C505 which lacks 
131 amino acids from the extreme C-terminus of p73a, significantly increased p73C505 
mediated activation of the box promoter in a dose dependent manner by up to 19 fold, 
compared to the activation of this promoter by p73C505 alone. This enhanced activity 
observed suggests that addition of the C-terminal polypeptide allows recruitment of a co­
activator back to the p73C505 complex on the box promoter. In contrast, addition of
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p73N423 to p73C424 did increase p73C424 activity on the bax promoter but not as 
significantly as p73C505. The struggle to recapitulate full activation of this p73 construct 
which lacks the C-terminal 213 amino acids, suggests that the region 424-505 that is lacking 
in the p73C424 protein is required for binding of a co-activator protein by p73 that allows 
maximal activation of this promoter.
Furthermore, the observation that co-transfection of Bm-3a with full length p73a in the 
presence of the C-terminal polypeptide did not further repress bax promoter activity, 
suggested that both the C-terminus and Bm-3a were repressing p73 mediated bax activation 
by a similar mechanism, probably by interfering with the binding of a co-activator to the 
p73a C-terminus. Moreover, since co-expression of the C-terminal polypeptide with 
p73C505 restored the ability of Bm-3a to significantly repress the p73C505 mediated 
activation of the bax promoter, it can be concluded that Bm-3a acts by interfering with the 
binding of a co-activator which is being added back to the complex by the C-terminal 
polypeptide. Additionally, co-expression of Bm-3a with p73C424 and the C-terminal 
polypeptide failed to repress further the p73C424 activation of the bax promoter suggesting 
that p73C424 lacked the sequences that bind the co-activator. Therefore, it is clear that Bm- 
3a can repress the p73 mediated activation of the bax promoter whilst co-operating with p73 
to activate the p21CIPI/Wafl promoter. Furthermore, specific regions of the p73 C-terminus is 
required for the ability of Bm-3a to repress p73 mediated activation of the bax promoter.
Although the specific co-activator which is affected by Bm-3a to represses p73 mediated bax 
activation requires further investigation, these results collectively, suggest that sequences 
within the region 400-494 that is encoded by exons 11 and 12 and the region 424-505 that is 
lacking from the C-terminal of the p73C424 is required for binding of a co-activator by p73, 
which is possibly disrupted by the presence of Bm-3a. This further narrows the region to 
425-494. The identification of this co-activator would be the next step in elucidating the 
mechanism by which Bm-3a represses p73 mediated activation on the bax promoter.
Transcriptional co-activators play a major role in enhancing both p53 and p73 in stimulating 
the expression of their target genes. For example the apoptosis stimulating protein of p53 
(ASPP) proteins, which bind to all p53 family members are required to potentiate p53 family 
mediated activation of pro-apoptotic promoters such as pig and bax and is an important
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determinant in the apoptotic pathway (Samuels-Lev et al., 2001;Bergamaschi et al., 2004). 
The co-activator PCAF, specifically stimulates p73 mediated transactivation on promoters 
such as PG13 (an artificial reporter construct containing several p53 binding sites) and 
p 2 i CIpi/wafi an(j bjnciing of PCAF to p73 is necessary for p73 transactivation activity (Zhao et 
al., 2003). Additionally, PCAF specific siRNA reduces p73 mediated activation of the PG13 
promoter by 50%, and co-transfection of PCAF and p73 leads to increased apoptosis. 
However, although these two co-activators are clearly involved in increasing p73 activation 
of apoptotic targets, neither of these co-activators bind to the extreme p73 C-terminus,
Interestingly, it has been recently demonstrated that the WW domain adaptor phosphoprotein 
YAP (Yes-associated protein) has been shown to interact with the C-terminal PPPPY proline 
rich region (482-488 amino acids encoded by exon 12) found in the p73a and p73{3 C- 
terminal but not in p73y, p738 or p53. Furthermore it was demonstrated that YAP stimulated 
p73a mediated activation of the bax and mdm promoters in HI299 cells and binding of YAP 
to p73 is necessary for the co-activation of p73 (Strano et al., 2001). Therefore it can be 
speculated that when bound to p73, Bm-3a may disrupt the interaction between p73 and a co­
activator such as YAP resulting in repression of p73 mediated bax activation. This can be 
addressed in future studies by titrating in YAP in cells co-transfected with Bm-3a and p73a 
with the bax reporter gene, to investigate whether increasing concentrations of YAP can 
antagonize Bm-3a mediated inhibition of p73a transactivation of the bax promoter. Further 
analysis would then require the use of siRNA-mediated inactivation of each of the 
endogenous proteins to test the effect on survival/apoptosis.
Also, to further identify other cellular proteins that interact with the p73 C-terminus, a 
strategy that can be employed would be to use the yeast based 2  hybrid screen, in which the 
cDNA encoding specific regions of the p73 C-terminus (particularly the cDNA spanning 
exons 11 and/or 12 of p73a) are used as bait. As both Bm-3a and p73 are highly expressed in 
the brain, and as most of the transient transfections were performed in the ND7 neuronal cell 
line, it would be appropriate to carry out the screening of the cDNA libraries derived from 
human fatal brain or a neuronal cell line. Once identified the effects of these cellular proteins 
that interact with the p73 C-terminus on p73 mediated bax transactivation and on the 
repression of this activation by Bm-3a can be investigated, in a similar manner mentioned
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above.
As well as interaction with other cellular proteins, the activities of p73 are also regulated by 
phosphorylation and acetylation. Thus modifications specific to the C-terminal of p73 may 
also affect the ability of Bm-3a to repress p73 mediated activation of the bax promoter. In 
this respect p73 is a substrate of p300 and PCAF acetylation of lysine residuals in the p73 
DBD and C-terminus of p73a respectively. Although the functional significance of the 
acetylation of the C-terminus by PCAF is not known, acetylation by p300, which is markedly 
increased in cells treated with DNA damage agents, enhances the transcriptional activity on 
pro-apoptotic targets such as p53AIPl (Costanzo et al., 2002;Zhao et al., 2003). To test 
whether these modifications on the C-terminus of p73 change the ability of Bm-3a to repress 
p73 mediated activation of the bax promoter, studies can be undertaken to assess the effects 
of mutating these sites to either express constitutively acetylated proteins or to prevent 
acetylation. The effects of these mutations in the absence or presence of Bm-3a can then be 
tested.
Hence, while Bm-3a can significantly repress both p53 and p73 mediated activation of the 
bax promoter, this study also demonstrates a further level of specificity in the ability of Bm- 
3a to repress p73 mediated bax activation which exists among the different C-terminal 
isomers of p73. Thus, whereas Bm-3a can repress p73a and p73p mediated activation of the 
bax promoter, and increase cell survival when co-expressed with either p73a or p73p in the 
ND7 cell line, Bm-3a has no effect on p73y and p738 mediated activation of this promoter. 
Like p73a and p73p, both p73y and p738 have been shown to be expressed in normal tissue 
(De Laurenzi et al., 1998;Ueda et al., 1999). However, these splice variants showed different 
expression patterns in different tissues as well as at different stages of differentiation 
suggesting that they perform different functions. Thus the role of Bm-3a in determining the 
selectivity of individual p73 members in controlling the expression of the bax promoter may 
have consequences on cell death/survival under different conditions or in different cell types.
Furthermore each of the splice variants exhibited different transactivation properties on a p53 
consensus site in transfection assays (De Laurenzi et al., 1998;Ueda et al., 1999). Moreover 
yeast- 2  hybrid system experiments demonstrated that each isoform can form both 
homodimeric and heterodimeric interactions to varying extents (De-Laurenzi et al., 1998)
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and these interactions between different variants can further modulate the transcriptional 
proficiency of the p73 complex on a p53 consensus site (Ueda et al., 2001). Hence it can be 
postulated that the array of p73 transcripts expressed in the cell at any given time and also 
which isoforms are dominant will determine the extent by which Bm-3a can repress bax 
activation and hence the ability of Bm-3a to modulate p73 mediated cell fate.
In summary, although the complete functional implications of this differential repression on 
p73 mediated bax transactivation conferred by Bm-3a requires further analysis, these 
observations provide an understanding in the fine tuning of the biological outputs of the p73 
family, as a result from interaction with other proteins such as Bm-3a.
In contrast the C-terminal was shown not to be of such critical importance in the ability of 
Bm-3a to enhance p73 mediated activation of the p21CIPI/Wafl promoter. Therefore, Bm-3a 
was able to enhance p21CIP1/Wa^  activation of all four p73 C-terminal isomers tested in this 
study. However, the ability of Bm-3a to enhance cell cycle arrest differed between the 
isoforms tested. Thus Bm-3a may differentially enhance cell cycle arrest depending on the 
p73 C-terminal isomers present in the cell.
The use of different regulatory mechanisms by Bm-3a to modify p73 transactivation of its 
target genes is reflected in the different mechanisms employed by Bm-3a to modulate p53 
target genes. Thus, on the p21CIP1/Wc** promoter, Bm-3a appeared to mediate its effects by 
recruitment to the basal transcription complex, whilst intact Bm-3a binding sites are required 
for it to repress p53 mediated activation of the bax promoter. These findings demonstrate the 
complexity of regulation of expression of genes associated with cell death/survival 
/differentiation by Bm-3a
Bm-3a and p73 are both implicated in the differentiation of neuronal cells by up-regulating 
genes involved in neuronal differentiation (Budhram-Mahadeo et al., 1995;Smith et al., 
1997a;Smith et al., 1997b;Huang et al., 1999;De Laurenzi et al., 2000). Similarly p53 has 
been associated with differentiation of sympathetic and sensory neurones (Eizenberg et al., 
1996;Hudson et al., 2004) (also see chapter 5). Clearly the effects of p53 or p73 on cells 
(apoptosis or differentiation) are dependent on the presence of other specific or common 
members of the p53 family of regulatory proteins that result in subtle modification of their
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biological effects. Bm-3a is one such protein, which has been shown to interact with and 
differentially regulate p53 or p73 mediated transcription. The ability of Bm-3a to synergize 
with p53 or p73 on the p21CIP1/Wafl promoter but strongly repress p73 or p53 mediated 
apoptotic gene expression {bax promoter) suggest that Bm-3a plays a critical role in 
determining the cellular status and survival of neuronal cells which co-express these 
proteins. In particular Bm-3a may be important in determining the fate of neuronal cells 
where it has been shown that p53 and p73 is also up-regulated during neuronal 
differentiation, during developmental death, or when cells are subject to stress or injury 
resulting in activation of the p53/p73 gene. Hence similar to the Bm-3a/p53 effect, it can be 
postulated that in developing neuronal cells that express both p73 and Bm-3a, the pro- 
apoptotic effect of p73 will be antagonized by Bm-3a whilst both proteins co-operate to 
induce cell cycle arrest. Because Bm-3a increases expression of neuronal proteins such as 
neurotrophic receptors (trkA), neurofilament and a-intemexin, this would enhance 
differentiation of surviving cells into mature neurones.
In this respect it was demonstrated that p53 co-localizes to a subset of Bm-3a positive neural 
crest derived cells fated for a sensory neuronal linage. Furthermore the distinct morphology 
of the Bm-3a/p53 co-expressing cells suggested a differentiated neuronal cell type which was 
confirmed by co-localizing p53 with the differentiation marker NF-160. The functional 
effects of the Bm-3a/p53 co-expression and the localization of TAp73 and ANp73 with 
respect to Bm-3a in the neural crest derived cells is investigated in chapter 5.
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CHAPTER 4
Mechanism by which the Bm-3a transcription factor blocks 
p53 and TAp73 mediated expression of pro-apoptotic 
target gene, Noxa.
4.1 Introduction
The ability of Bm-3a to enhance neuronal survival and differentiation is mediated by direct 
regulation of target genes or indirectly upon interaction with proteins such as p53 or p73. The 
ability of Bm-3a to directly repress the bax promoter and antagonise p53 and p73 activity on 
this promoter is interesting as bm-3a-/- embryos show significant loss of specific neurones as 
a consequence of increased apoptosis. Bax plays a role in naturally occurring apoptosis in 
many neurones during development including sensory neurones in the DRG and trigeminal 
ganglia which are known to express Bm-3a. In support of this, neuronal cells from bax-/- 
mice demonstrated decreased apoptosis (DRG, TG, spinal ganglia, brainstem nuclear 
complex and cerebellum). Moreover, neurones cultured from bax-/- mice survive even in the 
absence of neurotrophic factors (Deckwerth et al., 1996;White et al., 1998). However 
apoptosis is still observed in some sensory neutrons in bax-/- mice which is independent of 
Bax. This suggests that while Bax can contribute to some apoptosis in sensory neurones, 
other pro-apoptotic factors are likely to contribute to the fate of these cells.
Noxa is another known pro-apoptotic p53 target gene that is induced by stresses which can 
activate p53 expression (Oda et al., 2000). Noxa encodes a Bcl-2 homology 3 (BH3)-only 
member of the Bcl-2 family of proteins. When expressed, Noxa becomes localized to the 
mitochondria where it interacts with the anti-apoptotic Bcl-2 family members via its BH3 
domain and inhibits their pro-survival function (Oda et al., 2000;Chen et al., 2005). This in 
turn leads to bax activation and subsequent Cytochrome c release, though the mechanism is 
as yet unclear (Green et al., 2004). Both Noxa and Bax expression are elevated upon 
induction of p53 in neuronal cells (Yang et al., 2004) while p73 has been shown to activate 
noxa directly (Flores et al., 2002;Flinterman et al., 2004) or by co-operation with adenovirus 
El A (Flinterman et al., 2004). Therefore it is possible that like Bax, Noxa may also 
contribute to apoptosis during neuronal development and their regulation by p53 and/or p73
205
may be important in controlling cell fate. The antagonistic effect of Bm-3a on p53 and 
TAp73 mediated activation of the bax promoter suggests that Bm-3a may be important in 
controlling expression of pro-apoptotic factors and hence determine cellular status and 
survival of neuronal cells that co-express Bm-3a and p53/p73 during development. The 
effect of the Bm-3a/p53 and Bm-3a/p73 interaction on the noxa promoter and functional 
effects of this interaction were investigated in this study.
4.2 The p53 and TAp73 mediated activation of the noxa promoter is 
repressed by Brn-3a
Since Bm-3a could block p53 or TAp73 mediated activation of the box promoter but enhance 
expression of the cell cycle arrest associated gene, p21CIP1/Wqfl, the possibility that Bm-3a 
could also modulate the effect of p53 on the promoter of another pro-apoptotic target gene, 
noxa was investigated. As the effect of p73 on the noxa promoter in ND7 cells had not been 
investigated, experiments were also carried out to test if the noxa promoter is responsive to 
p73 in these cells and whether Bm-3a could modify p73 mediated effect on this promoter.
Similar to co-transfection experiments carried out previously in the ND7 neuronal cell line, a 
reporter construct in which the regulatory region of the noxa gene (-183 to +158) (Oda et al., 
2 0 0 0 ) drives expression of the luciferase reporter gene was co-transfected with increasing 
concentrations of expression vectors encoding either p53 (2-20 ng) or p73a (10-50 ng) in the 
presence of either 1 |ig of Bm-3a expression vector or empty vector. As expected, co­
transfection with p53 expression vector resulted in strong transactivation of the noxa 
promoter (Fig 4.1a) with up to 8  fold increased activity compared with the empty vector 
control (p<0.0005). Similarly co-transfection with p73a could also strongly activate the noxa 
promoter with up to 13 fold increased activity compared with the empty vector control 
(p<0.0005), suggesting that like other p53 target promoters, noxa is also responsive to p73. 
As was the case on the bax promoter, p73 appeared to activate the noxa promoter more 
strongly than p53, with increasing transactivation seen with increasing p73 concentration. 
Whilst Bm-3a alone did not significantly alter noxa promoter activity, co-transfection of Bm- 
3a with either p53 or p73a resulted in a significant decrease of the transactivation observed 
with either p53 or p73a alone (p<0.005), respectively on this promoter. These effects resulted
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Figure 4.1: Brn-3a antagonizes p53/p73a mediated activation of the noxa promoter and this 
effect is lost upon mutation of the p53 site in the noxa promoter
a) Brn-3a alone had a minimal effect on noxa promoter activity compared with vector only control. Co­
expression of p53 or p73a alone resulted in significant activation of the promoter. Co-transfection of 
Bm-3a with p53 or p73a resulted in significant loss of p53 or p73a mediated transactivation of the 
noxa promoter, b) Whereas Brn-3a alone had a minimal effect on the noxa promoter lacking the p53 
site, the stimulation of the promoter by p53 or p73 is lost. Co-transfection of Brn-3a with p53 or p73 
did not significantly modify the promoter activity. The ND7 cells were transfected with 1 pg of the noxa 
promoter luciferase reporter construct (wild type or Ap53-Noxa) and increasing amounts of p53 or 
p73a (2-50ng) in the presence of 1 pg of either empty vector or Brn-3a. All luciferase values were 
equalized to the activity of a co-transfected renilla expression vector and expressed as a percentage 
of the empty LTR control vector. The results represent the mean and standard error of three 
independent experiments, c) Brn-3a and/or p53, p73a, ANp73a expression in transiently transfected 
ND7 cells were analyzed by Western blot after whole cell lysis.
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from the changes in the expression of Bm-3a, p53 and p73 proteins in the transfected cells 
(fig 4.1c). Therefore, similar to the bax promoter, Bm-3a can strongly inhibit the stimulatory 
effect of p53 and p73a on the noxa promoter, highlighting a trend in which Bm-3a down- 
regulates the expression of apoptotic genes, which could contribute to its ability to enhance 
survival. However, while Bm-3a alone reduced the endogenous activity of the bax promoter 
(Budram-Mahadeo et al., 2002), no such direct repressive effect was observed on the noxa 
promoter.
Whereas the bax promoter contains p53 sites flanked by two Bm-3 binding sites, both of 
which are required for Bm-3a to repress the promoter directly or indirectly via p53 (Perez- 
Sanchez et al., 2002), no such Bm-3 consensus sites were observed in the sequence of the 
noxa promoter used in these studies. However since Bm-3a could still efficiently block p53 
or p73 mediated transactivation of this promoter, it was investigated whether this effect 
resulted from the direct interaction of Bm-3a with p53 or p73 and hence was dependent on 
the p53 consensus site present in the promoter.
Co-transfection studies were carried out using a reporter construct containing the noxa 
promoter in which just the p53 site was deleted (Ap53-noxa). While the basal promoter 
activity was still present and similar to the wild type noxa promoter (basal activity of Ap53- 
noxa =7.46 RLU ±0.18 compared with wild type noxa = 6.31 RLU ± 0.77), p53 and p73a 
mediated activation of the noxa promoter is greatly reduced upon loss of the p53 binding site 
(Fig 4.1b). Bm-3a on its own had little effect on promoter activity while co-expression of 
Bm-3a and p53 or Bm-3a and p73a had no effect compared with p53 or p73a only, 
respectively. The expression of Bm-3a, p53 and p73a proteins are clearly increased in the 
transfected cells as shown by Western blot (Fig 4.1c). Therefore loss of transcription by 
p53/p73 on the Ap53-woxa promoter occurs as a result of loss of the p53 consensus site 
which prevented binding of the p53 or p73 proteins. Therefore it appears that the association 
of Bm-3a with p53 or p73a antagonizes their activity on the noxa promoter and this effect is 
dependent on the p53 cognate DNA site being present on the promoter.
ANp73a was shown to have no direct effect on bax or p2]clpl/Wa-f1 promoter activity in ND7 
cells, but its effect on the noxa promoter is not known. In order to investigate the effect of 
ANp73a on the noxa promoter in ND7 cells, and effect of the ANp73a/Bm-3a interaction on
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the possible regulation o f this promoter, co-transfection experiments were carried out as 
previously described in the ND7 neuronal cell line. The reporter construct containing the 
wild type noxa promoter (-183 to +158) (Oda et al., 2000) was co-transfected with increasing 
concentrations of expression vector encoding ANp73a (10-50 ng) in the presence o f 1 pg of 
either the empty vector or Bm-3a expression vector. Co-transfection with ANp73a 
expression vector resulted in a slight repression o f the basal activity o f the noxa promoter, 
but this was not significant (Fig 4.2). As previously shown, Bm-3a alone did not significantly 
alter noxa promoter activity and similarly, co-expression of Bm-3a with ANp73a did not 
affect noxa promoter activity compared with Bm-3a alone. Levels of expression of 
transfected constructs were assessed by western blotting, showing that both transfected Bm- 
3a and ANp73 are expressed in these cells (Fig 4.1c). Hence lack o f transactivation by both 
Bm-3a and ANp73 of this promoter was not due to their lack o f expression, but reflect 
different functional effects on this promoter.
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Figure 4.2: ANp73a does not significantly alter noxa promoter activity
Brn-3a alone had a minimal effect on noxa promoter activity compared with vector only control. Co­
expression of ANp73a alone did not significantly alter promoter activity. Co-transfection of Brn-3a with 
ANp73a did not significantly modify the promoter activity compared to control. The ND7 cells were 
transfected with 1 pg of wild type noxa promoter luciferase reporter construct and increasing amounts 
of ANp73a (10-50ng) in the presence of 1 pg of either empty vector or Brn-3a(l). All luciferase values 
were equalized to the activity of a co-transfected renilla expression vector and expressed as a 
percentage of the empty LTR control vector. The results represent the mean and standard error of 
three independent experiments.
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4.3 Brn-3a does not prevent p53 binding to its cognate sequence in 
the noxa promoter
In order to investigate whether Bm-3a acted by blocking p53 binding to its consensus site in 
the noxa promoter or whether its association with p53 prevented the interaction with other 
co-factors which may be required for the activation of the noxa promoter, electrophoretic 
mobility shift assays (EMSA) were carried out using cellular extracts obtained from 
neuroblastoma cells (IMR-32 cells stably over-expressing Bm-3a made by Shazia Irshad, 
ICH). These cells, which express high levels of Bm-3a, are known to express wild type p53 
which is also shown by Western blot analysis (Fig 4.3a). As shown in figure Fig 4.3b, 
incubation of IMR-32 cell extract with 32P labelled oligonucleotide probe corresponding to 
the noxa p53 binding site resulted in specific complexes (lane 1) which were competed by 
addition of x50 and xlOO excess of unlabelled p53 binding site (lanes 2+3) but not the non­
specific oligonucleotide (lane 4). The presence of two main retarded complexes would 
suggest that p53 associates with either itself or other cellular proteins to form complexes of 
different sizes. Furthermore, addition of p53 pAb resulted in further retardation of the 
complexes, indicated by asterix (lanes 5+6) but this was not seen upon addition of the pAb 
against the unrelated actin protein (lane 7), confirming that p53 protein is present in these 
complexes. Interestingly, addition of an excess of the oligonucleotide that corresponds to the 
Bm-3a site resulted in a loss of the complex binding to the probe (lanes 8+9). This suggests 
that Bm-3a is associated with p53 in this complex and the excess Bm-3a site is competing 
away the Bm-3a/p53 complex from the labelled probe. Moreover, addition of Bm-3a mAb 
resulted in a supershift of the complex with one larger complex observed, further showing 
that Bm-3a interacts with p53 when p53 is bound to the noxa promoter (lane 9). However 
there also appears to be some competition when Bm-3a antibody is added suggesting that 
binding of this antibody to Bm-3a within the complex may prevent p53 binding to the 
labelled DNA, perhaps by steric hindrance.
The results described above confirm that Bm-3a is bound to p53 on the p53 consensus site 
found in the noxa promoter. Moreover, it appears that Bm-3a does not prevent p53 binding to 
this sequence but may act by preventing the recruitment of co-factors such as ASPP
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Figure 4.3: Brn-3a does not prevent p53 binding to its cognate sequence in the noxa promoter
a) Western blot using IMR-32 cell extract (used in EMSA assay) showing expression of Brn-3a and 
wild type p53. b) Electrophoretic mobility shift assays (EMSA) of protein binding on the p53 DNA 
sequence element taken from the noxa promoter. Cellular extracts were made from IMR-32 cells. 32P- 
labelled oligonucleotide comprising the p53 DNA binding site in the noxa promoter were incubated 
with the cellular lysate and subjected to non denaturing gel electrophoresis. Specific competition was 
50 and 100x excess of the same oligonucleotide, unlabelled; non-specific competition was 100x 
excess CREB oligonucleotide. Addition of p53 pAb or Brn-3a mAb resulted in supershift of the 
complexes (indicated by asterices). Addition of a Brn-3a consensus site resulted in competition of this 
complex.
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(apoptosis-stimulating protein of p53 family members) proteins required for stimulation of 
pro-apoptotic proteins such as Bax (Bergamaschi et al., 2004).
Next, the association of Bm-3a with the noxa promoter was investigated further in intact 
cells by carrying out Chromatin Immunoprecipitation (ChIP) assays in order to determine 
whether Bm-3a is associated with the wild type but not mutant noxa promoter. ND7 cells 
were transfected with the wild type noxa promoter with the intact p53 site or the Ap53-noxa 
promoter which does not contain the p53 binding site. Expression vectors encoding Bm-3a 
and p53 were also co-transfected as endogenous levels of both proteins are relatively low in 
normal proliferating ND7 cells. Primers were designed to amplify 152 bp-ffagment of the 
promoter encompassing the p53 binding site. As can be seen in fig 4.4, lane 2 and 5 indicates 
the input sample whilst lanes 3 and 6  shows amplification following immuno-precipitation of 
cells transfected with the wild type and Ap53-woxa promoters respectively, with Bm-3a 
mouse mAb. Lanes 4 and 7 indicate the amplification from cells that were immuno- 
precipitated with the control anti-mouse secondary antibody only. Significantly higher 
amplification of the noxa promoter region was observed in cells transfected with the wild 
type promoter compared with those with the promoter lacking the p53 site from which low 
levels of the promoter sequence were amplified. Lane 1 indicates the lOObp ladder.
These results demonstrate that in the intact cell, Bm-3a is associated with the region of the 
noxa promoter that contains the p53 binding site. The failure of the mutant promoter to be 
immuno-precipitated with Bm-3a suggests that Bm-3a is bound to p53 that is bound to this 
site so that loss of p53 binding to this site prevents the promoter from being immuno- 
precipitated with Bm-3a in the ChIP assay in these cells.
The finding that TAp73 activated the wild type noxa promoter but not the Ap53-»ojrar 
promoter suggests that TAp73 activates this promoter by binding to the p53 RE, though 
evidence of direct binding would need to be tested (e.g. EMSAs, whereas ChIP assays will 
determine if TAp73 binds this site in the intact cell). Investigation of the mechanism by 
which Bm-3a inhibits TAp73-mediated activation of the noxa promoter can then be carried 
out by performing similar EMSA/ChIP assays described above. Due to time constraints this 
work was not undertaken.
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Figure 4.4: Immunoprecipitation of Brn-3a on wild type noxa promoter but not on the mutant 
noxa promoter
Chromatin immunoprecipitation assay were carried out in ND7 cells transfected with p53 and Brn-3a 
with either wild type or p53 site deleted noxa promoters. Following immunoprecipitation with Brn-3a 
antibody, PCR amplification was carried out using specific primers flanking the p53 site in the noxa 
promoter. PCR amplification of the positive control input (total chromatin extract before 
immunoprecipitation) is shown in lane 2. The wild type noxa promoter immuno-precipitated with Brn- 
3a is shown on lane 3 whist the negative control in which secondary antibody was used to immuno- 
precipitate the wild type noxa promoter is shown in lane 4. Lane 5 shows the input from cells 
transfected with the p53 site deleted noxa promoter whist lane 6 shows immunoprecipitation with the 
Brn-3a antibody which is similar to the background level seen with the control secondary antibody 
only in both wild type and control experiments.
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4.4 Levels of pro-apoptotic proteins, Bax and Noxa in Brn-3a -/ 
mice
Knock out mice lacking Bm-3a demonstrate significant loss of specific neuronal cells as a 
result of apoptosis that peaks at E l5.5. In order to address the question of whether loss of 
Bm-3a resulted in increased levels of pro-apoptotic p53/p73 target genes in vivo, Bax and 
Noxa protein levels were analyzed in pooled neuronal tissue known to express Bm-3a 
(midbrain, hindbrain, trigeminal ganglia, spinal cord and DRG) dissected from Bm-Sa-/- 
embryos compared with similar tissue taken from wild type litter mates (Fig 4.5-this work 
was done by Peter Morris and Budram-Mahadeo, ICH). Quantification for protein levels 
obtained from a number of litters showed significant increased levels of both Bax and Noxa 
protein in E l4.5 Bm-3a—/~ embryos compared with levels in wild type litter mates. However, 
by E l6.5 the levels of both Bax and Noxa proteins were similar in the wild type and knock 
out litter mates with no significant differences evident upon quantification (Fig 4.5) (Hudson 
et al., 2005)
Therefore loss of Bm-3a in mice with wild type p53/p73 expression, results in higher levels 
of the pro-apoptotic proteins, Bax and Noxa, at a time preceding maximal apoptosis in the 
Bm-3a-/- embryos. This suggests that Bm-3a may be important in regulating the expression 
of these pro-apoptotic target proteins during development.
4.5 Discussion
These results discussed in this chapter has demonstrated that Bm-3a represses the 
transcriptional activity of p53 on another pro-apoptotic p53 target gene, noxa, in a manner 
similar to that seen on the bax promoter (Budram-Mahadeo et al., 2002). Similar to p53, 
p73a was also shown to strongly activate the noxa promoter in ND7 cells, while co­
expression of Bm-3a with p73a resulted in a strong repression of the p73 mediated activation 
of the noxa promoter. Hence Bm-3a antagonizes p53 and p73a mediated activation of the 
noxa gene promoter in reporter assays.
ANp73a acts as a potent transdominant inhibitor of gene expression by p53 or TAp73,
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Figure 4.5: Elevated levels of Bax and Noxa protein in Brn-3a-/- embryos at E14.5 but not at 
E16.5
a) Representative western blot analysis showing the expression of Bax and Noxa proteins in tissues 
taken from either Brn-3a-/~ embryos or from wild type embryos at E14.5. Actin levels are shown for 
the same samples, b) Representative western blot analysis showing the expression of Bax and Noxa 
proteins in tissues taken from either Brn-3a-/- embryos or from wild type embryos at E16.5. Actin 
levels are shown for the same samples.
E16.5 Brn-3a-/- embrvos E l6.5 wild tvoe embrvos
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(Grob et al., 2001;Kartasheva et al., 2002;Stiewe et al., 2002;Zaika et al., 2002;Vossio et al., 
2002) as well as regulating the expression of a variety of genes independently of p53 
(Kartasheva et al., 2003). Thus the effect of ANp73a on the noxa promoter was tested. As 
was the case on the p21CIP1/Wa*1 and bax promoters, ANp73a did not significantly alter the 
activity of the noxa promoter.
It is interesting that while Bm-3a alone could mildly repress bax promoter activity this was 
not observed on the noxa promoter used in this study. However whereas the bax promoter 
contains two consensus binding sites for Bm-3a that flanks the p53 sites, no such Bm-3a sites 
were observed on the noxa promoter tested in this study. In the bax promoter both Bm-3a 
binding sites are required for its effects on this promoter as mutation of these sites resulted in 
a failure of Bm-3a to repress transcription either alone or via association with p53 (Perez- 
Sanchez et al., 2002). The lack of Bm-3a consensus binding sites on the noxa promoter may 
explain why Bm-3a did not directly repress promoter activity in these experiments. However, 
since Bm-3a could significantly antagonize p53 or p73 mediated stimulation of this 
promoter, this effect must arise from its ability to physically interact with the p53 and p73 
proteins. Hence, Bm-3a could block p53/p73 mediated activation either by 1) the association 
of Bm-3a with p53/p73 prevents the p53/p73 protein from binding to its consensus site in the 
noxa promoter, or 2) interaction of Bm-3a with p53/p73 when it is bound to the promoter 
prevents the association of other proteins that are required for full p53/p73 transactivation of 
this promoter. Results of electrophoretic mobility shift assay shows that Bm-3a is, in fact, 
associated with p53 when it is bound to its DNA binding site in the noxa promoter. This 
suggest that the interaction of Bm-3a with p53 may prevent the transactivation of the noxa 
promoter possibly by excluding binding of co-activators required for the stimulation of pro- 
apoptotic gene promoters by p53. This was strengthened by the finding that in ChIP assays, 
immunoprecipitation of Bm-3a in ND7 cells containing the wild type p53 site in the noxa 
promoter resulted in amplification of the promoter DNA but this was not observed on the 
same promoter lacking the p53 site.
In response to a stress signal, activated p53 regulates genes involved in many cellular 
functions, the most important being cell cycle arrest and apoptosis. It is clear that cellular 
proteins co-expressed with the p53 family of proteins can alter the effect of this protein on 
determining cell fate by modifying target genes regulated by the p53 family. The co­
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expression of ASPP proteins (ASPP1/2) which interacts with p53, p73 and p63 increases 
expression of pro-apoptotic genes such as bax, pig3 and puma and are clearly important for 
determining the apoptotic pathway (Samuels-Lev et al., 2001;Bergamaschi et al., 2004). The 
apoptotic function of p73 is also potentiated by c-abl kinase activity and the co-activators 
p300 and PCAF by increasing its ability to activate the transcription of pro-apoptotic gene 
targets (Gong et al., 1999;Costanzo et al., 2002;Zhao et al., 2003). In contrast co-expression 
of Bm-3a with p53 or p73 increases expression of p21CIPI/Wa^  but antagonizes the expression 
of the p53/p73 apoptotic target bax (Budram-Mahadeo et al., 2002), as well as noxa and so 
contribute to increased survival and cell cycle arrest. Whether Bm-3a has similar biological 
impacts on p63 remains to be established.
The ability of Bm-3a to differentially modulate expression of p53 target genes appears to be 
achieved by different mechanisms. Whilst Bm-3a binding sites are required for it to repress 
p53 mediated transcription on the bax promoter (Budram-Mahadeo et al., 2002), it can 
repress activity on the noxa promoter by direct protein-protein interaction with p53. In 
contrast, on the p2 lCIPI/WafI promoter, Bm-3a appeared to mediate its effect by recruitment to 
the basal transcriptional complex (Perez-Sanchez et al., 2002). These findings demonstrate 
the complexity of regulation of expression of genes associated with cell death/survival by 
Bm-3a.
In this regard, it is therefore possible that during neuronal development, cells which co­
express Bm-3a and p53 and/or p73 will survive because of the repression of pro-apoptotic 
factors whereas co-operation on p21CIP1/Wqfl promoter would enhance cell cycle arrest. 
Additionally, Bm-3a increases the expression of genes involved in neuronal differentiation 
(the neurofilament genes, a-intemexin, Snap-25) and neurotrophic receptors (TrkA) which 
would enhance differentiation of surviving cells into mature neurones. In agreement with this 
hypothesis it has been demonstrated that in neuronal tissue taken from Bm-3a -/- mice 
compared with wild type, loss of Bm-3a resulted in significant increases in levels of both 
Bax and Noxa at specific times during development. Both Bax and Noxa proteins are 
elevated by E l4.5 in Bm-3a -/- embryos compared with wild type litter mates at a time that 
coincides with increased apoptosis in these mutants (Eng et al., 2001). By E l6.5 when most 
neurones which would normally express Bm-3a are lost in Bm-3a -/- embryos, the levels of 
Bax and Noxa proteins remained similar in the wild type embryos compared with the
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mutants. Therefore in Bm-3a expressing cells such as sensory neurones, it is likely that the 
expression of bax and noxa are controlled by the ability of this transcription factor to alter 
p53/Tap73 mediated gene transcription
Thus, the increase in pro-apoptotic Bax and Noxa, in the absence of Bm-3a, may result from 
lack of antagonism of p53/TAp73 mediated transcription and contribute to the increased 
death of sensory neurones which would normally express Bm-3a. As well as having a clear 
role in naturally occurring apoptosis in many sensory and sympathetic neurones during 
development (Deckwerth et al., 1996;White et al., 1998;Cregan et al., 1999), Bax mediated 
apoptosis is also clearly important for loss of sensory neurones in Bm-3a -/- embryos since 
crosses of Bm-3a KO with Bax KO resulted in rescue of many sensory neurones that would 
normally express Bm-3a (Ma et al., 2003). However, there is still apoptosis in some sensory 
neurones which is independent of Bax and it is likely that other pro-apoptotic factors 
contribute to the fate of these cells. The finding that Bm-3a antagonizes p53/TAp73 activity 
on the pro-apoptotic noxa promoter, as well as the bax promoter, suggests that during normal 
development, the interaction of Bm-3a with p53/TAp73 will be important in determining the 
fate of neuronal cells which co-express these proteins by the ability of Bm-3a to repress 
p53/p73 target genes involved in apoptosis. Thus the transcriptional regulation of p53 and 
TAp73 function by Bm-3a describes an alternative mechanism by which this transcription 
factor can control the fate of cells which express it and supports previous findings showing 
that Bm-3a is a critical regulator of neuronal cell fate (Smith et al., 1997;Ensor et al., 
2001;Budram-Mahadeo et al., 2002;Faulkes et al., 2004).
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CHAPTER 5
Co-expression of Brn-3a with p53 and p73 proteins in 
Neural Crest cell cultures
5.1 Introduction
Sensory neurones in the peripheral nervous system (PNS) arise from neural crest cells 
(NCC). These are pluripotent neuroepithelial cells that migrate from the neural tube during 
early development and colonize target tissues, where they differentiate into specific cell 
types. The cell types formed depend both on their anterior/posterior origin in the neural tube, 
the environment they encounter as they migrate and on their ultimate destination in the 
periphery (Dupin et al., 1993;Sieber-Blum, 2000). The factors that influence the survival and 
fate of these cells are still poorly understood, but transcription factors expressed in these cells 
appear to play a critical role in their specification and subsequent differentiation into distinct 
phenotypes (Sieber-Blum, 2000) (refer to sections 1.16.2).
Bm-3a is detected in the migrating neuronal precursors arising from the neural tube as early 
as E9.0. This transcription factor is expressed in a sub population of neuronal precursor cells 
destined for a sensory lineage (Fedtsova and Turner, 1995;Greenwood et al., 1999) and is 
considered a marker of sensory neuronal precursor and differentiated sensory neuronal cells. 
Bm-3a plays a critical role in the survival and differentiation of sensory neurones by 
regulating expression of target genes associated with survival and differentiation either 
directly or indirectly e.g. via its interaction with p53 or p73. In the ND7 neuronal cell line 
model, co-expression of Bm-3a with p53 or TAp73 isoforms resulted in increased survival 
and cell cycle arrest, whilst co-expression of Bm-3a and ANp73a resulted in increased 
survival but did not increase cell cycle arrest. However the effects of the Bm-3a/p73 
interaction in progenitor cells, such as those that arise from the neural crest are not known.
Extensive studies have shown that p53 and TAp73 play critical roles in the pathways that 
determine cell death in the developing and mature nervous system (Aloyz et al., 
1998;Pozniak et al., 2000), but their role in neuronal differentiation though less well studied, 
is now shown to be important in cell fate determination. Eizenberg et al (1996) demonstrated
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transient up-regulation of p53 in sympathetic neurones undergoing differentiation. A role for 
p73 in neuronal differentiation is suggested by the findings that RA-induced differentiation 
of a mouse neuroblastoma line depends on p73, and overexpression of p73 in these cells 
induces their differentiation in the absence of RA (De, Laurenzi et al., 2000).
In this regard a role for p53 with Bm-3a in sensory neuronal differentiation has been 
demonstrated. Nuclear p53 expression was shown in a population of Bm-3a positive neural 
crest-derived cells displaying distinct morphology of differentiated neurones, implicating p53 
in the differentiation of sensory neurones. p53 expression in these differentiated neurones 
was further confirmed by co-localization of p53 with the differentiation marker NF-160. 
Furthermore induction of p53 by cisplatin treatment of NCC resulted in p53 co-expression 
with activated caspase-3, which is a marker of irreversible apoptosis, but also there were 
several p53 expressing populations which were negative for activated caspase-3 staining and 
had intact flattened morphology that suggested they were differentiated cells (Hudson et al., 
2004). This observation further supports the hypothesis that expression of p53 in cells arising 
from the neural crest is not just associated with apoptosis. Thus p53 is associated with 
differentiation of some NCC and the co-expression of other factors such as Bm-3a can 
enhance p53 mediated differentiation by modulating its apoptotic effects.
In order to investigate the functional effect of the interaction between Bm-3a and p73 during 
sensory neuronal development, analysis of the expression of p73 in Bm-3a positive neural 
crest-derived cells destined for sensory neuronal lineage were carried out in a similar manner 
to p53. The importance of the Bm-3a/p53 and Bm-3a/p73 co-expression in determining cell 
fate was further analyzed using NCC cultured from both wild type and Bm-3a-/- embryos.
5.2 Expression of p53, TAp73, ANp73 and Brn-3a in NCC.
Bm-3a expressing cells derived from trunk neural crest cultures have previously been shown 
to be destined for a sensory lineage (Greenwood et al., 1999), but the expression of p53 and 
the pro-apoptotic and anti-apoptotic isoforms of p73 (TAp73 and ANp73, respectively) had 
not been studied in these NCC. Therefore to determine the expression levels of p53, TAp73 
and ANp73 in NCC, primary neural tube explants were prepared from E9.5 mouse embryos 
by dissecting out the portion of neural tube corresponding to the trunk level (somites 7
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to 18). After separation of the fetal membranes, explants were enzymatically treated to 
separate the neural tube from the ectoderm and somites and then transferred onto poly-lysine 
and ffibronectin coated coverslips in DMEM supplemented with 10% fetal calf serum (FCS), 
basic fibroblast growth factor (bFGF), neurotrophin-3 (NT-3) and antibiotic/antimycotic to 
prevent infections. Explants were maintained in a humidified incubator with 5% CO2 at 
37°C. After 24 hrs, the neural tube explant was removed and discarded, and the NCC 
cultures were maintained for the required period, replacing the media every 2-3 days (see 
Materials and Methods). Cells were then harvested for extraction of total RNA after 3, 5, 7, 
8 , 9 and 12 days. Bm-3a expression was also included to determine the time of maximal 
expression, in order to facilitate subsequent studies to analyze whether p53 and the p73 
proteins are localized in Bm-3a positive cells. Because of the limited amount of RNA 
obtained from each neural crest culture, changes in the levels of Bm-3a, p53 and p73 mRNA 
were quantified by using real-time (quantitative) reverse transcriptase-polymerase chain 
reaction (qRT-PCR). RNA obtained from the cultured NCC was digested with DNAse 1 (to 
remove genomic DNA) and cDNA was synthesized from approximately 0.1 pg total RNA by 
using Superscript enzyme (Invitrogen). qRT-PCR for specific mRNA was carried out on the 
MJ Opticon by using primers designed for use with the Sybr green detection system. 
Conditions were optimised for each set of primers used to amplify Bm-3a, p53, TAp73 and 
ANp73 to ensure that a single product was seen. A set of standards was generated by serial 
dilution of known amounts of each aplicon, and these standards were used to generate 
standard curves in all subsequent experiments. The transcript encoding the invariant GAPD 
was amplified and used to correct for variation in RNA prepared from different samples (see 
Materials and Methods).
The standards preparation for quantification, for Bm-3a, p53, TAp73 and ANp73 are shown 
in Fig 5.1a + b. Aliquots of the same standard curves were used in all experiments to allow 
for comparison between experiments. Fig 5.1c shows an example of the quantification of a 
set of samples (cDNA from NCC harvested for RNA at the relevant time points) for each 
aplicon. Fig 5.Id shows the melting curve for each aplicon to confirm the specificity of 
amplification. Initially the melting curve for GAPD showed a smaller peak at 76°C which 
represents primer dimers in addition to the major peak at 85°C that represents the GAPD 
product. The smaller peak was eliminated by the addition of an extra step, at 80°C, for 10
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Figure 5.1: Measurement of Brn-3a, p53, TAp73 and ANp73 mRNA in neural crest-derived cells 
maintained for different times in culture by qRT-PCR using primers designed specifically to 
amplify Brn-3a, p53, TAp73 or ANp73
For each aplicon a) shows the standards generated following serial dilution of known amount of 
aplicon. Red, 1000 fg/pg green 500 fg/pg, purple 100 fg/pg, yellow 1 fg/pg, pink 0.1 fg/pg, blue 0.001 
fg/pg, brown 0.00001 fg/pg b) Plot of the standards gives rise to a linear curve, c) Plot showing 
standards together with samples from one experiment. The samples fall within the range of the 
standards validating the use of the standard curve for quantification of unknown samples, d) The 
melting curve, for each aplicon, showing that conditions were optimized so that one product is 
detected. Whereas conditions for Brn-3a(i), p53(ii), TAp73(iii) and ANp73(iv) gave rise to a single 
peak, Initial conditions for GAPDH(v) resulted in two peaks, with the lower melting peak representing 
primer dimers in addition to the major peak at 85°C that represents the GAPD product, e) The smaller 
peak was eliminated by the addition of an extra incubation step at 80°C for 10 second just before 
florescence reading.
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seconds just before florescence reading (the plate read step), which resulted in melting of 
primer dimers. This was used in all subsequent PCR reactions when amplifying GAPD, to 
ensure only the fluorescence emitted from the GAPD product was detected.
Analysis of mRNA prepared from NCC at different times in culture demonstrated low levels 
of Bm-3a at day 3, which increased over time with a peak observed between 7 and 8  days in 
culture, followed by a decrease so that by day 9 the level of Bm-3a expression correspond to 
those observed at day 5 (Fig 5.2a). Since Greenwood et al. (1999) showed that Bm-3a 
expression is restricted to cells of sensory neuronal lineage in NCC, the change in Bm-3a 
expression may reflect changes in the relative ratio of this subset of cells in relation to the 
total cell population as well as possible changes in the levels of mRNA encoding Bm-3a in 
specific cells. In contrast, relatively low levels of p53 mRNA were detected. There is a 
modest increase from day 3 to day 5 after which the levels of p53 mRNA remained 
unchanged over the rest of the period of study. This may result from the expression of p53 in 
NCC destined for other lineages, such as sympathetic neurones, which also express p53 
(Eizenberg et al., 1996).
The levels of p73 mRNA are shown in Fig 5.2b. Low levels of both TAp73 and ANp73 
isoforms were found to be expressed in NCC. A modest increase in ANp73 mRNA is 
detected between day 3 and day 5 after which the levels of ANp73 mRNA remain unchanged 
over the rest of the period of study. TAp73 mRNA levels is detected at a slightly higher level 
than ANp73 at day 3. However between days 3 and 8  the level of TAp73 mRNA decreases, 
after which there is a significant increase in the levels of TAp73 mRNA (p< 0.05) which 
continues until day 12 which was the last time point collected in these studies. As TAp73 has 
been shown to be up-regulated during neuronal differentiation (De Laurenzi et al., 2000), the 
increase in TAp73 expression after day 8  may reflect an increase in the number of neuronal 
cells undergoing differentiation in the cultured NCC at this time. The initial modest increase 
in mRNA levels of the anti-apoptotic ANp73 isoform between day 3 and 5 may reflect 
survival of the neuronal precursor cells in the neural crest cultures, prior to differentiation.
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Figure 5.2: Expression of Brn-3a, p53, full length TAp73 and N-terminal truncated ANp73 in 
neural crest-derived cells maintained in culture for different times as established by qRT-PCR 
using primers designed specifically to amplify either Brn-3a, p53, TAp73 or ANp73
a) Whereas Brn-3a levels peak between day 7 and 8 in culture, there was a modest increase in p53 
mRNA between day 3 and 5, followed by a relatively steady level over the time course studied, b) 
Low levels of both TAp73 and ANp73 isoforms were expressed in NCC. Initially ANp73 mRNA levels 
increase above the levels of TAp73. After the initial modest increase in ANp73 levels between day 3 
and 5, the levels of ANp73 mRNA remains constant. In contrast at day 8, TAp73 levels significantly 
increase. As TAp73 expression is not restricted to Brn-3a expressing cells, the increase at this time 
can be contributed by many cell types that express TAp73 in this culture. Amplification of the invariant 
GAPD was used to equalize for variation in mRNA from different samples. The results represent the 
data from three independent cultures.
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5.3 Localization of both ANp73 and TAp73 isoforms in a subset of 
Brn-3a positive NCC
In order to investigate the co-expression of these factors in NCC, immunostaining 
experiments were carried out in NCC grown in DMEM supplemented with 10% FCS and 
neurotrophic factors NT-3 and FGF. After 7 days, when Bm-3a levels are high, the NCC was 
fixed in 4% paraformaldehyde (PFA) and processed for immunostaining (see methods). 
Initial studies were carried out to assess the expression of Bm-3a in the NCC cultures. As 
shown in figure 5.3, two morphologically distinct populations of Bm-3a positive cells were 
observed within the neural crest cultures which is in accordance with previously published 
data (Greenwood et al., 1999). The typically smaller, more rounded Bm-3a expressing cells 
(figure 5.3a) that were more commonly found nearer the site of migration, were clearly 
distinct from the larger, more flattened Bm-3a positive cells, many of which display neurite 
outgrowth (figure 5.3b). Greenwood et al (1999) previously showed that the smaller Bm-3a- 
positive population of cells were neuronal precursor cells fated for the sensory lineage that 
were still undergoing cell division as demonstrated by bromodeoxyuridine (BrdU) 
incorporation. These cells were also negative for the differentiation marker NF-160, 
indicating an undifferentiated, dividing phenotype. However the larger Bm-3a positive cells 
were differentiated sensory neurones that also expressed DRG11 which marks differentiated 
sensory neurones and NF-160. The observation that Bm-3a is expressed in precursor cells 
that are still dividing, but clearly destined for a sensory lineage as well as in differentiated 
sensory neurones is interesting, suggesting that Bm-3a expression may commit neuronal 
progenitor cells to a specific cell fate and underscores its importance in determining the fate 
of these cells.
Co-localization studies were undertaken to look at p53 expression in Bm-3a expressing cells. 
The results shown in Fig 5.4 show that nuclear p53 is only observed in the more flattened 
Bm-3a positive cells with neurite extensions but not in the smaller, more rounded Bm-3a 
positive cells (Conditions for Bm-3a/p53 co-expression were set up and carried out by 
Jennifer Podesta, ICH).
To investigate whether p73 co-localized with Bm-3a in cells derived from neural crest, co- 
immunostaining experiments were carried out in NCC grown in culture for 7 days as
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P h ase  X40 Brn-3a mAB-FITC X40
Figure 5.3: Brn-3a is expressed in two morphologically distinct populations in Neural crest- 
derived cell cultures.
Bm-3a protein was observed in two subsets of neural crest-derived cells with distinct morphology 
characteristics. The smaller more rounded cells are shown in (a) which are typically nearer the site of 
migration, whereas the larger, more flattened cells with neurite processes are shown in (b). Neural 
crest cells were fixed in PFA after 7 days in culture and immunostained for Brn-3a expression (Brn-3a 
mouse Mab, Chemicon). Magnification x40
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Figure 5.4: Nuclear localization of p53 with Brn-3a in larger neural crest derived cells
Larger more flattened cells express both Brn-3a (a) and p53 (b) and the proteins are co-expressed in 
the nucleus (c). In contrast, smaller Brn-3a positive cells (asterisks) are negative for p53 expression. 
Neural crest cells were fixed in PFA after 7 days in culture and immunostained for Brn-3a expression 
(Brn-3a mouse Mab, Chemicon) and p53 expression (p53 sheep PAb, PC35, Oncogene). 
Magnification x60
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described previously. Three different antibodies were used to detect the p73 proteins. These 
include the anti-p73-AN (p73-AN) which was raised against the first 16 amino acids of 
ANp73 and thus specifically recognises the ANp73 isoform only, the anti-p73-SAM (p73- 
SAM) which was raised against the SAM domain and so recognizes TAp73a and ANp73a 
only (the only two p73 isoforms that contain the SAM domain) and anti-p73-Total (p73- 
Total) that recognizes all isoforms, i.e. ANp73 isoforms a, (3 and C-terminal isoforms 
TAp73a, p, y, £, 5 and £. (All three p73 antibodies were a kind gift from Emre Sayan, 
University of Leicester).
As shown in figure 5.5i, the p73-SAM antibody could positively stain Bm-3a expressing 
cells with the more flattened phenotype. This antibody recognises both TAp73a and 
ANp73a. Within this population it can be seen that some of these cells that co-express Bm-3a 
and p73, have neurite outgrowth indicative of differentiated neurones (fig5.5i a-d). In 
contrast, there was no apparent co-localization in the smaller, more rounded Bm-3a positive 
cells that were commonly found near the site of migration (fig5.5ii a-c). Co-immunostaining 
experiments using p73-AN or p73-Total antibodies with Bm-3a also gave the same pattern of 
co-expression observed with p73-SAM, in that no p73 protein was observed in the small 
rounded Bm-3a positive population, but co-expression was seen in the larger Bm-3a positive 
population (data not shown). Furthermore, all 3 antibodies appeared to stain equally well. 
Thus, as was the case with p53, the cells that co-expressed Bm-3a and p73 were 
morphological distinct from those expressing Bm-3a alone.
Upon closer inspection at higher magnification, cells co-expressing Bm-3a and p73 
recognised by p73-SAM (detects both ANp73a and TAp73a) and p73-Total, shows 
localization of p73 protein being cytoplasmic as well as nuclear (Fig 5.6i p73-SAM antibody 
and Fig 5.6iii +iv p73-Total antibody). However the AN specific antibody showed mostly 
cytoplasmic localisation in Bm-3a positive cells (Fig 5.6ii p73-AN antibody). This suggests 
that the cytoplasmic staining seen with the p73-SAM and p73-Total antibodies is likely to be 
the ANp73 form whereas the nuclear staining detected by p73-SAM and p73-Total in Bm-3a 
positive cells is likely to be the TA forms. This suggests parallel roles between Bm- 
3a/TAp73 and Bm-3a/p53 in which p53 is also found in the nucleus when co-expressed with
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Figure 5.5: p73 co-localizes in a subset Brn-3a positive cells displaying distinct morphology of 
differentiated neurones.
fig 5.5i Expression of p73 (b, c) is clearly observed in the larger Brn-3a expressing cells (a, c) which 
display a flattened morphology and neurite outgrowth (d) but not in the more rounded Brn-3a positive 
cells that were more commonly found near the site of migration (fig5.5ii a-c). Neural crest cells were 
fixed in PFA after 7 days in culture and immunostained for Brn-3a expression (Brn-3a mouse Mab, 
Chemicon) and p73 expression (p73-SAM, rabbit PAb). Magnification X20
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Figure 5.6: Examples of localization of p73 protein in NCC derived cells.
i). Staining with p73-SAM antibody that detects both TAp73a and ANp73a expression shows p73 
expression in the large flattened Brn-3a positive cells. In these cells p73 can either be cytoplasmic 
(two bottom cells) as well as nuclear (asterisk). Hoechst staining is shown insert of phase, with the 
nucleus of the cells co-expressing Brn-3a and p73 are marked (asterisk). Neural crest cells were fixed 
in PFA after 7 days in culture and immunostained for Brn-3a expression (Brn-3a mouse Mab, 
Chemicon) and p73 expression (p73-SAM, rabbit PAb). Magnification X40
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Figure 5.6 continued: ii) Staining with p73-AN antibody to detect ANp73a expression only, shows 
that ANp73a is also expressed in the large flattened Brn-3a positive cells and that staining is mostly 
cytoplasmic. Neural crest cells were processed for immunostaining with Brn-3a and p73-AN 
antibodies. Magnification X40
233
Fig5.6iii
Brn-3a mAB-FITC p73-Full pAB-Rh Brn-3a/p73-Total overlay Phase
Fig5.6iv
Figure 5.6 continued: iii) Staining with p73-Total antibody which detects all isoforms of TAp73 and 
ANp73 expression shows that expression of p73 in the large flattened Brn-3a positive neural crest 
cells can be evenly distributed in both the nucleus and cytoplasm or iv) shows predominantly nuclear 
staining. Hoechst staining is shown, insert of overlay. Cells were processed for immunostaining with 
Brn-3a and p73-Total antibodies. Magnification X40
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Bm-3a. Thus, similar to p53, TAp73 may also have a role in sensory neuronal differentiation. 
The availability of good TA specific antibodies will help clarify the location of AN versus 
TA proteins in cells co-expressing Bm-3a.
Both p73-SAM and p73-Total antibodies also stained other NCC that were not Bm-3a 
positive. Some of these cells appeared to be undergoing apoptosis as assessed by 
morphological changes in the NCC. Therefore in NCC, TAp73 is co-expressed in Bm-3a 
positive cells that are more differentiated but is also seen in Bm-3a negative cells that have 
the morphology indicative of cells undergoing apoptosis e.g. nuclear condensation and DNA 
fragmentation (Fig 5.7).
This is an interesting observation as it supports a crucial role for Bm-3a in determining the 
pathway taken by p73 (by antagonizing p73 mediated activation of pro-apoptotic genes such 
as box and noxa, whilst co-operating on the p21CIPI/Wa^  promoter) when co-expressed during 
development and thus in controlling the fate of these cells. Hence, under the conditions used 
in these experiments, p73 is detected in Bm-3a expressing neurones that display flattened 
morphology with some displaying neurite extensions suggestive of differentiated neurones, 
whereas its expression in cells not expressing Bm-3a demonstrate morphology that is 
indicative of apoptosis. However this is assessed on morphology alone. Co-immunostaining 
with p73 and a marker of apoptosis (i.e. Caspase-3 or Bax) would need to be carried out to 
confirm the presence of p73 proteins in cells undergoing apoptosis.
It is clear that as was found with p53, the p73 proteins are also co-expressed with Bm-3a in a 
subpopulation of NCC. Under the growth conditions used in these experiments, p73 shows 
cytoplasmic as well as nuclear expression in cells co-expressing Bm-3a. Similar to p53, p73 
function is regulated by cellular location, with sequestration in the cytoplasm being a 
mechanism by which its activity is regulated. As nuclear p73 expression is seen in Bm-3a 
positive cells with neurite outgrowth, it suggests that p73 proteins are associated with 
differentiated sensory neurones and may have a role in this process.
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Figure 5.7: p73 is expressed in Brn-3a positive and Brn-3a negative cells
Co-immunostaining studies show that p73 (as detected by p73-SAM) is expressed in cells not 
expressing Brn-3a that showed distinct morphological changes indicative of apoptotic cells (asterisk), 
as well as being co-expressed with Brn-3a in intact cells with flattened morphology that would 
suggest that these cells are differentiated. Magnification X40.
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5.4 Co-expression of Brn-3a and TAp73 but not ANp73 in 
differentiated sensory neurones
The co-expression of Bm-3a and p73 in NCC with flattened morphology, many of which 
showed extensive neurite outgrowth, suggested that these cells may be undergoing 
differentiation or were already differentiated. Previous studies have shown that nuclear p53 is 
co-expressed with NF-160 (which marks differentiated neurones), in cells that had similar 
morphology to those that co-expressed p53 and Bm-3a. Similarly studies to look at co­
localization of Bm-3a and NF-160 showed that the larger Bm-3a positive cells with neurite 
extensions also expressed the neurofilament protein, but co-expression was not observed in 
the smaller Bm-3a positive cells (see figure 5.8iii). Whilst triple immunostaining was not 
possible in these experiments, given the similar morphology of cells that co-expressed Bm- 
3a/p53 and NF-160/p53, it is likely that the NF-160/p53 co-expressing cells will also be Bm- 
3a positive, supporting the hypothesis that p53 is involved in differentiation of sensory 
neurones (Hudson et al., 2004).
Given the results obtained for co-localisation of Bm-3a and p73 in the NCC cultures, the next 
step was to investigate whether the large flattened cells expressing p73, as seen when co­
expressed with Bm-3a, were differentiated neurones. Similar co-immunostaining 
experiments were carried out using an antibody to NF-160 and either p73-SAM to detect 
both TAp73a and ANp73a or p73-AN to detect the truncated form of p73 only. As shown in 
figure 5.8i, the p73-SAM antibody stained a number of cells expressing p73 proteins that 
were also positive for neurofilament expression. In contrast figure 5.8ii shows that NF 
expression is not co-localised with ANp73 although other cells expressing NF were seen in 
this culture. These co-immunostaining results suggest that there are 2 populations of p73 
positive cells, one identified by p73-SAM Ab which will include TAp73a and ANp73a and 
the other by p73-AN that only detects the ANp73 proteins. Thus the co-expression of p73 
with NF-160 observed with the p73-SAM antibody is likely to be the TA isoform, p73a but 
not the ANp73a isoform. As with the p53 studies, TAp73/NF-160 and Bm-3a/NF-160 were 
observed in similar cell types so it is likely that NF-160/TAp73 co-expressing cells will also 
be positive for Bm-3a.
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Figure 5.8 i
P73-SAM pAB-Rh NF-160 mAB-FITC NF-160/p73-SAM overlay Phase
Figure 5.8ii
P 73-AN pAB-Rh NF-160 mAB-FITC NF-160/p73-AN overlay Phase
Figure 5.8iii
Brn-3a pAB-Rh NF-160 mAB-FITC Brn-3a/NF-160 overlay
Figure 5.8: Co-expression of NF-160, a marker of differentiated neurones with TAp73 but not 
with ANp73
5.8i) demonstrates that some p73 expressing cells (TAp73a and ANp73a as detected by p73-SAM) 
were also positive for NF-160. These large, flattened cells had intact morphology and neurite 
extensions characteristic of cells either undergoing differentiation or differentiated, ii) Cells expressing 
ANp73 (stained for by AN specific antibody) were negative for NF-160 expression suggesting that the 
co-localization of p73 with NF-160 shown in figure 4.8i is due to the TA isoform that is detected by 
p73-SAM. This suggests that not all large, flattened Brn-3a positive cells are differentiated and that 
these cells co-express ANp73 while differentiated Brn-3a cells co-express TAp73. Insert shows that 
differentiated neurones are stained with NF-160 in this culture iii) co-localization of NF-160 with Brn- 
3a protein in the larger more flattened Brn-3a positive cells (*), but not in the smaller Brn-3a positive 
cells confirms that a subset of Brn-3a positive neural crest cells are differentiated.
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normal development of the embryonic nervous system (Armstrong et al., 
1995). This partial penetrance observed in the p53 -/- phenotype was difficuh 
the identification of p73 and p63, both of which are expressed in the eml 
system and which could potentially play a compensatory role in a p53-/- 
order to assess whether p73 compensates for p53 function in sensory neurona 
the expression of p73 in relation to Bm-3a was analyzed in NCC cultun 
embryos.
Figure 5.9 shows the location of staining of NCC using p73-SAM that i 
proteins including TAp73 and ANp73, in NCC cultured from p53 +/+, +/- or 
before, co-localization of p73 with Bm-3a was observed in the larger, more : 
positive cells in NCC cultures prepared from p53 wild type (fig5.9i), heteros 
and KO (fig5.9iii) embryos, while no co-localization was found in the small* 
Bm-3a positive cells (data not shown). Similar results were obtained when th 
were repeated with p73- AN and p73-Full antibodies to detect just the ANp73 
isoforms (data not shown). In these co-localization experiments, there w< 
differences in the expression of p73 in relation to Bm-3a observed in the NC 
the different p53 genotypes. Lack of gross differences in p73 expression 
cultured from p53 +/+, -/+ and -/- made it difficult to ascertain if p73 compen 
p53 in sensory neuronal development. To better answer this question, it woi 
to assess the levels of p73 mRNA in NCC cultured from p53 -/- embryos cc 
type. If p73 compensates for loss of p53, then it would be expected that 
would be increased in NCC taken from p53 -/- embryos. But due to time cons 
of investigation was not pursued.
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Figure 5.9i
Brn-3a mAB-FITC p73-SAM pAB-Rh Brn-3a/p73-SAM overlay Phase
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Figure 5.9ii
Brn-3a mAB-FITC p73-SAM pAB-Rh Brn-3a/p73-SAM overlay
Figure 5.9iii
Brn-3a mAB-FITC p73-SAM pAB-Rh Brn-3a/p73-SAM overlay
a
Figure 5.9: p73 expression in relation to Brn-3a is not significantly altered in NCC grown from 
p53-/- or p53-/+ embryos.
NCC cultures prepared from i) wild type, ii) p53-/+ or iii) p53-/- embryos were immunostained for Brn- 
3a and p73 expression (p73-SAM which recognizes both TA and ANp73 isoforms). As before, co­
expression was found in the more flattened Brn-3a positive population while no co-localization was 
found in the smaller, more rounded Brn-3a population. No changes in p73 expression or location 
were detected in the NCC cultured from the different p53 genotypes, in relation to Brn-3a.
Phase
Phase
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embryos were grown in culture for 7 days, before treatment with 20 |iM of c 
hr to induce p53/p73 expression. The NCC were then immunostained f< 
activated caspase-3 which is used as a marker of cells undergoing apopl 
positive cells were counted in matched NCC cultures from Bm-3a -/-, -/+ an 
and used as a measure of cells undergoing apoptosis.
As shown in figure 5.10, a significantly greater number of caspase-3-po 
found in cultures prepared from Bm-3a -/- embryos compared with wild typ< 
students t-test, p<0.0005). This suggests that, in the absence of Bm-3a prot 
p53/p73 expression results in an increase in the number of cells undei 
compared with cultures prepared from wild type littermates.
Cultures prepared from heterozygous (+/-) mice demonstrated a response sir 
with wild type. This is as expected since Bm-3a +/- embryos develop normal 
result o f a positive feed back mechanism (Trieu et al., 1999;Trieu et al., 20( 
expression of Bm-3a to compensate for loss of one allele. Thus, induction c 
in the absence of Bm-3a leads to increased apoptosis in NCC, supporting p 
that Bm-3a is required to modulate the effects of p53/p73 in cells that 
proteins.
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Levels of apoptotic death observed in cis-platinum treated 
NCC prepared from Bm-3a wild type, heterozygous and 
Knock Out littermates
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Figure 5.10: NCC cultured from Brn-3a embryos demonstrated signifi 
apoptosis upon stimulation of p53/TAp73 expression with cis-platinum
Measurement of apoptotic ceils immunostained for activated caspase-3 showed t 
apoptotic cells in NCC cultures prepared from Bm-3a -/- embryos compared u 
cultures prepared from wild-type littermates. The level of apoptotic cells in cultu 
Bm-3a -/+ littermates were similar to wild type, which is expected as the levels of 
increases in the Brn-3a heterozygote due to a positive feedback mechanism. The 
the counts from cultures taken from at least six independent embryos.
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neural crest cultures m which Bm-Ja is expressed m progenitor cells that are 
sensory lineage, as well as in differentiated sensory neurones, allowed for the 
mechanism by which Bm-3a mediates its effect in these cells, with specif 
association with p73
The levels of mRNA encoding p53, TAp73 and ANp73 were assessed in the 
over a time period of 3-12 days in culture, using qRT-PCR and these were 
Bm-3a mRNA expression over the same time period. The levels of p5 
expressed at relatively low but steady levels over the time course studied, whi 
with findings that p53 is not restricted to Bm-3a expressing cells in this cultu 
p73 isoforms showed that ANp73 mRNA levels modestly increase between da 
which the levels of ANp73 mRNA remained constant. TAp73 mRNA is deteci 
higher level than ANp73 at day 3 which is followed by a slight decrease ir 
until day 8. This is consistent with findings that TAp73 induces expression o 
ANp73 (Grob et al., 2001;Kartasheva et al., 2002;Vossio et al., 2002;Nakagai 
Nakagawa et al., 2003). At day 8, there is a significant rise in TAp73 mRNA. 
been shown to be up-regulated during neuronal differentiation (De, Laurenzi e 
increase in TAp73 expression may reflect an increase in the number of 
undergoing differentiation in the cultured NCC at this time. The initial sm 
mRNA levels of the anti-apoptotic ANp73 between day 3 and 5 may be a 
survival preceding differentiation of the neuronal cells in the neural crest cul 
of ANp73 in neuronal survival has been well characterised in developing neu 
et al., 2000;Lee et al., 2004). Furthermore recent evidence suggests that . 
required to maintain the survival of mature sensory neurones (Walsh et al., 20C
Bm-3a mRNA levels showed a significant increase in cells that were kept in 
days, followed by a decrease to basal levels. The striking changes in Bm-i
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total RNA. It is interesting that TAp73 levels increases at day 8 while Bm-3a 
to decrease at this time. However since TAp73 expression is not restrii 
expressing cells, the increase at this time may be contributed by many cell tyj 
TAp73 in this culture. Hence these results provide an indication of changes in 
of mRNA encoding Bm-3a, p53, TAp73 and ANp73 in the total cell popul 
used to determine the best time for subsequent co-localization studies of Bm-2 
destined for a sensory neuronal lineage.
The data so far generated has shown that Bm-3a can physically interact wi 
isoforms of p73 and can modulate p73 transcriptional activity and functional 
cycle and apoptosis in the ND7 cell line in a similar manner shown previously 
ability of Bm-3a to synergize with p53 or TAp73 on the p21CIP1/Wa^  promol 
repress p53 or TAp73 mediated activation of the box and noxa promoters sugj 
plays a critical role in determining the cellular status and survival of neuroi 
co-express these proteins. Thus co-immunostaining experiments were carrie 
crest derived cells which provides a dynamic model to investigate prot< 
Furthermore Bm-3a expression has been well characterized in NCC c 
agreement with published data (Greenwood) Bm-3a was detected in two disti 
of NCC, a smaller more rounded Bm-3a positive population that were commc 
the site of migration and a Bm-3a positive population that displayed a larger 
morphology with many showing neurite extensions indicative of differential 
previous studies, p53 was shown to co-localise in the more flattened Bm-3i 
with neurite extensions but not in the smaller, more rounded Bm-3a positive c<
In this study co-immunostaining experiments also demonstrated that p73 co 
Bm-3a in a subset of neural crest cells. Thus, whereas Bm-3a was detected 
populations of NCC, co-expression with p73 was observed only in
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deduced by comparing the staining for p73 expression with the p73-SAM antil 
with that obtained with the AN-specific antibody.
Interestingly, when co-expressed with Bm-3a, localisation of p73 protein c 
p73-AN Ab was mostly cytoplasmic, whereas p73-SAM and p73-Total anti 
both cytoplasmic and nuclear staining. This suggests that ANp73a is mostly 
these cells and the nuclear staining detected by the p73-SAM and p73-Toh 
likely to be the TA isoforms. This is an interesting observation, as lik 
synthesized in the cytoplasm and must transport into the nucleus to exert its 
effect on downstream targets. Thus, subcellular sequestration o f p73 or p53 
inactivate their activity. Thus, the findings that p53 was always nuclear m 
isoforms of p73 also appear to be nuclear in Bm-3a positive cells, suggests tha 
in an active state when co-expressed with Bm-3a.
Interestingly, under these growth conditions, the expression of TAp73 and A 
in NCC were observed in Bm-3a expressing cells with flattened morphol 
membranes, while TAp73 was also detected in some cells not expressii 
undergoing apoptosis as shown by morphological changes. These results 
hypothesis that Bm-3a can modulate TAp73 as well as p53 mediated cell fai 
which co-express Bm-3a and TAp73 and p53 are more likely to survive ai 
because of the repression of pro-apoptotic box and noxa and co-operation on 
promoter to promote cell cycle arrest.
To characterize the phenotype of p73 expressing cells further, co-immunosta 
Ab and NF-160 Ab was carried out and this showed that TAp73 but not ANp 
with NF-160 in cells with flattened morphology. The differences in express 
length and truncated forms of p73 with NF-160 suggests that the large fl;
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protect neuronal cells from apoptosis (Smith et al., 1998;Pozniak et al., 20( 
2001;Ensor et al., 2001;Nakagawa et al., 2003). However the co-expression of 
in the large flattened cells and co-expression of TAp73/NF-160 and Bm-3a 
same cell types suggest that TAp73, as with p53, is associated with differe 
neurones.
Hence, given these results it is possible that there is a switch in expression of 
isoforms during sensory neuronal differentiation, so that ANp73 is the 
expressed with Bm-3a in these cells preceding differentiation, whilst upon di 
these cells, TAp73 is the major isoform co-expressed with Bm-3a. Indeed, t 
be an important factor in cell fate determination during sensory neuronal devel
The finding that TAp73 as well as p53 is associated with differentiation of se 
is interesting as it is possible that TAp73 and p53 may co-operate or comp< 
other during sensory neuronal differentiation. These proteins may also ac 
targets involved in neuronal differentiation. For example p73 but not p53 
activate the neuronal differentiation marker N-CAM during neuroblastoma 
Furthermore, TAp73 isoforms have been shown to be required to induce neuri 
a mouse neuroblastoma cell line, suggesting that TAp73 can directly affect di 
neuronal cells (De Laurenzi et al., 2000). The observation that ANp73 is nc 
with NF-160 in sensory neurones would support the hypothesis that expressic 
the Bm-3a positive cells, occurs preceding differentiation which may reflect i 
as a pro-survival protein in the nervous system (Pozniak et al., 2000;Nakagav 
In addition the Bm-3a/ANp73 interaction may act to further enhance survival 
ND7 neuronal cell line model in which co-expression of Bm-3a and A> 
survival of these cells compared to the levels seen when either factor was expri
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of Bm-3a /TAp73 /NF-160 and Bm-3a/ANp73 but not NF-160 in the same 
experiments can also be done by combining in-situ for one factor with co-i 
for other proteins. For example, analysing for p73 mRNA expression can 
using either TA or AN-specific ribo-probes, followed by immunostaining for ] 
160 expression. This approach would also help to analyze AN versus 
separately in these cells in the absence of good TA specific antibodies.
The results of the studies discussed above implicate TAp73 in set 
differentiation, which has already been demonstrated for p53. It is likely that < 
development both p53 and p73 might contribute to both differentiation ar 
neurones depending on which other proteins are co-expressed with it. To fiirtl 
the requirement for co-expression of p53/TAp73 with Bm-3a in determining 
cultures were prepared from Bm-3a -/- embryos and induced for p53/TAp7. 
cis-platinum treatment. Induction of wild type p53/TAp73 proteins in thes< 
loss of Bm-3a gave rise to significantly increased apoptosis compared to wi 
grown in similar conditions. In support of this finding, neuronal progenitor 
null embryos are formed but die by apoptosis at later stages of developmi 
2001), so the increased cell death observed in Bm-3a -/- NCC must be associa 
cells that would normally express Bm-3a. These findings suggest that Bm-3a 
overcome the apoptotic pathway by repressing the expression of pro-apoptotic 
box and noxa that are stimulated by both p53 and TAp73 in specifi 
development. Since p53 and p73 expression is not restricted to Bm-3a pos 
conceivable that other factors in cells of other lineages may also interact wi 
survival and p53/p73 mediated cell cycle arrest, in a manner similar to th< 
observed in sensory neurones.
The co-expression of TAp73 with Bm-3a (and similarly the co-expres
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mediated transcription of pro-apoptotic factors such as box and noxa, t 
TAp73/p53 mediated p21clpl/Wafl expression, would increase cell survival 
arrest. At the same time, direct activation by Bm-3a of neuronal target ge 
intemexin, neurofilament, synaptophysin, Trk receptors and Snap-25 wouli 
differentiation of these cells. Also direct activation of neuronal target genes 1 
as the N-CAM would further enhance differentiation.
The co-expression of ANp73 in a subset of Bm-3a positive cells which ar 
differentiated but not in the small, rounded proliferating Bm-3a positive popu 
that ANp73 has a role in sensory neuronal survival just preceding differ* 
though both factors alone can directly affect the survival of cells that expresj 
(Smith et al., 1998;Smith et al., 2001;Ensor et al., 2001;Zaika et al., 2002;N 
2002;Nakagawa et al., 2003) the promoter targets that are possibly modulat 
3a/ANp73 interaction that would result in increased survival of cells that c< 
proteins are not yet known. However, it is possible that ANp73 may have co-o 
on some Bm-3a gene targets such as Bcl-2 and B c 1-x l .
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preferentially switch on particular subsets of genes. The molecular basis tor 
activation of particular sets of genes by the p53 family is not fully understoo 
molecular mechanisms are thought to contribute to target gene selectivity 
covalent modifications have been shown to play a critical role in target f 
instance phosphorylation of ser 46 is required for p53 to efficiently transac 
apoptotic p53AIPl gene (Oda et al., 2000) and p73 acetylation by p300 has 
direct p73 to pro-apoptotic targets (Costanzo et al., 2002). Cellular proteins th 
the p53 family members have also been demonstrated to dictate the choice of f 
genes that are activated by the p53 family members. Such proteins include 
protein JMY which favor the transactivation of pro-apoptotic genes by p53 ar 
the p53 response towards apoptosis (Shikama et al., 1999). The ASPP fami 
p53, p73 and p63 to pro-apoptotic targets (Samuels-Lev et al., 2001;Berg 
2004). In contrast, WT1 inhibits the pro-apoptotic effect o f p53 and p73 (Scl 
2000). The Bm-3a transcription factor has also been demonstrated to ir 
apoptotic effects of p53 whilst enhancing p53 mediated cell cycle arrest (Bu< 
et al., 2002). (see below). Similarly this study shows that Bm-3a also interact 
inhibits p73 mediated apoptosis but enhances p73 mediated cell cycle arrest.
The POU proteins are a family of gene regulators found in organisms as divers 
Drosophila, Xenopus, zebrafish and humans (reviewed by Anderson and Ro: 
All members of this family have been demonstrated to play importanl 
development of specific cell types, particularly in the nervous system, where 
identified as powerful transcription factors. The Bm-3a and Bm-3b transc 
belong to the class IV subgroup of the POU family transcription factoi 
particularly high homology to Unc-86 which has been shown to be critical f 
specific neuronal cell types, especially sensory lineages in C.elegans. It 
speculated that the Bm-3 transcription factors may have a similar rc
249
inferior olivary nucleus and medial habenula (Xiang et al., 1996;McEvilly et a 
et al., 1999). Thus it appears that the neurones that would normally expr< 
specified, but once they are committed to their cell fate Bm-3a is necessary f< 
differentiation. In vivo and in vitro studies also showed that the N-terminal doi 
is required for its survival effects whereas the POU domain of Bm-3a is suffici 
differentiation of cells that express Bm-3a (Lakin et al., 1995;Smith et al., 199 
1998a Smith et al., 1998b; Smith et al., 2001;Ensor et al., 2001;Faulkes et al., ^
The ability of Bm-3a to enhance neuronal survival and differentiation was fu 
be mediated by direct regulation of target genes associated with protection ag 
(Bcl-2 and B c 1-x l )  and differentiation (the neurofilament genes, a-intem< 
synaptophysin and TrkA) (Budhram-Mahadeo et al., 1995b;Lakin et al., 199 
1997c;Smith et al., 1998a;Smith et al., 1998b; Smith et al., 2001;Ensor et 
further elucidate the mechanisms by which the Bm-3a transcription facto 
promote neuronal survival and differentiation, studies were undertaken to 
physical interactions that occur between Bm-3a and other cellular proteins, 
interaction with other transcription factors would effectively increase the r 
genes regulated by the Bm-3 proteins and provide further insight into the n 
which Bm-3a controls cell fate.
Initially, yeast 2 hybrid studies demonstrated association of Bm-3a with tl 
suppressor protein and affinity chromatography showed a direct physical inten 
the POU domain of Bm-3a and the DNA binding domain of p53. Fui 
immunoprecipitation experiments showed that this interaction occurred in vivc 
(Budhram-Mahadeo et al., 1999). Critically this interaction resulted in differer 
of both Bm-3a and p53 mediated gene targets. Thus Bm-3a was shown tc 
mediated transcription of the p21CIPI/Wqft gene associated with cell eye
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The p53 related gene, p73 shares high homology to p53 in the TAD, DBD a 
(reviewed by Melino et al., 2003). The high homology shared between 
particularly in the DBD lead to the idea that Bm-3a may also interact with p7 
p73 mediated cell fate. Moreover, p73-/- knock out mice exhibit severe neurc 
highlighting the importance of the p73 protein in neuronal development, (Ya 
further suggesting that a functional Bm-3a/p73 interaction may be important i 
fate of particular neuronal cell types that co-express these proteins.
In contrast to p53, the p73 gene encodes multiple alternatively spliced C-termi 
well as N-terminally truncated isoforms (TAp73a-£ and ANp73a-P) (Kaghad 
Laurenzi et al., 1998;Ueda et al., 1999). The TA isoforms, which similar to 
cell cycle arrest or apoptosis, have been shown to be differentially regulat 
tissues and at different stages of differentiation, suggesting that they pla 
(Kaghad et al., 1997;Jost et al., 1997;Zhu et al., 1998;De, V et al., 1998b;Ue< 
Furthermore, the AN isoforms act as dominant inhibitory proteins towards the 
and p53. Thus the TA and AN isoforms of p73 show pro- apoptotic and 
functions respectively (reviewed by Melino et al., 2002). This increased o 
explain the distinct biological roles shown by the p53 and p73 proteins tha 
analysis of knock out mice in which the genes encoding p53 or p73 have b* 
deleted (Donehower et al., 1992;Armstrong et al., 1995;Sah et al., 1995;Yan 
Furthermore many gene targets specifically activated by the p73 family men 
identified (Zheng and Chen, 2001;Sasaki et al., 2003;Tullo et al., 2003).
In chapter 3, the physical interaction between Bm-3a and p73 and the functi 
this association was investigated. Using affinity chromatography it was sho^  
could physically interact with the p73 isoforms tested (the TA isoforms p73
251
of p73 which was critical for this interaction, with contributions from the DI 
contribution of the DBD for this interaction was highlighted by findings tl 
POU domain of Bm-3a required the DBD for interaction but the OD domain i 
strong interaction with the intact Bm-3a protein. The essential requirement of 
for this interaction suggests that either Bm-3a contacts specific regions in the 
can only bind to tetrameric p73. The possibility that Bm-3a specifically bin< 
p73 is interesting as tetramerisation of p73 is required for it to transactivate ge
Furthermore the Bm-3a/p73 interaction was shown to be modulated by tl 
termini present in the various p73 isoforms so that the extended C-terminus s 
appears to interfere with high affinity association with the Bm-3a/Bm-31 
instance Bm-3a(l) retained 10.5 % of IVT p73a whereas Bm-3a(l) retained i 
and 33.2 % of IVT p73p, p73y and p738 respectively. Indeed deletion of eit 
amino acids of the p73a C-terminus resulted in increased binding to both Bm 
compared to that observed with wild type p73a. Such differential binding conl 
terminus could be a determinant of precise biological outputs. Indeed Bm-3* 
differentially regulate the activity of the different p73 isoforms on the box 
later).
The observation that the p73 protein interacts with both Bm-3a and Bm-3b is 
as the interaction occurs via the POU domain, which is highly conserved 
proteins. Additionally, the longer isoforms Bm-3a(l) and Bm-3b(l) interact 
affinity with the p73 proteins than the shorter Bm-3a(s) and Bm-3b(s) isofc 
isolated Bm-3a N-terminal alone did not interact strongly with p73, this sugg 
terminal domain might contribute to stronger binding of the p73 proteins, poss 
the conformation of the longer Bm-3 isoforms that results in tighter binding. 1 
interaction observed between the long and short forms of Bm-3a with the ]
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between TAp73 and Bm-3a(l) proteins may have consequences for the survivj 
differentiation of neuronal cells that express both these proteins in the dev€ 
system. The importance of the Bm-3b N-terminal domain found in Bm-3b(l) 
3b(s) in carrying out specific functions remains to be determined.
The effect of the Bm-3a/p73 interaction was tested on the p53/p73 target gei 
and bax as Bm-3a was shown to differentially regulate p53 transcription 
Furthermore the greater molecular complexity exhibited by p73 suggested thi 
mediate differential regulation of the different p73 members on these target ge 
demonstrated to be the case on the bax promoter.
As seen previously with p53, results in chapter 3 show that in the ND7 a 
antagonized p73a and p73p mediated activation of the bax promoter in repc 
this is reflected in a decrease of endogenous Bax protein upon co-expression 
p73a or p73p compared with levels seen with p73a or p73p respectively. Si 
co-operates with p73a or p73p on the p21CIP1/Wafl promoter in reporter ass 
reflected in increased endogenous p2iCIP1/Wafl protein levels in cells co-exj 
with p73a or p73p compared with either p73a or p73p expressing c 
antagonistic effects of Bm-3a on p73a or p73p mediated activation of the ba 
synergy on the p21clpl/fVq^  promoter was also reproduced in the SAC 
demonstrating that these differential effects of Bm-3a on p73 mediated trans 
neuronal specific or dependent on the presence of p53 in these cells.
Importantly, the interaction of Bm-3a and the different p73 isoforms had dis 
regulation of cell cycle arrest and cell survival in the ND7 neuronal cell lin 
can co-operate with p73a and p73p but not with ANp73a in inducing cell 
contrast the anti-apoptotic effects of Bm-3a co-operate with ANp73a to furth
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survival by both p53-dependent and independent mechanisms, with the 1 
inhibiting JNK which is activated by NGF withdrawal (Lee et al., 2004). This 
that ANp73 can also enhance survival independently of p53 by interacting  ^
transcription factor. Though the molecular mechanism remains to be detem 
hypothesized that the Bm-3a/ANp73a interaction may act co-operatively 
apoptotic targets such as the Bcl-2 and Bcl-xL, both of which are known targe 
on as yet unknown targets of ANp73a.
The ability of Bm-3a to directly repress the bax promoter and antagonise p5: 
activity on this promoter is interesting as Bm-3a-/- embryos show significant 
neurones as a consequence of increased apoptosis. Bax plays a critical r< 
occurring apoptosis in many neurones during development including sensory 
are known to express Bm-3a (Deckwerth et al., 1996;White et al., 1998 
crosses o f Bm-3a-/- with Bax-/- resulted in rescue of many sensory neuro 
normally express Bm-3a (Ma et al., 2003). However there is still apoptosis i 
neurones which is independent of Bax and it is likely that other pro-aj 
contribute to the fate of these cells.
It was therefore tested whether Bm-3a could repress other p53/p73 target ge 
apoptosis. Results in chapter 4 demonstrated that Bm-3a also inhibits p5 
mediated activation of the noxa gene which encodes a BH3 only, pro-apopt 
the Bcl-2 family (Oda et al., 2000). The mechanism by which Bm-3a inhibit 
activation of the noxa gene was further investigated. Unlike the bax promoter 
two Bm-3a sites required for Bm-3a mediated repression, either directly oi 
with p53 (Perez-Sanchez et al., 2002), the noxa promoter contains no Bm-3a; 
since Bm-3a could significantly antagonize p53 or p73 mediated stimi 
promoter, this effect must arise from its ability to physically interact
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promoter resulted in amplification of the promoter DNA but this was not c 
same promoter lacking the p53 site.
Therefore, the antagonistic effect of Bm-3a on p53/p73 mediated activation 
noxa genes is interesting as it suggests that one mechanism by which B 
survival is by repressing p53/p73 target genes involved in apoptosis. In agrei 
hypothesis it has been demonstrated that in neuronal tissue taken from E 
compared with wild type, loss of Bm-3a resulted in significant increases ir 
Bax and Noxa at specific times during development. Both Bax and No: 
elevated by E14.5 in Bm-3a -/- embryos compared with wild type litter mate 
coincides with increased apoptosis in these mutants (Eng et al., 2001). By E] 
neurones which would normally express Bm-3a are lost in Bm-3a -/- embryc 
Bax and Noxa proteins remained similar in the wild type embryos com 
mutants. Therefore, in Bm-3a expressing cells such as sensory neurones, it ii 
expression of Bax and Noxa are controlled by the ability o f this transcriptioi 
p53/TAp73 mediated gene transcription.
Thus Bm-3a was shown to repress two p53/p73 pro-apoptotic targets i] 
mitochondrial death pathway. It would be of interest to determine if Bm-3a c 
p53/p73 targets that mediate cell death, such as Puma, which is shown 
mediator of p53/p73 induced apoptosis (Yu et al., 2001;Melino et al., 2004). /  
ability of Bm-3a to repress p53/p73 target genes involved in the extrinsic dea 
also be investigated as both the intrinsic and extrinsic pathways play an in 
neuronal cell death.
The ability of Bm-3a to repress p73a and p73p mediated activation of the 
whilst enhancing p73a and p73p mediated activation of the p21CIP1/Wqfl prom
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bax transactivation. Furthermore, it was demonstrated that the region 424-50! 
from the C-terminal of p73C424 is required for binding of a co-activator b; 
possibly disrupted by the presence of Bm-3a on the bax promoter. In conti 
terminal was shown not to be important for Bm-3a mediated co-operation a 
p 2i CIpl/w<tfi promoter, thus this differential regulation of the p73 splice variai 
specific to the bax promoter.
Interestingly this region contains the PPPPY motif (residues 482-488, encoc 
underlined in Fig 3.18) that has been shown to interact with cellular proteins 
mediated transcription. The WW adaptor, Yes-associated protein (Y, 
demonstrated to interact with the p73 PPPPY motif (Strano et al., 2001). YA 
stimulate p73a mediated activation of the bax and mdm promoters in H 
binding of YAP to p73 is necessary for the co-activation of p73 (Stran< 
Therefore it can be speculated that when bound to p73 on the bax promot 
disrupt the interaction between p73 and a co-activator such as YAP resulting 
p73 mediated bax activation. The identification of this co-activator would be 
discussed in chapter 3.
Therefore Bm-3a can differentially regulate transcriptional activation by the c 
C-terminal isomers on the bax promoter. This is interesting as these TA splio 
different abilities to transactivate target genes and increase cell cycle arresi 
(De-Laurenzi et al., 1998;Ueda et al., 1999; Ueda et al., 2001). One mecha 
these isoforms may achieve this is by interacting with cellular proteins whicl 
the selectivity of individual p73 members in controlling the expression o: 
targets. The effect of Bm-3a on p73y and p738 mediated apoptosis was nc 
study but it is anticipated that addition of Bm-3a would not increase surv
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bax promoter may have consequences on cell death/survival under different < 
different cell types. Hence it can be postulated that the array of p73 transcrij 
the cell at any given time and also which isoforms are dominant will determii 
which Bm-3a can repress bax activation and hence the ability of Bm-3a t< 
mediated cell fate. Additionally, Bm-3a was shown to enhance p730 med 
arrest to a greater extent than p73a. Thus Bm-3a may differentially enhance < 
depending on the p73 C-terminal isomers present in the cell.
The ability of Bm-3a to synergize with p53 or p73 on the p21CIP1/Wqfl promo 
repress p73 or p53 mediated apoptotic gene expression {bax and noxa proi 
that Bm-3a plays a critical role in determining the cellular status and survi 
cells which co-express these proteins. In particular Bm-3a may be important 
the fate of neuronal cells where it has been shown that p53 and p73 are al: 
during neuronal differentiation, during developmental cell death or when cell 
stress or injury resulting in activation of the p53/p73 gene.
Therefore, the co-expression of Bm-3a and p73 was analyzed in neuronal ] 
during development and the effects of this interaction were investigated by si 
of cells destined for a sensory neuronal linage, under different conditions (c 
utilization of neural crest cultures in which Bm-3a is expressed in progenitc 
committed to a sensory linage (Greenwood et al., 1999) provides a dynamic m 
the mechanism by which Bm-3a mediates its effect on these cells, with speci 
association with p53 and p73.
In accordance with published data, analysis of Bm-3a expression in neural cr< 
showed that Bm-3a was detected in two distinct populations of NCC, a smalle 
proliferative Bm-3a-positive population that were commonly found near the si
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was further confirmed by co-localization of p53 with the differentiation i 
(Hudson et al., 2004 and Chapter 5).
It was therefore hypothesized that TAp73 may also be involved in se 
development, particularly in the view of findings that TAp73 is itself suffi 
differentiation of certain neuronal cell lines (De Laurenzi et al., 2000). 
antibodies to detect the p73 protein were used in this study. These were p 
detects the alpha isoforms of both TAp73 and ANp73, p73-AN that detects tl 
only and p73-Total which detects all p73 isoforms. Similar to p53, co-i 
experiments also demonstrated that p73 co-localized in the larger Bm-3a expr 
displayed flattened morphology with many showing neurite extensions, 
smaller, more rounded Bm-3a positive cells. Interestingly both p73-Total 
showed both nuclear and cytoplasmic staining whereas staining with p73-AN 
cytoplasmic localisation. It can therefore be inferred that the cytoplasmic stair 
both p73-Total and p73-SAM is likely to be due to the ANp73 isoform in mos 
whereas nuclear staining detected by these two antibodies is likely to be 
isoforms. This suggests parallel roles between TAp73 and p53, both of whic 
staining when co-expressed with Bm-3a, suggesting that similar to p53, 
involved in the differentiation of these cells. Obviously the availability c 
specific antibody will help to clarify the sub cellular locations of the TA ar 
NCC co-expressing Bm-3a.
To characterize the phenotype of p73 expressing cells further, co-immunosta 
160 showed that TAp73 but not ANp73 co-localizes with NF-160 in cells 
morphology. As TAp73/NF-160, Bm-3a/NFl-60 and Bm-3a/p73 were obse 
cell types it is likely that Bm-3a/TAp73 positive cells arising from the ne 
differentiated neurones. In contrast the co- expression of ANp73/Bm
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2. The large flattened ANp73/Bm-3a positive population that has not 
differentiation (lacking NF-160 expression).
3. The large flattened TAp73/Bm-3a positive population which i 
differentiation or are differentiated (co-expressing NF-160)
Hence, these results suggest that there is a switch in expression of the AN ai 
during sensory neuronal differentiation and that TAp73 is associated with di 
sensory neurones. p73 has been shown to be up-regulated during muse 
hematopoietic differentiation (Tschan et al., 2000;De, V et al., 2000;Fontemaj 
suggesting a general role in the differentiation of a variety of cell types. In 
ANp73 plays an essential anti-apoptotic role in developing neurones as well ai 
for the survival of adult DRGs (Pozniak et al., 2000; Walsh et al., 2004), Inter* 
isoforms have been shown to be required to induce neurite outgrowt 
neuroblastoma cell line, suggesting that TAp73 can directly affect differential 
cells (De, Laurenzi et al., 2000).
Additionally, the TAp73 and ANp73 forms have also been shown to be d 
regulated during kidney organogenesis. Thus, TAp73 is predominantly e> 
differentiation domain of the renal cortex whereas ANp73 isoforms are in 
development and are preferentially expressed in proliferating nephron precun 
et al., 2005). In this study TAp73 is co-expressed with Bm-3a in differ© 
neurones, suggesting a role for TAp73 in this process. In contrast, the cc 
ANp73 in a subset of Bm-3a positive cells which have not yet differentiatec 
small, rounded proliferating Bm-3a positive population might suggest that At 
in sensory neuronal survival just preceding differentiation. This will need to I
259
activate genes involved in neuronal differentiation. However, TAp73 was sh< 
the neuronal differentiation marker N-CAM during neuroblastoma diffei 
Laurenzi et al., 2000). It would be interesting to see if Bm-3a and TAp73 cai 
others effects on genes involved in neuronal differentiation. Indeed, p53 
enhance Bm-3a mediated activation of the a-intemexin promoter (Budhram-1 
1999). The observation that ANp73 is not co-expressed with NF-160 may reft 
act as a pro-survival factor rather than a differentiation factor (Pozniak et al., 2 
et al., 2003). In addition the Bm-3a/ANp73 interaction may act to further enlu 
a manner seen in the ND7 neuronal cell line model, in which co-expression 
ANp73 enhanced survival of these cells compared to the levels seen when ei 
expressed alone.
Due to the limitations of double staining techniques used in this study, the e 
Bm-3a, TAp73 and NF-160 are expressed in the same cell and NF-160 is n 
cells that co-express Bm-3a/ANp73 is based on similarity in the distinct i 
subsets of cells. Clearly, if triple co-immunostaining techniques can be optin 
dependent on suitable antibodies becoming available), this will further c< 
expression of Bm-3a /TAp73 /NF-160 and Bm-3a/ANp73 but not NF-160 ii 
type. However, in the absence of suitable antibodies, such experiments c< 
combined in-situ for one factor and co-immunostaining for other proteins. /  
TA or AN-specific ribo-probes, would help in deciphering TA verses AN is 
expression in these cells in the absence of good TA-specific antibodies.
However, on the available evidence it is likely that during neuronal develop 
and p73 contribute to both differentiation and apoptosis of neurones depen 
other proteins are co-expressed with it. To further demonstrate the requii 
expression of p53/TAp73 with Bm-3a in determining cell fate, NCC cultures
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further support the hypothesis that Bm-3a is necessary to overcome the apopto 
repressing the expression of pro-apoptotic factors such as bax and noxa that ar< 
both p53 and TAp73 in specific cells during development.
Therefore similar to the Bm-3a/p53 effect, the results of studies carried out i 
this thesis support the hypothesis that during neuronal development Bm-3a rej 
by repressing p73 mediated activation of pro-apoptotic genes such as bax an< 
operating on the p21CIP1/fVc** promoter to enhance cell survival and cell cycle a 
differentiation. Thus, interaction with Bm-3a in sensory neurones may 
modulating p73/p53 mediated gene expression and hence cell fate of neurons 
express these proteins.
Future direction
In this study, Bm-3a was shown to differentially regulate p73 mediated ac 
p21clpl/Wa^ , bax and noxa promoters, and modulate p73 mediated cell fate, 
possible role of p73 in sensory neuronal differentiation, it would be inte 
whether p73 modulates Bm-3a expression of its target promoters associated 
development. Also many genes specifically regulated by p73 are being id< 
would be interesting to assess whether Bm-3a can modulate p73 mediated 
these genes, particularly gene targets involved in neuronal development such ai
It will be interesting to determine whether or not the Bm-3a enhancement o 
mediated activation of the p 2 lCIP1/Wafl promoter would result in an additive 
expressing all three proteins. This can be assessed by carrying out triple tr 
which Bm-3a and p53 are co-expressed with the p21CIP1/w<** reporter co 
presence or absence of the different p73 isoforms. Similarly the effect
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Given the data obtained in these studies, it appears that there may be possib 
for p53 and TAp73 in sensory neuronal differentiation, and that the TAp7 
compensate for loss of p53 in these neurones during development. Therefc 
interesting to test whether the levels of TAp73 mRNA in NCC taken from p5 
elevated compared to NCC prepared from p53 wild type embryos. This mij 
the low penetrance of the neural phenotype in the p53-/- mice. Similarly, to 
p53 compensates for loss of p73 in sensory neuronal development, the levels < 
p53 in NCC can be assessed and compared in NCC cultures prepared from 
wild type embryos.
Double crosses between Bm-3a and p73 knock out mice to generate Bm 
knockouts (Bm-3a-/-p73-/-) and analysis of the NCC prepared from the dc 
embryos would greatly help to decipher the roles of these proteins in sensoi 
fate. It would be anticipated that in NCC cultures prepared from these double 
there would be a reduced number of sensory neurones present and less 
differentiation markers compared to controls (Bm-3a +/- p73+/-, or wild tj 
The ability of Bm-3a to modulate p53/p73 mediated cell fate can also be invej 
cells cultured from either p53-/-, p73-/- or Bm-3a-/- animals.
The promoters that produce the TA and AN forms of p73 (PI and P2 re 
differentially regulated. For instance, the TA isoforms and p53 were shown 
the AN promoter but not the TA promoter, leading to increased ANp73 
inhibition of TAp73/p53 transactivation (Grob et al., 2001;Kartasheva et al., 
al., 2002;Nakagawa et al., 2002). The interaction of the Bm-3a and p7 
modulation of p73 mediated cell fate suggests that these proteins may regul 
expression. Indeed it has been shown that Bm-3a transactivates the p53 g
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factor alone (data not shown). Similarly p53/p73 may regulate Bm-3a expressi 
be assessed by carrying out co-transfection assays.
If p53 and/or p73 are shown to regulate Bm-3a expression, it can be assessed 
p53 or p73 affects Bm-3a expression in NCC. Therefore the levels of Bm-3a i 
taken from p53-/- and p73-/- embryos can be measured and compared to the 
controls (NCC cultures prepared from wild type littermates).
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can selectively rescue neurotrophic factor-dependent neurons from apoptosis 
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